Cell cycle progressional proteins

Abstract

Polynucleotides encoding a number of Drosophila gene products are provided. Polynucleotide probes derived from these nucleotide sequences, polypeptides encoded by the polynucleotides and antibodies that bind to the polypeptides are also provided.

Description

The present invention relates to a number of genes implicated in the processes of cell cycle progression, including mitosis and meiosis.

We have now identified a number of genes in the X chromosome of Drosophila, mutations in which disrupt cell cycle progression, for example the processes of mitosis and/or meiosis. We have determined the phenotypes of these mutations and relate the mutations to the total genome sequence and so identify individual genes essential for cell cycle progression.

According to one aspect of the present invention, we provide a use of a polynucleotide as set out in Table 5, or a polypeptide encoded by the polypeptide, in a method of prevention, treatment or diagnosis of a disease in an individual.

Preferably, the polynucleotide comprises a human polypeptide as set out in column 3 of Table 5. In preferred embodiments, the polynucleotide or polypeptide is used to identify a substance capable of binding to the polypeptide, which method comprises incubating the polypeptide with a candidate substance under suitable conditions and determining whether the substance binds to the polypeptide.

Alternatively or in addition, the polynucleotide or polypeptide is used to identify a substance capable of modulating the function of the polypeptide, the method comprising the steps of: incubating the polypeptide with a candidate substance and determining whether activity of the polypeptide is thereby modulated.

The polynucleotide or polypeptide may be administered to an individual in need of such treatment. Alternatively, or in addition, the substance identified by the method is administered to an individual in need of such treatment.

The use may be for a method of diagnosis, in which the presence or absence of a polynucleotide is detected in a biological sample in a method comprising: (a) bringing the biological sample containing nucleic acid such as DNA or RNA into contact with a probe comprising a fragment of at least 15 nucleotides of the polynucleotide as set out in Table 5 under hybridising conditions; and (b) detecting any duplex formed between the probe and nucleic acid in the sample.

Alternatively, or in addition, the presence or absence of a polypeptide is detected in a biological sample in a method comprising: (a) providing an antibody capable of binding to the polypeptide; (b) incubating a biological sample with said antibody under conditions which allow for the formation of an antibody-antigen complex; and (c) determining whether antibody-antigen complex comprising said antibody is formed.

In highly preferred embodiments, the disease comprises a proliferative disease such as cancer.

In a further aspect of the invention, we provide a method of modulating, preferably down-regulating, the expression of a polynucleotide as set out in Table 5 in a cell, the method comprising introducing a double stranded RNA (dsRNA) corresponding to the polynucleotide, or an antisense RNA corresponding to the polynucleotide, or a fragment thereof, into the cell.

According to another aspect of the present invention, we provide a polynucleotide selected from: (a) polynucleotides comprising any one of the nucleotide sequences set out in Example 19, preferably Shp2 polynucleotide, or the complement thereof; (b) polynucleotides comprising a nucleotide sequence capable of hybridising to the nucleotide sequences set out in Example 19, preferably Shp2 polynucleotide, or a fragment thereof; (c) polynucleotides comprising a nucleotide sequence capable of hybridising to the complement of the nucleotide sequences set out in Example 19, preferably Shp2 polynucleotide, or a fragment thereof; (d) polynucleotides comprising a polynucleotide sequence which is degenerate as a result of the genetic code to the polynucleotides defined in (a), (b) or (c).

There is provided, according to a further aspect of the present invention, a polynucleotide selected from: (a) polynucleotides comprising any one of the nucleotide sequences set out in Example 28, preferably Dlg1 or Dlg2 polynucleotide, or the complement thereof; (b) polynucleotides comprising a nucleotide sequence capable of hybridising to the nucleotide sequences set out in Example 28, preferably Dlg1 or Dlg2 polynucleotide, or a fragment thereof; (c) polynucleotides comprising a nucleotide sequence capable of hybridising to the complement of the nucleotide sequences set out in Example 28, preferably Dlg1 or Dlg2 polynucleotide, or a fragment thereof; (d) polynucleotides comprising a polynucleotide sequence which is degenerate as a result of the genetic code to the polynucleotides defined in (a), (b) or (c).

We provide, according to another aspect of the present invention, a polynucleotide selected from: (a) polynucleotides comprising any one of the nucleotide sequences set out in Table 5 or the complement thereof; (b) polynucleotides comprising a nucleotide sequence capable of hybridising to the nucleotide sequences set out in Table 5, or a fragment thereof; (c) polynucleotides comprising a nucleotide sequence capable of hybridising to the complement of the nucleotide sequences set out in Table 5, or a fragment thereof; (d) polynucleotides comprising a polynucleotide sequence which is degenerate as a result of the genetic code to the polynucleotides defined in (a), (b) or (c).

As a further aspect of the present invention, there is provided a polynucleotide selected from: (a) polynucleotides comprising any one of the nucleotide sequences set out in Examples 1 to 18, 20 to 27 and 29 or the complement thereof; (b) polynucleotides comprising a nucleotide sequence capable of hybridising to the nucleotide sequences set out in Examples 1 to 18, 20 to 27 and 29, or a fragment thereof; (c) polynucleotides comprising a nucleotide sequence capable of hybridising to the complement of the nucleotide sequences set out in Examples 1 to 18, 20 to 27 and 29, or a fragment thereof; (d) polynucleotides comprising a polynucleotide sequence which is degenerate as a result of the genetic code to the polynucleotides defined in (a), (b) or (c).

We provide, according to a further aspect of the present invention, a polynucleotide selected from: (a) polynucleotides comprising any one of the nucleotide sequences set out in Examples 1, 2, 2A, 2B and 2C or the complement thereof; (b) polynucleotides comprising a nucleotide sequence capable of hybridising to the nucleotide sequences set out in Examples 1, 2, 2A, 2B and 2C, or a fragment thereof; (c) polynucleotides comprising a nucleotide sequence capable of hybridising to the complement of the nucleotide sequences set out in Examples 1, 2, 2A, 2B and 2C, or a fragment thereof; (d) polynucleotides comprising a polynucleotide sequence which is degenerate as a result of the genetic code to the polynucleotides defined in (a), (b) or (c).

The present invention, in another aspect, provides polynucleotide selected from: (a) polynucleotides comprising any one of the nucleotide sequences set out in Examples 3 to 9 and 9A or the complement thereof; (b) polynucleotides comprising a nucleotide sequence capable of hybridising to the nucleotide sequences set out in Examples 3 to 9 and 9A, or a fragment thereof; (c) polynucleotides comprising a nucleotide sequence capable of hybridising to the complement of the nucleotide sequences set out in Examples 3 to 9 and 9A, or a fragment thereof; (d) polynucleotides comprising a polynucleotide sequence which is degenerate as a result of the genetic code to the polynucleotides defined in (a), (b) or (c).

In a further aspect of the present invention, there is provided polynucleotide selected from: (a) polynucleotides comprising any one of the nucleotide sequences set out in Examples 10 to 29 or the complement thereof; (b) polynucleotides comprising a nucleotide sequence capable of hybridising to the nucleotide sequences set out in Examples 10 to 29, or a fragment thereof; (c) polynucleotides comprising a nucleotide sequence capable of hybridising to the complement of the nucleotide sequences set out in Examples 10 to 29, or a fragment thereof; (d) polynucleotides comprising a polynucleotide sequence which is degenerate as a result of the genetic code to the polynucleotides defined in (a), (b) or (c).

As a further aspect of the invention, we provide a polynucleotide probe which comprises a fragment of at least 15 nucleotides of a polynucleotide according to any of the above aspects of the invention.

The present invention also provides a polypeptide which comprises any one of the amino acid sequences set out in Examples 1 to 29 or in any of Examples 1 to 2, 2A, 2B and 2C, Examples 3 to 9 and 9A and Examples 10 to 29, or a homologue, variant, derivative or fragment thereof.

Preferably the polypeptide is encoded by a cDNA sequence obtainable from a eukaryotic cDNA library, preferably a metazoan cDNA library (such as insect or mammalian) said DNA sequence comprising a DNA sequence being selectively detectable with a nucleotide sequence, preferably a Drosophila nucleotide sequence, as shown in any one of Examples 1 to 29.

The term “selectively detectable” means that the cDNA used as a probe is used under conditions where a target cDNA is found to hybridize to the probe at a level significantly above background. The background hybridization may occur because of other cDNAs present in the cDNA library. In this event background implies a level of signal generated by interaction between the probe and a non-specific cDNA member of the library which is less than 10 fold, preferably less than 100 fold as intense as the specific interaction observed with the target cDNA. The intensity of interaction may be measured, for example, by radiolabelling the probe, e.g. with ³²P. Suitable conditions may be found by reference to the Examples, as well as in the detailed description below.

A polynucleotide encoding a polypeptide as described here is also provided.

We further provide a vector comprising a polynucleotide of the invention, for example an expression vector comprising a polynucleotide of the invention operably linked to a regulatory sequence capable of directing expression of said polynucleotide in a host cell.

Also provided is an antibody capable of binding such a polypeptide.

In a further aspect the present invention provides a method for detecting the presence or absence of a polynucleotide of the invention in a biological sample which method comprises: (a) bringing the biological sample containing DNA or RNA into contact with a probe comprising a nucleotide of the invention under hybridising conditions; and (b) detecting any duplex formed between the probe and nucleic acid in the sample.

In another aspect the invention provides a method for detecting a polypeptide of the invention present in a biological sample which comprises: (a) providing an antibody of the invention; (b) incubating a biological sample with said antibody under conditions which allow for the formation of an antibody-antigen complex; and (c) determining whether antibody-antigen complex comprising said antibody is formed.

Knowledge of the genes involved in cell cycle progression allows the development of therapeutic agents for the treatment of medical conditions associated with aberrant cell cycle progression. Accordingly, the present invention provides a polynucleotide of the invention for use in therapy. The present invention also provides a polypeptide of the invention for use in therapy. The present invention further provides an antibody of the invention for use in therapy.

In a specific embodiment, the present invention provides a method of treating a tumour or a patient suffering from a proliferative disease, comprising administering to a patient in need of treatment an effective amount of a polynucleotide, polypeptide and/or antibody of the invention.

The present invention also provides the use of a polypeptide of the invention in a method of identifying a substance capable of affecting the function of the corresponding gene. For example, in one embodiment the present invention provides the use of a polypeptide of the invention in an assay for identifying a substance capable of inhibiting cell cycle progression. The assay involves contacting the polypeptide with a candidate substance or molecule, and detecting modulation of activity of the polypeptide. In preferred embodiments, further steps of isolating or synthesising the substance so identified are carried out.

The substance may inhibit any of the steps or stages in the cell cycle, for example, formation of the nuclear envelope, exit from the quiescent phase of the cell cycle (G0), G1 progression, chromosome decondensation, nuclear envelope breakdown, START, initiation of DNA replication, progression of DNA replication, termination of DNA replication, centrosome duplication, G2 progression, activation of mitotic or meiotic functions, chromosome condensation, centrosome separation, microtubule nucleation, spindle formation and function, interactions with microtubule motor proteins, chromatid separation and segregation, inactivation of mitotic functions, formation of contractile ring, and cytokinesis functions. For example, possible functions of genes of the invention for which it may be desired to identify substances which affect such functions include chromatin binding, formation of replication complexes, replication licensing, phosphorylation or other secondary modification activity, proteolytic degradation, microtubule binding, actin binding, septin binding, microtubule organising centre nucleation activity and binding to components of cell cycle signalling pathways.

In a further aspect the present invention provides a method for identifying a substance capable of binding to a polypeptide of the invention, which method comprises incubating the polypeptide with a candidate substance under suitable conditions and determining whether the substance binds to the polypeptide.

In an additional aspect, the invention provides kits comprising polynucleotides, polypeptides or antibodies of the invention and methods of using such kits in diagnosing the presence of absence of polynucleotides and polypeptides of the invention including deleterious mutant forms.

Also provided is a substance identified by the above methods of the invention. Such substances may be used in a method of therapy, such as in a method of affecting cell cycle progression, for example mitosis and/or meiosis.

The invention also provides a process comprising the steps of: (a) performing one of the above methods; and (b) preparing a quantity of those one or more substances identified as being capable of binding to a polypeptide of the invention.

Also provided is a process comprising the steps of: (a) performing one of the above methods; and (b) preparing a pharmaceutical composition comprising one or more substances identified as being capable of binding to a polypeptide of the invention.

We further provide a method for identifying a substance capable of modulating the function of a polypeptide of the invention or a polypeptide encoded by a polynucleotide of the invention, the method comprising the steps of: incubating the polypeptide with a candidate substance and determining whether activity of the polypeptide is thereby modulated.

A substance identified by a method or assay according to any of the above methods or processes is also provided, as is the use of such a substance in a method of inhibiting the function of a polypeptide. Use of such a substance in a method of regulating a cell division cycle function is also provided.

We further provide a method of identifying a human nucleic acid sequence, by: (a) selecting a Drosophila polypeptide identified in any of Examples 1 to 29; (b) identifying a corresponding human polypeptide; (c) identifying a nucleic acid encoding the polypeptide of (b).

Preferably, a human homologue of the Drosophila sequence, or a human sequence similar to the Drosophila sequence, is identified in step (b).

Preferably, the human polypeptide has at least one of the biological activities, preferably substantially all the biological activities of the Drosophila polypeptide.

We provide a human polypeptide identified by a method according to the previous aspect of the invention.

BRIEF DESCRIPTION OF THE FIGURES

FIG. 1 shows mitotic index after RNAi knockdown of Corkscrew (CG3954) in Dmel-2 Drosophila cultured cells. Values are an average of triplicate samples. Positive controls are siRNA with the mitotic genes Polo kinase and Orbit, negative controls are siRNA with water and with an siRNA against non-endogenous gene GL3

FIG. 2 shows a BLASTP alignment of Drosophila Corkscrew (CG3954) (query sequence), identified in Example 19 as a cell cycle gene, and human Shp2 Protein-tyrosine phosphatase, non-receptor type 11 (genbank accession D13540) (subject sequence).

FIG. 3 shows a histogram of Facs analysis of cell cycle compartment as determined by DNA content in U20S cells after human Shp2 siRNA transfection for 48 hours. The negative control is transfection with siRNA against the non-endogenous gene GL3.

FIG. 4 shows fluorescence micrographs showing the effect of Shp2 siRNAi in U2OS cells. A) Irregular nuclear shape, B) Increase in apoptosis.

FIG. 5 shows Mitotic index after RNAi knockdown of Drosophila discs large 1 Dlg1 (CG1725) in Dmel-2 Drosophila cultured cells. Values are an average of triplicate samples. Positive controls are siRNA with the mitotic genes Polo kinase and Orbit, negative controls are siRNA with water and with an siRNA against non-endogenous gene GL3

FIG. 6A shows a BLASTP alignment of Drosophila discs large 1 Dlg1 (CG1725), identified in Example 28 as a cell cycle gene, and human discs, large (Drosophila) homolog 1 (genbank accession U13896).

FIG. 6B shows a ClustalW alignment of Drosophila discs large 1 Dlg1 (CG1725) and human discs, large (Drosophila) homolog 1 (genbank accession U13896).

FIG. 6C shows a BLASTP alignment of Drosophila discs large 1 Dlg1 (CG1725), and human discs, large (drosophila) homolog 2 (genbank accession U32376).

FIG. 6D shows a ClustalW alignment of Drosophila discs large 1 Dlg1 (CG1725) and human discs, large (drosophila) homolog 2 (genbank accession U32376).

FIG. 7 shows a ClustalW alignment Drosophila Dlg1 and 5 human Dlg genes (Dlg 1-5) so far described.

FIG. 8 shows a histogram of FACS analysis of cell cycle status after siRNA in U2OS cells. Negative control is siRNA against the non-endogenous GL3 gene.

FIG. 9 fluorescence micrographs showing the dominant phenotype observed with Dlg1 COD1654 siRNAi in U2OS cells. A) Multicentrosomal cells at prometaphase and anaphase. B) Cytokinesis defect

FIG. 10 fluorescence micrographs showing the dominant phenotype observed with Dlg2 COD1652 siRNAi in U2OS cells. A) Multicentrosomal cell at telophase. B) Cytokinesis defects.

DETAILED DESCRIPTION

We provide for polynucleotide sand polypeptides whose sequences are set out, or which are referred to, in any of Examples 1 to 29, including Drosophila and human sequences. In particular, we provide for the sequences, including human sequences, and their use in diagnosis and treatment of disease (including prevention and treatment of diseases, syndromes and symptoms) as described in further detail below. A particularly suitable disease for treatment or diagnosis is a proliferative disease such as cancer or any tumour. The polynucleotides and polypeptides disclosed here may be used in screening assays to identify compounds which are capable of binding to, or inhibiting an activity of, the polypeptide or polynucleotide.

Particularly preferred polypeptides include those set out in Example 19 and referred to as Shp2, as well as those set out in Example 28 and referred to as Dlg1 and Dlg2. Accordingly, we provide for Shp2 polypeptide and polynucleotide, as well as Dlg1 and Dlg2 polypeptide and polynucleotide, for the treatment and diagnosis of diseases such as cancer, as described in further detail below.

By the term “Shp2”, we mean a sequence as set out in Example 19 and having the accession number NM_—002834, together with its variants, homologues, derivatives, fragments and complements as described in further detail below. Preferably, the term “Shp2” should be taken to refer to the human sequence itself. Two transcript variants (variants 1 and 2 as set out in Example 19) are known, and both are encompassed in the term “Shp2”. Shp2 is also known as Homo sapiens protein tyrosine phosphatase, non-receptor type 11 (PTPN11). Furthermore, various sequences differing in length are known for Shp2, and each of these is intended to be included for the uses and compositions described here.

As used in this document, the terms “Dlg1” and “Dlg2” mean the sequences as set out in Example 28 and having the GENBANK accession numbers U13896 and U32376 respectively. Variants, homologues, derivatives, fragments and complements (as described in further detail below) of each of these sequences are also included within the meaning of these terms.

Dlg1 is also known as “human discs, large (Drosophila) homolog 1” while Dlg2 is also known as “human discs, large (Drosophila) homolog 2, chapsyn-110 channel-associated protein of synapses-110′”. Various sequences differing in length are known for Dlg1 and Dlg2, and each of these is intended to be included for the uses and compositions described here.

Preferably, the polypeptides and polynucleotides are such that they give rise to or are associated with defined phenotypes when mutated.

For example, mutations in the polypeptides and polynucleotides may be associated with female sterility; such polypeptides and polynucleotides are conveniently categorised as “Category 1”. Phenotypes associated with Category 1 polypeptides and polynucleotides include any one or more of the following, singly or in combination: Female semi-sterile, brown eggs laid; female sterile, few eggs laid, several fully matured eggs in ovarioles; female semi-sterile, lays eggs, but arrest before cortical migration; “Female sterile, no eggs laid. Fully mature eggs, but “retained eggs” phenotype. Also has a mitotic phenotype: higher mitotic index, uneven chromosome staining, tangled and badly defined chromosomes with frequent bridges”; Female sterile (semi-sterile), 2-3 fully matured eggs in each of the ovarioles.

Alternatively, mutations in the polypeptides and polynucleotides may be associated with male sterility; such polypeptides and polynucleotides are conveniently categorised as “Category 2”. Phenotypes associated with Category 2 polypeptides and polynucleotides include any one or more of the following, singly or in combination: Lethal phase pharate adult, cytokinesis defect—some onion stage cysts with large nebenkerns; reduced adult viability, cytokinesis defect—onion stage cysts have variable sized Nebenkerns—mitotic phenotype: tangled unevenly condensed chromosomes, anaphases with lagging chromosomes and bridges; semi-lethal male and female, cytokinesis defect—in some cysts, variable sized Nebenkerns; male sterile, cytokinesis defect, different meiotic stages within one cyst, variable sized nuclei, 2-4 nuclei, mitotic phenotype:

semi-lethal, rod-like overcondensed chromosomes, high mitotic index, lagging chromosomes and bridges; male sterile, asynchronous meiotic divisions, cysts with large Nebenkern and 1-2 larger nuclei, testis from 2-3 old males become smaller, high mitotic index, colchicine type overcondensaton, many anaphases and telophases, no decondensation in telophase, mitotic phenotype: high mitotic index, colchicines-type overcondensed chromosomes, many ana- and relophases, no decondensation in telophase; cytokinesis defect, small testis, no meiosis observed, variable sized Nebenkerns with 2-4N nuclei; male sterile, cytokinesis defect, larger Nebenkerns with 2-4N nuclei; Male sterile, Cytokinesis defect: variable sized Nebenkerns with 4N nuclei, some nuclei detached from Nebenkern.

Mutations in the polypeptides and polynucleotides may be associated with a mitotic (neuroblast) phenotype (“Category 3”). Phenotypes associated with Category 3 polypeptides and polynucleotides include any one or more of the following, singly or in combination: lethal phase between pupil and pharate adult (P-pA), high mitotic index, rod-like overcondensed chromosomes, a few circular metaphases, many overcondensed anaphases and telophases, a few tetraploid cells; lethal phase pharate adult, high mitotic index, rod-like overcondensed chromosomes, lagging chromosomes and bridges in anaphase, highly condensed; lethal phase pupal-pharate adult, high mitotic index, colchicines-type overcondensation, high frequency of polyploids; lethal phase pupal-pharate adult, high mitotic index, colchicines-type overcondensed chromosomes, many strongly stained nuclei; lethal phase larval stage 3-pre-pupal-pupal, small optic lobes, missing or small imaginal discs, badly defined chromosomes; lethal phase pharate adult, Dot and rod-like overcondensed chromosomes, high mitotic index, overcondensed anaphases some with lagging chromosomes, a few tetraploid cells with overcondensed chromosomes, XYY males; lethal phase embryonic larval phase3-pre-pupal-pupal, high mitotic index, dot-like chromosomes, strong metaphase arrest; lethal phase larval phase 3 D pre-pupal-pupal-pharate adult-adult, high mitotic index, dot and rod-like overcondensed chromosomes, high frequency of polyploids; lethal phase larval stage 3 (few pupae), high mitotic index, colchicine-type overcondensation of chromosomes, polyploid cells, mininuclei formation; lethal phase larval stage 1-2, low mitotic index, few cells in mitosis, metaphase with separated chromosomes; viable, high mitotic index, colchicines-type overcondensed chromosomes, a few polyploid cells; lethal phase pharate adult, high mitotic index, rod like overcondensed chromosomes, few anaphases with lagging chromosomes; lethal phase larval stage 3-pharate adult, small brain and optic lobes, high mitotic index, rod-like overcondensed chromosomes, fewer ana- and telophases, overcondensed chromosomes in ana- and telophase; lethal phase larval stage 3, small brain, few cells in mitosis, badly defined chromosomes, weak chromosome condensation, abnormal anaphases with broken chromosomes; lethal phase larval stage 3, small brain, high mitotic index, rod-like overcondensed chromosomes, fewer ana- and telophases; semilethal male and female, Low mitotic index, badly defined chromosomes, weak/uneven staining, fewer ana- and telophases; lethal phase pupal to pharate adult, lagging chromosomes and bridges in ana- and telophase; lethal phase, pupal, uneven chromosome condensation, lagging chromosomes in anaphase; lethal phase pupal, higher mitotic index, colchicine-like overcondensed chromosomes, many ana- and telophases, lagging chromosomes; lethal phase, prepupal-pupal, high mitotic index, colchicines-like chromosome condensation, metaphase arrest.

The polypeptides and polynucleotides described here may also be categorised according to their function, or their putative function.

For example, the polypeptides described here preferably comprise, and the polynucleotides described here are ones which preferably encode polypeptides comprising, any one or more of the following: CREB-binding proteins, transcription factors, casein kinases, serine threonine kinases, preferably involved in replication and cell cycle, protein phosphatases, membrane associated proteins, preferably involved in priming synaptic vesicles, dynein light chains, microtubule motor proteins, protein phosphatases, protein phosphatases with p53 dependent expression, proteins capable of inhibiting cell division, ribosomal proteins, motor proteins, cytoskeletal binding proteins linking to plama membrane, proteins involved in cytokinesis and cell shape, phosphatidylinositol 3-kinases, C-myc oncogenes, transcription factors, dehydrogenases, thioredoxin reductases, cell cycle regulators preferably involved in cyclin degradation; centrosome components, protein tyrosine phosphatases, Wnt oncogenes, ubiquitin ligases, ubiquitin conjugating enzymes, vesicle trafficking proteins, protein kinases (including protein kinases which regulate the G1/S phase transition and/or DNA replication in mammalian cells), serine/threonine kinases, including serine/threonine kinases involved in winglwess signaling pathway, components of cell junctions, including components of cell junctions having a role in proliferation and Ras associated effector proteins; hydroxymethyltransferase; glycosylation/membrane protein; hydrogen transporting ATP synthase; role in cell cycle progression.

The practice of the present invention will employ, unless otherwise indicated, conventional techniques of chemistry, molecular biology, microbiology, recombinant DNA and immunology, which are within the capabilities of a person of ordinary skill in the art. Such techniques are explained in the literature. See, for example, J. Sambrook, E. F. Fritsch, and T. Maniatis, 1989, Molecular Cloning: A Laboratory Manual, Second Edition, Books 1-3, Cold Spring Harbor Laboratory Press; Ausubel, F. M. et al. (1995 and periodic supplements; Current Protocols in Molecular Biology, ch. 9, 13, and 16, John Wiley & Sons, New York, N.Y.); B. Roe, J. Crabtree, and A. Kahn, 1996, DNA Isolation and Sequencing: Essential Techniques, John Wiley & Sons; J. M. Polak and James O'D. McGee, 1990, In Situ Hybridization: Principles and Practice; Oxford University Press; M. J. Gait (Editor), 1984, Oligonucleotide Synthesis: A Practical Approach, Irl Press; D. M. J. Lilley and J. E. Dahlberg, 1992, Methods of Enzymology: DNA Structure Part A: Synthesis and Physical Analysis of DNA Methods in Enzymology, Academic Press; Using Antibodies: A Laboratory Manual: Portable Protocol NO. I by Edward Harlow, David Lane, Ed Harlow (1999, Cold Spring Harbor Laboratory Press, ISBN 0-87969-544-7); Antibodies: A Laboratory Manual by Ed Harlow (Editor), David Lane (Editor) (1988, Cold Spring Harbor Laboratory Press, ISBN 0-87969-314-2), 1855. Handbook of Drug Screening, edited by Ramakrishna Seethala, Prabhavathi B. Fernandes (2001, New York, N.Y., Marcel Dekker, ISBN 0-8247-0562-9); and Lab Ref: A Handbook of Recipes, Reagents, and Other Reference Tools for Use at the Bench, Edited Jane Roskams and Linda Rodgers, 2002, Cold Spring Harbor Laboratory, ISBN 0-87969-630-3. Each of these general texts is herein incorporated by reference.

Polypeptides

It will be understood that polypeptides as described here are not limited to polypeptides having the amino acid sequence set out in Examples 1 to 29 or fragments thereof but also include homologous sequences obtained from any source, for example related viral/bacterial proteins, cellular homologues and synthetic peptides, as well as variants or derivatives thereof.

Thus polypeptides also include those encoding homologues from other species including animals such as mammals (e.g. mice, rats or rabbits), especially primates, more especially humans. More specifically, such homologues include human homologues.

Thus, we describe variants, homologues or derivatives of the amino acid sequence set out in Examples 1 to 29, as well as variants, homologues or derivatives of the nucleotide sequence coding for the amino acid sequences as described here.

In the context of this document, a homologous sequence is taken to include an amino acid sequence which is at least 15, 20, 25, 30, 40, 50, 60, 70, 80 or 90% identical, preferably at least 95 or 98% identical at the amino acid level over at least 50 or 100, preferably 200, 300, 400 or 500 amino acids with any one of the polypeptide sequences shown in the Examples. In particular, homology should typically be considered with respect to those regions of the sequence known to be essential for protein function rather than non-essential neighbouring sequences. This is especially important when considering homologous sequences from distantly related organisms.

Although homology can also be considered in terms of similarity (i.e. amino acid residues having similar chemical properties/functions), in the context of this document, it is preferred to express homology in terms of sequence identity.

Homology comparisons can be conducted by eye, or more usually, with the aid of readily available sequence comparison programs. These publicly and commercially available computer programs can calculate % homology between two or more sequences.

% homology may be calculated over contiguous sequences, i.e. one sequence is aligned with the other sequence and each amino acid in one sequence directly compared with the corresponding amino acid in the other sequence, one residue at a time. This is called an “ungapped” alignment. Typically, such ungapped alignments are performed only over a relatively short number of residues (for example less than 50 contiguous amino acids).

Although this is a very simple and consistent method, it fails to take into consideration that, for example, in an otherwise identical pair of sequences, one insertion or deletion will cause the following amino acid residues to be put out of alignment, thus potentially resulting in a large reduction in % homology when a global alignment is performed. Consequently, most sequence comparison methods are designed to produce optimal alignments that take into consideration possible insertions and deletions without penalising unduly the overall homology score. This is achieved by inserting “gaps” in the sequence alignment to try to maximise local homology.

However, these more complex methods assign “gap penalties” to each gap that occurs in the alignment so that, for the same number of identical amino acids, a sequence alignment with as few gaps as possible—reflecting higher relatedness between the two compared sequences—will achieve a higher score than one with many gaps. “Affine gap costs” are typically used that charge a relatively high cost for the existence of a gap and a smaller penalty for each subsequent residue in the gap. This is the most commonly used gap scoring system. High gap penalties will of course produce optimised alignments with fewer gaps. Most alignment programs allow the gap penalties to be modified. However, it is preferred to use the default values when using such software for sequence comparisons. For example when using the GCG Wisconsin Bestfit package (see below) the default gap penalty for amino acid sequences is −12 for a gap and −4 for each extension.

Calculation of maximum % homology therefore firstly requires the production of an optimal alignment, taking into consideration gap penalties. A suitable computer program for carrying out such an alignment is the GCG Wisconsin Bestfit package (University of Wisconsin, U.S.A; Devereux et al., 1984, Nucleic Acids Research 12:387). Examples of other software than can perform sequence comparisons include, but are not limited to, the BLAST package (see Ausubel et al., 1999 ibid—Chapter 18), FASTA (Atschul et al., 1990, J. Mol. Biol., 403-410) and the GENEWORKS suite of comparison tools. Both BLAST and FASTA are available for offline and online searching (see Ausubel et al., 1999 ibid, pages 7-58 to 7-60). However it is preferred to use the GCG Bestfit program.

Although the final % homology can be measured in terms of identity, the alignment process itself is typically not based on an all-or-nothing pair comparison. Instead, a scaled similarity score matrix is generally used that assigns scores to each pairwise comparison based on chemical similarity or evolutionary distance. An example of such a matrix commonly used is the BLOSUM62 matrix—the default matrix for the BLAST suite of programs. GCG Wisconsin programs generally use either the public default values or a custom symbol comparison table if supplied (see user manual for further details). It is preferred to use the public default values for the GCG package, or in the case of other software, the default matrix, such as BLOSUM62.

Once the software has produced an optimal alignment, it is possible to calculate % homology, preferably % sequence identity. The software typically does this as part of the sequence comparison and generates a numerical result.

The terms “variant” or “derivative” in relation to the amino acid sequences includes any substitution of, variation of, modification of, replacement of, deletion of or addition of one (or more) amino acids from or to the sequence providing the resultant amino acid sequence retains substantially the same activity as the unmodified sequence, preferably having at least the same activity as the polypeptides presented in the sequence listings in the Examples.

Polypeptides having the amino acid sequence shown in the Examples, or fragments or homologues thereof may be modified for use in the methods and compositions described here. Typically, modifications are made that maintain the biological activity of the sequence. Amino acid substitutions may be made, for example from 1, 2 or 3 to 10, 20 or 30 substitutions provided that the modified sequence retains the biological activity of the unmodified sequence. Alternatively, modifications may be made to deliberately inactivate one or more functional domains of the polypeptides described here. Amino acid substitutions may include the use of non-naturally occurring analogues, for example to increase blood plasma half-life of a therapeutically administered polypeptide.

Conservative substitutions may be made, for example according to the Table below. Amino acids in the same block in the second column and preferably in the same line in the third column may be substituted for each other:

	ALIPHATIC	Non-polar	G A P
			I L V
		Polar - uncharged	C S T M
			N Q
		Polar - charged	D E
			K R
	AROMATIC		H F W Y

Polypeptides also include fragments of the full length sequences mentioned above. Preferably said fragments comprise at least one epitope. Methods of identifying epitopes are well known in the art. Fragments will typically comprise at least 6 amino acids, more preferably at least 10, 20, 30, 50 or 100 amino acids.

Proteins as described here are typically made by recombinant means, for example as described below. However they may also be made by synthetic means using techniques well known to skilled persons such as solid phase synthesis. Proteins may also be produced as fusion proteins, for example to aid in extraction and purification. Examples of fusion protein partners include glutathione-S-transferase (GST), 6xHis, GAL4 (DNA binding and/or transcriptional activation domains) and β-galactosidase. It may also be convenient to include a proteolytic cleavage site between the fusion protein partner and the protein sequence of interest to allow removal of fusion protein sequences. Preferably the fusion protein will not hinder the function of the protein of interest sequence. Proteins as described here may also be obtained by purification of cell extracts from animal cells.

The proteins may be in a substantially isolated form. It will be understood that the protein may be mixed with carriers or diluents which will not interfere with the intended purpose of the protein and still be regarded as substantially isolated. A protein may also be in a substantially purified form, in which case it will generally comprise the protein in a preparation in which more than 90%, e.g. 95%, 98% or 99% of the protein in the preparation is a protein as described in this document.

A polypeptide may be labeled with a revealing label. The revealing label may be any suitable label which allows the polypeptide to be detected. Suitable labels include radioisotopes, e.g. ¹²⁵I, enzymes, antibodies, polynucleotides and linkers such as biotin. Labeled polypeptides as described here may be used in diagnostic procedures such as immunoassays to determine the amount of a polypeptide in a sample. Polypeptides or labeled polypeptides may also be used in serological or cell-mediated immune assays for the detection of immune reactivity to said polypeptides in animals and humans using standard protocols.

A polypeptide or labeled polypeptide or fragment thereof may also be fixed to a solid phase, for example the surface of an immunoassay well or dipstick. Such labeled and/or immobilised polypeptides may be packaged into kits in a suitable container along with suitable reagents, controls, instructions and the like. Such polypeptides and kits may be used in methods of detection of antibodies to the polypeptides or their allelic or species variants by immunoassay.

Immunoassay methods are well known in the art and will generally comprise: (a) providing a polypeptide comprising an epitope bindable by an antibody against said protein; (b) incubating a biological sample with said polypeptide under conditions which allow for the formation of an antibody-antigen complex; and (c) determining whether antibody-antigen complex comprising said polypeptide is formed.

The polypeptides described here may be used in in vitro or in vivo cell culture systems to study the role of their corresponding genes and homologues thereof in cell function, including their function in disease. For example, truncated or modified polypeptides may be introduced into a cell to disrupt the normal functions which occur in the cell. The polypeptides may be introduced into the cell by in situ expression of the polypeptide from a recombinant expression vector (see below). The expression vector optionally carries an inducible promoter to control the expression of the polypeptide.

The use of appropriate host cells, such as insect cells or mammalian cells, is expected to provide for such post-translational modifications (e.g. myristolation, glycosylation, truncation, lapidation and tyrosine, serine or threonine phosphorylation) as may be needed to confer optimal biological activity on recombinant expression products. Such cell culture systems in which such polypeptides are expressed may be used in assay systems to identify candidate substances which interfere with or enhance the functions of the polypeptides described here in the cell.

Polynucleotides

We demonstrate here that mutations in genes encoding the polypeptides disclosed in the Examples demonstrate a cell cycle defect, and that accordingly these genes and the proteins encoded by them are responsible for cell cycle function.

Polynucleotides as described in this document include polynucleotides that comprise any one or more of the nucleic acid sequences encoding the polypeptides set out in Examples 1 to 29 and fragments thereof. Such polynucleotides also include polynucleotides encoding the polypeptides described here. It is straightforward to identify a nucleic acid sequence which encodes such a polypeptide, by reference to the genetic code. Furthermore, computer programs are available which translate a nucleic acid sequence to a polypeptide sequence, and/or vice versa. Each and all of sequences which are capable of encoding the polypeptides disclosed in the Examples is considered disclosed in this document, and the disclosure of a polypeptide sequence includes a disclosure of all nucleic acids (and their sequences) which encodes that polypeptide sequence.

It will be understood by a skilled person that numerous different polynucleotides can encode the same polypeptide as a result of the degeneracy of the genetic code. In addition, it is to be understood that skilled persons may, using routine techniques, make nucleotide substitutions that do not affect the polypeptide sequence encoded by the polynucleotides described here to reflect the codon usage of any particular host organism in which the polypeptides are to be expressed.

In preferred embodiments, the polynucleotides comprise those polypeptides, such as cDNA, mRNA, and genomic DNA of the relevant organism, which encode the polypeptides disclosed in the Examples. Such polynucleotides may typically comprise Drosophila cDNA, mRNA, and genomic DNA, Homo sapiens cDNA, mRNA, and genomic DNA, etc. Accession numbers are provided in the Examples for the polypeptide sequences, and it is straightforward to derive the encoding nucleic acid sequences by use of such accession numbers in a relevant database, such as a Drosophila sequence database, a human sequence database, including a Human Genome Sequence database, GadFly, FlyBase, etc. in particular, the annotated Drosophila sequence database of the Berkeley Drosophila Genome Project (GadFly: Genome Annotation Database of Drosophil at http://www.fruitfly.org/annot/) may be used to identify such Drosophila and human polynucleotide sequences. Relevant sequences may also be obtained by searching sequence databases such as BLAST with the polypeptide sequences. In particular, a search using TBLASTN may be employed.

Furthermore, we provide a method of identifying a human nucleic acid sequence, by: (a) selecting a Drosophila polypeptide identified in any of Examples 1 to 29; (b) identifying a corresponding human polypeptide; (c) identifying a nucleic acid encoding the polypeptide of (b). Step (b) may in particular involve identifying a human homologue of the Drosophila sequence, or a human sequence similar to the Drosophila sequence. Preferably, such a polypeptide has at least one of the biological activities, preferably substantially all the biological activities (such as identified in the Examples) of the Drosophila polypeptide. Preferably, the human polypeptide is involved in an aspect of cell cycle control. A human polypeptide identified as above, as well as a sequence of the human polypeptide and a sequence of the human nucleic acid are also provided.

Polynucleotides as described here may comprise DNA or RNA. They may be single-stranded or double-stranded. They may also be polynucleotides which include within them synthetic or modified nucleotides. A number of different types of modification to oligonucleotides are known in the art. These include methylphosphonate and phosphorothioate backbones, addition of acridine or polylysine chains at the 3′ and/or 5′ ends of the molecule. For the purposes of this document, it is to be understood that the polynucleotides described herein may be modified by any method available in the art. Such modifications may be carried out in order to enhance the in vivo activity or life span of polynucleotides.

The terms “variant”, “homologue” or “derivative” in relation to a nucleotide sequence include any substitution of, variation of, modification of, replacement of, deletion of or addition of one (or more) nucleic acid from or to the sequence. Preferably said variant, homologues or derivatives code for a polypeptide having biological activity.

As indicated above, with respect to sequence homology, preferably there is at least 50 or 75%, more preferably at least 85%, more preferably at least 90% homology to the sequences shown in the sequence listing herein. More preferably there is at least 95%, more preferably at least 98%, homology. Nucleotide homology comparisons may be conducted as described above. A preferred sequence comparison program is the GCG Wisconsin Bestfit program described above. The default scoring matrix has a match value of 10 for each identical nucleotide and −9 for each mismatch. The default gap creation penalty is −50 and the default gap extension penalty is −3 for each nucleotide.

This document also encompasses nucleotide sequences that are capable of hybridising selectively to the sequences presented herein, or any variant, fragment or derivative thereof, or to the complement of any of the above. Nucleotide sequences are preferably at least 15 nucleotides in length, more preferably at least 20, 30, 40 or 50 nucleotides in length.

The term “hybridization” as used herein shall include “the process by which a strand of nucleic acid joins with a complementary strand through base pairing” as well as the process of amplification as carried out in polymerase chain reaction technologies.

Polynucleotides which capable of selectively hybridising to the nucleotide sequences presented herein, or to their complement, will be generally at least 70%, preferably at least 80 or 90% and more preferably at least 95% or 98% homologous to the corresponding nucleotide sequences presented herein over a region of at least 20, preferably at least 25 or 30, for instance at least 40, 60 or 100 or more contiguous nucleotides.

The term “selectively hybridizable” means that the polynucleotide used as a probe is used under conditions where a target polynucleotide is found to hybridize to the probe at a level significantly above background. The background hybridization may occur because of other polynucleotides present, for example, in the cDNA or genomic DNA library being screening. In this event, background implies a level of signal generated by interaction between the probe and a non-specific DNA member of the library which is less than 10 fold, preferably less than 100 fold as intense as the specific interaction observed with the target DNA. The intensity of interaction may be measured, for example, by radiolabelling the probe, e.g. with ³²P.

Hybridization conditions are based on the melting temperature (Tm) of the nucleic acid binding complex, as taught in Berger and Kimmel (1987, Guide to Molecular Cloning Techniques, Methods in Enzymology, Vol 152, Academic Press, San Diego Calif.), and confer a defined “stringency” as explained below.

Maximum stringency typically occurs at about Tm−5° C. (5° C. below the Tm of the probe); high stringency at about 5° C. to 10° C. below Tm; intermediate stringency at about 10° C. to 20° C. below Tm; and low stringency at about 20° C. to 25° C. below Tm. As will be understood by those of skill in the art, a maximum stringency hybridization can be used to identify or detect identical polynucleotide sequences while an intermediate (or low) stringency hybridization can be used to identify or detect similar or related polynucleotide sequences.

In a preferred aspect, we describe nucleotide sequences that can hybridise to the nucleotide sequence as described here under stringent conditions (e.g. 65° C. and 0.1×SSC {1×SSC=0.15 M NaCl, 0.015 M Na₃ Citrate pH 7.0).

Where the polynucleotide is double-stranded, both strands of the duplex, either individually or in combination, are encompassed by the methods and compositions described here. Where the polynucleotide is single-stranded, it is to be understood that the complementary sequence of that polynucleotide is also included.

Polynucleotides which are not 100% homologous to the sequences of described here but are encompassed can be obtained in a number of ways. Other variants of the sequences described herein may be obtained for example by probing DNA libraries made from a range of individuals, for example individuals from different populations. In addition, other viral/bacterial, or cellular homologues particularly cellular homologues found in mammalian cells (e.g. rat, mouse, bovine and primate cells), may be obtained and such homologues and fragments thereof in general will be capable of selectively hybridising to sequences which encode the polypeptides shown in the Examples. Such sequences may be obtained by probing cDNA libraries made from or genomic DNA libraries from other animal species, and probing such libraries with probes comprising all or part of any on of the sequences under conditions of medium to high stringency. The nucleotide sequences of or which encode the human homologues described in the Examples, may preferably be used to identify other primate/mammalian homologues since nucleotide homology between human sequences and mammalian sequences is likely to be higher than is the case for the Drosophila sequences identified herein.

Similar considerations apply to obtaining species homologues and allelic variants of the polypeptide or nucleotide sequences described here.

Variants and strain/species homologues may also be obtained using degenerate PCR which will use primers designed to target sequences within the variants and homologues encoding conserved amino acid sequences within the sequences described here. Conserved sequences can be predicted, for example, by aligning the amino acid sequences from several variants/homologues. Sequence alignments can be performed using computer software known in the art. For example the GCG Wisconsin PileUp program is widely used.

The primers used in degenerate PCR will contain one or more degenerate positions and will be used at stringency conditions lower than those used for cloning sequences with single sequence primers against known sequences. It will be appreciated by the skilled person that overall nucleotide homology between sequences from distantly related organisms is likely to be very low and thus in these situations degenerate PCR may be the method of choice rather than screening libraries with labeled fragments.

In addition, homologous sequences may be identified by searching nucleotide and/or protein databases using search algorithms such as the BLAST suite of programs. This approach is described below and in the Examples.

Alternatively, such polynucleotides may be obtained by site directed mutagenesis of characterised sequences, such as the sequences encoding polypeptides disclosed in the Examples. This may be useful where for example silent codon changes are required to sequences to optimise codon preferences for a particular host cell in which the polynucleotide sequences are being expressed. Other sequence changes may be desired in order to introduce restriction enzyme recognition sites, or to alter the property or function of the polypeptides encoded by the polynucleotides. For example, further changes may be desirable to represent particular coding changes found in the sequences coding polypeptides disclosed in the Examples which give rise to mutant genes which have lost their regulatory function. Probes based on such changes can be used as diagnostic probes to detect such mutants.

The polynucleotides described here may be used to produce a primer, e.g. a PCR primer, a primer for an alternative amplification reaction, a probe e.g. labeled with a revealing label by conventional means using radioactive or non-radioactive labels, or the polynucleotides may be cloned into vectors. Such primers, probes and other fragments will be at least 8, 9, 10, or 15, preferably at least 20, for example at least 25, 30 or 40 nucleotides in length, and are also encompassed by the term “polynucleotides” as used herein.

Polynucleotides such as a DNA polynucleotides and probes as described here may be produced recombinantly, synthetically, or by any means available to those of skill in the art. They may also be cloned by standard techniques.

In general, primers will be produced by synthetic means, involving a step wise manufacture of the desired nucleic acid sequence one nucleotide at a time. Techniques for accomplishing this using automated techniques are readily available in the art.

Longer polynucleotides will generally be produced using recombinant means, for example using a PCR (polymerase chain reaction) cloning techniques. This will involve making a pair of primers (e.g. of about 15 to 30 nucleotides) flanking a region of the lipid targeting sequence which it is desired to clone, bringing the primers into contact with mRNA or cDNA obtained from an animal or human cell, performing a polymerase chain reaction under conditions which bring about amplification of the desired region, isolating the amplified fragment (e.g. by purifying the reaction mixture on an agarose gel) and recovering the amplified DNA. The primers may be designed to contain suitable restriction enzyme recognition sites so that the amplified DNA can be cloned into a suitable cloning vector

The polynucleotides or primers may carry a revealing label. Suitable labels include radioisotopes such as ³²P or ³⁵S, enzyme labels, or other protein labels such as biotin. Such labels may be added to the polynucleotides or primers and may be detected using by techniques known per se.

Polynucleotides or primers or fragments thereof labeled or unlabeled may be used by a person skilled in the art in nucleic acid-based tests for detecting or sequencing polynucleotides in the human or animal body.

Such tests for detecting generally comprise bringing a biological sample containing DNA or RNA into contact with a probe comprising a polynucleotide or primer as described here under hybridising conditions and detecting any duplex formed between the probe and nucleic acid in the sample. Such detection may be achieved using techniques such as PCR or by immobilising the probe on a solid support, removing nucleic acid in the sample which is not hybridised to the probe, and then detecting nucleic acid which has hybridised to the probe. Alternatively, the sample nucleic acid may be immobilised on a solid support, and the amount of probe bound to such a support can be detected. Suitable assay methods of this and other formats can be found in for example WO89/03891 and WO90/13667.

Tests for sequencing nucleotides include bringing a biological sample containing target DNA or RNA into contact with a probe comprising a polynucleotide or primer under hybridising conditions and determining the sequence by, for example the Sanger dideoxy chain termination method (see Sambrook et al.).

Such a method generally comprises elongating, in the presence of suitable reagents, the primer by synthesis of a strand complementary to the target DNA or RNA and selectively terminating the elongation reaction at one or more of an A, C, G or T/U residue; allowing strand elongation and termination reaction to occur; separating out according to size the elongated products to determine the sequence of the nucleotides at which selective termination has occurred. Suitable reagents include a DNA polymerase enzyme, the deoxynucleotides dATP, dCTP, dGTP and dTTP, a buffer and ATP. Dideoxynucleotides are used for selective termination.

Tests for detecting or sequencing nucleotides in a biological sample may be used to determine particular sequences within cells in individuals who have, or are suspected to have, an altered gene sequence, for example within cancer cells including leukaemia cells and solid tumours such as breast, ovary, lung, colon, pancreas, testes, liver, brain, muscle and bone tumours. Cells from patients suffering from a proliferative disease may also be tested in the same way.

In addition, the identification of the genes described in the Examples will allow the role of these genes in hereditary diseases to be investigated. In general, this will involve establishing the status of the gene (e.g. using PCR sequence analysis), in cells derived from animals or humans with, for example, neurological disorders or neoplasms.

The probes as described here may conveniently be packaged in the form of a test kit in a suitable container. In such kits the probe may be bound to a solid support where the assay format for which the kit is designed requires such binding. The kit may also contain suitable reagents for treating the sample to be probed, hybridising the probe to nucleic acid in the sample, control reagents, instructions, and the like.

Homology Searching

Sequence homology (or identity) may be determined using any suitable homology algorithm, using for example default parameters.

Advantageously, the BLAST algorithm is employed, with parameters set to default values. The BLAST algorithm is described in detail at http://www.ncbi.nih.gov/BLAST/blast_help.html, which is incorporated herein by reference. The search parameters are defined as follows, and are advantageously set to the defined default parameters.

Advantageously, “substantial homology” when assessed by BLAST equates to sequences which match with an EXPECT value of at least about 7, preferably at least about 9 and most preferably 10 or more. The default threshold for EXPECT in BLAST searching is usually 10.

BLAST (Basic Local Alignment Search Tool) is the heuristic search algorithm employed by the programs blastp, blastn, blastx, tblastn, and tblastx; these programs ascribe significance to their findings using the statistical methods of Karlin and Altschul (see http://www.ncbi.nih.gov/BLAST/blast_help.html) with a few enhancements. The BLAST programs were tailored for sequence similarity searching, for example to identify homologues to a query sequence. The programs are not generally useful for motif-style searching. For a discussion of basic issues in similarity searching of sequence databases, see Altschul et al. (1994).

The five BLAST programs available at http://www.ncbi.nlm.nih.gov perform the following tasks:

blastp compares an amino acid query sequence against a protein sequence database;

blastn compares a nucleotide query sequence against a nucleotide sequence database;

blastx compares the six-frame conceptual translation products of a nucleotide query sequence (both strands) against a protein sequence database;

tblastn compares a protein query sequence against a nucleotide sequence database dynamically translated in all six reading frames (both strands). tblastx compares the six-frame translations of a nucleotide query sequence against the six-frame translations of a nucleotide sequence database.

BLAST uses the following search parameters:

HISTOGRAM Display a histogram of scores for each search; default is yes. (See parameter H in the BLAST Manual).

DESCRIPTIONS Restricts the number of short descriptions of matching sequences reported to the number specified; default limit is 100 descriptions. (See parameter V in the manual page). See also EXPECT and CUTOFF.

ALIGNMENTS Restricts database sequences to the number specified for which high-scoring segment pairs (HSPs) are reported; the default limit is 50. If more database sequences than this happen to satisfy the statistical significance threshold for reporting (see EXPECT and CUTOFF below), only the matches ascribed the greatest statistical significance are reported. (See parameter B in the BLAST Manual).

EXPECT The statistical significance threshold for reporting matches against database sequences; the default value is 10, such that 10 matches are expected to be found merely by chance, according to the stochastic model of Karlin and Altschul (1990). If the statistical significance ascribed to a match is greater than the EXPECT threshold, the match will not be reported. Lower EXPECT thresholds are more stringent, leading to fewer chance matches being reported. Fractional values are acceptable. (See parameter E in the BLAST Manual).

CUTOFF Cutoff score for reporting high-scoring segment pairs. The default value is calculated from the EXPECT value (see above). HSPs are reported for a database sequence only if the statistical significance ascribed to them is at least as high as would be ascribed to a lone HSP having a score equal to the CUTOFF value. Higher CUTOFF values are more stringent, leading to fewer chance matches being reported. (See parameter S in the BLAST Manual). Typically, significance thresholds can be more intuitively managed using EXPECT.

MATRIX Specify an alternate scoring matrix for BLASTP, BLASTX, TBLASTN and TBLASTX. The default matrix is BLOSUM62 (Henikoff & Henikoff, 1992). The valid alternative choices include: PAM40, PAM120, PAM250 and IDENTITY. No alternate scoring matrices are available for BLASTN; specifying the MATRIX directive in BLASTN requests returns an error response.

STRAND Restrict a TBLASTN search to just the top or bottom strand of the database sequences; or restrict a BLASTN, BLASTX or TBLASTX search to just reading frames on the top or bottom strand of the query sequence.

FILTER Mask off segments of the query sequence that have low compositional complexity, as determined by the SEG program of Wootton & Federhen (1993) Computers and Chemistry 17:149-163, or segments consisting of short-periodicity internal repeats, as determined by the XNU program of Claverie & States (1993) Computers and Chemistry 17:191-201, or, for BLASTN, by the DUST program of Tatusov and Lipman (see http://www.ncbi.nlm.nih.gov). Filtering can eliminate statistically significant but biologically uninteresting reports from the blast output (e.g., hits against common acidic-, basic- or proline-rich regions), leaving the more biologically interesting regions of the query sequence available for specific matching against database sequences.

Low complexity sequence found by a filter program is substituted using the letter “N” in nucleotide sequence (e.g., “NNNNNNNNNNNNN”) and the letter “X” in protein sequences (e.g., “XXXXXXXXX”).

Filtering is only applied to the query sequence (or its translation products), not to database sequences. Default filtering is DUST for BLASTN, SEG for other programs.

It is not unusual for nothing at all to be masked by SEG, XNU, or both, when applied to sequences in SWISS-PROT, so filtering should not be expected to always yield an effect. Furthermore, in some cases, sequences are masked in their entirety, indicating that the statistical significance of any matches reported against the unfiltered query sequence should be suspect.

NCBI-gi Causes NCBI gi identifiers to be shown in the output, in addition to the accession and/or locus name.

Most preferably, sequence comparisons are conducted using the simple BLAST search algorithm provided at http://www.ncbi.nlm.nih.gov/BLAST.

Nucleic Acid Vectors

Polynucleotides as described in this document can be incorporated into a recombinant replicable vector. The vector may be used to replicate the nucleic acid in a compatible host cell. Thus in a further embodiment, we provide a method of making polynucleotides by introducing a polynucleotide as described here into a replicable vector, introducing the vector into a compatible host cell, and growing the host cell under conditions which bring about replication of the vector. The vector may be recovered from the host cell. Suitable host cells include bacteria such as E. Coli, yeast, mammalian cell lines and other eukaryotic cell lines, for example insect Sf9 cells.

Preferably, a polynucleotide in a vector is operably linked to a control sequence that is capable of providing for the expression of the coding sequence by the host cell, i.e. the vector is an expression vector. The term “operably linked” means that the components described are in a relationship permitting them to function in their intended manner. A regulatory sequence “operably linked” to a coding sequence is ligated in such a way that expression of the coding sequence is achieved under condition compatible with the control sequences.

The control sequences may be modified, for example by the addition of further transcriptional regulatory elements to make the level of transcription directed by the control sequences more responsive to transcriptional modulators.

Vectors as described here may be transformed or transfected into a suitable host cell as described below to provide for expression of a protein. This process may comprise culturing a host cell transformed with an expression vector as described above under conditions to provide for expression by the vector of a coding sequence encoding the protein, and optionally recovering the expressed protein. Vectors will be chosen that are compatible with the host cell used.

The vectors may be for example, plasmid or virus vectors provided with an origin of replication, optionally a promoter for the expression of the said polynucleotide and optionally a regulator of the promoter. The vectors may contain one or more selectable marker genes, for example an ampicillin resistance gene in the case of a bacterial plasmid or a neomycin resistance gene for a mammalian vector. Vectors may be used, for example, to transfect or transform a host cell.

Control sequences operably linked to sequences encoding a polypeptide described here include promoters/enhancers and other expression regulation signals. These control sequences may be selected to be compatible with the host cell for which the expression vector is designed to be used in. The term promoter is well-known in the art and encompasses nucleic acid regions ranging in size and complexity from minimal promoters to promoters including upstream elements and enhancers.

The promoter is typically selected from promoters which are functional in mammalian cells, although prokaryotic promoters and promoters functional in other eukaryotic cells, such as insect cells, may be used. The promoter is typically derived from promoter sequences of viral or eukaryotic genes. For example, it may be a promoter derived from the genome of a cell in which expression is to occur. With respect to eukaryotic promoters, they may be promoters that function in a ubiquitous manner (such as promoters of α-actin, β-actin, tubulin) or, alternatively, a tissue-specific manner (such as promoters of the genes for pyruvate kinase). They may also be promoters that respond to specific stimuli, for example promoters that bind steroid hormone receptors. Viral promoters may also be used, for example the Moloney murine leukaemia virus long terminal repeat (MMLV LTR) promoter, the rous sarcoma virus (RSV) LTR promoter or the human cytomegalovirus (CMV) IE promoter.

It may also be advantageous for the promoters to be inducible so that the levels of expression of the heterologous gene can be regulated during the life-time of the cell. Inducible means that the levels of expression obtained using the promoter can be regulated.

In addition, any of these promoters may be modified by the addition of further regulatory sequences, for example enhancer sequences. Chimeric promoters may also be used comprising sequence elements from two or more different promoters described above.

The polynucleotides may also be inserted into the vectors described above in an antisense orientation to provide for the production of antisense RNA. Antisense RNA or other antisense polynucleotides may also be produced by synthetic means. Such antisense polynucleotides may be used in a method of controlling the levels of RNAs transcribed from genes comprising any one of the polynucleotides as described.

Host Cells

The vectors and polynucleotides may be introduced into host cells for the purpose of replicating the vectors/polynucleotides and/or expressing the polypeptides encoded by the polynucleotides described here. Although such polypeptides may be produced using prokaryotic cells as host cells, it is preferred to use eukaryotic cells, for example yeast, insect or mammalian cells, in particular mammalian cells.

Vectors/polynucleotides as described here may be introduced into suitable host cells using a variety of techniques known in the art, such as transfection, transformation and electroporation. Where vectors/polynucleotides are to be administered to animals, several techniques are known in the art, for example infection with recombinant viral vectors such as retroviruses, herpes simplex viruses and adenoviruses, direct injection of nucleic acids and biolistic transformation.

Protein Expression and Purification

Host cells comprising polynucleotides as described here may be used to express polypeptides. Host cells may be cultured under suitable conditions which allow expression of the proteins. Expression of the polypeptides as described may be constitutive such that they are continually produced, or inducible, requiring a stimulus to initiate expression. In the case of inducible expression, protein production can be initiated when required by, for example, addition of an inducer substance to the culture medium, for example dexamethasone or IPTG.

Polypeptides can be extracted from host cells by a variety of techniques known in the art, including enzymatic, chemical and/or osmotic lysis and physical disruption.

The polypeptides may also be produced recombinantly in an in vitro cell-free system, such as the TnT™ (Promega) rabbit reticulocyte system.

Antibodies

We also provide monoclonal or polyclonal antibodies to polypeptides as described here, or fragments thereof. Thus, we further provide a process for the production of monoclonal or polyclonal antibodies to polypeptides.

If polyclonal antibodies are desired, a selected mammal (e.g., mouse, rabbit, goat, horse, etc.) is immunised with an immunogenic polypeptide bearing an epitope(s) from a polypeptide as described here. Serum from the immunised animal is collected and treated according to known procedures. If serum containing polyclonal antibodies to an epitope from a polypeptide contains antibodies to other antigens, the polyclonal antibodies can be purified by immunoaffinity chromatography. Techniques for producing and processing polyclonal antisera are known in the art. In order that such antibodies may be made, we also provide polypeptides as described here, or fragments thereof, haptenised to another polypeptide for use as immunogens in animals or humans.

Monoclonal antibodies directed against epitopes in the polypeptides described here can also be readily produced by one skilled in the art. The general methodology for making monoclonal antibodies by hybridomas is well known. Immortal antibody-producing cell lines can be created by cell fusion, and also by other techniques such as direct transformation of B lymphocytes with oncogenic DNA, or transfection with Epstein-Barr virus. Panels of monoclonal antibodies produced against epitopes in the polypeptides can be screened for various properties; i.e., for isotype and epitope affinity.

An alternative technique involves screening phage display libraries where, for example the phage express scFv fragments on the surface of their coat with a large variety of complementarity determining regions (CDRs). This technique is well known in the art.

Antibodies, both monoclonal and polyclonal, which are directed against epitopes from polypeptides described here are particularly useful in diagnosis, and those which are neutralising are useful in passive immunotherapy. Monoclonal antibodies, in particular, may be used to raise anti-idiotype antibodies. Anti-idiotype antibodies are immunoglobulins which carry an “internal image” of the antigen of the agent against which protection is desired.

Techniques for raising anti-idiotype antibodies are known in the art. These anti-idiotype antibodies may also be useful in therapy.

For the purposes of this document, the term “antibody”, unless specified to the contrary, includes fragments of whole antibodies which retain their binding activity for a target antigen. Such fragments include Fv, F(ab′) and F(ab′)₂ fragments, as well as single chain antibodies (scFv). Furthermore, the antibodies and fragments thereof may be humanised antibodies, for example as described in EP-A-239400.

Antibodies may be used in method of detecting polypeptides as described in this document present in biological samples by a method which comprises: (a) providing an antibody as described here; (b) incubating a biological sample with said antibody under conditions which allow for the formation of an antibody-antigen complex; and (c) determining whether antibody-antigen complex comprising said antibody is formed.

Suitable samples include extracts tissues such as brain, breast, ovary, lung, colon, pancreas, testes, liver, muscle and bone tissues or from neoplastic growths derived from such tissues.

Such antibodies may be bound to a solid support and/or packaged into kits in a suitable container along with suitable reagents, controls, instructions and the like.

Assays

We also provide assays that are suitable for identifying substances which bind to polypeptides as described here and which affect, for example, formation of the nuclear envelope, exit from the quiescent phase of the cell cycle (G0), G1 progression, chromosome decondensation, nuclear envelope breakdown, START, initiation of DNA replication, progression of DNA replication, termination of DNA replication, centrosome duplication, G2 progression, activation of mitotic or meiotic functions, chromosome condensation, centrosome separation, microtubule nucleation, spindle formation and function, interactions with microtubule motor proteins, chromatid separation and segregation, inactivation of mitotic functions, formation of contractile ring, cytokinesis functions, chromatin binding, formation of replication complexes, replication licensing, phosphorylation or other secondary modification activity, proteolytic degradation, microtubule binding, actin binding, septin binding, microtubule organising centre nucleation activity and binding to components of cell cycle signalling pathways.

In addition, assays suitable for identifying substances that interfere with binding of polypeptides as described here, where appropriate, to components of cell division cycle machinery. This includes not only components such as microtubules but also signalling components and regulatory components as indicated above. Such assays are typically in vitro. Assays are also provided that test the effects of candidate substances identified in preliminary in vitro assays on intact cells in whole cell assays. The assays described below, or any suitable assay as known in the art, may be used to identify these substances.

In particular, we provide for the use of a polynucleotide as set out in Table 5, or a polypeptide encoded by the polypeptide, in a method of identifying a substance capable of binding to the polypeptide, which method comprises incubating the polypeptide with a candidate substance under suitable conditions and determining whether the substance binds to the polypeptide.

We further provide for use of a polynucleotide as set out in Table 5, or a polypeptide encoded by the polypeptide, in a method of identifying a substance capable of modulating the function of the polypeptide, the method comprising the steps of: incubating the polypeptide with a candidate substance and determining whether activity of the polypeptide is thereby modulated.

The substance identified may be isolated or synthesised, and used for prevention, treatment or diagnosis of a disease in an individual. The substance may be adminstered to an individual in need of such treatment. Alternatively or in addition, the substance identified by the assay is administered to an individual in need of such treatment. Preferably, the polynucleotide comprises a human polypeptide as set out in column 3 of Table 5.

Therefore, we provide one or more substances identified by any of the assays described below, viz, mitosis assays, meiotic assays, polypeptide binding assays, microtubule binding/polymerisation assays, microtubule purification and binding assays, microtubule organising centre (MTOC) nucleation activity assays, motor protein assay, assay for spindle assembly and function, assays for dna replication, chromosome condensation assays, kinase assays, kinase inhibitor assays, and whole cell assays, each as described in further detail below.

Candidate Substances

A substance that inhibits cell cycle progression as a result of an interaction with a polypeptide as described here may do so in several ways. For example, if the substance inhibits cell division, mitosis and/or meiosis, it may directly disrupt the binding of a polypeptide as described here to a component of the spindle apparatus by, for example, binding to the polypeptide and masking or altering the site of interaction with the other component. A substance which inhibits DNA replication may do so by inhibiting the phosphorylation or de-phosphorylation of proteins involved in replication. For example, it is known that the kinase inhibitor 6-DMAP (6-dimethylaminopurine) prevents the initiation of replication (Blow, J J, 1993, J Cell Biol 122, 993-1002). Candidate substances of this type may conveniently be preliminarily screened by in vitro binding assays as, for example, described below and then tested, for example in a whole cell assay as described below. Examples of candidate substances include antibodies which recognise a polypeptide as described in this document.

A substance which can bind directly to such a polypeptide may also inhibit its function in cell cycle progression by altering its subcellular localisation and hence its ability to interact with its normal substrate. The substance may alter the subcellular localisation of the polypeptide by directly binding to it, or by indirectly disrupting the interaction of the polypeptide with another component. For example, it is known that interaction between the p68 and p180 subunits of DNA polymerase alpha-primase enzyme is necessary in order for p180 to translocate into the nucleus (Mizuno et al (1998) Mol Cell Biol 18, 3552-62), and accordingly, a substance which disrupts the interaction between p68 and p180 will affect nuclear translocation and hence activity of the primase. A substance which affects mitosis may do so by preventing the polypeptide and components of the mitotic apparatus from coming into contact within the cell.

These substances may be tested using, for example the whole cells assays described below. Non-functional homologues of a polypeptide as described here may also be tested for inhibition of cell cycle progression since they may compete with the wild type protein for binding to components of the cell division cycle machinery whilst being incapable of the normal functions of the protein or block the function of the protein bound to the cell division cycle machinery. Such non-functional homologues may include naturally occurring mutants and modified sequences or fragments thereof.

Alternatively, instead of preventing the association of the components directly, the substance may suppress the biologically available amount of a polypeptide as described here. This may be by inhibiting expression of the component, for example at the level of transcription, transcript stability, translation or post-translational stability. An example of such a substance would be antisense RNA or double-stranded interfering RNA sequences which suppresses the amount of mRNA biosynthesis.

Suitable candidate substances include peptides, especially of from about 5 to 30 or 10 to 25 amino acids in size, based on the sequence of the polypeptides described in the Examples, or variants of such peptides in which one or more residues have been substituted. Peptides from panels of peptides comprising random sequences or sequences which have been varied consistently to provide a maximally diverse panel of peptides may be used.

Suitable candidate substances also include antibody products (for example, monoclonal and polyclonal antibodies, single chain antibodies, chimeric antibodies and CDR-grafted antibodies) which are specific for a polypeptide as described here. Furthermore, combinatorial libraries, peptide and peptide mimetics, defined chemical entities, oligonucleotides, and natural product libraries may be screened for activity as inhibitors of binding of a polypeptide as described here to the cell division cycle machinery, for example mitotic/meiotic apparatus (such as microtubules). The candidate substances may be used in an initial screen in batches of, for example 10 substances per reaction, and the substances of those batches which show inhibition tested individually. Candidate substances which show activity in in vitro screens such as those described below can then be tested in whole cell systems, such as mammalian cells which will be exposed to the inhibitor and tested for inhibition of any of the stages of the cell cycle.

Polypeptide Binding Assays

One type of assay for identifying substances that bind to a polypeptide as described here involves contacting a polypeptide as described here, which is immobilised on a solid support, with a non-immobilised candidate substance determining whether and/or to what extent the polypeptide as described here and candidate substance bind to each other. Alternatively, the candidate substance may be immobilised and the polypeptide non-immobilised.

In a preferred assay method, the polypeptide is immobilised on beads such as agarose beads. Typically this is achieved by expressing the component as a GST-fusion protein in bacteria, yeast or higher eukaryotic cell lines and purifying the GST-fusion protein from crude cell extracts using glutathione-agarose beads (Smith and Johnson, 1988). As a control, binding of the candidate substance, which is not a GST-fusion protein, to the immobilised polypeptide is determined in the absence of the polypeptide as described here. The binding of the candidate substance to the immobilised polypeptide is then determined. This type of assay is known in the art as a GST pulldown assay. Again, the candidate substance may be immobilised and the polypeptide non-immobilised.

It is also possible to perform this type of assay using different affinity purification systems for immobilising one of the components, for example Ni-NTA agarose and histidine-tagged components.

Binding of the polypeptide as described here to the candidate substance may be determined by a variety of methods well-known in the art. For example, the non-immobilised component may be labeled (with for example, a radioactive label, an epitope tag or an enzyme-antibody conjugate). Alternatively, binding may be determined by immunological detection techniques. For example, the reaction mixture can be Western blotted and the blot probed with an antibody that detects the non-immobilised component. ELISA techniques may also be used.

Candidate substances are typically added to a final concentration of from 1 to 1000 nmol/ml, more preferably from 1 to 100 nmol/ml. In the case of antibodies, the final concentration used is typically from 100 to 500 μg/ml, more preferably from 200 to 300 μg/ml.

Microtubule Binding/Polymerisation Assays

In the case of polypeptides as described here that bind to microtubules, another type of in vitro assay involves determining whether a candidate substance modulates binding of such a polypeptide to microtubules. Such an assay typically comprises contacting a polypeptide as described here with microtubules in the presence or absence of the candidate substance and determining if the candidate substance has an affect on the binding of the polypeptide as described here to the microtubules. This assay can also be used in the absence of candidate substances to confirm that a polypeptide as described here does indeed bind to microtubules. Microtubules may be prepared and assays conducted as follows:

Microtubule Purification and Binding Assays

Microtubules are purified from 0-3 h-old Drosophila embryos essentially as described previously (Saunders, et al., 1997). About 3 ml of embryos are homogenized with a Dounce homogenizer in 2 volumes of ice-cold lysis buffer (0.1 M Pipes/NaOH, pH 6.6, 5 mM EGTA, 1 mM MgSO4, 0.9 M glycerol, 1 mM DTT, 1 mM PMSF, 1 μg/ml aprotinin, 1 μg/ml leupeptin and 1 μg/ml pepstatin). The microtubules are depolymerized by incubation on ice for 15 min, and the extract is then centrifuged at 16,000 g for 30 min at 4° C. The supernatant is recentrifuged at 135,000 g for 90 min at 4° C. Microtubules in this later supernatant are polymerized by addition of GTP to 1 mM and taxol to 20 μM and incubation at room temperature for 30 min. A 3 ml aliquot of the extract is layered on top of 3 ml 15% sucrose cushion prepared in lysis buffer. After centrifuging at 54,000 g for 30 min at 20° C. using a swing out rotor, the microtubule pellet is resuspended in lysis buffer.

Microtubule overlay assays are performed as previously described (Saunders et al., 1997). 500 ng per lane of recombinant Asp, recombinant polypeptide, and bovine serum albumin (BSA, Sigma) are fractionated by 10% SDS-PAGE and blotted onto PVDF membranes (Millipore). The membranes are preincubated in TBST (50 mM Tris pH 7.5, 150 mM NaCl, 0.05% Tween 20) containing 5% low fat powdered milk (LFPM) for 1 h and then washed 3 times for 15 min in lysis buffer. The filters are then incubated for 30 minutes in lysis buffer containing either 1 mM GDP, 1 mM GTP, or 1 mM GTP-γ-S. MAP-free bovine brain tubulin (Molecular Probes) is polymerised at a concentration of 2 μg/ml in lysis buffer by addition of GTP to a final concentration of 1 mM and incubated at 37° C. for 30 min. The nucleotide solutions are removed and the buffer containing polymerised microtubules added to the membanes for incubation for 1 h at 37° C. with addition of taxol at a final concentration of 10 μM for the final 30 min. The blots are then washed 3 times with TBST and the bound tubulin detected using standard Western blot procedures using anti-p-tubulin antibodies (Boehringer Manheim) at 2.5 μg/ml and the Super Signal detection system (Pierce).

It may be desirable in one embodiment of this type of assay to deplete the polypeptide as described here from cell extracts used to produce polymerise microtubules. This may, for example, be achieved by the use of suitable antibodies.

A simple extension to this type of assay would be to test the effects of purified polypeptide as described here upon the ability of tubulin to polymerise in vitro (for example, as used by Andersen and Karsenti, 1997) in the presence or absence of a candidate substance (typically added at the concentrations described above). Xenopus cell-free extracts may conveniently be used, for example as a source of tubulin.

Microtubule Organising Centre (MTOC) Nucleation Activity Assays

Candidate substances, for example those identified using the binding assays described above, may be screening using a microtubule organising centre nucleation activity assay to determine if they are capable of disrupting MTOCs as measured by, for example, aster formation. This assay in its simplest form comprises adding the candidate substance to a cellular extract which in the absence of the candidate substance has microtubule organising centre nucleation activity resulting in formation of asters.

In a preferred embodiment, the assay system comprises (i) a polypeptide as described here and (ii) components required for microtubule organising centre nucleation activity except for functional polypeptide as described here, which is typically removed by immunodepletion (or by the use of extracts from mutant cells). The components themselves are typically in two parts such that microtubule nucleation does not occur until the two parts are mixed. The polypeptide as described here may be present in one of the two parts initially or added subsequently prior to mixing of the two parts.

Subsequently, the polypeptide as described here and candidate substance are added to the component mix and microtubule nucleation from centrosomes measured, for example by immunostaining for the polypeptide and visualising aster formation by immuno-fluorescence microscopy. The polypeptide may be preincubated with the candidate substance before addition to the component mix. Alternatively, both the polypeptide as described here and the candidate substance may be added directly to the component mix, simultaneously or sequentially in either order.

The components required for microtubule organising centre formation typically include salt-stripped centrosomes prepared as described in Moritz et al., 1998. Stripping centrosome preparations with 2 M KI removes the centrosome proteins CP60, CP190, CNN and γ-tubulin. Of these, neither CP60 nor CP190 appear to be required for microtubule nucleation. The other minimal components are typically provided as a depleted cellular extract, or conveniently, as a cellular extract from cells with a non-functional variant of a polypeptide as described here. Typically, labeled tubulin (usually β-tubulin) is also added to assist in visualising aster formation.

Alternatively, partially purified centrosomes that have not been salt-stripped may be used as part of the components. In this case, only tubulin, preferably labeled tubulin is required to complete the component mix.

Candidate substances are typically added to a final concentration of from 1 to 1000 nmol/ml, more preferably from 1 to 100 nmol/ml. In the case of antibodies, the final concentration used is typically from 100 to 500 μg/ml, more preferably from 200 to 300 μg/ml.

The degree of inhibition of aster formation by the candidate substance may be determined by measuring the number of normal asters per unit area for control untreated cell preparation and measuring the number of normal asters per unit area for cells treated with the candidate substance and comparing the result. Typically, a candidate substance is considered to be capable of disrupting MTOC integrity if the treated cell preparations have less than 50%, preferably less than 40, 30, 20 or 10% of the number of asters found in untreated cells preparations. It may also be desirable to stain cells for γ-tubulin to determine the maximum number of possible MTOCs present to allow normalisation between samples.

Motor Protein Assay

The polypeptides may interact with motor proteins such as the Eg5-like motor protein in vitro. The effects of candidate substances on such a process may be determined using assays wherein the motor protein is immobilised on coverslips. Rhodamine labeled microtubules are then added and their translocation can be followed by fluorescent microscopy. The effect of candidate substances may thus be determined by comparing the extent and/or rate of translocation in the presence and absence of the candidate substance. Generally, candidate substances known to bind to a polypeptide as described here, would be tested in this assay. Alternatively, a high throughput assay may be used to identify modulators of motor proteins and the resulting identified substances tested for affects on a polypeptide as described above.

Typically this assay uses microtubules stabilised by taxol (e.g. Howard and Hyman 1993; Chandra and Endow, 1993—both chapters in “Motility Assays for Motor Proteins” Ed Jon Scholey, pub Academic Press). If however, a polypeptide as described here were to promote stable polymerisation of microtubules (see above) then these microtubules could be used directly in motility assays.

Simple protein-protein binding assays as described above, using a motor protein and a polypeptide as described here may also be used to confirm that the polypeptide binds to the motor protein, typically prior to testing the effect of candidate substances on that interaction.

Assay for Spindle Assembly and Function

A further assay to investigate the function of polypeptide as described here and the effect of candidate substances on those functions is an assay which measures spindle assembly and function. Typically, such assays are performed using Xenopus cell free systems, where two types of spindle assembly are possible. In the “half spindle” assembly pathway, a cytoplasmic extract of CSF arrested oocytes is mixed with sperm chromatin. The half spindles that form subsequently fuse together. A more physiological method is to induce CSF arrested extracts to enter interphase by addition of calcium, whereupon the DNA replicates and kinetochores form. Addition of fresh CSF arrested extract then induces mitosis with centrosome duplication and spindle formation (for discussion of these systems see Tournebize and Heald, 1996).

Again, generally, candidate substances known to bind to a polypeptide as described here, or non-functional polypeptide variants, would be tested in this assay. Alternatively, a high throughput assay may be used to identify modulators of spindle formation and function and the resulting identified substances tested for affects binding of the polypeptide as described above.

Assays for DNA Replication

Another assay to investigate the function of polypeptide as described here and the effect of candidate substances on those functions is as assay for replication of DNA. A number of cell free systems have been developed to assay DNA replication. These can be used to assay the ability of a substance to prevent or inhibit DNA replication, by conducting the assay in the presence of the substance. Suitable cell-free assay systems include, for example the SV-40 assay (Li and Kelly, 1984, Proc. Natl. Acad. Sci USA 81, 6973-6977; Waga and Stillman, 1994, Nature 369, 207-212.). A Drosophila cell free replication system, for example as described by Crevel and Cotteril (1991), EMBO J 10, 4361-4369, may also be used. A preferred assay is a cell free assay derived from Xenopus egg low speed supernatant extracts described in Blow and Laskey (1986, Cell 47, 577-587) and Sheehan et al. (1988, J. Cell Biol. 106, 1-12), which measures the incorporation of nucleotides into a substrate consisting of Xenopus sperm DNA or HeLa nuclei. The nucleotides may be radiolabelled and incorporation assayed by scintillation counting. Alternatively and preferably, bromo-deoxy-uridine (BrdU) is used as a nucleotide substitute and replication activity measured by density substitution. The latter assay is able to distinguish genuine replication initiation events from incorporation as a result of DNA repair. The human cell-free replication assay reported by Krude, et al (1997), Cell 88, 109-19 may also be used to assay the effects of substances on the polypeptides.

Other In Vitro Assays

Other assays for identifying substances that bind to a polypeptide as described here are also provided. For example, substances which affect chromosome condensation may be assayed using the in vitro cell free system derived from Xenopus eggs, as known in the art.

Substances which affect kinase activity or proteolysis activity are of interest. It is known, for example, that temporal control of ubiquitin-proteasome mediated protein degradation is critical for normal G1 and S phase progression (reviewed in Krek 1998, Curr Opin Genet Dev 8, 36-42). A number of E3 ubiquitin protein ligases, designated SCFs (Skp1-cullin-F-box protein ligase complexes), confer substrate specificity on ubiquitination reactions, while protein kinases phosphorylate substrates destined for destruction and convert them into preferred targets for ubiquitin modification catalyzed by SCFs. Furthermore, ubiquitin-mediated proteolysis due to the anaphase-promoting complex/cyclosome (APC/C) is essential for separation of sister chromatids during mitosis, and exit from mitosis (Listovsky et al., 2000, Exp Cell Res 255, 184-191).

Substances which inhibit or affect kinase activity may be identified by means of a kinase assay as known in the art, for example, by measuring incorporation of ³²P into a suitable peptide or other substrate in the presence of the candidate substance. Similarly, substances which inhibit or affect proteolytic activity may be assayed by detecting increased or decreased cleavage of suitable polypeptide substrates.

Assays for these and other protein or polypeptide activities are known to those skilled in the art, and may suitably be used to identify substances which bind to a polypeptide and affect its activity.

Whole Cell Assays

Candidate substances may also be tested on whole cells for their effect on cell cycle progression, including mitosis and/or meiosis. Preferably the candidate substances have been identified by the above-described in vitro methods. Alternatively, rapid throughput screens for substances capable of inhibiting cell division, typically mitosis, may be used as a preliminary screen and then used in the in vitro assay described above to confirm that the affect is on a particular polypeptide.

The candidate substance, i.e. the test compound, may be administered to the cell in several ways. For example, it may be added directly to the cell culture medium or injected into the cell. Alternatively, in the case of polypeptide candidate substances, the cell may be transfected with a nucleic acid construct which directs expression of the polypeptide in the cell. Preferably, the expression of the polypeptide is under the control of a regulatable promoter.

Typically, an assay to determine the effect of a candidate substance identified by the method as described here on a particular stage of the cell division cycle comprises administering the candidate substance to a cell and determining whether the substance inhibits that stage of the cell division cycle. Techniques for measuring progress through the cell cycle in a cell population are well known in the art. The extent of progress through the cell cycle in treated cells is compared with the extent of progress through the cell cycle in an untreated control cell population to determine the degree of inhibition, if any. For example, an inhibitor of mitosis or meiosis may be assayed by measuring the proportion of cells in a population which are unable to undergo mitosis/meiosis and comparing this to the proportion of cells in an untreated population.

The concentration of candidate substances used will typically be such that the final concentration in the cells is similar to that described above for the in vitro assays.

A candidate substance is typically considered to be an inhibitor of a particular stage in the cell division cycle (for example, mitosis) if the proportion of cells undergoing that particular stage (i.e., mitosis) is reduced to below 50%, preferably below 40, 30, 20 or 10% of that observed in untreated control cell populations.

Therapeutic Uses

Many tumours are associated with defects in cell cycle progression, for example loss of normal cell cycle control. Tumour cells may therefore exhibit rapid and often aberrant mitosis. One therapeutic approach to treating cancer may therefore be to inhibit mitosis in rapidly dividing cells. Such an approach may also be used for therapy of any proliferative disease in general. Thus, since the polypeptides described here appear to be required for normal cell cycle progression, they represent targets for inhibition of their functions, particularly in tumour cells and other proliferative cells.

The term proliferative disorder is used herein in a broad sense to include any disorder that requires control of the cell cycle, for example, cardiovascular disorders such as restenosis and cardiomyopathy, auto-immune disorders such as glomerulonephritis and rheumatoid arthritis, dermatological disorders such as psoriasis, anti-inflammatory, anti-fungal, antiparasitic disorders such as malaria, emphysema and alopecia.

One possible approach is to express anti-sense constructs directed against polynucleotides described in this document, preferably selectively in tumour cells, to inhibit gene function and prevent the tumour cell from progressing through the cell cycle. Anti-sense constructs may also be used to inhibit gene function to prevent cell cycle progression in a proliferative cell. Such anti-sense constructs may comprise anti-sense molecules corresponding to any of the polynucleotides, in particular, those identified in Table 5.

Alternatively, or in addition, RNAi may be used to modulate expression of the polynucleotide in a cell. Double stranded RNA may be made as described in the Examples, e.g., by transcribing both strands of a polynucleotide sequence in a suitable vector (e.g., from T7 or other promoters on either side of the cloned sequence), denatured and annealed. The double stranded RNA (ds RNA) may then be introduced into a relevant cell to inhibit the transcription or expression of the relevant polynucleotide or polypeptide.

We therefore describe a method of modulating, preferably down-regulating, the expression of a polynucleotide as described here, preferably a polynucleotide as set out in Table 5 in a cell, the method comprising introducing a double stranded RNA (dsRNA) corresponding to the polynucleotide, or an antisense RNA corresponding to the polynucleotide, or a fragment thereof, into the cell.

Another approach is to use non-functional variants of the polypeptides that compete with the endogenous gene product for cellular components of cell cycle machinery, resulting in inhibition of function. Alternatively, compounds identified by the assays described above as binding to a polypeptide may be administered to tumour or proliferative cells to prevent the function of that polypeptide. This may be performed, for example, by means of gene therapy or by direct administration of the compounds. Suitable antibodies may also be used as therapeutic agents.

Alternatively, double-stranded (ds) RNA is a powerful way of interfering with gene expression in a range of organisms that has recently been shown to be successful in mammals (Wianny and Zernicka-Goetz, 2000, Nat Cell Biol 2000, 2, 70-75). Double stranded RNA corresponding to the sequence of a polynucleotide can be introduced into or expressed in oocytes and cells of a candidate organism to interfere with cell division cycle progression.

In addition, a number of the mutations described herein exhibit aberrant meiotic phenotypes. Aberrant meiosis is an important factor in infertility since mutations that affect only meiosis and not mitosis will lead to a viable organism but one that is unable to produce viable gametes and hence reproduce. Consequently, the elucidation of genes involved in meiosis is an important step in diagnosing and preventing/treating fertility problems. Thus the polypeptides identified in mutant Drosophila having meiotic defects (as is clearly indicated in the Examples) may be used in methods of identifying substances that affect meiosis. In addition, these polypeptides, and corresponding polynucleotides, may be used to study meiosis and identify possible mutations that are indicative of infertility. This will be of use in diagnosing infertility problems.

Administration

Substances identified or identifiable by the assay methods described here may preferably be combined with various components to produce compositions. Preferably the compositions are combined with a pharmaceutically acceptable carrier or diluent to produce a pharmaceutical composition (which may be for human or animal use). Suitable carriers and diluents include isotonic saline solutions, for example phosphate-buffered saline. The composition as described here may be administered by direct injection. The composition may be formulated for parenteral, intramuscular, intravenous, subcutaneous, intraocular or transdermal administration. Typically, each protein may be administered at a dose of from 0.01 to 30 mg/kg body weight, preferably from 0.1 to 10 mg/kg, more preferably from 0.1 to 1 mg/kg body weight.

Polynucleotides/vectors encoding polypeptide components (or antisense constructs) for use in inhibiting cell cycle progression, for example, inhibiting mitosis or meiosis, may be administered directly as a naked nucleic acid construct. They may further comprise flanking sequences homologous to the host cell genome. When the polynucleotides/vectors are administered as a naked nucleic acid, the amount of nucleic acid administered may typically be in the range of from 1 μg to 10 mg, preferably from 100 μg to 1 mg. It is particularly preferred to use polynucleotides/vectors that target specifically tumour or proliferative cells, for example by virtue of suitable regulatory constructs or by the use of targeted viral vectors.

Uptake of naked nucleic acid constructs by mammalian cells is enhanced by several known transfection techniques for example those including the use of transfection agents. Example of these agents include cationic agents (for example calcium phosphate and DEAE-dextran) and lipofectants (for example lipofectam™ and transfectam™). Typically, nucleic acid constructs are mixed with the transfection agent to produce a composition.

Preferably the polynucleotide, polypeptide, compound or vector described here may be conjugated, joined, linked, fused, or otherwise associated with a membrane translocation sequence.

Preferably, the polynucleotide, polypeptide, compound or vector, etc described here may be delivered into cells by being conjugated with, joined to, linked to, fused to, or otherwise associated with a protein capable of crossing the plasma membrane and/or the nuclear membrane (i.e., a membrane translocation sequence). Preferably, the substance of interest is fused or conjugated to a domain or sequence from such a protein responsible for the translocational activity. Translocation domains and sequences for example include domains and sequences from the HIV-1-trans-activating protein (Tat), Drosophila Antennapedia homeodomain protein and the herpes simplex-1 virus VP22 protein. In a highly preferred embodiment, the substance of interest is conjugated with penetratin protein or a fragment of this. Penetratin comprises the sequence RQIKIWFQNRRMKWKK (SEQ ID NO:1) and is described in Derossi, et al., (1994), J. Biol. Chem. 269, 10444-50; use of penetratin-drug conjugates for intracellular delivery is described in WO/00/01417. Truncated and modified forms of penetratin may also be used, as described in WO/00/29427.

Preferably the polynucleotide, polypeptide, compound or vector is combined with a pharmaceutically acceptable carrier or diluent to produce a pharmaceutical composition. Suitable carriers and diluents include isotonic saline solutions, for example phosphate-buffered saline. The composition may be formulated for parenteral, intramuscular, intravenous, subcutaneous, intraocular or transdermal administration.

The routes of administration and dosages described are intended only as a guide since a skilled practitioner will be able to determine readily the optimum route of administration and dosage for any particular patient and condition.

Further Aspects

Further aspects of the invention are set out in the following numbered paragraphs; it is to be understood that the invention includes these aspects.

Paragraph 1. A polynucleotide selected from: (a) polynucleotides encoding any one of the polypeptide sequences set out in Examples 1 to 30 or the complement thereof; (b) polynucleotides comprising a nucleotide sequence capable of hybridising to the polynucleotides defined in (a) above, or a fragment thereof; (c) polynucleotides comprising a nucleotide sequence capable of hybridising to the complement of the polynucleotides defined in (a) above, or a fragment thereof; (d) polynucleotides comprising a polynucleotide sequence which is degenerate as a result of the genetic code to the polynucleotides defined in (a), (b) or (c).

Paragraph 2. A polynucleotide selected from: (a) polynucleotides encoding any one of the polypeptide sequences set out in Examples 1, 2, 2A, 2B and 2C or the complement thereof; (b) polynucleotides comprising a nucleotide sequence capable of hybridising to the polynucleotides defined in (a) above, or a fragment thereof; (c) polynucleotides comprising a nucleotide sequence capable of hybridising to the complement of the polynucleotides defined in (a) above, or a fragment thereof; (d) polynucleotides comprising a polynucleotide sequence which is degenerate as a result of the genetic code to the polynucleotides defined in (a), (b) or (c).

Paragraph 3. A polynucleotide selected from: (a) polynucleotides encoding any one of the polypeptide sequences set out in Examples 3 to 9 and 9A or the complement thereof; (b) polynucleotides comprising a nucleotide sequence capable of hybridising to the polynucleotides defined in (a) above, or a fragment thereof; (c) polynucleotides comprising a nucleotide sequence capable of hybridising to the complement of the polynucleotides defined in (a) above, or a fragment thereof; (d) polynucleotides comprising a polynucleotide sequence which is degenerate as a result of the genetic code to the polynucleotides defined in (a), (b) or (c).

Paragraph 4. A polynucleotide selected from: (a) polynucleotides encoding any one of the polypeptide sequences set out in Examples 10 to 29 or the complement thereof; (b) polynucleotides comprising a nucleotide sequence capable of hybridising to the polynucleotides defined in (a) above, or a fragment thereof; (c) polynucleotides comprising a nucleotide sequence capable of hybridising to the complement of the polynucleotides defined in (a) above, or a fragment thereof; (d) polynucleotides comprising a polynucleotide sequence which is degenerate as a result of the genetic code to the polynucleotides defined in (a), (b) or (c).

Paragraph 5. A polynucleotide probe which comprises a fragment of at least 15 nucleotides of a polynucleotide according to any of Paragraphs 1 to 4.

Paragraph 6. A polypeptide which comprises any one of the amino acid sequences set out in Examples 1 to 30 or in any of Examples 1 to 2, 2A, 2B and 2C, Examples 3 to 9 and 9A and Examples 10 to 29 or a homologue, variant, derivative or fragment thereof.

Paragraph 7. A polynucleotide encoding a polypeptide according to Paragraph 6.

Paragraph 8. A vector comprising a polynucleotide according to any of Paragraphs 1 to 5 and 7.

Paragraph 9. An expression vector comprising a polynucleotide according to any of Paragraphs 1 to 5 and 7 operably linked to a regulatory sequence capable of directing expression of said polynucleotide in a host cell.

Paragraph 10. An antibody capable of binding a polypeptide according to Paragraph 6.

Paragraph 11. A method for detecting the presence or absence of a polynucleotide according to any of Paragraphs 1 to 5 and 7 in a biological sample which comprises: (a) bringing the biological sample containing DNA or RNA into contact with a probe according to Paragraph 5 under hybridising conditions; and (b) detecting any duplex formed between the probe and nucleic acid in the sample.

Paragraph 12. A method for detecting a polypeptide according to Paragraph 6 present in a biological sample which comprises: (a) providing an antibody according to Paragraph 10; (b) incubating a biological sample with said antibody under conditions which allow for the formation of an antibody-antigen complex; and (c) determining whether antibody-antigen complex comprising said antibody is formed.

Paragraph 13. A polynucleotide according to according to any of Paragraphs 1 to 5 and 7 for use in therapy.

Paragraph 14. A polypeptide according to Paragraph 6 for use in therapy.

Paragraph 15. An antibody according to Paragraph 10 for use in therapy.

Paragraph 16. A method of treating a tumour or a patient suffering from a proliferative disease comprising administering to a patient in need of treatment an effective amount of a polynucleotide according to any of Paragraphs 1 to 5 and 7.

Paragraph 17. A method of treating a tumour or a patient suffering from a proliferative disease, comprising administering to a patient in need of treatment an effective amount of a polypeptide according to Paragraph 6.

Paragraph 18. A method of treating a tumour or a patient suffering from a proliferative disease, comprising administering to a patient in need of treatment an effective amount of an antibody according to Paragraph 10 to a patient.

Paragraph 19. Use of a polypeptide according to Paragraph 6 in a method of identifying a substance capable of affecting the function of the corresponding gene.

Paragraph 20. Use of a polypeptide according to Paragraph 6 in an assay for identifying a substance capable of inhibiting the cell division cycle.

Paragraph 21. Use as Paragraph ed in Paragraph 20, in which the substance is capable of inhibiting mitosis and/or meiosis.

Paragraph 22. A method for identifying a substance capable of binding to a polypeptide according to Paragraph 6, which method comprises incubating the polypeptide with a candidate substance under suitable conditions and determining whether the substance binds to the polypeptide.

Paragraph 23. A method for identifying a substance capable of modulating the function of a polypeptide according to Paragraph 6 or a polypeptide encoded by a polynucleotide according to any of Paragraphs 1 to 5 and 7, the method comprising the steps of: incubating the polypeptide with a candidate substance and determining whether activity of the polypeptide is thereby modulated.

Paragraph 24. A substance identified by a method or assay according to any of Paragraphs 19 to 23.

Paragraph 25. Use of a substance according to Paragraph 24 in a method of inhibiting the function of a polypeptide.

Paragraph 26. Use of a substance according to Paragraph 24 in a method of regulating a cell division cycle function.

Paragraph 27. A method of identifying a human nucleic acid sequence, by: (a) selecting a Drosophila polypeptide identified in any of Examples 1 to 30; (b) identifying a corresponding human polypeptide; (c) identifying a nucleic acid encoding the polypeptide of (b).

Paragraph 28. A method according to Paragraph 27, in which a human homologue of the Drosophila sequence, or a human sequence similar to the Drosophila sequence, is identified in step (b).

Paragraph 29. A method according to Paragraph 27 or 28, in which the human polypeptide has at least one of the biological activities, preferably substantially all the biological activities of the Drosophila polypeptide.

Paragraph 30. A human polypeptide identified by a method according to Paragraph 27, 28 or 29.

The invention will now be further described by way of Examples, which are meant to serve to assist one of ordinary skill in the art in carrying out the invention and are not intended in any way to limit the scope of the invention.

EXAMPLES

Examples Section A

Identification of Human Cell Cycle Genes

Introduction

In order to identify new cell cycle regulatory genes in Drosophila and their human counterparts, we investigated 33 fly lines obtained by P-element mutagenesis carried out on the X chromosome. All those fly lines are screened directly for mitotic phenotypes at developmental stages where division is crucial (i.e. the syncytial embryo, larval brains, and male and female meiosis). In each case, the P-element insertion site is identified leading to the selection of 62 genes flanking the insertion site.

In order to clarify the identity of the mutated “mitotic genes”, we use an RNAi-based knockdown approach in cultured Drosophila cells followed by FACS analysis, mitotic index evaluation (Cellomics Arrayscan) and immunofluorescence observations of mitotic phenotypes for all 63 genes.

The microscope phenotyping approach led to the identification of 30 gene candidates that are required for cell cycle progression, some of which are also detected as presenting some changes in the FACS profile and/or in the mitotic index (see Table 5 for a full summary). Data relating to these genes is presented in Examples Section B, Examples 1 to 29 below.

These genes encode a variety of novel proteins: 6 protein kinases; 2 protein phosphatases, 2 proteins of the ubiquitin-mediated protein degradation pathway, a cytosketal protein, a microtubule-binding protein, a homologue of a suspected kinesin-like protein, a RNA polymerase 2 associated cyclin, a ribosomal protein; a protein involved in retrograde (Golgi to ER) transport, a member of the family of thioredoxin reductases, a hydroxymethyltransferase, a Cdk associated protein, an RNA binding protein, an O-acetyl transferase and 9 other novel proteins with no particularly characteristic identifying features.

Human counterparts of the selected genes are identified and tested as described below. A short list of Drosophila and human genes and proteins useful for screening for anti-proliferative molecules is presented as Table 5.

TABLE 5
Short list of potentially new interesting gene candidates
Drosophila		Human Homologue
Gene Name	Human Homologue Gene Name	Accession Number
CG2028	Casein kinase I	P48729
CG3011	Serine hydroxymethyl	AAA63258
	transferase
CG15309	DiGeorge syndrome related	AAL09354
	protein FKSG4
CG15305	Human homologue of CG15305	None
CG2222	Hypothetical protein FLJ13912	NP_073607
CG2938	CAS1 O-acetyltransferase	NP_075051
CG1524	Ribosomal protein S14	A25220
CG10778	Hypothetical protein FLJ13102	NP_079163
	(kinesin like)
CG18292	Cdk associated protein 1	BAA22937
	(deleted in oral cancer)
CG10701	Moesin	A41289
CG10648	Mak16-like RNA binding protein	NP_115898
CG2854	CAD38627 hypothetical protein	CAD38627
CG2845	B-raf	AAA35609
CG1486	BAA19780 novel protein	BAA19780
CG10964	11-cis retinal dehydrogenase	AAC50725
CG2151	Thioredoxin reductase beta	XP_033135
CG10988	Gamma tubulin ring complex 3	AAC39727
CG1558	Human homologue of CG1558	NONE
CG11697	Novel protein	BAB14444 unamed
		protein - similar
		to a hypothetical
		protein in the
		region deleted in
		human familial
CG3954	Protein tyrosine phosphatase	AAH08692
	non-receptor type 11 (Shp2)
CG16903	Cyclin L ania-6a	AAD53184
CG16983	Skp1 ubiquitin ligase	XP_054159
CG13363	CGI-85	NP_057112
CG18319	Ubc13 ubiquitin conjugating	BAA11675
	enzyme
CG14813	archain	CAA57071
CG8655	Cdc7	AAB97512
CG2621	GSK 3 beta	NP_002084
CG1725	Dlg1/Dlg2	XP_012060
CG1594	JAK-2 Janus kinase 2	NP_004963
CG2096	Protein phosphatase 1	NP_002700

Results

Table 6 shows all significant cell cycle phenotypes observed after RNAi with the Drosophila genes flanking P-element insertion sites identified in Examples 1 to 29. The PCR primers used to create the double stranded RNA (see Materials and Methods above) are shown in each case together with the RNA ID number. Results derived from Facs analysis of cell cycle compartment, mitotic index as determined by the Cellomics mitotic index assay, and cellular phenotypes determined by microscopy are shown.

FACS Analysis of Cell Cycle

FACS analysis is used to assess the effects of Drosophila gene specific RNAi on the cell cycle. Through the determination of the DNA content by propidium iodide quantitation, any changes in the cell cycle distribution in sub-G1 (apoptotic), G1, G2/M can be observed. 24 genes in the Facs assessment present some changes in cell cycle distribution. (Table 6).

Mitotic Index Evaluation with Cellomics Arrayscan

An evaluation of mitotic index is performed using the Cellomics arrayscan and the Cellomics proprietary mitotic index HitKit procedure (see Materials and Methods above).

The basic principle of this method is that cells in mitosis are decorated by an antibody directed against a specific mitotic marker. Their proportion relatively to the total number of cells is determined, giving a proportion of cells in mitosis. This automated method presents the advantage of being more rapid than the microscope observations, however it only measures one feature of the cycling cells. Some mitotic genes that do not significantly affect the overall proportion of cells in mitosis will therefore not be detected. The reverse is also true as the knockdown of some gene products might affect the mitotic index without displaying any obvious increase in chromosomal or spindle defects. Table 6 presents data only where there was a statistically significant variation in the mitotic index (determined by a Ttest value of <0.1) as compared to the RFP RNAi control.

An increase in mitotic index can indicate that the knockdown of a gene essential for completion of mitosis has blocked more cells in mitosis, however many of the gene knockdowns listed in Table 6 result in a decrease in the mitotic index, suggesting that the population of cells overall are spending less time in mitosis. Possible interpretations of this, are that defects in the centrosome duplication cycle block some cells in GI/S and they are unable to enter mitosis, or that defects in cytokinesis block cells on the exit from mitosis at a point after the assay specific marker is lost. The loss of checkpoints at mitosis may also allow cells to move faster through mitosis. The increase in mitotic defects observed for most of these genes might then be the result of this lack of checkpoint control.

13 genes in the phenotype assessment present some changes in the mitotic index (Table 6).

Microscope Observation and Cellular Phenotyping

The primary goal of the cell phenotype assessment is to find abnormalities in the following: chromosome number in prometaphase (ploidy), chromosome behaviour in metaphase or anaphase, spindle morphology, number of centrosomes, and cell viability. The secondary goal of the assessment is to evaluate and quantify these abnormalities, this is an essential step as control cells also present some defects.

The wild-type Drosophila DMEL2 cells present a large range and a significant proportion of chromosomal defects (between 30-40%). Therefore, between 300 and 500 mitotic cells were counted for each experiment in order to obtain a statistically significant evaluation of any change in the proportion of defects. The cells categorized as presenting chromosomal defects in the study encompass aneuploid and polyploid prometaphase cells, cells that apparently fail to align their chromosomes at metaphase and the cells with lagging or stretched chromosomes in anaphase. Spindle defects are also noted, but not quantified in the same group. Some candidates are also noted as presenting a significant decrease in the number of mitotic cells (mitotic index) or as affecting the viability of the cells (decrease in cell confluency or presence of apoptotic cells).

A noteworthy observation is that it is difficult to find a unique representative phenotype for most of the genes tested. Rather than one gene=one phenotype, an overall increase in the different categories of chromosomal defects is observed. However, one can often see a more significant increase in one particular subcategory of defects as for example in the proportion of lagging chromatids or the number of centrosomes.

Table 6 describes the data obtained from these studies for genes where a significant phenotype is observed. 30 of the candidate genes show a significant phenotype, 26 of which show an increase in chromosomal defects. This increase in mitotic chromosome behaviour abnormalities is sometimes associated with an increase in mitotic spindle defects. Of the remaining 4 with no increase in chromosomal defects, CG1725 (RNA528/529) shows a clear increase in spindle defects, with CG1524 (RNA 482/483) there are not enough mitotic cells to do a proper quantification (as the gene product is a ribosomal protein, it is highly probable that its inactivation results in a net increase in the proportion of cell death explaining the drop in cell confluency also observed) and for CG14813 (RNA 586/587), a large proportion of cells are dying and there is an obvious decrease in the number of mitotic cells, this might affect the relative proportion of normal and abnormal mitotic cells. Finally CG10648 (RNA 488/489) had a lower proportion of chromosomal defects but a high proportion of monopolar and small spindles. The proportion of prometaphase cells and apoptotic cells was also high.

Conclusion

From a collection of Drosophila P-element insertion lines which display phenotypes consistent with an effect on mitosis we derived a series of novel Drosophila and human genes which represent targets for the development of anti-proloiferative therapies. We used three different approaches to validate the role of each gene in the cell cycle and to gather phenotype information following an RNAi-based gene knockdown approach.

Table 5 shows a short list of 30 new interesting human genes demonstrated to play a role in mitosis. This short list is mainly based on the results of the detailed microscope phenotype evaluation (see Table 6), although all of the 42 genes listed in Table 6 show a cell cycle related phenotype in one or more of the 3 assays.

Materials and Methods

Generation and Identification of Lethal, Semi-Lethal and Sterile X Chromosome Mutants Having Defects in Mitosis and/or Meiosis

P-Element Mutagenesis

Transposable elements are widely used for mutagenesis in Drosophila melanogaster as they couple the advantages of providing effective genetic lesions with ease of detecting disrupted genes for the purpose of molecular cloning. To achieve near saturation of the genome with mutations resulting from mobilisation of the P-lacW transposon (a P-element marked with a mini-white gene, bearing the E. coli lacZ gene as an enhancer trap, and an E. coli replicon and ampicillin resistance gene to facilitate ‘plasmid rescue’ of sequences at the site of the P-insertion), Drosophila females that are homozygous for P-lacW (inserted on the second chromosome) are crossed with males carrying the transposase source P(Δ2-3) (Deak et al., 1997). Random transpositions of the mutator element are then ‘captured’ in lines lacking transposase activity. Stable, or balanced, stocks bearing single lethal P-lacW insertions are made to give a collection of 501 lines (Peter et al., submitted) and a further 73 lines that are either sterile or carry a mutation giving a visible morphological phenotype.

Screening for Mitotic and Meiotic Defects

About half of the mutants in the collection are embryonic lethals.

Screens for mutants affecting spermatogenesis within this collection of 501 recessive lethal, semi-lethal and sterile mutants were carried out.

We have carried out cytological screens of the lines that comprise late larval lethals, pupal lethals, pharate and adult semi-lethals and steriles for defective mitosis in the developing larval CNS. This has identified 20 complementation groups that affect all stages of the mitotic cycle. The cytological screens involve examining orcein-stained squashed preparations of the larval CNS to detect abnormal mitotic cells. In lines where defects are identified, the larval CNS is subjected to immunostaining to identify centromeres, spindle microtubules and DNA for further examination. This leads to clarification of the mitotic defect.

As a set of common functions are essential to both mitosis and meiosis, we then identify mutations resulting in sterility and failed progression through male meiosis. This involves examining squashed preparations larval, pupal or adult testes by phase contrast microscopy. We examine “onion stage” spermatids in the 24 pupal and pharate lethal lines and adult “semi-lethal” and viable lines for variations in size and number of nuclei which provides an indication of whether there have been defects in either chromosome segregation or cytokinesis, respectively. A total of 8 lines show such defects.

Further phenotype information for each mutant described in the results section, as observed by phase contrast microscopy of dividing meiocytes, is provided in the “Phenotype” field.

We then examined the ovaries and eggs of females that when homozygous are either sterile or produce embryos that fail to develop. Dissected ovaries are examined by microscopy for defects in the mitotic divisions that lead to the formation of the 16 cell egg chambers, for defects in the endoreduplication of 15 nurse cell nucleic; for cytoskeletal defects in the development of the egg chamber; for defects in meiosis; and for mitotic defects in embryos derived from mutant mothers.

We examined 24 lines that show female sterility or maternal effect lethality when homozygous and identify 5 that display defects of the type described above. In the Examples 1 to 29 below, lines exhibiting mitotic and meiotic phenotypes are categorised generally into three categories:

Category 1: Female Sterile

Category 2: Male Sterile

Category 3: Mitotic (Neuroblast) Phenotypes

Category 1 phenotypes are exhibited by mutations in Examples 1, 2, 2A, 2B and 2C; while Category 2 phenotypes are exhibited by mutations in Examples 3 to 9 and 9A. Category 3 phenotypes are exhibited by mutations in Examples 10 to 29.

Plasmid Rescue of P-Elements from Mutant Drosophila Lines

Genomic DNA was isolated from adult flies by the method of Jowett et al., 1986. Inverse PCR is used to identify flanking chromosomal sequences. The position of the inserted P-element is indicated in the Examples.

Sequence Analysis of P Element Insertion Lines

The open reading frame(s) (ORF(s)) immediately adjacent to the insertion site are identified from the annotated total genome sequence of Drosophila with reference to the ‘GADFLY’ section of the ‘FLYBASE’ Drosophila genome database (database of the Berkeley Drosophila Genome Project). The site of P element insertion and the GenBank accession number of the genomic file which contains the insertion site are included in the results section.

Where the insertion site was within a gene or close to the 5′ end of a gene, disruption of this gene is likely to be responsible for the phenotype, and it is included in the results section under the field heading “Annotated Drosophila Genome Complete Genome Candidate”, as both an accession number and an amino acid sequence. Where the insertion site indicates that the P-element may be affecting expression of two diverging genes (on opposite strands of the DNA) both are included in the results section.

The Drosophila gene sequence is then used to identify a human homologue. Data on homologues is derived from the Blink (“BLAST Link”) facility provided by the NCBI (National Center for Biotechnology Information) database. Where homologues are not apparent, further searches are made against the NCBI database using BLASTX (which compares the nucleotide query sequence virtually translated in all 6 frames against an amino acid database) or TBLASTN (amino acid query sequence against a nucleotide database virtually translated in all 6 frames) or TBLASTX (nucleotide query sequence against nucleotide database, both virtually translated in all 6 frames). Human homologues are included in the results section under the heading “Human Homologue of Complete Genome Candidate”, as both an accession number and an amino acid.

Additional Sequence Analysis using the Annotated D. melanogaster Sequence (GadFly)

As indicated above, rescue sequences are also used to search the fully annotated version of the Drosophila genome (GadFly; Adams, et al., 2000, Science 287, 2185-2195), using GlyBLAST at the Berkeley Drosophila Genome Projects web site (http://www.fruitfly.org/annot/) to identify the genome segment (usually approximately 200-250 kb) containing the P-element insertion site. The graphic representation of the genomic fragment available at GadFly allows the identification of all real and theoretical genes which flank the site of insertion. Candidate genes where the P-element is either inserted within the gene or close to the 5′ end of the gene are identified. In GadFly, the Drosophila genes are given the designation CG (Complete gene) and usually details of human homologues are also given. Such human sequences may also be obtained using the fly sequences to screen databases using the BLAST series of programs. They may also be found by nucleic acid hybridisation techniques. In both cases homologies are defined using the parameters taught earlier in this patent. In most cases, this data confirms the data derived from the sequence analysis procedure described above, and in some cases new data is obtained. Where available both sets of data are included in the individual Examples described below.

Confirmation of Cell Cycle Involvement of Candidate Genes Using Double Stranded RNA Interference (RNAi)

P-elements usually insert into the region 5′ to a Drosophila gene. This means that there is sometimes more than one candidate gene affected, as the P-element can insert into the 5′ regions of two diverging genes (one on each DNA strand). In order to confirm which of the candidate genes is responsible for the cell cycle phenotype observed in the fly line, we use the technique of double stranded RNA interference to specifically knock out gene expression in Drosophila cells in tissue culture (Clemens, et al., 2000, Proc. Natl. Acad. Sci. USA, 6499-6503). The overall strategy is to prepare double stranded RNA (dsRNA) specific to each gene of interest and to transfect this into Schneider's Drosophila line 2 (Dmel-2) to inhibit the expression of the particular gene. The dsRNA is prepared from a double stranded, gene specific PCR product with a T7 RNA polymerase binding site at each end. The PCR primers consist of 25-30 bases of gene specific sequence fused to a T7 polymerase binding site (TAATACGACTCACTATAGGGACA) (SEQ ID NO:2), and are designed to amplify a DNA fragment of around 500 bp. Although this is the optimal size, the sequences in fact range from 450 bp to 650 bp. Where possible, PCR amplification is performed using genomic DNA purified from Schneider's Drosophila line 2 (Dmel-2) as a template. This is only feasible where the gene has an exon of 450 bp or more. In instances where the gene possesses only short exons of less than 450 bp, primers are designed in different exons and PCR amplification is performed using cDNA derived from Schneider's Drosophila line 2 (Dmel-2) as a template.

A sample of PCR product is analysed by horizontal gel electrophoresis and the DNA purified using a Qiagen QiaQuick PCR purification kit. 1 μg of DNA is used as the template in the preparation of gene specific single stranded RNA using the Ambion T7 Megascript kit. Single stranded RNA is produced from both strands of the template and is purified and immediately annealed by heating to 90 degrees C. for 15 mins followed by gradual cooling to room temperature overnight. A sample of the dsRNA is analysed by horizontal gel electrophoresis.

3 μg of dsRNA is transfected into Schneider's Drosophila line 2 (Dmel-2) using the transfection agent, Transfect (Gibco) and the cells incubated for 72 hours prior to fixation. The DNA content of the cells is analysed by staining with propidium iodide and standard FACS analysis for DNA content. The cells in G1 and G2/S phases of the cell cycle are visualised as two separate population peaks in normal cycling S2 cells. In each experiment, Red Fluorescent Protein dsRNA is used as a negative control.

Preparation of dsRNA

RNA is prepared using an Ambion T7 Megascript kit in the following reaction: μl 10×T7 reaction buffer, 2 μl 75 mM ATP, 2 μl 75 mM GTP, 2 μl 75 mM UTP, 2 μl 75 mM CTP, 2 μl T7 RNA polymerase enzyme mix, 8 μl purified PCR product

Incubate at 37° C. for 6 hours. For convenience this can be done overnight in a PCR machine, such that the reaction is due to finish the next day e.g. 10 hrs 4° C., 6 hrs 37° C., 4° C. ∞ (prog. LISA6)

To degrade the DNA, add 1 ml DNase I (2U/ml) and incubate at 37° C. for 15 mins.

Add 115 μl DEPC-treated water and 15 μl ammonium acetate stop solution (5M ammonium acetate, 100 mM EDTA)

Extract with an equal volume of phenol/chloroform, an equal volume of chloroform and then precipitate the RNA by adding 1 volume of isopropanol. Chill at −20° C. for 15-30 mins, then spin at top speed in a microfuge at 4° C. Remove the supernatant avoiding the RNA pellet, which appears as a clear, jelly-like pellet at the base of the tube. Dry briefly then dissolve the RNA in 20-100 μl DEPC-treated water, depending on the size of the pellet.

At this stage there are 2 complimentary single stranded RNAs. To anneal these, incubate the tube at 90° C. for 10 mins, then cool slowly, by transferring to a hot block at 37° C. and then setting the thermostat to room temperature.

Once the hot block has reduced to room temperature, spin down the liquid to the bottom of the tube and run 1 μl on a 1% agarose TBE horizontal gel to check the RNA yield and size.

Transfection of Schneider Line 2 (Dmel-2) Cells with dsRNA (Adherent Protocol)

Transfect 3 μg dsRNA into Schneider line 2 (Dmel-2) cells using Promega Transfast transfection reagent.

Schneider line 2 (Dmel-2) cells are grown in Schneider's medium+10% FCS+penicillin/Streptomycin, at 25° C. For the purpose of transfection with dsRNA, 25 ml of a healthy growing culture should be sufficient for 24-30 transfections. Knock off cells adhering to the bottom of the flask by banging it sharply against the side of the bench, then aliquot 1 ml into each well of 5 six-well plates. Add an additional 2 ml Schneider's medium+10% FCS+penicillin/Streptomycin to each well and incubate the plates overnight in a humid chamber at 25° C.

Vortex the Transfast, then add 9 μl to a sterile eppendorf containing the 3 μg dsRNA. Add 1 ml Schneider's medium (no additives), vortex immediately and incubate at room temperature for 15 mins. In the mean time, carefully remove the Schneider's medium from the six-well plates and replace with Schneider's medium (no additives); ˜1 ml/well.

Once the dsRNA+ Transfast has finished its 15 min incubation, remove the medium from the cells in the six-well plates, replace with the 1 ml dsRNA/Transfast/Schneider's medium and incubate at 25° C. for 1 hr in a humid chamber.

Add 2 ml Schneider's medium containing 10% FCS+pen/strep and return to humid chamber in 25° C. incubator for 24-72 hrs.

Initially, observations of the affects of dsRNA transfection on the Schneider line 2 cell cycle are made after 72 hrs incubation, but where a significant phenotype is observed, additional transfections are performed and observations made at earlier time points.

For each experiment, transfection with RFP dsRNA is used as a negative control. Cells which have been treated with transfast, but which have not been transfected with dsRNA are also included as a control. Transfection with polo or orbit dsRNA, shown in preliminary studies to have an observable affect on Schneider line 2 cell cycle, is used as a positive control in each experiment.

Immunostaining of DMEL-2 Cells for Microscopic Analysis

• • For microscopic analysis of DMEL-2 insect cell line, ˜4×10⁶ cells (0.5×10⁶ cells for 3 day incubations) are grown on coverslips in the bottom of the wells of six-well plates
  • Following any required treatments, the media is carefully removed and replaced with 1 ml PHEMgSO₄ fixation buffer (60 mM PIPES, 25 mM Hepes, 10 mM EGTA, 4 mM MgSO₄, pH to 6.8 with KOH)+3.7% formaldehyde. Until the cells are fixed they do not adhere strongly to the coverslip, so it is important to pipette gently at this stage.
  • The cells are left to fix for 20 mins, then the buffer replaced with PBS+0.1% Triton X-100 for 2 mins to permeablise the cells.
  • Cells are then blocked using PBS+0.1% Triton X-100+1% BSA (freshly prepared) and incubated for 1 hr at RT.
  • Next cells are incubated with the primary rat α-tubulin antibody YL½ (1:300 dil.) (+any other primary antibodies to be used, ex: gamma-tub at 1/500) in PBS+0.1% Triton X-100+1% BSA 2-3 hrs at RT or alternatively overnight at 4° C.
  • Wash the cells 3 times for 5 mins in PBS+0.1% Triton X-100 and then incubate with the secondary antibody, TRITC-donkey anti-rat (1:500 dil.) (+any other secondary antibodies to be used) in PBS+0.1% Triton X-100+1% BSA, at room temperature for 1 hr.
  • Wash the cells 3 times for 5 mins in PBS+0.1% Triton X-100 and once in PBS alone, then mount on a slide on a drop of N-propyl gallate mounting medium containing DAPI to stain the DNA and seal with nail varnish
  • View using fluorescent microscopy.

Primary antibodies: anti α-tub, 1:300 (rat YL½; SEROTEC); anti γ-tub, 1:500 (mouse; Sigma GTU-88)

Secondary antibodies: TRITC donkey anti-rat IgG at 1:300 (Jackson Immunoresearch, 712-026-150); AlexaFluor 488 goat anti-mouse, 1:300 (Molecular Probes; A-11001)

Transfections of S2 cells were carried out in 6 well tissue culture plates using 3 μg ds RNA per gene. The cells were harvested following three days for immunostaining.

Microscope Observations and Cellular Phenotyping

All studies were performed using a standard operating procedure. For every gene, each phenotypic test was performed following a 48 hours period of RNAi induction in duplicate and in two independent sets of experiments. The observations were carried out using a Zeiss Axioskop 2 motorized microscope with a 63×/1.4 plan-apochromat Zeiss objective.

Cells were fixed and stained with DAPI, alpha-tubulin and gamma-tubulin to visualise the nucleus/DNA, the microtubule network/spindle and the centrosomes respectively (see immunostaining section).

For each experiment, the number of normal looking mitotic cells in prophase/prometaphase, metaphase, anaphase and telophase is quantified as well as the abnormal looking ones in those various stages. These comprise abnormal chromosome number in prometaphase, misaligned chromosomes and lagging chromosomes in metaphase and anaphase respectively. Also, the abnormalities in the spindle morphology and the number of centrosomes are carefully noted. To get a more complete characterisation of the phenotype, the cell viability (cell confluency and number of apoptotic cells) is also assessed as well as the number of multinucleated interphase cells and the nucleus and cell morphology if different from control. If a phenotype appears to be more representative some images were stored for presentation of data.

FACS Analysis of Transfected Schneider Line 2 Cells

Following transfection and incubation for the desired length of time, then transfer the cells to a 15 ml centrifuge tube and pellet by spinning at 2000 rpm for 5 mins. Remove the supernatant, resuspend the cell pellet in 1 ml PBS and pellet a second time by spinning at 2000 rpm for 5 mins. Remove 900 μl of the PBS, resuspend the cells in the remaining PBS and then add 900 μl ethanol drop-wise while vortexing the tube. Transfer the cells to an eppendorf tube and store at −20° C.

On the day of analysis, pellet the cells by spinning in a microfuge for 5 mins at 2000 rpm, remove the supernatant, resuspend the cells in the residual ethanol and add 500 μl PBS. To remove clumps take the cells up through a 25 gauge needle and transfer to FACS tube. Add 3 μl 6 mg/ml Rnase A (Pharmacia) and 2.5 μl 25 mg/ml propidium iodide and incubate at 37° C. for 30 mins, then store on ice.

Analyse DNA content of the Schneider line 2 cells using FACSCalibur at Babraham Institute. Mutant phenotypes are determined by comparing profiles relative to cells transfected with RFP dsRNA.

Cellomics Mitotic Index HitKit Procedure

• • To Packard Viewplates containing pre-aliquoted dsRNA samples (1000 ng/well) add 35 μl of logarithmically growing D.Mel-2 cells diluted to 2.3×10⁵ cells/ml in fresh Drosophila-SFM/glutamine/Pen-Strep pre-warmed to 28° C.
  • Incubate the cells with the dsRNA (60 nM) in a humid chamber at 28° C. for 1 hr.
  • Add 100 μl Drosophila-SFM/glutamine/Pen-Strep pre-warmed to 28° C. and return the cells containing the dsRNA to the humid chamber at 28° C. for 72 hrs.
  • Gently remove the medium and slowly add 100 μl Fixation Solution (3.7% formaldehyde, 1.33 mM CaCl₂, 2.69 mM KCI, 1.47 mM KH₂PO₄, 0.52 mM MgCl₂-6H₂O, 137 mM NaCl, 8.50 mM Na₂HPO₄-7H₂O) pre-warmed to 28° C. Incubate in the fume hood for 15 minutes. It is imperative to use care when manipulating cells before and during fixation.
  • Remove the Fixation Solution and wash with 100 μl Wash Buffer (1.33 mM CaCl₂, 2.69 mM KCI, 1.47 mM KH₂PO₄, 0.52 mM MgCl₂-6H₂O, 137 mM NaCl, 8.50 mM Na₂HPO₄-7H₂O).
  • Remove the Wash buffer, add 100 μl Permeabilisation Buffer (30.8 mM NaCl, 0.31 mM KH₂PO₄, 0.57 mM Na₂HPO₄-7H₂O, 0.02% Triton X-100), and incubate for 15 minutes.
  • Remove the Permeabilisation Buffer and wash with 100 μl Wash Buffer.
  • Remove the Fixation Solution and wash with 100 μl Wash Buffer (1.33 mM CaCl₂, 2.69 mM KCI, 1.47 mM KH₂PO₄, 0.52 mM MgCl₂-6H₂O, 137 mM NaCl, 8.50 mM Na₂HPO₄-7H₂O).
  • Remove the Wash buffer, add 100 μl Permeabilisation Buffer (30.8 mM NaCl, 0.31 mM KH₂PO₄, 0.57 mM Na₂HPO₄-7H₂O, 0.02% Triton X-100), and incubate for 15 minutes.
  • Remove the Permeabilisation Buffer and wash with 100 μl Wash Buffer.
  • Remove the Wash Buffer and add 50 μl of Staining Solution (1 μg/ml Hoechst 33258, 1.33 mM CaCl₂, 2.69 mM KCI, 1.47 mM KH₂PO₄, 0.52 mM MgCl₂-6H₂O, 137 mM NaCl, 8.50 mM Na₂HPO₄-7H₂O) per well. Incubate for 1 hour protected from the light.
  • Remove the Staining Solution and wash twice with 100 μl Wash Buffer.
  • Remove the Wash Buffer and replace with 200 μL Wash Buffer containing 0.02% sodium azide.

Seal the plates and analyse the transfection efficiency using the ArrayScan HCS System, running the Application protocol Percent_Transfection_—200602_—10×_p2.0 with the 10× objective and the QuadBGRFR filter set.

TABLE 6
Results of Facs, Mitotic Index, and Cell phenotype assays after siRNA gene
knockdown in Dmel-2 cells
Example	Fly	Drosophila	RNA
number	Line	gene	ID	RNAi primers
1	464	CG15319	452	TAATACGACTCACTATAGGGAGAACGGCACTTCTTTTTCTGTCACCT
				(SEQ ID NO:3)
			453	TAATACGACTCACTATAGGGAGAATGATGAGCAGCTCCAGCAGTCTCT
				(SEQ ID NO:4)
2	492	CG2028	458	TAATACGACTCACTATAGGGAGAGAAGCGGATCGTTTGGCGACATTTA
				(SEQ ID NO:5)
			459	TAATACGACTCACTATAGGGAGAAGATGGGCATTGATCGAGGCATAGC
				(SEQ ID NO:6)
2A	ccr-a2	CG3011	598	TAATACGACTCACTATAGGGAGATGGCAACGAGTACATCGACCGCATA
				(SEQ ID NO:7)
			599	TAATACGACTCACTATAGGGAGATACCTTGTCTCCATTGGCCTTGGTG
				(SEQ ID NO:8)
2B	ewv-b	CG2446	602	TAATACGACTCACTATAGGGAGACCCCAAGGCGATAGATACCACGATA
				(SEQ ID NO:9)
			603	TAATACGACTCACTATAGGGAGAATCTCTGGTATGGCCATCAGGCACT
				(SEQ ID NO:10)
2C	Fs(1)06	CG15309	608	TAATACGACTCACTATAGGGAGAGGTGAAGACGTTTCAGGCCTATCTA
				(SEQ ID NO:11)
			609	TAATACGACTCACTATAGGGAGATCCCAGCCGTTCTCCTTGATCATGT
				(SEQ ID NO:12)
3	167	CG15305	462	TAATACGACTCACTATAGGGAGATATGTGCATCCATTCGAAAGACTTT
				(SEQ ID NO:13)
			463	TAATACGACTCACTATAGGGAGAATAGGGGAGGTTGTTCTTAGATTGA
				(SEQ ID NO:14)
4	224	CG2096	468	TAATACGACTCACTATAGGGAGATGAAACCATCCGAGAAGAAGGCCAA
				(SEQ ID NO:15)
			469	TAATACGACTCACTATAGGGAGACAGATAATCATCAAATGCAGGAATC
				(SEQ ID NO:16)
		CG2222	464	TAATACGACTCACTATAGGGAGAACGGAATGAACTATTTTCCGAACTATTACT
				(SEQ ID NO:17)
			465	TAATACGACTCACTATAGGGAGAGATGTACTGACTGTTGGTGCGCACT
				(SEQ ID NO:18)
5	231	CG2941	470	TAATACGACTCACTATAGGGAGAATCTGTAGACAGACGGCAGAATTGC
				(SEQ ID NO:19)
			471	TAATACGACTCACTATAGGGAGACGCAATAGCAGTACTTCCATCTTGT
				(SEQ ID NO:20)
		CG2938	474	TAATACGACTCACTATAGGGAGAATTGGATTGCGAATCGCTCAGGATC
				(SEQ ID NO:21)
			475	TAATACGACTCACTATAGGGAGATTTTCGCGAAGGACATCAATATCAG
				(SEQ ID NO:22)
6	248	CG6998	476	TAATACGACTCACTATAGGGAGAGGCCTACATCAAGAAGGAGTTCGAC
				(SEQ ID NO:23)
			477	TAATACGACTCACTATAGGGAGATGGTTAGTTGTATTTGCGAATCTTC
				(SEQ ID NO:24)
8	ms(1)04	CG1524	482	TAATACGACTCACTATAGGGAGAGTTGCTGATCGACAAACAAACCCAG
				(SEQ ID NO:25)
			483	TAATACGACTCACTATAGGGAGACTTTCCAGATACTGCCATCTACAGA
				(SEQ ID NO:26)
		CG10778	484	TAATACGACTCACTATAGGGAGAGAGTGTCGCGTGTAGAGGCATTCTT
				(SEQ ID NO:27)
			485	TAATACGACTCACTATAGGGAGAAAGTACACATGGACGGAGCGGATAG
				(SEQ ID NO:28)
9	thb-a	CG1453	556	TAATACGACTCACTATAGGGAGAGGCTGCCGTTTTTCCTTTTTGTTATCC
				(SEQ ID NO:29)
			557	TAATACGACTCACTATAGGGAGATGATCCTTCCTCTTTGACTCCACCT GTT
				(SEQ ID NO:30)
		CG18292	558	TAATACGACTCACTATAGGGAGACGCTAAAAACTAGTAGTTTTGTGTGCCAGG
				(SEQ ID NO:31)
			559	TAATACGACTCACTATAGGGAGAACCACCATTGCTGGAGCACATGTTG
				(SEQ ID NO:32)
9A	ms(1)13	CG5941	610	TAATACGACTCACTATAGGGAGAGGATTAGCACCGTCGACCACGAAAA
				(SEQ ID NO:33)
			611	TAATACGACTCACTATAGGGAGAAATTTCCTGTGTGGATAACGTGAGGAGTCC
				(SEQ ID NO:34)
10	187	CG10701	490	TAATACGACTCACTATACGGGAGACGTTCCTGCTGTTTGGCATTCTTCT
				(SEQ ID NO:35)
			491	TAATACGACTCACTATAGGGAGAACCACAATAAGACCACCCACACAGC
				(SEQ ID NO:36)
		CG10648	488	TAATACGACTCACTATAGGGAGACACCTTCTGCCGCCATGAGTACAAT
				(SEQ ID NO:37)
			489	TAATACGACTCACTATAGGGAGATTCCGCCTCCAGAGCCTTGTTGAAA
				(SEQ ID NO:38)
11	226	CG2865	492	TAATACGACTCACTATAGGGAGATCAAGGCGTCCATGATCACCTCGAAAT
				(SEQ ID NO:39)
			493	TAATACGACTCACTATAGGGAGAACCTGTCCAGCTGCAACTTGGTCAA
				(SEQ ID NO:40)
		CG2854	494	TAATACGACTCACTATAGGGAGAGGAGATGGAAAAGGAGCTCGGAAAA
				(SEQ ID NO:41)
			495	TAATACGACTCACTATAGGGAGATCTCAATCCGTATGCCAAGGAGCAC
				(SEQ ID NO:42)
		CG2845	496	TAATACGACTCACTATAGGGAGAAGTTGACCTCCAAGCTCCACGAACT
				(SEQ ID NO:43)
			497	TAATACGACTCACTATAGGGAGACTGGTGCTTGATGTGTGTCCTAATG
				(SEQ ID NO:44)
12	269	CG1696	500	TAATACGACTCACTATAGGGAGACACTTGGCGATTGAACATGAAACAA
				(SEQ ID NO:45)
			501	TAATACGACTCACTATAGGGAGAATATAAAAAGCCCCCAAAAGAATTG
				(SEQ ID NO 46)
		CG1486	502	TAATACGACTCACTATAGGGAGAATTGCACTTTGATTGCAGTCGATTGCG
				(SEQ ID NO:47)
			503	TAATACGACTCACTATAGGGAGAGATGTGGAATGGTGTGACCGTAGTG
				(SEQ ID NO:48)
13	291	CG10798	504	TAATACGACTCACTATAGGGAGAGACAGGCATATAACTCAGGAACTTA
				(SEQ ID NO:49)
			505	TAATACGACTCACTATAGGGAGACTTGATGATCACCGGCATGTTCTCG
				(SEQ ID NO:50)
15	379	CG10964	552	TAATACGACTCACTATAGGGAGACGGAGTGCCGTCGTAGTTGACAAAA
				(SEQ ID NO:51)
			553	TAATACGACTCACTATAGGGAGATGACCAAGGACCAAGGCCTCAATGT
				(SEQ ID NO:52)
		CG2151	554	TAATACGACTCACTATAGGGAGAAGCCCACTGTGATGGTGCGTTCTAT
				(SEQ ID NO:53)
			555	TAATACGACTCACTATAGGGAGAATCTCATCGGCTCCGAACTGCTTGA
				(SEQ ID NO:54)
17	121	CG10988	560	TAATACGACTCACTATAGGGAGACATTTAAGCAAAATGATTGCCGCCAATAGT
				(SEQ ID NO:55)
			561	TAATACGACTCACTATAGGGAGATCTCAATCCGATGCTGGACTGTGTG
				(SEQ ID NO:56)
18	237	CG1558	562	TAATACGACTCACTATAGGGAGAGCCCAGAAGGAGCAGCAAAAGTTCT
				(SEQ ID NO:57)
			563	TAATACGACTCACTATAGGGAGATAAGTTACCTGCATCGAGGCATTGT
				(SEQ ID NO:58)
		CG11697	564	TAATACGACTCACTATAGGGAGAATGATTTATGCGATCGTGATACACA
				(SEQ ID NO:59)
			565	TAATACGACTCACTATAGGGAGACCGCTTCTCTTCCAACTGCCTTTTG
				(SEQ ID NO:60)
19	171	CG3954	566	TAATACGACTCACTATAGGGAGAGGAGCCGAGTACATCAATGCCAACT
				(SEQ ID NO:61)
			567	TAATACGACTCACTATAGGGAGAATGTAGGTCTTAAACATCTCGCGCT
				(SEQ ID NO:62)
		CG16903	568	TAATACGACTCACTATAGGGAGAGGAAATCTCGCCCATGGTGCTAGAT
				(SEQ ID NO:63)
			569	TAATACGACTCACTATAGGGAGATGTTCCGATCCACGGTGATTACAGC
				(SEQ ID NO:64)
20	500	CG4399	570	TAATACGACTCACTATAGGGAGATGCCCCCCTGGATGATAATGCCAAT
				(SEQ ID NO:65)
			571	TAATACGACTCACTATAGGGAGAACTTGCAGCTCGTGACTCTGATGCT
				(SEQ ID NO:65)
		CG4406	572	TAATACGACTCACTATAGGGAGAATGCTTGTTAAATTTGTTGTCATCTTTTGCC
				(SEQ ID NO:67)
			573	TAATACGACTCACTATAGGGAGAATCTCCTCCGAGTCCTGGAACTTGA
				(SEQ ID NO:68)
23	37	CG16983	580	TAATACGACTCACTATAGGGAGAATGCCCAGCATCAAGTTGCAATCTT
				(SEQ ID NO:69)
			581	TAATACGACTCACTATAGGGAGACGAAATGCCGCGCTTTACTTCTCCT
				(SEQ ID NO:70)
		CG13363	582	TAATACGACTCACTATAGGGAGATCCGATACCTGCGCGTCTTTGACAA
				(SEQ ID NO:71)
			583	TAATACGACTCACTATAGGGAGAGCCATTATTACCAGGTCCACTGCTG
				(SEQ ID NO:72)
24	186	CG18319	584	TAATACGACTCACTATAGGGAGACTCAACGAGAAGGTCCAGACTCAAC
				(SEQ ID NO:73)
			585	TAATACGACTCACTATAGGGAGATCGACGGCATATTTCTGGGTCCACT
				(SEQ ID NO:74)
25	301	CG14813	586	TAATACGACTCACTATAGGGAGAAATGTGCAGCCTTCGGTGGCGGAGTACGAC
				(SEQ ID NO:75)
			587	TAATACGACTCACTATAGGGAGACAATTACTCGCTCTGAGAAGCTGTC
				(SEQ ID NO:76)
26	148	CG8655	590	TAATACGACTCACTATAGGGAGAATGCCCTTCATGGCACATGACCGAT
				(SEQ ID NO:77)
			591	TAATACGACTCACTATAGGGAGATTGCTGCTCTTGCTGCACTAGCTGT
				(SEQ ID NO:78)
27	335	CG2621	594	TAATACGACTCACTATAGGGAGAAATAATAATAACAACGTTATAAGCCAGCCG
				(SEQ ID NO:79)
			595	TAATACGACTCACTATAGGGAGATAATGCGGCTGCGCAAGATGCTGTT
				(SEQ ID NO:80)
28	342	CG1725	528	TAATACGACTCACTATAGGGAGAGCCACGTTGAAATCGATCACCGACA
				(SEQ ID NO:81)
		CT4934	529	TAATACGACTCACTATAGGGAGAATAGAAGGAGTTGGCGGGTGGAGAT
				(SEQ ID NO:82)
		CT41310	530	TAATACGACTCACTATAGGGAGATCTCTTTCGATTTCTTCTCTTCTGT
				(SEQ ID NO:83)
			531	TAATACGACTCACTATAGGGAGATTGATGAACACGGCGACGGGATACA
				(SEQ ID NO:84)
		CG1594	532	TAATACGACTCACTATAGGGAGAAGGGAATCGTGTGGAAAGACTCGCA
				(SEQ ID NO:85)
			533	TAATACGACTCACTATAGGGAGAACAAGGACAAATCAACGGGACTGGC
				(SEQ ID NO:86)
29	419	CG12638	596	TAATACGACTCACTATAGGGAGATGTTTGCCATATCATTGCAGCTGCT
				(SEQ ID NO:87)
			597	TAATACGACTCACTATAGGGAGAGATGTCATATTGGCCAGGTCACTGG
				(SEQ ID NO:88)
	RNAi phenotype
	Mitotic
	Index
	(% of
	Example	RFP		Human
	number	Facs	control)	Microscopy	homologue
1	Fewer G1	wt	wt	AAC51331-
	cells, with			CREB-binding
	correspond-			protein
	ing increase
	in G2/M
2	Fewer cells		20% increase in	P48729 Casein
	in G2/M,		chromosomal defects.	kinase 1, alpha
	with a		Some bright spots	isoform
	correspond-		scattered in the
	ing increase		cytoplasm in the DAPI
	in sub-G1		channel, most of the
	events		nuclei are irregularly
			shaped, M1 decreases, and
			DNA appears hypocondensed
			Shape of the cells is
			also very affected.
2A	wt	91%	12% increase in	AAA63258-
			chromosomal defects	serine
			Multipolar and tripolar	hydroxymethyl-
			spindles	transferase
2B	wt	74%	wt	none
2C	wt	111%	20% increase in	AAL09354
			chromosomal defects	DiGeorge
			spindle defects,	syndrome-related
			some bipolar spindle	protein FKSG4
3	Very slightly	wt	20% increase in	None
	fewer		chromosomal defects
	cycling cells		Difficult to see a normal
	& a corres-		spindle
	ponding
	increase in
	sub-G1 cells
4	wt	wt	20% increase in	NP_002700
			chromosomal defects, no	protein
			defects in centrosomes or	phosphatase 1
			spindle
	wt	Not done	40% increase in	NP_073607
			chromosomal defects	hypothetical
			Multipolar and monopolar	protein
			spindles	FLJ13912
			Many polyploid cells
			Some hyper-condensed
			chromosomes
5	Fewer cells	wt	wt	None
	in G2/M,
	with a
	correspond-
	ing increase
	in sub-G1
	events
	wt	wt	10% increase in	NP_075051 Cas1
			chromosomal defects	O-
			Fewer cells indicating cell	acelyltransferase
			death
			Multipolar spindles
6	Very slightly	wt	wt	AAH10744
	fewer cells in			Similar to
	G2/M & a			RIKEN cDNA
	correspond-			6720463E02
	ing increase			gene
	in sub-G1
	cells
8	Fewer G2/M	63%	Only 38 mitotic cells	A25220
	events, with		remained on the	ribosomal
	a corres-		slide, cells are very	protein S14
	ponding		scattered and some
	increase in		are dying. Nuclei are
	sub-G1		degraded.
	events and a
	different G1
	profile
	wt	78%	20% increase in	hypothetical
			chromosomal defects	protein
			High number of multipolar	FLJ13102
			spindles	(54%) Similarity
				to Mouse
				kinesin-like
				protein KIF4
9	Slight	wt	wt	(CG1453)-
	increase in			CAA69621-
	G1 and sub-			kinesin-2
	G1 cells, but
	no obvious
	correspond-
	ing decrease
	in S or G2/M
	cells
	wt	91%	20% increase in	BAA22937-
			chromosomal defects	cdk2-
			Possible decrease in mitotic	associated
			index	protein 1;
			Some multipolar spindles,	cdk2ap1,
			few normal looking spindles	deleted in oral
				cancer 1
9A	Very slight	wt	wt	MCT-1 (multiple
	decrease in			copies in a T-cell
	G1 peak, but			malignancies)
	no other			(BAA86055),
	obvious
	variation
	from wt
	profile
10	Fewer G2/M	wt	20% increase in	A41289 human
	events with a		chromosomal defects,	moesin
	correspond-		misaligned chromosome
	ing increase		(40%), spindle with free
	in sub-G1		extracentrosome, cells with
	events		more than one spindle.
	wt	wt	Proportion of mitotic	NP_115898
			chromosomal defects a bit	Mak16-like RNA
			lower than normal, high	binding protein
			proportion of monopolar
			spindles and small spindles.
			Very high proportion of
			prometaphase cells
			Cell death
11	Fewer cells	wt	wt	none
	in G2/M and
	also S.
	Increased
	percentage
	of cells in
	sub-G1 and
	G1
	wt	wt	17% increase in	CAD38627
			chromosomal defects	hypothetical
			Higher level of polyploid,	protein
			prometaphase cells and
			misaligned chromosomes,
			anaphase normal
	wt	wt	More than 20% increase in	AAA35609 B-
			chromosomal defects	raf protein
			More multipolar spindles
12	Fewer cells	wt	wt	NP_056158
	in G2/M and			hypothetical
	also S.			protein
	Increased
	percentage
	of cells in
	sub-G1 and
	G1
	wt	wt	10% increase in	BAA19780
			chromosomal defects	Similar to a
			More prometaphase cells	C. elegans protein
				in cosmid
				C14H10
13	Fewer cells	wt	wt	CAA23831 c-
	in G2/M.			myc oncogene
	Increased
	percentage
	of cells in
	sub-G1 and
	G1
15	wt	wt	15% increase in	AAC50725 11-
			chromosomal defects	cis retinol
			high number of disorganised	dehydrogenase
			spindles
	wt	81%	20% increase in	XP_033135
			chromosomal defects	thioredoxin
			High proportion of	reductase beta
			polyploid cells
17	wt	wt	22% increase of	AAC39727-
			chromosomal defects	spindle pole
			Main feature is a high	body protein
			proportion of metaphase	spc98 homolog
			figures with misaligned	GCP3
			chromosomes (75% vs 20%
			in normal cells) Some cells
			without any centrosomes
18	wt	117%	18% increase in	none
			chromosomal defects
			Abnormal spindle structures
			(increased number of
			centrosomes)
	Fewer G2/M	wt	18% increase in	BAB14444
	events, with		chromosomal defects	unamed protein-
	a corres-		More polyploid cells	similar to a
	ponding			hypothetical
	increase in			protein in the
	sub-G1			region deleted in
	events. Also			human familial
	a different			adenomatous
	G1 profile			polyposis 1
	from wt.
19	Very slight	45%	20% increase in	AAH08692-
	increase in		chromosomal defects	protein tyrosine
	G1 and sub-		Spindle and centrosome	phosphatase,
	G1 cells, but		seem normal.	non-receptor
	no obvious		Higher level of aneuploidy	type 11
	correspond-		and polyploidy
	ing decrease
	in S or G2/M
	cells
	wt	wt	20% increase in	AAD53184-
			chromosomal defects	cyclin L. ania-6a
			Clear decrease in mitotic
			index
			A lot of spindles seem to be
			affected in their structure,
			poles not well defined and
			microtubule array irregular
			Many cells with fused
			interphase or decondensed
			nuclei
20	Fewer cells	88%	wt	AAF13722-
	in G2/M,			neurofilament
	with a			protein
	corresponding
	increase in
	sub-G1
	events. Also
	a different
	G1 profile
	from wt.
	Slight	wt	wt	XP_131206
	decrease in			similar to GP1-
	G2/M and			anchor
	correspond-			transamidase
	ing slight
	increase in
	sub-G1 cells.
23	Significant	wt	30% increase in	XP_054159-
	decrease in		chromosomal defects	hypothetical
	sub-G1 &		All types of spindle and	protein
	G1 peaks,		chromosomal defects are
	with a		visible but no obvious main
	correspond-		one
	ing increase		Higher proportion of
	in the G2/M		aneuploid and polyploid cells
	peak, indicat-		Possible decrease in mitotic
	ing mitotic		index
	arrest.		Cells with excess centrosomes
	wt	wt	40% increase in	NP_057112
			chromosomal defects	CGI-85 protein
			A lot of polyploid cells,
			multicentrosome but some
			normal spindle also
24	Significant	91%	30% increase in	BAA11675-
	decrease in		chromosomal defects	ubiquitin-
	sub-G1 &		Various chromosomal	conjugating
	G1 peaks,		defects ranging from	enzyme E2
	but no		number of centrosomes,	UbcH-ben
	correspond-		spindle structure and
	ing increase		stretched/lagging chromatids
	in the G2/M		High number of abnormal
	peak.		anaphases 75% of anaphases
	Probably		(compared to 10-15% in
	indicates		normal cells)
	mitotic
	arrest.
25	Fewer G1	81%	Cell death	CAA57071-
	events, with		Lower proportion of	archain
	an increased		chromosomal defects
	number of
	cells in
	G2/M
	indicating
	mitotic arrest
26	very slight	wt	40% increase in	AAB97512-
	decrease in		chromosomal defects	HsCdc7
	G1 and		Some chromosomal defects
	G2/M peaks,		in spindle structure but no
	but no		clear single phenotype
	significant
	increase in
	sub-G1 cells
	or polypoid
	cells.
27	wt	wt	20% increase in	NP_002084-
			chromosomal defects	glycogen
			Many obvious mitotic	synthase kinase 3
			chromosomal defects and	beta
			too many centrosomes per
			cell
			Very difficult to find a
			normal looking mitotic
			spindle
			Most of the anaphases are
			abnormal with lagging
			chromosomes
28	Essentially		No increase in chromosomal	XP_012060-
	wt profile.		defects but many with more	discs, large
	Very slight		than two centrosomes	(Drosophila)
	reduction in			homolog 2
	G1 peak, but
	no obvious
	correspond-
	ing increase
	in other
	peaks
	Very slight	wt	20% increase in	NP_004963
	reduction in		chromosomal defects	JAK-2 kinase
	G1 peak,		Polyploid cells	(Janus kinase 2),
	with a		Abnormal number of	involved in
	correspond-		centrosomes in many cells	cytokine receptor
	ing increase		but some normal bipolar	signaling
	in sub-G1		spindles
	cells.
29	Decrease in	94%	wt	B38637-Ras
	the number			inhibitor (clone
	of cells in			JC265)-human
	G2/M, with			(fragment)
	an increase
	in the sub-
	G1 popula-
	tion. The G1
	peak differs
	in profile
	from wt.

Examples Section B

P-Element Screening Results

The layout of a typical entry in the results section is shown below. Not all fields present in the actual results section contain information for each individual Drosophila line described.

Results Layout (Examples 1 to 29)

Line ID

(Drosophila line designation)

Phenotype

(Description of Drosophila phenotype)

Annotated Drosophila genome genomic segment containing P element insertion site (and map position)

(Accession number, map position according to the Bridges map, Lefevre, 1976)

P element Insertion site

(Base pair position within genomic segment)

Annotated Drosophila Genome Complete Genome candidate

(derived from GADFLY Berkley Drosophila Genome Project database, accession number, mRNA sequence (complete CDS) and Peptide sequence)

Human homologue of Complete Genome candidate

(Derived from Blink and BLAST searches, accession number, mRNA sequence (complete CDS) and peptide sequence)

Putative function

(Derived from homologies or Drosophila experimental data)

A specific example is as follows (Example 5, Category 2):

Line ID—231

Phenotype—Semi-lethal male and female, cytokinesis defect. In some cysts, variable sized Nebenkerns

Annotated Drosophila genome genomic segment containing P element insertion site (and map position)—AE003429 (3F)

P element insertion site—153,730

Annotated Drosophila genome Complete Genome candidate—CG5014—vap-33-1 vesicle associated membrane protein

(SEQ ID NO:124)
CACATCACTAGCTGACAGAATATATGGCTTTTTTACATTTTGCGTTTTCA
ACTGAAGTTTGCGAAGAAACCGAAGCGTGGTAAACCACTGAAATCGAAAA
TATCGACAGAAAAGCGACCTAAAGTCGGTGAAGAAGTCGGACGTTGATCG
TTGTGTTTTTTTCCCGAAATTTTCTGCAAAAAGCCCGTGCGTGCGTGAGT
TTCTCTGGCTCTTGGTTTTTTTTTGTCCATGCGTGTGTGTGTGGTGGCAT
AAATTTACCGATATTTCGCCTGTGAGAGCGAAACGAACGAAAAAGGAAAG
AAAAAAAGAGAGACGAGTAAAGTAAAACGAAACAGGCATAAAAACAGCAG
CAGTTTTCTTGATATATTTGGCTAAAAAACGCAAACCAAACAGCGAGCAA
GAACAACAAATAGCTGGGCAAAAACAGGACGCACAAAAAATAAAATTAAA
ACGATAAGAGGCGAAAAGCGGAGAGAGTGAAATTCTCGGCAGCAACAACG
ACAAGAACAACACCAGGAGCAGCAGCAACAACAACAAGAAAAGCCAGCCG
CCACAATGAGCAAATCACTCTTTGATCTTCCGTTGACCATTGAACCAGAA
CATGAGTTGCGTTTTGTGGGTCCCTTGACCCGACCCGTTGTCAGAATCAT
GACTCTGGGCAAGAACTCGGCTCTGCCTCTGGTCTTCAAGATCAAGACAA
CCGCCCCGAAACGCTACTGCGTACGTCCAAACATCGGCAAGATAATTCCC
TTTCGATCAACCCAGGTGGAGATCTGCCTTCAGCCATTCGTCTACGATCA
GCAGGAGAAGAACAAGCACAAGTTCATGGTGCAGAGCGTCCTGGGACCCA
TGGATGGTGATCTAAGCGATTTAAATAAATTGTGGAAGGATCTGGAGCCC
GAGCAGGTGATGGACGCCAAACTGAAGTGCGTTTTCGAGATGCCCACCGC
TGAGGCAAATGCTGAGAACACCAGCGGTGGTGGTGCCGTTGGCGGCGGAA
CCGGAGCTGGGGGAGGCGGAAGCGCGGGTGCCAATACTAGCTCAGCCAGC
GCTGAGGCGCTCGAGAGGAAGCCGAAGCTCTCCAGCGAGGATAAGTTTAA
GCGATCCAATTTGCTCGAAACGTCTGAGAGTGTGGACTTGCTGTGCGGAG
AGATCAAAGCGCTGCGTGAATGCAACATTGAATTGCGAAGAGAGAATCTT
CACTTGAAGGATCAAATCACACGTTTCCGGAGCTCGCCGGCCGTCAAACA
GGTGAATGAGCCCTATGCCCCAGTCCTGGCTGAGAAGCAGATTCCGGTCT
TTTACATTGCAGTTGCCATTGCTGCGGCCATCGTTAGCCTCCTGCTGGGC
AAATTCTTTCTCTGA
(SEQ ID NO:125)
MSKSLFDLPLTIEPEHELRFVGPFTRPVVTIMTLRNNSALPLVFKIKTTA
PKRYCVRPNIGKIIPFRSTQVEICLQPFVYDQQEKNKHKFMVQSVLAPMD
ADLSDLNKLWKDLEPEQLMDAKLKCVFEMPTAEANAENTSGGGAVGGGTG
AAGGGSAGANTSSASAEALESKPKLSSEDKFKPSNLLETSESLDLLSGEI
KALRECNIELRRENLHLKDQITRFRSSPAVKQVNEPYAPVLAEKQIPVFY
IAVAIAAAIVSLLLGKFFL

Human homologue of Complete Genome candidate

AAD13577 VAMP-associated protein B

(SEQ ID NO:126)
1    gcgcgcccac ccggtagagg acccccgccc gtgccccgac
     cggtccccgc ctttttgtaa
61   aacttaaagc gggcgcagca ttaacgcttc ccgccccggt
     gacctctcag gggtctcccc
121  gccaaaggtg ctccgccgct aaggaacatg gcgaaggtgg
     agcaggtcct gagcctcgag
181  ccgcagcacg agctcaaatt ccgaggtccc ttcaccgatg
     ttgtcaccac caacctaaag
241  cttggcaacc cgacagaccg aaatgtgtgt tttaaggtga
     agactacagc accacgtagg
301  tactgtgtga ggcccaacag cggaatcatc gatgcagggg
     cctcaattaa tgtatctgtg
361  atgttacagc ctttcgatta tgatcccaat gagaaaagta
     aacacaagtt tatggttcag
421  tctatgtttg ctccaactga cacttcagat atggaagcag
     tatggaagga ggcaaaaccg
481  gaagacctta tggattcaaa acttagatgt gtgtttgaat
     tgccagcaga gaatgataaa
541  ccacatgatg tagaaataaa taaaattata tccacaactg
     catcaaagac agaaacacca
601  atagtgtcta agtctctgag ttcttctttg gatgacaccg
     aagttaagaa ggttatggaa
661  gaatgtaaga ggctgcaagg tgaagttcag aggctacggg
     aggagaacaa gcagttcaag
721  gaagaagatg gactgcggat gaggaagaca gtgcagagca
     acagccccat ttcagcatta
781  gccccaactg ggaaggaaga aggccttagc acccggctct
     tggctctggt ggttttgttc
841  tttatcgttg gtgtaattat tgggaagatt gccttgtaga
     ggtagcatgc acaggatggt
901  aaattggatt ggtggatcca ccatatcatg ggatttaaat
     ttatcataac catgtgtaaa
961  aagaaattaa tgtatgatga catctcacag gtcttgcctt
     taaattaccc ctccctgcac
1021 acacatacac agatacacac acacaaatat aatgtaacga
     tcttttagaa agttaaaaat
1081 gtatagtaac tgattgaggg ggaaaagaat gatctttatt
     aatgacaagg gaaaccatga
1141 gtaatgccac aatggcatat tgtaaatgtc attttaaaca
     ttggtaggcc ttggtacatg
1201 atgctggatt acctctctta aaatgacacc cttcctcgcc
     tgttggtgct ggcccttggg
1261 gagctggagc ccagcatgct ggggagtgcg gtcagctcca
     cacagtagtc cccacgtggc
1321 ccactcccgg cccaggctgc tttccgtgtc ttcagttctg
     tccaagccat cagctccttg
1381 ggactgatga acagagtcag aagcccaaag gaattgcact
     gtggcagcat cagacgtact
1441 cgtcataagt gagaggcgtg tgttgactga ttgacccagc
     gctttggaaa taaatggcag
1501 tgctttgttc acttaaaggg accaagctaa atttgtattg
     gttcatgtag tgaagtcaaa
1561 ctgttattca gagatgttta atgcatattt aacttattta
     atgtatttca tctcatgttt
1621 tcttattgtc acaagagtac agttaatgct gcgtgctgct
     gaactctgtt gggtgaactg
1681 gtattgctgc tggagggctg tgggctcctc tgtctctgga
     gagtctggtc atgtggaggt
1741 ggggtttatt gggatgctgg agaagagctg ccaggaagtg
     ttttttctgg gtcagtaaat
1801 aacaactgtc ataggcaggg aaattctcag tagtgacagt
     caactctagg ttaccttttt
1861 taatgaagag tagtcagtct tctagattgt tcttatacca
     cctctcaacc attactcaca
1921 cttccagcgc ccaggtccaa gtttgagcct gacctcccct
     tggggaccta gcctggagtc
1981 aggacaaatg gatcgggctg caaagggtta gaagcgaggg
     caccagcagt tgtgggtggg
2041 gagcaaggga agagagaaac tcttcagcga atccttctag
     tactagttga gagtttgact
2101 gtgaattaat tttatgccat aaaagaccaa cccagttctg
     tttgactatg tagcatcttg
2161 aaaagaaaaa ttataataaa gccccaaaat taaga
(SEQ ID NO:127)
1    makveqvlsl epqhelkfrg pftdvvttnl klgnptdrnv
     cfkvkttapr rycvrpnsgi
61   idagasinvs vmlqpfdydp nekskhkfmv qsmfaptdts
     dmeavwkeak pedlmdsklr
121  cvfelpaend kphdveinki isttasktet pivskslsss
     lddtevkkvm eeckrlqgev
181  qrlreenkqf keedglrmrk tvqsnspisa laptgkeegl
     strllalvvl ffivgviigk
241  ial

Putative function

Membrane associated protein which may be involved in priming synaptic vesicles

Results Layout for Examples 2A, 2B, 2C and 9A

The results layout for Examples 2A, 2B, 2C and 9A includes, in place of the fourth field “P Element Insertion Site”, a field “P Element Insertion Site Sequence”. This field shows the actual sequence of the insertion site which is determined experimentally, as opposed to the base pair position within genomic segment present in the other Examples.

Category 1—Female Sterile

Example 1 (Category 1)

Line ID—464

Phenotype—Female semi-sterile, brown eggs laid

Annotated Drosophila genome genomic segment containing P element insertion site (and map position)—AE003448 (8F)

P element Insertion site—44,575

Annotated Drosophila genome Complete Genome candidate—CG15319-nejire (CREB binding protein, p300/CBP)

(SEQ ID NO:89)
CTTAACCAAACAAACAACCTGTGCAACAATTGTCAAAGTGCTAGGCGACA
AATAATTTCTGAAAGAAGATTTGACAAGTTCCAATAACGAAAATATCAGA
ACACACTCGAACTCCAACATAGACGGATCATTGGAGAGTTAGTGAAAAAA
AAAAGCGAAAAATCAGAAAAACTTTATAAACTAATAGAAACAATACTACT
CAGATTTTTCGAACGTTTTTCGTCTGCGTTTCTGTTTTTTTCCGAATCGA
AAGAATCAAACTAACTCTATATGATGGCCGATCACTTAGACGAACCGCCC
CAAAAGCGGGTTAAAATGGATCCAACGGATATCTCTTACTTTCTGGAGGA
GAACCTGCCCGATGAGCTGGTGTCCTCGAATAGTGGCTGGTCGGATCAGC
TGACCGGCGGAGCAGGCGGTGGCAATGGAGGTGGCGGCGCCTCCGGTGTA
ACCACAAATCCCACATCCGGCCCAAATCCCGGTGGCGGACCCAACAAGCC
GGCAGCCCAAGGACCCGGCTCTGGCACAGGCGGAGTCGGTGTTGGAGTGA
ATGTGGGTGTCGGCGGTGTTGTTGGCGTCGGCGTTGTGCCTTCCCAGATG
AACGGAGCCGGCGGCGGCAACGGATCCGGAACGGGTGGCGACGACGGCAG
TGGCAACGGCTCAGGAGCGGGCAACAGAATCAGTCAAATGCAACACCAGC
AACTGCAGCACCTACTCCAGCAGCAGCAGCAGGGCCAGAAGGGCGCCATG
GTGGTGCCCGGCATGCAGCAGCTGGGCAGCAAGTCGCCCAACCTGCAGTC
ACCCAACCAGGGCGGCATGCAGCAGGTGGTGGGCACTCAGATGGGTATGG
TCAACTCAATGCCCATGTCAATATCGAATAATGGCAACAATGGCATGAAC
GCCATACCAGGCATGAACACCATTGCGCAGGGCAATCTGGGAAACATGGT
GCTGACCAACAGCGTTGGCGGCGGCATGGGCGGCATGGTTAATCATCTTA
AGCAGCAGCCTGGCGGCGGCGGCGGTGGGATGATCAATTCCGTTTCAGTA
CCCGGAGGACCTGGAGCAGGAGCTGGTGGCGTTGGAGCTGGCGGCGGAGG
AGCCGTTGCCGCAAACCAAGGCATGCATATGCAGAACGGCCCAATGATGG
GACGCATGGTGGGGCAACAGCATATGCTTCGTGGCCCGCATCTCATGGGT
GCCTCTGGAGGAGCTGGTGGGCCAGGAAACGGGCCTGGTGGCGGAGGACC
ACGCATGCAGAATCCGAACATGCAAATGACTCAACTCAACAGTCTGCCCT
ACGGAGTGGGTCAGTATGGTGGCCCAGGCGGTGGTAACAATCCTCAGCAA
CAGCAGCAGCAACAGCAGCAACAACTTCTCGCCCAGCAGATGGCCCAAAG
AGGTGGCGTCGTACCGGGCATGCCGCAGGGTAATCGGCCCGTTGGCACAG
TGGTGCCCATGTCCACACTCGGCGGCGATGGATCAGGGCCCGCGGGGCAG
CTGGTAAGCGGGAATCCTCAGCAGCAGCAGATGCTGGCGCAGCAGCAAAC
CGGAGCCATGGGCCCGCGTCCTCCGCAACCAAACCAGCTGCTCGGTCATC
CCGGCCAGCAGCAGCAGCAGCAACAGCAGCCTGGCACCTCGCAGCAGCAG
CAACAGCAGCAGGGAGTCGGAATCGGAGGAGCAGGCGTTGTGGCCAATGC
AGGAACCGTGGCTGGCGTGCCGGCAGTGGCAGGCGGCGGAGCCGGTGGTG
CCGTACAATCTAGCGGCCCTGGTGGCGCCAATCGCGATGTGCCCGACGAC
CGTAAGCGACAGATCCAGCAGCAACTGATGCTGCTCCTCCATGCACACAA
ATGCAATCGCAGGGAGAACCTGAATCCGAACAGGGAAGTGTGCAACGTTA
ACTACTGCAAGGCGATGAAATCCGTGCTGGCCCACATGGGCACTTGCAAA
CAGAGCAAGGACTGCACCATGCAGCATTGTGCCTCTTCGCGCCAAATTCT
GTTGCATTATAAAACGTGCCAGAACAGTGGCTGCGTCATTTGCTATCCCT
TCCGGCAGAATCATTCGGTTTTTCAAAATGCGAATGTGCCGCCAGGAGGC
GGACCGGCAGGAATTGGAGGTGCGCCACCAGGTGGCGGCGGAGCGGGTGG
TGGAGCGGCTGGAGCAGGCGGTAATCTTCAGCAGCAACAGCAGCAGCAAC
AACAGCAGCAGCAGAACCAGCAGCCCAATCTGACGGGTCTGGTAGTGGAT
GGCAAGCAAGGACAGCAGGTTGCACCGGGAGGTGGCCAAAATACTGCCAT
AGTTCTTCCCCAGCAACAGGGAGCGGGCGGTGCACCGGGTGCGCCGAAAA
CGCCTGCGGATATGGTGCAACAATTGACCCAACAGCAGCAGCAGCAGCAA
CAGCAGGTTCACCAGCAACAGGTTCAGCAACAGGAACTCCGTCGATTCGA
TGGCATGAGCCAGCAAGTCGTAGCAGGTGGTATGCAACAGCAGCAGCAGC
AGGGTTTGCCTCCTGTGATTCGCATTCAAGGCGCTCAGCCGGCCGTCAGG
GTACTGGGACCAGGTGGTCCCGGCGGCCCAAGTGGACCAAATGTTCTGCC
GAACGATGTTAACAGCCTGCATCAACAACAGCAACAAATGCTGCAACAGC
AGCAGCAACAGGGCCAGAATCGACGACGCGGTGGCCTGGCCACCATGGTG
GAGCAACAACAGCAGCATCAGCAACAACAGCAGCAACCCAATCCCGCCCA
GCTGGGTGGCAACATTCCAGCACCACTCTCTGTCAACGTCGGTGGCTTTG
GCAATACCAATTTCGGTGGTGCAGCTGCCGGCGGAGCCGTGGGAGCCAAC
GATAAGCAGCAACTGAAGGTGGCCCAAGTGCATCCGCAGAGCCATGGCGT
AGGAGCGGGCGGTGCATCAGCGGGCGCCGGGGCGAGTGGTGGTCAAGTGG
CAGCCGGTTCCAGTGTCCTGATGCCAGCCGATACCACGGGCAGTGGTAAT
GCGGGCAATCCCAACCAGAATGCAGGCGGTGTAGCTGGAGGTGCCGGCGG
TGGCAATGGCGGAAACACTGGACCTCCGGGCGACAACGAGAAAGACTGGC
GGGAATCGGTGACCGCCGATCTGCGCAACCACCTCGTCCACAAACTGGTG
CAGGCCATCTTCCCCACCTCGGATCCTACGACCATGCAGGACAAACGGAT
GCATAATCTCGTTTCATACGCGGAAAAGGTCGAGAAGGACATGTACGAAA
TGGCCAAGTCCAGATCGGAGTACTATCACCTGCTGGCCGAGAAGATCTAC
AAGATTCAAAAGGAGCTGGAGGAGAAGCGACTGAAGCGTAAGGAGCAGCA
TCAGCAGATGCTGATGCAGCAACAGGGCGTTGCGAATCCAGTGGCTGGAG
GAGCGGCTGGCGGAGCAGGCAGTGCAGCTGGTGTAGCGGGCGGTGTAGTC
TTGCCCCAGCAGCAACAGCAGCAGCAACAACAACAGCAGCAGCAGGGTCA
GCAGCCTCTGCAGAGCTGTATCCATCCAAGCATCAGTCCAATGGGCGGTG
TGATGCCGCCGCAGCAGCTGCGTCCACAGGGACCACCTGGAATACTGGGC
CAACAGACGGCAGCAGGCCTGGGCGTCGGCGTGGGAGTGACCAACAATAT
GGTTACCATGCGCAGTCATTCGCCCGGTGGCAACATGCTCGCCTTGCAGC
AACAACAGCGCATGCAGTTCCCGCAACAACAGCAGCAACAACCGCCAGGG
TCTGGAGCCGGCAAAATGCTGGTCGGTCCACCAGGACCCAGTCCCGGTGG
CATGGTGGTCAATCCCGCGCTCTCGCCTTACCAGACGACCAATGTGCTCA
CCAGTCCGGTGCCAGGACAGCAGCAACAGCAGCAGTTCATTAATGCGAAC
GGCGGCACTGGCGCCAATCCTCAACTGAGCGAAATCATGAAGCAGCGTCA
CATTCACCAGCAGCAGCAGCAACAACAACAGCAGCAGCAGCAGGGAATGT
TGTTGCCGCAGTCGCCATTTAGCAATTCAACACCTCTACAACAACAACAG
CAGCAGCAGCAGCAACAACAGCAGCAGCAGGCGACTAGCAACAGTTTTAG
CTCACCAATGCAGCAACAGCAGCAAGGTCAGCAACAGCAACAACAGAAGC
CCGGCAGTGTGCTGAATAATATGCCGCCCACGCCCACGAGTCTGGAAGCC
CTGAATGCGGGGGCCGGAGCGCCGGGAACTGGAGGATCCGCCTCCAATGT
AACGGTTTCAGCTCCGAGCCCATCGCCTGGCTTCTTGTCCAACGGCCCGT
CGATTGGCACGCCCTCCAACAATAATAATAATAGTAGTGCTAACAACAAC
CCGCCCTCGGTGAGCAGTCTAATGCAACAGCCGCTGAGCAATCGGCCGGG
TACGCCTCCTTACATACCCGCTTCCCCAGTGCCGGCGACAAGTGCCTCCG
GATTAGCGGCGAGCAGTACGCCCGCATCAGCAGCAGCCACCTGTGCGAGT
AGTGGCAGTGGCAGCAATAGCAGCAGCGGAGCAACTGCAGCGGGTGCAAG
TTCCACGTCATCATCTTCCTCGGCGGGCTCGGGTACACCACTCAGCTCGG
TATCGACTCCTACATCGGCCACGATGGCCACCAGCAGCGGTGGTGGTGGT
GGTGGTGGGGGCAATGCAGGAGGCGGATCATCCACTACGCCCGCTAGCAA
TCCACTGCTCCTCATGTCTGGAGGAACGGCAGGAGGCGGAACGGGAGCAA
CGACCACCACATCGACATCCTCGAGCAGTCGCATGATGAGCAGCTCCAGC
AGTCTCTCCTCACAGATGGCTGCCCTGGAGGCTGCGGCGCGAGACAACGA
CGATGAGACGCCCTCGCCATCCGGCGAGAATACGAACGGCAGTGGTGGCA
GTGGAAATGCCGGCGGTATGGCCTCCAAGGGCAAACTGGACTCCATTAAG
CAAGATGATGATATCAAGAAGGAGTTTATGGATGACAGCTGTGGCGGAAA
TAACGATAGCTCGCAGATGGATTGCTCGACGGGTGGTGGCAAGGGCAAGA
ATGTGAACAACGACGGAACAAGCATGATCAAAATGGAGATCAAGACGGAG
GATGGACTCGATGGCGAGGTAAAGATCAAAACGGAGGCCATGGATGTGGA
CGAGGCTGGAGGATCGACAGCCGGAGAGCATCATGGCGAAGGTGGCGGCG
GCAGTGGTGTTGGCGGCGGTAAGGATAACATAAATGGTGCGCACGATGGC
GGAGCGACAGGCGGTGCTGTGGACATAAAACCCAAGACGGAGACGAAACC
ACTCGTACCGGAGCCACTGGCACCCAATGCAGGTGACAAGAAAAAGAAGT
GCCAATTCAATCCCGAGGAACTGCGCACCGCTCTCCTGCCAACGCTAGAG
AAGCTCTACAGGCAGGAGCCCGAATCCGTGCCCTTTCGCTACCCAGTTGA
TCCCCAGGCGCTGGGCATACCTGATTACTTTGAAATCGTTAAGAAGCCCA
TGGACCTGGGCACTATACGCACCAACATCCAGAATGGAAAGTACAGTGAT
CCCTGGGAATATGTGGACGACGTTTGGCTGATGTTCGACAATGCCTGGCT
GTATAATCGCAAAACATCGCGGGTCTATCGCTATTGCACAAAGCTTTCCG
AAGTCTTTGAGGCGGAGATTGATCCTGTGATGCAGGCACTGGGATATTGC
TGCGGCAGGAAGTACACATTCAATCCACAGGTGCTATGCTGCTACGGCAA
GCAGCTCTGCACGATTCCGCGGGATGCCAAGTACTACAGCTACCAGAACA
GTCTAAAGGAATACGGTGTCGCCTCAAATAGATACACCTACTGCCAAAAG
TGCTTTAACGACATCCAGGGCGATACGGTCACACTGGGCGACGATCCACT
GCAATCGCAAACCCAAATCAAAAAGGATCAGTTCAAGGAGATGAAGAACG
ATCACCTCGAACTGGAGCCGTTTGTCAATTGCCAGGAGTGCGGACGCAAA
CAGCACCAAATCTGCGTACTCTGGCTGGATTCTATCTGGCCCGGTGGCTT
CGTGTGCGATAACTGCCTGAAAAAGAAGAACTCAAAGCGGAAGGAGAACA
AGTTCAATGCGAAACGCCTGCCCACCACCAAGCTGGGCGTGTACATAGAG
ACGCGGGTGAATAATTTCCTCAAGAAGAAGGAGGCTGGTGCCGGCGAGGT
GCACATTCGTGTGGTCAGCTCATCGGACAAGTGTGTAGAGGTGAAGCCCG
GCATGCGTCGACGATTCGTCGAGCAGGGCGAGATGATGAACGAGTTCCCA
TACCGAGCCAAAGCGCTCTTTGCCTTCGAGGAGGTGGATGGCATCGATGT
GTGCTTCTTTGGCATGCACGTTCAGGAGTATGGATCCGAGTGCCCGGCGC
CGAATACGCGGCGTGTGTATATTGCCTATTTGGATTCCGTTCATTTCTTC
CGGCCAAGACAGTACCGTACAGCGGTATATCACGAAATCCTGCTCGGCTA
TATGGACTACGTGAAACAGCTGGGCTACACAATGGCCCATATCTGGGCCT
GTCCGCCATCCGAGGGCGATGACTACATCTTTCACTGCCATCCCACGGAC
CAGAAGATACCCAAGCCCAAGCGCCTGCAGGAGTGGTACAAAAAGATGCT
TGACAAGGGAATGATCGAGCGCATCATACAGGACTACAAGGATATCCTGA
AGCAGGCGATGGAGGACAAACTGGGCTCTGCCGCAGAGCTGCCCTACTTT
GAGGGCGACTTCTGGCCCAATGTGCTGGAGGAGAGCATCAAGGAACTGGA
CCAGGAGGAGGAAGAGAAGCGCAAACAGGCCGAGGCCGCGGAAGCAGCAG
CTGCGGCAAATCTTTTCTCTATCGAGGAAAATGAAGTAAGCGGCGATGGC
AAAAAGAAGGGCCAGAAGAAGGCCAAAAAGTCGAACAAATCGAAAGCGGC
GCAGCGTAAGAACAGCAAAAAGTCCAACGAACATCAGTCGGGCAATGATC
TCTCCACAAAGATATATGCGACCATGGAGAAGCACAAGGAGGTCTTCTTC
GTTATCCGTCTGCATTCGGCGCAGTCGGCAGCTAGTTTAGCGCCCATCCA
GGATCCCGATCCGCTGCTCACATGCGATCTGATGGATGGACGCGATGCCT
TCCTCACGCTCGCCCGCGACAAGCACTTTGAGTTCTCGTCGCTGCGGCGC
GCACAATTCTCCACTCTGTCCATGTTGTATGAGCTGCATAACCAGGGTCA
GGACAAGTTTGTTTACACCTGCAACCACTGCAAGACGGCCGTGGAGACGC
GCTACCACTGTACTGTTTGTGATGACTTCGATCTGTGTATCGTGTGCAAG
GAGAAGGTTGGCCATCAGCACAAGATGGAGAAGCTCGGCTTCGACATCGA
CGACGGCTCTGCGCTGGCGGATCACAAGCAGGCTAATCCACAGGAGGCCC
GCAAGCAATCCATCCAGCGTTGCATCCAATCGCTGGCGCACGCCTGCCAG
TGTCGCGATGCCAACTGCCGCCTGCCATCGTGCCAGAAGATGAAGCTCGT
TGTCCAGCATACGAAGAACTGCAAGCGCAAGCCCAACGGAGGATGCCCCA
TTTGCAAGCAGCTTATCGCACTCTGTTGCTATCACGCGAAGAACTGTGAG
GAGCAGAAGTGCCCCGTGCCGTTCTGTCCCAACATCAAGCACAAGCTCAA
GCAGCAGCAGTCACAGCAGAAATTCCAGCAGCAGCAGTTGCTGCGTCGCC
GTGTGGCGCTCATGTCGCGTACAGCAGCTCCAGCGGCTCTGCAAGGCCCA
GCTGCAGTAAGCGGTCCGACCGTCGTCTCTGGAGGAGTGCCCGTGGTGGG
CATGTCCGGTGTGGCAGTTAGCCAACAGGTGATCCCCGGCCAGGCGGGTA
TACTGCCTCCAGGGGCGGGTGGCATGTCGCCATCTACCGTGGCAGTTCCA
TCGCCTGTTTCAGGAGGAGCGGGAGCCGGTGGAATGGGTGGAATGACATC
ACCACATCCGCATCAACCAGGTATAGGTATGAAACCTGGTGGCGGTCACT
CGCCGTCTCCAAATGTCCTACAAGTGGTGAAGCAGGTCCAGGAAGAGGCA
GCTCGTCAGCAGGTATCGCATGGCGGTGGCTTCGGCAAGGGCGTACCCAT
GGCGCCGCCCGTAATGAATCGACCAATGGGCGGCGCTGGGCCCAACCAAA
ATGTTGTTAATCAACTTGGTGGCATGGGCGTTGGAGTTGAAGGTGTCGGT
GGTGTTGGCGTCGGAGGCGTTGGTGGAGTGGGTGTTAATCAACTGAATTC
GGGTGGTGGCAATACACCCGGTGCACCCATTTCCGGTCCCGGAATGAATG
TCAATCATCTAATGTCCATGGATCAGTGGGGCGGTGGCGGAGCCGGCGGC
GGAGGTGCCAATCCCGGCGGTGGCAATCCACAAGCCCGCTATGCCAACAA
TACCGGCGGCATGCGCCAACCCACCCATGTGATGCAAACGAATCTGATAC
CGCCGCAGCAACAGCAACAGATGATGGGCGGACTGGGCGGACCCAACCAA
CTGGGAGGTGGCCAAATGCCAGTCGGCGGACAGCATGGAGGAATGGGAAT
GGGCATGGGAGCACCACCAATGGCCGGAACTGTTGGCGGAGTGCGTCCAT
CTCCCGGAGCAGGAGGTGGAGGTGGAAGTGCGACTGGGGGCGGTCTAAAT
ACGCAACAACTCGCCCTGATTATGCAAAAGATTAAGAACAATCCCACCAA
CGAGAGCAACCAGCACATCCTTGCCATACTAAAACAGAATCCGCAGATCA
TGGCGGCGATCATCAAGCAGCGCCAGCAGTCGCAGAACAATGCGGCAGCG
GGCGGAGGAGCACCTGGCCCAGGTGGAGCCCTACAGCAGCAGCAGGCCGG
TAACGGACCGCAAAATCCTCAACAGCAGCAGCAGCAGCAGCAACAGCAAC
AGGTGATGCAGCAACAGCAGATGCAGCACATGATGAACCAGCAGCAGGGC
GGCGGCGGTCCACAGCAGATGAATCCCAACCAGCAGCAGCAACAGCAGCA
GGTTAATCTCATGCAGCAGCAGCAACAAGGTGGACCCGGAGGACCAGGTT
CTGGACTTCCCACGCGCATGCCCAATATGCCCAATGCCTTGGGTATGCTG
CAGAGTCTTCCGCCCAACATGTCGCCAGGCGTTTCTACTCAGGGAGGAAT
GGTGCCCAACCAAAACTGGAACAAGATGCGTTACATGCAAATGAGCCAGT
ACCCGCCACCGTATCCGCAGCGCCAGCGTGGCCCGCACATGGGCGGAGCG
GGACCTGGTCCCGGCCAGCAACAGTTCCCCGGTGGCGGAGGTGGAGCGGG
CAACTTTAATGCGGGTGGTGCTGGTGGTGCAGGCGGCGTTGTCGGTGTGG
GCGGAGTGCCCGGAGGTGCCGGCACGGTGCCCGGTGGCGATCAATACTCG
ATGGCGAATGCCGCGGCTGCCTCCAATATGCTGCAACAGCAGCAGGGCCA
GGTGGGCGTCGGAGTGGGCGTGGGCGTGAAACCAGGACCCGGCCAACAGC
AACAGCAGATGGGCGTTGGCATGCCGCCGGGTATGCAGCAGCAACAGCAG
CAACAGCAACCGCTGCAGCAGCAGCAGATGATGCAGGTAGCAATGCCAAA
TGCGAATGCCCAGAATCCGTCGGCGGTGGTTGGCGGACCCAATGCTCAGG
TGATGGGTCCGCCGACGCCGCACTCTCTGCAGCAGCAGCTGATGCAATCG
GCCCGCTCGTCGCCGCCTATTCGCTCCCCGCAGCCAACGCCATCGCCACG
TTCGGCTCCATCGCCACGTGCTGCTCCATCCGCCTCGCCTAGGGCACAGC
CCTCGCCGCACCATGTGATGAGCAGTCACTCGCCAGCGCCGCAGGGACCA
CCGCATGACGGCATGCACAATCATGGCATGCATCATCAGTCGCCACTGCC
AGGAGTGCCGCAGGATGTTGGCGTCGGAGTCGGTGTCGGCGTTGGCGTTG
GCGTTAACGTTAACGTCGGCAACGTGGGCGTCGGCAATGCCGGAGGAGCC
CTGCCCGACGCCTCCGACCAGCTGACCAAGTTTGTGGAGCGACTCTAGTG
CAGCAACAGCAGCAGCACCAGCACCAGCACCACCACCAGCTACAATGGTT
GGTAGGCGATGTGGCTAGAGGGCTAGGGCTAGACTGAATGAATGAATGAG
TGTCCAGTAGCCGCAGACGGGATGACGACGAAGACCAACCGGCAGGGATA
ACCAGTGTGTGTTAAGCGAATTAACAACTATTACTAACTTAAATCTTTTT
TTTTTTTTTAAACGGCACCACAAATAATTGTATATTGTTATAATTAAATC
AACAAATATCGCGCCTAATGTGTACTGTAGATTAAGATGACCCACCATTA
CAACCACTAACAAATACCTTATTATTTAAGTTTAAGACGAAAGTTGGACA
GAGCATTATGATTCGATTTCCATTTTATGTCCGCGATTTAGCAAATATAT
AATATCATATATTTCATATGCCCCCAAAACACACACACACCATGTATTAA
TTAATGCGATTCCTTCGTTTCCACTAAGCAGATATAGAAAAAAAAAAA
(SEQ ID NO:90)
MMADHLDEPPQKRVKMDPTDISYFLEENLPDELVSSNSGWSDQLTGGAGG
GNGGGGASGVTTNPTSGPNPGGGPNKPAAQGPGSGTGGVGVGVNVGVGGV
VGVGVVPSQMNGAGGGNGSGTGGDDGSGNGSGAGNRISQMQHQQLQHLLQ
QQQQGQKGAMVVPGMQQLGSKSPNLQSPNQGGMQQVVGTQMGMVNSMPMS
ISNNGNNGMNAIPGMNTIAQGNLGNMVLTNSVGGGMGGMVNHLKQQPGGG
GGGMINSVSVPGGPGAGAGGVGAGGGGAVAANQGMHMQNGPMMGRMVGQQ
HMLRGPHLMGASGGAGGPGNGPGGGGPRMQNPNMQMTQLNSLPYGVGQYG
GPGGGNNPQQQQQQQQQQLLAQQMAQRGGVVPGMPQGNRPVGTVVPMSTL
GGDGSGPAGQLVSGNPQQQQMLAQQQTGAMGPRPPQPNQLLGHPGQQQQQ
QQQPGTSQQQQQQQGVGIGGAGVVANAGTVAGVPAVAGGGAGGAVQSSGP
GGANRDVPDDRKRQIQQQLMLLLHAHKCNRRENLNPNREVCNVNYCKAMK
SVLAHMGTCKQSKDCTMQHCASSRQILLHYKTCQNSGCVICYPFRQNHSV
FQNANVPPGGGPAGIGGAPPGGGGAGGGAAGAGGNLQQQQQQQQQQQQNQ
QPNLTGLVVDGKQGQQVAPGGGQNTAIVLPQQQGAGGAPGAPKTPADMVQ
QLTQQQQQQQQQVHQQQVQQQELRRFDGMSQQVVAGGMQQQQQQGLPPVI
RIQGAQPAVRVLGPGGPGGPSGPNVLPNDVNSLHQQQQQMLQQQQQQGQN
RRRGGLATMVEQQQQHQQQQQQPNPAQLGGNIPAPLSVNVGGFGNTNFGG
AAAGGAVGANDKQQLKVAQVHPQSHGVGAGGASAGAGASGGQVAAGSSVL
MPADTTGSGNAGNPNQNAGGVAGGAGGGNGGNTGPPGDNEKDWRESVTAD
LRNHLVHKLVQAIFPTSDPTTMQDKRMWThVSYAEKVEKDMYEMAKSRSE
YYHLLAEKIYKIQKELEEKRLKRKEQHQQMLMQQQGVANPVAGGAAGGAG
SAAGVAGGVVLPQQQQQQQQQQQQQGQQPLQSCIHPSISPMGGVMPPQQL
RPQGPPGILGQQTAAGLGVGVGVTNNMVTMRSHSPGGNMLALQQQQRMQF
PQQQQQQPPGSGAGKMLVGPPGPSPGGMVVNPALSPYQTTNVLTSPVPGQ
QQQQQFINANGGTGANPQLSEIMKQRHIHQQQQQQQQQQQQGMLLPQSPF
SNSTPLQQQQQQQQQQQQQQATSNSFSSPMQQQQQGQQQQQQKPGSVLNN
MPPTPTSLEALNAGAGAPGTGGSASNVTVSAPSPSPGFLSNGPSIGTPSN
NNNNSSANNNPPSVSSLMQQPLSNRPGTPPYIPASPVPATSASGLAASST
PASAAATCASSGSGSNSSSGATAAGASSTSSSSSAGSGTPLSSVSTPTSA
TMATSSGGGGGGGGNAGGGSSTTPASNPLLLMSGGTAGGGTGATTTTSTS
SSSRMMSSSSSLSSQMAALEAAARDNDDETPSPSGENTNGSGGSGNAGGM
ASKGKLDSIKQDDDIKKEFMDDSCGGNNDSSQMDCSTGGGKGKNVNNDGT
SMIKMEIKTEDGLDGEVKIKTEAMDVDEAGGSTAGEHHGEGGGGSGVGGG
KDNINGAHDGGATGGAVDIKPKTETKPLVPEPLAPNAGDKKKKCQFNPEE
LRTALLPTLEKLYRQEPESVPFRYPVDPQALGIPDYFEIVKKPMDLGTIR
TNIQNGKYSDPWEYVDDVWLMFDNAWLYNRKTSRVYRYCTKLSEVFEAEI
DPVMQALGYCCGRKYTFNPQVLCCYGKQLCTIPRDAKYYSYQNSLKEYGV
ASNRYTYCQKCFNDIQGDTVTLGDDPLQSQTQIKKDQFKEMKNDHLELEP
FVNCQECGRKQHQICVLWLDSIWPGGFVCDNCLKKKNSKRKENKFNAKRL
PTTKLGVYIETRVNNFLKKKEAGAGEVHIRVVSSSDKCVEVKPGMRRRFV
EQGEMMNEFPYRAKALFAFEEVDGIDVCFFGMHVQEYGSECPAPNTRRVY
IAYLDSVHFFRPRQYRTAVYHEILLGYMDYVKQLGYTMAHIWACPPSEGD
DYIFHCHPTDQKIPKPKRLQEWYKKMLDKGMIERIIQDYKDILKQAMEDK
LGSAAELPYFEGDFWPNVLEESIKELDQEEEEKRKQAEAAEAAAAANLFS
IEENEVSGDGKKKGQKKAKKSNKSKAAQRKNSKKSNEHQSGNDLSTKIYA
TMEKHKEVFFVIRLHSAQSAASLAPIQDPDPLLTCDLMDGRDAFLTLARD
KHFEFSSLRRAQFSTLSMLYELHNQGQDKFVYTCNHCKTAVETRYHCTVC
DDFDLCIVCKEKVGHQHRMEKLGFDIDDGSALADHKQANPQEARKQSIQR
CIQSLAHACQCRDANCRLPSCQKMKLVVQHTKNCKRKPNGGCPICKQLIA
LCCYHAKNCEEQKCPVPFCPNIKHKLKQQQSQQKFQQQQLLRRRVALMSR
TAAPAALQGPAAVSGPTVVSGGVPVVGMSGVAVSQQVIPGQAGILPPGAG
GMSPSTVAVPSPVSGGAGAGGMGGMTSPHPHQPGIGMKPGGGHSPSPNVL
QVVKQVQEEAARQQVSHGGGFGKGVPMAPPVMNRPMGGAGPNQNVVNQLG
GMGVGVEGVGGVGVGGVGGVGVNQLNSGGGNTPGAPISGPGMNVNHLMSM
DQWGGGGAGGGGANPGGGNPQARYANNTGGMRQPTHVMQTNLIPPQQQQQ
MMGGLGGPNQLGGGQMPVGGQHGGMGMGMGAPPMAGTVGGVRPSPGAGGG
GGSATGGGLNTQQLALIMQKIKNNPTNESNQHILAILKQNPQIMAAIIKQ
RQQSQNNAAAGGGAPGPGGALQQQQAGNGPQNPQQQQQQQQQQQVMQQQQ
MQHMMNQQQGGGGPQQMNPNQQQQQQQVNLMQQQQQGGPGGPGSGLPTRM
PNMPNALGMLQSLPPNMSPGVSTQGGMVPNQNWNKMRYMQMSQYPPPYPQ
RQRGPHMGGAGPGPGQQQFPGGGGGAGNFNAGGAGGAGGVVGVGGVPGGA
GTVPGGDQYSMANAAAASNMLQQQQGQVGVGVGVGVKPGPGQQQQQMGVG
MPPGMQQQQQQQQPLQQQQMMQVAMPNANAQNPSAVVGGPNAQVMGPPTP
HSLQQQLMQSARSSPPIRSPQPTPSPRSAPSPRAAPSASPRAQPSPHHVM
SSHSPAPQGPPHDGMHNHGMHHQSPLPGVPQDVGVGVGVGVGVGVNVNVG
NVGVGNAGGALPDASDQLTKYVERL

Human homologue of Complete Genome candidate

AAC51331—CREB-binding protein

(SEQ ID NO:91)
1    tccgaattcc ttttttttaa ttgaggaatc aacagccgcc
     atcttgtcgc ggacccgacc
61   ggggcttcga gcgcgatcta ctcggccccg ccggtcccgg
     gccccacaac cgcccgcgca
121  ccccgctccg cccggccggc ccgctccgcc cggccctcgg
     cgcccgcccc ggcggccccg
181  ctcgcctctc ggctcggcct cccggagccc ggcggcggcg
     gcggcggcag cggcggcggc
241  ggcggcggaa cggggggtgg gggggccgcg gcggcggcgg
     cgaccccgct cggcgcattg
301  tttttcctca cggcggcggc ggcggcgggc cgcgggccgg
     gagcggagcc cggagccccc
361  tcgtcgtcgg gccgcgagcg aattcattaa gtggggcgcg
     gggggggagc gaggcggcgg
421  cggcggcggc accatgttct cggggactgc ctgagccgcc
     cggccgggcg ccgtcgctgc
481  cagccgggcc cgggggggcg gccgggccgc cggggcgccc
     ccaccgcgga gtgtcgcgct
541  cgggaggcgg gcaggggatg agggggccgc ggccggcggc
     ggcggcggcg gccgggggcg
601  ggcggtgagc gctgcggggc gctgttgctg tggctgagat
     ttggccgccg cctcccccac
661  ccggcctgcg ccctccctct ccctcggcgc ccgcccgcgc
     cgctcgcggc gcccgcgctc
721  gctcctctcc ctcgcagccg gcagggcccc cgacccccgt
     ccgggccctc gccggcccgg
781  ccgcccgtgc ccggggctgt tttcgcgagc aggtgaaaat
     ggctgagaac ttgctggacg
841  gaccgcccaa ccccaaaaga gccaaactca gctcgcccgg
     tttctcggcg aatgacagca
901  cagattttgg atcattgttt gacttggaaa atgatcttcc
     tgatgagctg atacccaatg
961  gaggagaatt aggcctttta aacagtggga accttgttcc
     agatgctgct tccaaacata
1021 aacaactgtc ggagcttcta cgaggaggca gcggctctag
     tatcaaccca ggaataggaa
1081 atgtgagcgc cagcagcccc gtgcagcagg gcctgggtgg
     ccaggctcaa gggcagccga
1141 acagtgctaa catggccagc ctcagtgcca tgggcaagag
     ccctctgagc cagggagatt
1201 cttcagcccc cagcctgcct aaacaggcag ccagcacctc
     tgggcccacc cccgctgcct
1261 cccaagcact gaatccgcaa gcacaaaagc aagtggggct
     ggcgactagc agccctgcca
1321 cgtcacagac tggacctggt atctgcatga atgctaactt
     taaccagacc cacccaggcc
1381 tcctcaatag taactctggc catagcttaa ttaatcaggc
     ttcacaaggg caggcgcaag
1441 tcatgaatgg atctcttggg gctgctggca gaggaagggg
     agctggaatg ccgtacccta
1501 ctccagccat gcagggcgcc tcgagcagcg tgctggctga
     gaccctaacg caggtttccc
1561 cgcaaatgac tggtcacgcg ggactgaaca ccgcacaggc
     aggaggcatg gccaagatgg
1621 gaataactgg gaacacaagt ccatttggac agccctttag
     tcaagctgga gggcagccaa
1681 tgggagccac tggagtgaac ccccagttag ccagcaaaca
     gagcatggtc aacagtttgc
1741 ccaccttccc tacagatatc aagaatactt cagtcaccaa
     cgtgccaaat atgtctcaga
1801 tgcaaacatc agtgggaatt gtacccacac aagcaattgc
     aacaggcccc actgcagatc
1861 ctgaaaaacg caaactgata cagcagcagc tggttctact
     gcttcatgct cataagtgtc
1921 agagacgaga gcaagcaaac ggagaggttc gggcctgctc
     gctcccgcat tgtcgaacca
1981 tgaaaaacgt tttgaatcac atgacgcatt gtcaggctgg
     gaaagcctgc caagttgccc
2041 attgtgcatc ttcacgacaa atcatctctc attggaagaa
     ctgcacacga catgactgtc
2101 ctgtttgcct ccctttgaaa aatgccagtg acaagcgaaa
     ccaacaaacc atcctggggt
2161 ctccagctag tggaattcaa aacacaattg gttctgttgg
     cacagggcaa cagaatgcca
2221 cttctttaag taacccaaat cccatagacc ccagctccat
     gcagcgagcc tatgctgctc
2281 tcggactccc ctacatgaac cagccccaga cgcagctgca
     gcctcaggtt cctggccagc
2341 aaccagcaca gcctcaaacc caccagcaga tgaggactct
     caaccccctg ggaaataatc
2401 caatgaacat tccagcagga ggaataacaa cagatcagca
     gcccccaaac ttgatttcag
2461 aatcagctct tccgacttcc ctgggggcca caaacccact
     gatgaacgat ggctccaact
2521 ctggtaacat tggaaccctc agcactatac caacagcagc
     tcctccttct agcaccggtg
2581 taaggaaagg ctggcacgaa catgtcactc aggacctgcg
     gagccatcta gtgcataaac
2641 tcgtccaagc catcttccca acacctgatc ccgcagctct
     aaaggatcgc cgcatggaaa
2701 acctggtagc ctatgctaag aaagtggaag gggacatgta
     cgagtctgcc aacagcaggg
2761 atgaatatta tcacttatta gcagagaaaa tctacaagat
     acaaaaagaa ctagaagaaa
2821 aacggaggtc gcgtttacat aaacaaggca tcttggggaa
     ccagccagcc ttaccagccc
2881 cgggggctca gccccctgtg attccacagg cacaacctgt
     gagacctcca aatggacccc
2941 tgtccctgcc agtgaatcgc atgcaagttt ctcaagggat
     gaattcattt aaccccatgt
3001 ccttggggaa cgtccagttg ccacaagcac ccatgggacc
     tcgtgcagcc tccccaatga
3061 accactctgt ccagatgaac agcatgggct cagtgccagg
     gatggccatt tctccttccc
3121 gaatgcctca gcctccgaac atgatgggtg cacacaccaa
     caacatgatg gcccaggcgc
3181 ccgctcagag ccagtttctg ccacagaacc agttcccgtc
     atccagcggg gcgatgagtg
3241 tgggcatggg gcagccgcca gcccaaacag gcgtgtcaca
     gggacaggtg cctggtgctg
3301 ctcttcctaa ccctctcaac atgctggggc ctcaggccag
     ccagctacct tgccctccag
3361 tgacacagtc accactgcac ccaacaccgc ctcctgcttc
     cacggctgct ggcatgccat
3421 ctctccagca cacgacacca cctgggatga ctcctcccca
     gccagcagct cccactcagc
3481 catcaactcc tgtgtcgtct tccgggcaga ctcccacccc
     gactcctggc tcagtgccca
3541 gtgctaccca aacccagagc acccctacag tccaggcagc
     agcccaggcc caggtgaccc
3601 cgcagcctca aaccccagtt cagcccccgt ctgtggctac
     ccctcagtca tcgcagcaac
3661 agccgacgcc tgtgcacgcc cagcctcctg gcacaccgct
     ttcccaggca gcagccagca
3721 ttgataacag agtccctacc ccctcctcgg tggccagcgc
     agaaaccaat tcccagcagc
3781 caggacctga cgtacctgtg ctggaaatga agacggagac
     ccaagcagag gacactgagc
3841 ccgatcctgg tgaatccaaa ggggagccca ggtctgagat
     gatggaggag gatttgcaag
3901 gagcttccca agttaaagaa gaaacagaca tagcagagca
     gaaatcagaa ccaatggaag
3961 tggatgaaaa gaaacctgaa gtgaaagtag aagttaaaga
     ggaagaagag agtagcagta
4021 acggcacagc ctctcagtca acatctcctt cgcagccgcg
     caaaaaaatc tttaaaccag
4081 aggagttacg ccaggccctc atgccaaccc tagaagcact
     gtatcgacag gacccagagt
4141 cattaccttt ccggcagcct gtagatcccc agctcctcgg
     aattccagac tattttgaca
4201 tcgtaaagaa tcccatggac ctctccacca tcaagcggaa
     gctggacaca gggcaatacc
4261 aagagccctg gcagtacgtg gacgacgtct ggctcatgtt
     caacaatgcc tggctctata
4321 atcgcaagac atcccgagtc tataagtttt gcagtaagct
     tgcagaggtc tttgagcagg
4381 aaattgaccc tgtcatgcag tcccttggat attgctgtgg
     acgcaagtat gagttttccc
4441 cacagacttt gtgctgctat gggaagcagc tgtgtaccat
     tcctcgcgat gctgcctact
4501 acagctatca gaataggtat catttctgtg agaagtgttt
     cacagagatc cagggcgaga
4561 atgtgaccct gggtgacgac ccttcacagc cccagacgac
     aatttcaaag gatcagtttg
4621 aaaagaagaa aaatgatacc ttagaccccg aacctttcgt
     tgattgcaag gagtgtggcc
4681 ggaagatgca tcagatttgc gttctgcact atgacatcat
     ttggccttca ggttttgtgt
4741 gcgacaactg cttgaagaaa actggcagac ctcgaaaaga
     aaacaaattc agtgctaaga
4801 ggctgcagac cacaagactg ggaaaccact tggaagaccg
     agtgaacaaa tttttgcggc
4861 gccagaatca ccctgaagcc ggggaggttt ttgtccgagt
     ggtggccagc tcagacaaga
4921 cggtggaggt caagcccggg atgaagtcac ggtttgtgga
     ttctggggaa atgtctgaat
4981 ctttcccata tcgaaccaaa gctctgtttg cttttgagga
     aattgacggc gtggatgtct
5041 gcttttttgg aatgcacgtc caagaatacg gctctgattg
     cccccctcca aacacgaggc
5101 gtgtgtacat ttcttatctg gatagtattc atttcttccg
     gccacgttgc ctccgcacag
5161 ccgtttacca tgagatcctt attggatatt tagagtatgt
     gaagaaatta gggtatgtga
5221 cagggcacat ctgggcctgt cctccaagtg aaggagatga
     ttacatcttc cattgccacc
5281 cacctgatca aaaaataccc aagccaaaac gactgcagga
     gtggtacaaa aagatgctgg
5341 acaaggcgtt tgcagagcgg atcatccatg actacaagga
     tattttcaaa caagcaactg
5401 aagacaggct caccagtgcc aaggaactgc cctattttga
     aggtgatttc tggcccaatg
5461 tgttagaaga gagcattaag gaactagaac aagaagaaga
     ggagaggaaa aaggaagaga
5521 gcactgcagc cagtgaaacc actgagggca gtcagggcga
     cagcaagaat gccaagaaga
5581 agaacaacaa gaaaaccaac aagaacaaaa gcagcatcag
     ccgcgccaac aagaagaagc
5641 ccagcatgcc caacgtgtcc aatgacctgt cccagaagct
     gtatgccacc atggagaagc
5701 acaaggaggt cttcttcgtg atccacctgc acgctgggcc
     tgtcatcaac accctgcccc
5761 ccatcgtcga ccccgacccc ctgctcagct gtgacctcat
     ggatgggcgc gacgccttcc
5821 tcaccctcgc cagagacaag cactgggagt tctcctcctt
     gcgccgctcc aagtggtcca
5881 cgctctgcat gctggtggag ctgcacaccc agggccagga
     ccgctttgtc tacacctgca
5941 acgagtgcaa gcaccacgtg gagacgcgct ggcactgcac
     tgtgtgcgag gactacgacc
6001 tctgcatcaa ctgctataac acgaagagcc atgcccataa
     gatggtgaag tgggggctgg
6061 gcctggatga cgagggcagc agccagggcg agccacagtc
     aaagagcccc caggagtcac
6121 gccggctgag catccagcgc tgcatccagt cgctggtgca
     cgcgtgccag tgccgcaacg
6181 ccaactgctc gctgccatcc tgccagaaga tgaagcgggt
     ggtgcagcac accaagggct
6241 gcaaacgcaa gaccaacggg ggctgcccgg tgtgcaagca
     gctcatcgcc ctctgctgct
6301 accacgccaa gcactgccaa gaaaacaaat gccccgtgcc
     cttctgcctc aacatcaaac
6361 acaagctccg ccagcagcag atccagcacc gcctgcagca
     ggcccagctc atgcgccggc
6421 ggatggccac catgaacacc cgcaacgtgc ctcagcagag
     tctgccttct cctacctcag
6481 caccgcccgg gacccccaca cagcagccca gcacacccca
     gacgccgcag ccccctgccc
6541 agccccaacc ctcacccgtg agcatgtcac cagctggctt
     ccccagcgtg gcccggactc
6601 agccccccac cacggtgtcc acagggaagc ctaccagcca
     ggtgccggcc cccccacccc
6661 cggcccagcc ccctcctgca gcggtggaag cggctcggca
     gatcgagcgt gaggcccagc
6721 agcagcagca cctgtaccgg gtgaacatca acaacagcat
     gcccccagga cgcacgggca
6781 tggggacccc ggggagccag atggcccccg tgagcctgaa
     tgtgccccga cccaaccagg
6841 tgagcgggcc cgtcatgccc agcatgcctc ccgggcagtg
     gcagcaggcg ccccttcccc
6901 agcagcagcc catgccaggc ttgcccaggc ctgtgatatc
     catgcaggcc caggcggccg
6961 tggctgggcc ccggatgccc agcgtgcagc cacccaggag
     catctcaccc agcgctctgc
7021 aagacctgct gcggaccctg aagtcgccca gctcccctca
     gcagcaacag caggtgctga
7081 acattctcaa atcaaacccg cagctaatgg cagctttcat
     caaacagcgc acagccaagt
7141 acgtggccaa tcagcccggc atgcagcccc agcctggcct
     ccagtcccag cccggcatgc
7201 aaccccagcc tggcatgcac cagcagccca gcctgcagaa
     cctgaatgcc atgcaggctg
7261 gcgtgccgcg gcccggtgtg cctccacagc agcaggcgat
     gggaggcctg aacccccagg
7321 gccaggcctt gaacatcatg aacccaggac acaaccccaa
     catggcgagt atgaatccac
7381 agtaccgaga aatgttacgg aggcagctgc tgcagcagca
     gcagcaacag cagcagcaac
7441 aacagcagca acagcagcag cagcaaggga gtgccggcat
     ggctgggggc atggcggggc
7501 acggccagtt ccagcagcct caaggacccg gaggctaccc
     accggccatg cagcagcagc
7561 agcgcatgca gcagcatctc cccctccagg gcagctccat
     gggccagatg gcggctcaga
7621 tgggacagct tggccagatg gggcagccgg ggctgggggc
     agacagcacc cccaacatcc
7681 agcaagccct gcagcagcgg attctgcagc aacagcagat
     gaagcagcag attgggtccc
7741 caggccagcc gaaccccatg agcccccagc aacacatgct
     ctcaggacag ccacaggcct
7801 cgcatctccc tggccagcag atcgccacgt cccttagtaa
     ccaggtgcgg tctccagccc
7861 ctgtccagtc tccacggccc cagtcccagc ctccacattc
     cagcccgtca ccacggatac
7921 agccccagcc ttcgccacac cacgtctcac cccagactgg
     ttccccccac cccggactcg
7981 cagtcaccat ggccagctcc atagatcagg gacacttggg
     gaaccccgaa cagagtgcaa
8041 tgctccccca gctgaacacc cccagcagga gtgcgctgtc
     cagcgaactg tccctggtcg
8101 gggacaccac gggggacacg ctagagaagt ttgtggaggg
     cttgtag
(SEQ ID NO:92)
1    maenlldgpp npkraldssp gfsandstdf gslfdlendl
     pdelipngge lgllnsgnlv
61   pdaaskhkql sellrggsgs sinpgignvs asspvqqglg
     gqaqgqpnsa nmaslsamgk
121  splsqgdssa pslpkqaast sgptpaasqa lnpqaqkqvg
     latsspatsq tgpgicmnan
181  fnqthpglln snsghslinq asqgqaqvmn gslgaagrgr
     gagmpyptpa mqgasssvla
241  etltqvspqm tghaglntaq aggmakmgit gntspfgqpf
     sqaggqpmga tgvnpqlask
301  qsmvnslptf ptdikntsvt nvpnmsqmqt svgivptqai
     atgptadpek rkliqqqlvl
361  llhahkcqrr eqangevrac slphcrtmkn vlnhmthcqa
     gkacqvahca ssrqiishwk
421  nctrhdcpvc lplknasdkr nqqtilgspa sgiqntigsv
     gtgqqnatsl snpnpidpss
481  mqrayaalgl pynmqpqtql qpqvpgqqpa qpqthqqmrt
     lnplgnnpmn ipaggittdq
541  qppnlisesa lptslgatnp lmndgsnsgn igtlstipta
     appsstgvrk gwhehvtqdl
601  rshlvhklvq aifptpdpaa lkdrrmenlv ayakkvegdm
     yesansrdey yhllaekiyk
661  iqkeleekrr srlhkqgilg nqpalpapga qppvipqaqp
     vrppngplsl pvnrmqvsqg
721  mnsfnpmslg nvqlpqapmg praaspmnhs vqmnsmgsvp
     gmaispsrmp qppnmmgaht
781  nnmmaqapaq sqflpqnqfp sssgamsvgm gqppaqtgvs
     qgqvpgaalp nplnmlgpqa
841  sqlpcppvtq splhptpppa staagmpslq httppgmtpp
     qpaaptqpst pvsssgqtpt
901  ptpgsvpsat qtqstptvqa aaqaqvtpqp qtpvqppsva
     tpqssqqqpt pvhaqppgtp
961  lsqaaasidn rvptpssvas aetnsqqpgp dvpvlemkte
     tqaedtepdp geskgeprse
1021 mmeedlqgas qvkeetdiae qksepmevde kkpevkvevk
     eeeesssngt asqstspsqp
1081 rkkifkpeel rqalmptlea lyrqdpeslp frqpvdpqll
     gipdyfdivk npmdlstikr
1141 kldtgqyqep wqyvddvwlm fnnawlynrk tsrvykfcsk
     laevfeqeid pvmqslgycc
1201 grkyefspqt lccygkqlct iprdaayysy qnryhfcekc
     fteiqgenvt lgddpsqpqt
1261 tiskdqfekk kndtldpepf vdckecgrkm hqicvlhydi
     iwpsgfvcdn clkktgrprk
1321 enkfsakrlq ttrlgnhled rvnkflrrqn hpeagevfvr
     vvassdktve vkpgmksrfv
1381 dsgemsesfp yrtkalfafe eidgvdvcff gmhvqeygsd
     cpppntrrvy isyldsihff
1441 rprclrtavy heiligyley vkklgyvtgh iwacppsegd
     dyithchppd qkipkpkrlq
1501 ewykkmldka faeriihdyk difkqatedr ltsakelpyf
     egdfwpnvle esikeleqee
1561 eerkkeesta asettegsqg dsknakkknn kktnknkssi
     srankkkpsm pnvsndlsqk
1621 lyatmekhke vffvihlhag pvintlppiv dpdpllscdl
     mdgrdafltl ardkhwefss
1681 lrrskwstlc mlvelhtqgq drfvytcnec khhvetrwhc
     tvcedydlci ncyntkshah
1741 kmvkwglgld degssqgepq skspqesrrl siqrciqslv
     hacqcrnanc slpscqkmkr
1801 vvqhtkgckr ktnggcpvck qlialccyha khcqenkcpv
     pfclnikhkl rqqqiqhrlq
1861 qaqlmrrrma tmntrnvpqq slpsptsapp gtptqqpstp
     qtpqppaqpq pspvsmspag
1921 fpsvartqpp ttvstgkpts qvpappppaq pppaaveaar
     qiereaqqqq hlyrvninns
1981 mppgrtgmgt pgsqmapvsl nvprpnqvsg pvmpsmppgq
     wqqaplpqqq pmpglprpvi
2041 smqaqaavag prmpsvqppr sispsalqdl lrtlkspssp
     qqqqqvlnil ksnpqlmaaf
2101 ikqrtakyva nqpgmqpqpg lqsqpgmqpq pgmhqqpslq
     nlnamqagvp rpgvppqqqa
2161 mgglnpqgqa lnimnpghnp nmasmnpqyr emlrrqllqq
     qqqqqqqqqq qqqqqqgsag
2221 maggmaghgq fqqpqgpggy ppamqqqqrm qqhlplqgss
     mgqmaaqmgq lgqmgqpglg
2281 adstpniqqa lqqrilqqqq mkqqigspgq pnpmspqqhm
     lsgajqashl pgqqiatsls
2341 nqvrspapvq sprpqsqpph sspspriqpq psphhvspqt
     gsphpglavt massidqghl
2401 gnpeqsamlp qlntpsrsal sselslvgdt tgdtlekfve
     gl

Putative function

CREB-binding protein, transcription factor

Example 2 (Category 1)

Line ID—492

Phenotype—Female sterile, few eggs laid, several fully matured eggs in ovarioles

Annotated Drosophila genome genomic segment containing P element insertion site (and map position)—AE003490 (11B4-14)

P element insertion site—30,773

Annotated Drosophila genome Complete Genome candidate—CG2028—CK1 alpha (2 splice variants)

(SEQ ID NO:93)
TAAAGTGCAAGCTGGAAAAGAAAAGCAAAACAAATTCCGGAGAGCAGAAA
GAGAGTTTTTCAAGTGAACGCGTCCAACTGTTTTTGAAGCGAAGCGCTTA
GGCGGAGGAGCAGCTAGCCAGGATGGACAAGATGCGGATATTGAAGGAAA
GTCGCCCCGAGATAATCGTCGGTGGCAAATATCGGGTGATCAGGAAGATT
GGAAGCGGATCGTTTGGCGACATTTACCTGGGCATGAGCATCCAGAGCGG
CGAAGAAGTGGCCATCAAGATGGAGAGCGCCCACGCCCGCCATCCGCAGC
TGTTGTACGAGGCCAAGCTGTACCGCATTCTGAGCGGCGGCGTTGGATTC
CCTCGTATACGTCACCATGGCAAGGAAAAGAACTTCAACACCCTGGTCAT
GGACCTGCTGGGACCCTCGCTGGAGGATCTGTTCAATTTCTGTACGCGCC
ATTTCACAATCAAAACGGTTCTGATGCTCGTCGACCAGATGATCGGACGC
TTGGAGTACATCCATCTCAAGTGCTTCATCCATCGCGACATCAAGCCGGA
TAACTTCCTAATGGGCATTGGTCGGCACTGCAATAAGCTGTTCCTGATCG
ATTTCGGTCTGGCCAAGAAGTTCCGCGATCCGCACACGCGCCATCACATC
GTTTACCGCGAGGACAAGAACCTCACCGGCACTGCCCGCTATGCCTCGAT
CAATGCCCATCTGGGCATCGAGCAGTCGCGGCGTGACGACATGGAATCGC
TTGGATACGTGATGATGTACTTCAATCGCGGCGTACTGCCATGGCAAGGC
ATGAAGGCCAACACCAAGCAGCAGAAATACGAGAAGATCTCCGAAAAGAA
GATGTCCACGCCCATCGAGGTCCTCTGCAAGGGCTCGCCGGCCGAGTTCT
CCATGTATCTGAACTATTGTCGTAGCCTGCGCTTCGAGGAGCAGCCAGAT
TACATGTACCTACGTCAATTGTTCCGCATACTGTTCAGAACGCTGAACCA
TCAGTATGACTACATCTACGACTGGACAATGCTGAAGCAGAAGACCCATC
AGGGTCAACCCAATCCAGCTATACTCTTGGAGCAATTGGACAAGGACAAG
GAGAAGCAGAACGGCAAGCCCCTGATCGCGGACTAAGAGCTGCAGCGCAT
TCAGACGAATGGGGGGAGTGCATCAGAGAAGGAGAACGTGGATGCGTGGA
TGTAAATGACGTTGATGTGGGCGAAAGGCCCGGCAAGGAGCGGAGCAAAT
ATGAAACAGACGCAACCGTAAAATTGAGTAACACCAGCGGTCGTCCGAAT
GTTTCTTAATATTAATTTAAATTCAATACTAAACAAATAAGGAACCACAA
ACAAGCAAGCAAC
(SEQ ID NO:94)
MDKMRILKESRPEIIVGGKYRVIRKIGSGSFGDIYLGMSIQSGEEVAIKM
ESAHARHPQLLYEAKLYRILSGGVGFPRIRHHGKEKNFNTLVMDLLGPSL
EDLFNFCTRHFTIKTVLMLVDQMIGRLEYIHLKCFIHRDIKPDNFLMGIG
RHCNKLFLIDFGLAKKERDPHTRHHIVYREDKNLTGTARYASINAHLGIE
QSRRDDMLSLGYVMMYFNRGVLPWQGMKANTKQQKYEKISEKKMSTPIEV
LCKGSPAEFSMYLNYCRSLRFEEQPDYMYLRQLFRILFRTLNHQYDYIYD
WTMLKQKTHQGQPNPAILLEQLDKDKEKQNGKPLIAD
(SEQ ID NO:95)
TTTGGTTGAACCTATCGGGCCCTATCGATATAAGCAAAAGCATTTTTGCT
GGATCTACCATTTTATTTTAGTTAATAAAATACATATATTTCCTCTCTTT
TTGTTCCGTTTGTGCGCGTACAAAACTAGCTGCGAACTCGTGCAATATTT
CATAAACTGAATGGGAAAACAACGATAACGACGAAAGAAAACGAAAACGG
ATCTGCGACGAAATTTTCCCCGTTCCGTTTTTTTTTCTCCACCAGCAGCA
GAAGCAGCAGAGCAAAAGCAGCGAATATATTTGTAAAAGAGAGCCCCAAC
CTTGAGAAAAAACAACCAGCAGGGCAATAATTAGTTGAATTTATCGTCTG
CTGTTTTTCAAGTGAACGCGTCCAACTGTTTTTGAAGCGAAGCGCTTAGG
CGGAGGAGCAGCTAGCCAGGATGGACAAGATGCGGATATTGAAGGAAAGT
CGCCCCGAGATAATCGTCGGTGGCAAATATCGGGTGATCAGGAAGATTGG
AAGCGGATCGTTTGGCGACATTTACCTGGGCATGAGCATCCAGAGCGGCG
AAGAAGTGGCCATCAAGATGGAGAGCGCCCACGCCCGCCATCCGCAGCTG
TTGTACGAGGCCAAGCTGTACCGCATTCTGAGCGGCGGCGTTGGATTCCC
TCGTATACGTCACCATGGCAAGGAAAAGAACTTCAACACCCTGGTCATGG
ACCTGCTGGGACCCTCGCTGGAGGATCTGTTCAATTTCTGTACGCGCCAT
TTCACAATCAAAACGGTTCTGATGCTCGTCGACCAGATGATCGGACGCTT
GGAGTACATCCATCTCAAGTGCTTCATCCATCGCGACATCAAGCCGGATA
ACTTCCTAATGGGCATTGGTCGGCACTGCAATAAGCTGTTCCTGATCGAT
TTCGGTCTGGCCAAGAAGTTCCGCGATCCGCACACGCGCCATCACATCGT
TTACCGCGAGGACAAGAACCTCACCGGCACTGCCCGCTATGCCTCGATCA
ATGCCCATCTGGGCATCGAGCAGTCGCGGCGTGACGACATGGAATCGCTT
GGATACGTGATGATGTACTTCAATCGCGGCGTACTGCCATGGCAAGGCAT
GAAGGCCAACACCAAGCAGCAGAAATACGAGAAGATCTCCGAAAAGAAGA
TGTCCACGCCCATCGAGGTCCTCTGCAAGGGCTCGCCGGCCGAGTTCTCC
ATGTATCTGAACTATTGTCGTAGCCTGCGCTTCGAGGAGCAGCCAGATTA
CATGTACCTACGTCAATTGTTCCGCATACTGTTCAGAACGCTGAACCATC
AGTATGACTACATCTACGACTGGACAATGCTGAAGCAGAAGACCCATCAG
GGTCAACCCAATCCAGCTATACTCTTGGAGCAATTGGACAAGGACAAGGA
GAAGCAGAACGGCAAGCCCCTGATCGCGGACTAAGAGCTGCAGCGCATTC
AGACGAATGGGGGGAGTGCATCAGAGAAGGAGAACGTGGATGCGTGGATG
TAAATGACGTTGATGTGGGCGAAAGGCCCGGCAAGGAGCGGAGCAAATAT
GAAACAGACGCAACCGTAAAATTGAGTAACACCAGCGGTCGTCCGAATGT
TTCTTAATATTAAYFTAAATTCAATACTAAACAAATAAGGAACCACAAAC
AAGCAAGCAAC
(SEQ ID NO:96)
MDKMRILKESRPEIIVGGKYRVIRKIGSGSFGDIYLGMSIQSGEEVAIKM
ESAHARHPQLLYEAKLYRILSGGVGFPRIRHHGKEKNFNTLVMDLLGPSL
EDLFNFCTRHFTIKTVLMLVDQMIGRLEYIHLKCFIHRDIKPDNFLMGIG
RHCNKLFLIDFGLAKKFRDPHTRHHIVYREDKNLTGTARYASINAHLGIE
QSRRDDMESLGYVMMYFNRGVLPWQGMKANTKQQKYEKISEKKMSTPTEV
LCKGSPAEFSMYLNYCRSLRFEEQPDYMYLRQLFRILFRTLNHQYDYIYD
WTMLKQKTHQGQPNPAILLEQLDKDKEKQNGKPLIAD

Human homologue of Complete Genome candidate

P48729 Casein kinase I, alpha isoform (cki-alpha) (ckl)

(SEQ ID NO: 97)
1    ccgcctccgt gttccgtttc ctgccgccct cctctcgtag
     ccttgcctag tgtggagccc
61   caggcctccg tcctcttccc agaggtgtcg aggcttggcc
     ccagcctcca tcttcgtctc
121  tcaggatggc gagtagcagc ggctccaagg ctgaattcat
     tgtcggtggg aaatataaac
181  tggtacggaa gatcgggtct ggctccttcg gggacatcta
     tttggcgatc aacatcacca
241  acggcgagga agtggcactg aagctagaat ctcagaaggc
     caggcatccc cagttgctgt
301  acgagagcaa gctctataag attcttcaag gtggggttgg
     catcccccac atacggtggt
361  atggtcagga aaaagactac aatgtactag tcatggatct
     tctgggacct agcctcgaag
421  acctcttcaa tttctgttca agaaggttca caatgaaaac
     tgtacttatg ttagctgacc
481  agatgatcag tagaattgaa tatgtgcata caaagaattt
     tatacacaga gacattaaac
541  cagataactt cctaatgggt attgggcgtc actgtaataa
     gttattcctt attgattttg
601  gtttggccaa aaagtacaga gacaacagga caaggcaaca
     cataccatac agagaagata
661  aaaacctcac tggcactgcc cgatatgcta gcatcaatgc
     acatcttggt attgagcaga
721  gtcgccgaga tgacatggaa tcattaggat atgttttgat
     gtattttaat agaaccagcc
781  tgccatggca agggctaaag gctgcaacaa agaaacaaaa
     atatgaaaag attagtgaaa
841  agaagatgtc cacgcctgtt gaagttttat gtaaggggtt
     tcctgcagaa tttgcgatgt
901  acttaaacta ttgtcgtggg ctacgctttg aggaagcccc
     agattacatg tatctgaggc
961  agctattccg cattcttttc aggaccctga accatcaata
     tgactacaca tttgattgga
1021 caatgttaaa gcagaaagca gcacagcagg cagcctcttc
     aagtgggcag ggtcagcagg
1081 cccaaacccc cacaggcaag caaactgaca aatccaagag
     taacatgaaa ggtttctaat
1141 ttctaagcat gaattgagga acagaagaag cagacgagat
     gatcggagca gcatttgttt
1201 ctccccaaat ctagaaattt tagttcatat gtacactagc
     cagtggttgt ggacaacca
(SEQ ID NO: 98)
1    masssgskae fivggkyklv rkigsgsfgd iylainitng
     eevalklesq karhpqllye
61   sklykilqgg vgiphirwyg qekdynvlvm dllgpsledl
     fnfcsrrftm ktvlmladqm
121  isrieyvhtk nfihrdikpd nflmgigrhc nklflidfgl
     akkyrdnrtr qhipyredkn
181  ltgtaryasi nahlgieqsr rddmeslgyv lmyfnrtslp
     wqglkaatkk qkyekisekk
241  mstpvevlck gfpaefamyl nycrglrfee apdymylrql
     frilfrtlnh qydytfdwtm
301  lkqkaaqqaa sssgqgqqaq tptgkqtdks ksnmkgf

Putative function

Casein kinase

Example 2A (Category 1)

Line ID—ccr-a2

Phenotype—Female semi-sterile, Lays eggs, but arrest before cortical migration

Annotated Drosophila genome genomic segment containing P element insertion site (and map position)—AE003435 (5C6)

P element insertion site sequence

(SEQ ID NO: 99)
GATCAGACGATATTCGGACTCCAAGCAGAGCACTTTGAAGGTGAGTTCGC
CGGAAACCAGGCAAAGCGCCATTCGCCATTCAGGCTGCGCAACTGTTGGG
AAGGGCGATCGGTGCGGGCCTCTTCGCTATTACGCCAGCTGGCGAAAGGG
GGATGTGCTGCAAGGCGATTAAGTTGGGTAACGCCAGGGTTTTCCCAGTC
ACGACGTTGTAAAACGACGGCCAGTGCCAAGCTCTGCTGCTCTAAACGAC
GCATTTCGTACTCCAAAGTACGAATTTTTTCCCTCAAGCTCTTATTTTCA
TTAAACAATGAACAGGACCTAACGCCACAGTA

Annotated Drosophila genome Complete Genome candidate—CG3011—glycine hydroxymethyltransferase

(SEQ ID NO: 100)
GTAAATGTTGTTTACCAACGTAACGCGTGTTTTCGCTTCGTTGTATTTTC
GGTGTCGAATATTTTGGATGCTGGCCAAGAGATAGCGCAGCGATCGGGTC
GGAACTCTTGGGCGGACTTATCACTGGGTCGGTCAGGGGTCACGGGTTAT
CGTTATCGCTTATCAGCCAGCGGCGGCGTCATCTCAGCGCCGGCGACTCT
TCTCACTTTGCGGCAGTTCCGATTCGAACGCAGCCGTTTACAAAGACATG
CAGCGGGCGCGCTCTACACTGACACAAAAGCTTCGGTTTTGCCTTAGTCG
GGACCTGAACACCAAAGTTGGCAACCCGGTTAACTTCGAGACTGGAAAGC
TTAGCGGAGCTTTAACTCGCATCGCCGCCAAAAAACAACCATCACCAACG
CCATTCTTACCGGCGATCAGACGATATTCGGACTCCAAGCAGAGCACTTT
GAAGAATATGGCCGATCAGAAACTGCTGCAAACCCCGCTGGCACAGGGCG
ATCCGGAGCTGGCCGAGCTGATCAAGAAGGAGAAGGAGCGCCAGCGCGAA
GGACTCGAGATGATCGCCAGTGAGAACTTCACCTCGGTGGCGGTTCTCGA
GAGCCTGAGCTCCTGCCTGACCAACAAGTACTCCGAGGGATATCCCGGCA
AGAGGTACTACGGTGGCAACGAGTACATCGACCGCATAGAGCTGCTCGCC
CAGCAACGCGGACGCGAGCTGTTCAACCTGGACGATGAGAAGTGGGGCGT
TAATGTGCAGCCTTATTCCGGATCCCCGGCCAATCTGGCTGTCTACACGG
GCGTCTGCCGGCCCCACGATCGCATCATGGGCCTGGATCTGCCCGATGGC
GGTCACTTGACGCACGGTTTCTTCACGCCCACCAAGAAGATATCGGCCAC
ATCGATCTTCTTCGAGAGCATGCCGTACAAAGTGAACCCGGAGACGGGCA
TCATCGATTACGATAAGTTGGCGGAGGCGGCGAAGAATTTCCGGCCGCAG
ATCATCATTGCTGGCATATCGTGCTACTCCCGTCTGCTGGACTATGCGCG
TTTCCGACAGATTTGCGATGATGTGGGCGCCTACCTGATGGCCGACATGG
CCCATGTGGCGGGCATTGTGGCCGCGGGATTGATACCATCGCCGTTCGAA
TGGGCCGACATTGTGACCACCACCACGCACAAGACACTGCGAGGTCCGCG
CGCCGGCGTGATCTTCTTCCGCAAGGGCGTGCGCAGCACCAAGGCCAATG
GAGACAAGGTACTCTACGATCTGGAGGAGCGCATCAACCAGGCGGTGTTT
CCATCACTCCAGGGTGGTCCGCACAACAACGCCGTGGCTGGCATTGCCAC
CGCCTTCAAGCAGGCCAAGAGTCCCGAATTCAAGGCCTACCAGACGCAGG
TGCTCAAGAATGCCAAGGCCCTGTGCGATGGCCTCATTTCGCGAGGCTAT
CAGGTGGCCACCGGCGGCACCGACGTCCATTTGGTGCTGGTCGATGTGCG
TAAGGCTGGCCTGACCGGCGCCAAGGCCGAGTACATCCTCGAGGAGGTGG
GCATCGCGTGCAACAAGAACACTGTGCCCGGCGACAAGTCCGCCATGAAT
CCCTCCGGCATCCGGCTGGGCACACCGGCCCTGACCACTCGCGGCCTTGC
CGAGCAGGACATCGAGCAGGTGGTGGCCTTCATCGATGCTGCCCTAAAGG
TTGGCGTCCAGGCAGCCAAGCTGGCCGGCAGTCCCAAGATAACCGATTAC
CACAAGACGCTGGCCGAGAATGTGGAGCTCAAGGCCCAGGTGGACGAGAT
CCGCAAGAATGTGGCCCAGTTCAGCAGGAAATTCCCGCTGCCCGGCCTGG
AGACCCTGTAG
(SEQ ID NO: 101)
MQRARSTLTQKLRFCLSRDLNTKVGNPVNFETGKLSGALTRIAAKKQPSP
TPFLPAIRRYSDSKQSTLKNMADQKLLQTPLAQGDPELAELIKKEKERQR
EGLEMIASENFTSVAVLESLSSCLTNKYSEGYPGKRYYGGNEYIDRIELL
AQQRGRELFNLDDEKWGVNVQPYSGSPANLAVYTGVCRPHDRIMGLDLPD
GGHLTHGFFTPTKKISATSIFFESMPYKVNPETGIIDYDKLAEAAKNFRP
QIIIAGISCYSRLLDYARFRQICDDVGAYLMADMAHVAGIVAAGLIPSPF
EWADLVTTTTHKTLRGPRAGVIFFRKGVRSTKANGDKVLYDLEERINQAV
FPSLQGGPHNNAVAGIATAFKQAKSPEFKAYQTQVLKNAKALCDGLISRG
YQVATGGTDVHLVLVDVRKAGLTGAKAEYILEEVGIACNKNTVPGDKSAM
NPSGIRLGTPALTTRGLAEQDIEQVVAFIDAALKVGVQAAKLAGSPKITD
YHKTLAENVELKAQVDEIRKNVAQFSRKFPLPGLETL

Human homologue of Complete Genome candidate

AAA63258—serine hydroxymethyltransferase

(SEQ ID NO: 102)
1    ggcacgaggc ctgcgacttc cgagttgcga tgctgtactt
     ctctttgttt tgggcggctc
61   ggcctctgca gagatgtggg cagctggtca ggatggccat
     tcgggctcag cacagcaacg
121  cagcccagac tcagactggg gaagcaaaca ggggctggac
     aggccaggag agcctgtcgg
181  acagtgatcc tgagatgtgg gagttgctgc agagggagaa
     ggacaggcag tgtcgtggcc
241  tggagctcat tgcctcagag aacttctgca gccgagctgc
     gctggaggcc ctggggtcct
301  gtctgaacaa caagtactcg gagggttatc ctggcaagag
     atactatggg ggagcagagg
361  tggtggatga aattgagctg ctgtgccagc gccgggcctt
     ggaagccttt gacctggatc
421  ctgcacagtg gggagtcaat gtccagccct actccgggtc
     cccagccaac ctggccgtct
481  acacagccct tctgcaacct cacgaccgga tcatggggct
     ggacctgccc gatgggggcc
541  agtgatctca cccacggcta catgtctgac gtcaagcgga
     tatcagccac gtccatcttc
601  ttcgagtcta tgccctataa gctcaacccc aaaactggcc
     tcattgacta caaccagctg
661  gcactgactg ctcgactttt ccggccacgg ctcatcatag
     ctggcaccag cgcctatgct
721  cgcctcattg actacgcccg catgagagag gtgtgtgatg
     aagtcaaagc acacctgctg
781  gcagacatgg cccacatcag tggcctggtg gctgccaagg
     tgattccctc gcctttcaag
841  cacgcggaca tcgtcaccac cactactcac aagactcttc
     gaggggccag gtcagggctc
901  atcttctacc ggaaaggggt gaaggctgtg gaccccaaga
     ctggccggga gatcccttac
961  acatttgagg accgaatcaa ctttgccgtg ttcccatccc
     tgcagggggg cccccacaat
1021 catgccattg ctgcagtagc tgtggcccta aagcaggcct
     gcacccccat gttccgggag
1081 tactccctgc aggttctgaa gaatgctcgg gccatggcag
     atgccctgct agagcgaggc
1141 tactcactgg tatcaggtgg tactgacaac cacctggtgc
     tggtggacct gcggcccaag
1201 ggcctggatg gagctcgggc tgagcgggtg ctagagcttg
     tatccatcac tgccaacaag
1261 aacacctgtc ctggagaccg aagtgccatc acaccgggcg
     gcctgcggct tggggcccca
1321 gccttaactt ctcgacagtt ccgtgaggat gacttccgga
     gagttgtgga ctttatagat
1381 gaaggggtca acattggctt agaggtgaag agcaagactg
     ccaagctcca ggatttcaaa
1441 tccttcctgc ttaaggactc agaaacaagt cagcgtctgg
     ccaacctcag gcaacgggtg
1501 gagcagtttg ccagggcctt ccccatgcct ggttttgatg
     agcattgaag gcacctggga
1561 aatgaggccc acagactcaa agttactctc cttcccccta
     cctgggccag tgaaatagaa
1621 agcctttcta ttttttggtg cgggagggaa gacctctcac
     ttagggcaag agccaggtat
1681 agtctccctt cccagaattt gtaactgaga agatcttttc
     tttttccttt ttttggtaac
1741 aagacttaga aggagggccc aggcactttc tgtttgaacc
     cctgtcatga tcacagtgtc
1801 agagacgcgt cctctttctt ggggaagttg aggagtgccc
     ttcagagcca gtagcaggca
1861 ggggtgggta ggcaccctcc ttcctgtttt tatctaataa
     aatgctaacc tgcaaaaaaa
1921 aaaaaaaaaa a
(SEQ ID NO: 103)
1    aaqtqtgean rgwtgqesls dsdpemwell qrekdrqcrg
     leliasenfc sraalealgs
61   clnnkysegy pgkryyggae vvdeiellcq rraleafdld
     paqwgvnvqp ysgspanlav
121  ytallqphdr imgldlpdgg hlthgymsdv krisatsiff
     esmpyklnpk tglidynqla
181  ltarlfrprl iiagtsayar lidyarmrev cdevkahlla
     dmahisglva akvipspfkh
241  adivtttthk tlrgarsgli fyrkgvkavd pktgreilyt
     fedrinfavf pslqggphnh
301  aiaavavalk qactpmfrey slqvlknara madallergy
     slvsggtdnh lvlvdlrpkg
361  ldgaraervl elvsitankn tcpgdrsait pgglrlgapa
     ltsrqfredd frrvvdfide
421  gvniglevks ktaklqdfks fllkdsetsq rlanlrqrve
     qfarafpmpg fdeh

Putative function

hydroxymethyltransferase

Example 2B (Category 1)

Line ID—ewv-b

Phenotype—Female sterile, No eggs laid. Fully mature eggs, but “retained eggs” phenotype. Also has a mitotic phenotype: higher mitotic index, uneven chromosome staining, tangled and badly defined chromosomes with frequent bridges

Annotated Drosophila genome genomic segment containing P element insertion site (and map position)—AE003486 (10D4-6)

P element insertion site sequence

(SEQ ID NO: 104)
GACAGGAGCAGCTCGGAACGGACAGGAAAAGCAGGAGACTAAACAGTAAG
CAATAAATTGATTTGGCGTATAGTAGCTTACACCAAAGTACATATATTGC
CGCATATATAGCCAGCCGGTCACTTGCGGATCAGCCAACGTCCTGGGCCC
CAAGGCGATAGATACCACGATAAGGAGATACAGCGATACCACCAATCATT
AGCAGGCGACAACGACACATCCGCATCCGCAGAAGATGTCCAACGGCAAG
GCGACGGTCTCGTTCTTCGAGACCGGGAGCACCAAACAGTTCGAGTACTG
CTACCAGCTCTATCCCCAGGTTCTTAAGCTAAAGGCCGAGAAGCGCAACT
GTTGGGAAGGGCGATCGGTGCGGGCCTCTTCGCTATTACGCCAGCTGGCG
AAAGGGGGATGTGCTGCAAGGCGATTAAGTTGGGTAACGCCAGGGTTTTC
CCAGNCACGACGNTGNAAAACGACGGNCANNGCCANNCTNTGNTGNTNTA
AACNACNCATT

Annotated Drosophila genome Complete Genome candidate—CG2446 (2 transcripts)—encodes a novel protein which may be a glycosylation/membrane protein

(SEQ ID NO: 105)
AGATAGAACGACAACTCCTGTTCCCGGTTCGTCGTCGTTCGTCATTCCCA
TATTCGCTTCTCGTATTCCCTCCCATTCCCATTCGCAATCCCAATTCCCA
ATTCCCGTCACACGAGTTAGCAGCACATCGCACAGCTGCATCGCTCCGCT
CCGATCCTTTTTAATTTTTTGTTGTGCCTTCGGTGGCGTGCTCATTTCGA
GAACAGAGTAACCCCTTTTTATTTGTCAGTTGTCAACGGCGCCCCTGCAG
GCAGAAAGCAGAAACTGAAACAGCAGAGGAAGAAGAAGAAGCAGCACAGC
ACGGGCACAGCACGAAGCACGCAGCACAGCACAAGCACAGAGGCGAAGCG
AAGCAAAGCAAAGCAGAGGCAACACAGAAAAACAGCAAAGCATTGGAGTA
GTTGTTTGGATGTGGACGGAAAGGAAGACTGGCGGCGACTAACTAAAAGC
AGTACGTTGACAGGAGCAGCTCGGAACGGACAGGAAAAGCAGGAGACTAA
ACACCAGCCGGTCACTTGCGGATCAGCCAACGTCCTGGGCCCCAAGGCGA
TAGATACCACGATAAGGAGATACAGCGATACCACCAATCATTAGCAGGCG
ACAACGACACATCCGCATCCGCAGAAGATGTCCAACGGCAAGGCGACGGT
CTCGTTCTTCGAGACCGGGAGCACCAAACAGTTCGAGTACTGCTACCAGC
TCTATCCCCAGGTTCTTAAGCTAAAGGCCGAGAAGCGCTGCAAGAAGCCG
CAAGAGCTGATCCGCCTGGATCAGTGGTATCAGAATGAACTGCCCAAATT
GATTAAGGCACGCGGCAAGGACGCGCATATGGTATACGATGAGCTCGTCC
AGTCGATGAAGTGGAAGCAGTCGCGCGGCAAATTCTATCCGCAGCTATCC
TACCTGGTCAAGGTCAACACACCGCGCGCCGTCATCCAGGAGACAAAGAA
GGCCTTCCGCAAGCTGCCCAATCTGGAGCAGGCGATCACAGCTTTATCGA
ACCTCAAGGGCGTTGGCACCACAATGGCCAGTGCACTGCTGGCAGCCGCA
GCTCCCGATTCGGCACCATTCATGGCCGACGAGTGCCTGATGGCCATACC
AGAGATCGAGGGCATCGATTACACCACCAAGGAGTACCTCAACTTCGTCA
ATCACATTCAGGCCACCGTGGAGCGCCTCAATGCGGAGGTGGGCGGGGAT
ACGCCGCACTGGTCGCCTCATCGCGTGGAGCTGGCCCTCTGGTCACACTA
TGTGGCCAATGATCTCAGTCCCGAGATGCTCGACGATATGCCGCCGCCTG
GATCCGGCGCCTCCACTGGCACCGGTTCACTCAGCACAAACGGCAACAGC
AGCAAGGTGCTCGATGGCGACGATACCAACGATGGTGTGGGTGTTGATTT
GGACGACGAAAGCCAAGGAGCAGGCGGTCGCAACACTGCTACAGAATCGG
AGACAGAGAATGAGAACACCAACCCGGCTGCTCTGACGCCTCTACAGTCG
GGCGAGGCCAAGAACAACGCAGCTGCCGTTGGCGCCGCCCTGCAGGACGG
TGACTCCAACTTTGTTTCGAACGATTCCACCTCCCAGGAGCCGATCATCG
ATGACAACGATGGCACCACACAGACAACGGCCACCACTTCCACAGAGGAC
GGTGAGCCCATCGCCCTAGACATTGGCATTGGCATCGGTTCGAGTGGAAC
ACCGCTCGCCTCGGACTCTGAAAGCAATCAGGAGGCGCCGCCCAAGACCA
ACAGCCTGCCCATCCTGACTCCCACACAGCACTCGAGCCAGAATCAGAAT
CAAAAGCAGTCGCCGAGCCAGCCCCACAAAACTAACAATTCGATCACCAA
CAACGGTCAGCCTGCTCCTTTGGCAGAAGAGGAAGCGGTTACAGCAGCAC
CACAGCCAGCCAGCAAAGCGACTGCAGCACCAGCCAATGGAAATGGTAAC
GGGAACGGCGTCCTGGGCGACGAGGATGAGGATGAGGCGGAGGACGAGGA
GGAAGATGAGCTGGACGAGGAGGAGGATAATGAGGCGGAGCTAGAGGCTG
ACGAGAGCAATAGCAGCAACGGCATTGTGAGGGACAGTAAACTGCAGCAG
CTGGCGGCGAACAAGGCGGTGGATGCGGTTTCACCGGTAGCAGCGGGTGC
AGACTCGGCACCAGCCATTGGACAGAAGCGTACTGCCCTGCACTGCGATA
TGGAGCTGAAGAACGCCGGCGGAGTGGGTGTGGGCGTGGGGGAGAAGTCA
CCGGATCTAAAGAAACTGCGCAGCGAATGA
(SEQ ID NO: 106)
MSNGKATVSFFETGSTKQFEYCYQLYPQVLKLKAEKRCKKPQELIRLDQW
YQNELPKLIKARGKDAHMVYDELVQSMKWKQSRGKFYPQLSYLVKVNTPR
AVIQETKKAFRKLPNLEQAITALSNLKGVGTTMASALLAAAAPDSAPFMA
DECLMAIPEIEGIDYTTKEYLNFVNHIQATVERLNAEVGGDTPHWSPHRV
ELALWSHYVANDLSPEMLDDMPPPGSGASTGTGSLSTNGNSSKVLDGDDT
NDGVGVDLDDESQGAGGRNTATESETENENTNPAALTPLQSGEAKNNAAA
VGAALQDGDSNFVSNDSTSQEPIIDDNDGTTQTTATTSTEDGEPIALDIG
IGIGSSGTPLASDSESNQEAPPKTNSLPILTPTQHSSQNQNQKQSPSQPH
KTNNSITNNGQPAPLAEEEAVTAAPQPASKATAAPANGNGNGNGVLGDED
EDEAEDEEEDELDEEEDNEAELEADESNSSNGIVRDSKLQQLAANKAVDA
VSPVAAGADSAPAIGQKRTALHCDMELKNAGGVGVGVGEKSPDLKKLRSE
(SEQ ID NO: 107)
GCCTGTCAGTTTGACTGTGTGAGTGCATGGCGGACTAAAAAGAACCCGAC
GACAGCACTGTAAAAATTCGATTTGTGTGCTGTGCAAACGGCGGCGGAAG
CGAGCAGATTTTTGGCAAATAGTGAGCGATTATCGGATTGAGTAAATACA
ACAAACAACAGAGACACGGCCGCAGCAGCAGCAGCATTAACACAGTACGT
TGACAGGAGCAGCTCGGAACGGACAGGAAAAGCAGGAGACTAAACACCAG
CCGGTCACTTGCGGATCAGCCAACGTCCTGGGCCCCAAGGCGATAGATAC
CACGATAAGGAGATACAGCGATACCACCAATCATTAGCAGGCGACAACGA
CACATCCGCATCCGCAGAAGATGTCCAACGGCAAGGCGACGGTCTCGTTC
TTCGAGACCGGGAGCACCAAACAGTTCGAGTACTGCTACCAGCTCTATCC
CCAGGTTCTTAAGCTAAAGGCCGAGAAGCGCTGCAAGAAGCCGCAAGAGC
TGATCCGCCTGGATCAGTGGTATCAGAATGAACTGCCCAAATTGATTAAG
GCACGCGGCAAGGACGCGCATATGGTATACGATGAGCTCGTCCAGTCGAT
GAAGTGGAAGCAGTCGCGCGGCAAATTCTATCCGCAGCTATCCTACCTGG
TCAAGGTCAACACACCGCGCGCCGTCATCCAGGAGACAAAGAAGGCCTTC
CGCAAGCTGCCCAATCTGGAGCAGGCGATCACAGCTTTATCGAACCTCAA
GGGCGTTGGCACCACAATGGCCAGTGCACTGCTGGCAGCCGCAGCTCCCG
ATTCGGCACCATTCATGGCCGACGAGTGCCTGATGGCCATACCAGAGATC
GAGGGCATCGATTACACCACCAAGGAGTACCTCAACTTCGTCAATCACAT
TCAGGCCACCGTGGAGCGCCTCAATGCGGAGGTGGGCGGGGATACGCCGC
ACTGGTCGCCTCATCGCGTGGAGCTGGCCCTCTGGTCACACTATGTGGCC
AATGATCTCAGTCCCGAGATGCTCGACGATATGCCGCCGCCTGGATCCGG
CGCCTCCACTGGCACCGGTTCACTCAGCACAAACGGCAACAGCAGCAAGG
TGCTCGATGGCGACGATACCAACGATGGTGTGGGTGTTGATTTGGACGAC
GAAAGCCAAGGAGCAGGCGGTCGCAACACTGCTACAGAATCGGAGACAGA
GAATGAGAACACCAACCCGGCTGCTCTGACGCCTCTACAGTCGGGCGAGG
CCAAGAACAACGCAGCTGCCGTTGGCGCCGCCCTGCAGGACGGTGACTCC
AACTTTGTTTCGAACGATTCCACCTCCCAGGAGCCGATCATCGATGACAA
CGATGGCACCACACAGACAACGGCCACCACTTCCACAGAGGACGGTGAGC
CCATCGCCCTAGACATTGGCATTGGCATCGGTTCGAGTGGAACACCGCTC
GCCTCGGACTCTGAAAGCAATCAGGAGGCGCCGCCCAAGACCAACAGCCT
GCCCATCCTGACTCCCACACAGCACTCGAGCCAGAATCAGAATCAAAAGC
AGTCGCCGAGCCAGCCCCACAAAACTAACAATTCGATCACCAACAACGGT
CAGCCTGCTCCTTTGGCAGAAGAGGAAGCGGTTACAGCAGCACCACAGCC
AGCCAGCAAAGCGACTGCAGCACCAGCCAATGGAAATGGTAACGGGAACG
GCGTCCTGGGCGACGAGGATGAGGATGAGGCGGAGGACGAGGAGGAAGAT
GAGCTGGACGAGGAGGAGGATAATGAGGCGGAGCTAGAGGCTGACGAGAG
CAATAGCAGCAACGGCATTGTGAGGGACAGTAAACTGCAGCAGCTGGCGG
CGAACAAGGCGGTGGATGCGGTTTCACCGGTAGCAGCGGGTGCAGACTCG
GCACCAGCCATTGGACAGAAGCGTACTGCCCTGCACTGCGATATGGAGCT
GAAGAACGCCGGCGGAGTGGGTGTGGGCGTGGGGGAGAAGTCACCGGATC
TAAAGAAACTGCGCAGCGAATGA
(SEQ ID NO: 108)
MSNGKATVSFFETGSTKQFEYCYQLYPQVLKLKAEKRCKKPQELIRLDQW
YQNELPKLIKARGKDAHMVYDELVQSMKWKQSRGKFYPQLSYLVKVNTPR
AVIQETKKAFRKLPNLEQAITALSNLKGVGTTMASALLAAAAPDSAPFMA
DECLMAIPEIEGIDYTTKEYLNFVNHIQATVERLNAEVGGDTPHWSPHRV
ELALWSHYVANDLSPEMLDDMPPPGSGASTGTGSLSTNGNSSKVLDGDDT
NDGVGVDLDDESQGAGGRNTATESETENENTNPAALTPLQSGEAKNNAAA
VGAALQDGDSNFVSNDSTSQEPIIDDNDGTTQTTATTSTEDGEPIALDIG
IGIGSSGTPLASDSESNQEAPPKTNSLPILTPTQHSSQNQNQKQSPSQPH
KTNNSITNNGQPAPLAEEEAVTAAPQPASKATAAPANGNGNGNGVLGDED
EDEAEDEEEDELDEEEDNEAELEADESNSSNGIVRDSKLQQLAANKAVDA
VSPVAAGADSAPAIGQKRTALHCDMELKNAGGVGVGVGEKSPDLKKLRSE

Human homologue of Complete Genome candidate

CG2446—none

Putative function

glycosylation/membrane protein

Example 2C (Category 1)

Line ID—fs(1)06

Phenotype—Female sterile (semi-sterile), 2-3 fully matured eggs seen in each of the ovarioles

Annotated Drosophila genome genomic segment containing P element insertion site (and map position)—AE003449 (9B6-7)

P element insertion site sequence

(SEQ ID NO: 109)
CTNCATGNTGNAGGAGACAAGGCGTTCTATATTATATAGNNGATTTTNNT
GTATATAAAGGAAGANCTGNGCTAANGNAANAGGCATCTCGATGANTTTN
ATAATNAGGGCAANTGGTANNAANGGTTTATGCCAAAGTATTACACACCA
GGGNTGGGCACAACAGATCTTAACTNANNATAGGNNATTGGNATAANCTT
AAATTTGTAAGATTNTGNAATAATATAGTAGAGANNNTCAATACGCATTA
NTAATNGTGACGATCCCNAGCATAAACTCAAAAAAANCTTATANTTTTAT
AAAGGCNANNCCNNACTAANNAATTAAANGAANNNCNGNCGCCNCNAAAN
GATGATTGNGCTATATAANNANANNATTGATNGAGGCACTTATATTATTA
TAATTAAAACACTTAATTATTNTGTGTGAAATGATTGCACTNNNNATTGG
GCNAGAGCCTNNNNCGTATTGANANNNNNNNATTTNGGCTNNANCTGTAA
ATATCNTACAAACTCGTNATTGCTAAATAACTTTTGTATNCCCCNCTGGT
CACTCTGACTTAAACGTNNTTCGNNAAAACAGCGGCTGATCACTGANGTT
TTCTCCCGNNTTTCGCTNTCAANCCGAANTANAAACAGGNGAANNTCCCN
GATAATTTGNGGNNTANCCCACTGATCACAGNGCCCNNGGATNNNCAAGG
AANNGCGATCGAAACCCGNCCTGGNGNAACACNNTTTCCC

Annotated Drosophila genome Complete Genome candidate—CG2968—hydrogen transporting ATP synthase

(SEQ ID NO: 110)
CAAAAACAGCGGCTGATCACTGAAGTTTTCTCGTGTTTTTCGCTATCAAA
CCGAAATAAAAACAGCCCAAAATGTCCTTCGTTAAGAACGCCCGTTTGCT
GGCCGCCCGCGGCGCTCGCTTGGCCCAGAACCGCAGCTACTCGGATGAGA
TGAAGCTGACCTTCGCCGCCGCCAACAAAACCTTCTACGATGCCGCTGTG
GTGCGCCAAATCGATGTGCCTTCCTTCTCGGGATCCTTCGGCATCCTGGC
CAAGCACGTGCCCACTCTGGCTGTCCTGAAGCCCGGCGTTGTCCAGGTGG
TGGAAAACGATGGCAAGACCCTCAAGTTCTTCGTCTCCAGCGGTTCCGTC
ACCGTCAACGAGGATTCCTCCGTTCAGGTTCTGGCCGAGGAGGCCCACAA
CATCGAGGACATCGATGCCAATGAGGCGCGCCAGCTGCTCGCGAAATACC
AGTCACAGCTTAGCTCCGCTGGCGACGACAAGGCCAAGGCCCAGGCTGCC
ATTGCCGTGGAGGTCGCCGAAGCGTTAGTCAAGGCTGCCGAATAGACGTA
ATCACCACACAACCGCCACCAATAAACCACAATCGATGCTTTGTGTCTGA
AATAAATAAAAAACATAACGATCACCTTAAAAAGCCAGAGAGTTATGAAA
CAATAAAAAAGCGA
(SEQ ID NO: 111)
MSFVKNARLLAARGARLAQNRSYSDEMKLTFAAANKTFYDAAVVRQIDVP
SFSGSFGILAKHVPTLAVLKPGVVQVVENDGKTLKFFVSSGSVTVNEDSS
VQVLAEEAHNIEDIDANEARQLLAKYQSQLSSAGDDKAKAQAAIAVEVAE
ALVKAAE

Human homologue of Complete Genome candidate

CAA45016—H(+)-transporting ATP synthase, delta-subunit of the human mitochondrial ATP synthase complex

(SEQ ID NO: 112)
1   gtcctcctcg ccctccaggc cgcccgcgcc gcgccggagt
    ccgctgtccg ccagctaccc
61  gcttcctgcc gcccgccgct gccatgctgc ccgccgcgct
    gctccgccgc ccgggacttg
121 gccgcctcgt ccgccacgcc cgtgcctatg ccgaggccgc
    cgccgccccg gctgccgcct
181 ctggccccaa ccagatgtcc ttcaccttcg cctctcccac
    gcaggtgttc ttcaacggtg
241 ccaacgtccg gcaggtggac gtgcccacgc tgaccggagc
    cttcggcatc ctggcggccc
301 acgtgcccac gctgcaggtc ctgcggccgg ggctggtcgt
    ggtgcatgca gaggacggca
361 ccacctccaa atactttgtg agcagcggtt ccatcgcagt
    gaacgccgac tcttcggtgc
421 agttgttggc cgaagaggcc gtgacgctgg acatgttgga
    cctgggggca gccaaggcaa
481 acttggagaa ggcccaggcg gagctggtgg ggacagctga
    cgaggccacg cgggcagaga
541 tccagatccg aatcgaggcc aacgaggccc tggtgaaggc
    cctggagtag gcggtgcgta
601 cccggtgtcc cgaggcccgg ccaggggctg ggcagggatg
    ccaggtgggc ccagccagct
661 cctggggtcc cggccacctg gggaagccgc gcctgccaag
    gaggccacca gagggcagtg
721 caggcttctg cctgggcccc aggccctgcc tgtgttgaaa
    gctctgggga ctgggccagg
781 gaagctcctc ctcagctttg agctgtggct gccacccatg
    gggctctcct tccgcctctc
841 aagatccccc cagcctgacg ggccgcttac catcccctct
    gccctgcaga gccagccgcc
901 aaggttgacc tcagcttcgg agccacctct ggatgaactg
    cccccagccc ccgccccatt
961 aaagacccgg aagcctgaaa aaaaaaaaaa aaaa
(SEQ ID NO: 113)
1   mlpaallrrp glgrlvrhar ayaeaaaapa aasgpnqmsf
    tfasptqvff nganvrqvdv
61  ptltgafgil aahvptlqvl rpglvvvhae dgttskyfvs
    sgsiavnads svqllaeeav
121 tldmldlgaa kanlekaqae lvgtadeatr aeiqiriean
    ealvkale

Putative function

hydrogen transporting ATP synthase

Category 2—Male Steriles

Example 3 (Category 2)

Line ID—167

Phenotype—lethal phase pharate adult, cytokinesis defect.

Some onion stage cysts with large nebenkerns

Annotated Drosophila genome genomic segment containing P element insertion site (and map position)—AE003428 (3F4-5)

P element insertion site—293,654

Annotated Drosophila genome Complete Genome candidate—CG2829—BcDNA:GH07910 tousled kinase (2 splice variants)

(SEQ ID NO: 114)
AGTTTCATTCGGGGATGCTTGGCCTATCGCAAGGAGGATCGCATGGATGT
GTTCGCACTGGCCAGGCACGAGTACATTCAGCCACCGATACCGAAACATG
GGCGCGGTTCGCTCAATCAGCAACAGCAGGCGCAACAACAGCAGCAGCAA
CAACAGCAACAGCAGCAGCAACAGTCGTCGACGTCACAGGCCAATTCTAC
AGGCCAGACATCTTTCTCTGCCCACATGTTTGGCAATATGAATCAGTCGA
GTTCGTCCTAGATGAGAGCGACTGCAAAAAAATCGGAATAAACACGGTTA
TAATATATAAGTACAAATAAACCATATATATGTGTTTATGTTATGTATAT
ATACATAAAGGAAAATAACAAGGCAAATGTGAAAATTAGTGCAAACTGAA
CGAAAAGACAAAAATAAAACAAAAGGAAACCCAAATGTGATAATATTGTA
ATATAATGTGAAAAGCAAAACACACACAAATACACAACTCACGCACTTAG
CCACGTATGTGTGTGCAGAAAAATATGCGGCGCTTAAAAAAGATGTCCCC
CGGCGCCCATTTGCAGATGTCCCCGCAGAACACTTCGTCCCTAAGTCAAC
ACCATCCACATCAACAGCAACAGTTACAACCCCCACAGCAGCAACAACAG
CATTTCCCTAACCATCACAGCGCCCAGCAACAGTCGCAGCAGCAGCAGCA
ACAGGAGCAACAGAATCCCCAGCAGCAGGCGCAACAGCAGCAGCAGATAC
TCCCACATCAACATTTGCAGCACCTGCACAAGCATCCGCATCAGCTGCAA
CTGCATCAGCAGCAGCAACAACAACTCCACCAGCAACAGCAGCAACACTT
CCACCAGCAGTCGCTGCAAGGGCTGCATCAGGGTAGCAGCAATCCGGATT
CGAATATGAGCACTGGCTCCTCGCATAGCGAGAAGGATGTCAATGATATG
CTGAGTGGCGGTGCAGCAACGCCAGGAGCTGCAGCAGCAGCGATTCAACA
GCAACATCCCGCCTTTGCGCCCACACTGGGAATGCAGCAACCACCGCCGC
CCCCACCTCAACACTCCAATAATGGAGGCGAGATGGGCTACTTGTCGGCA
GGCACGACCACGACGACGTCGGTGTTAACGGTAGGCAAGCCTCGGACGCC
AGCGGAGCGGAAACGGAAGCGAAAAATGCCTCCATGTGCCACTAGTGCGG
ATGAGGCGGGGAGTGGCGGTGGCTCTGGCGGAGCAGGAGCAACCGTTGTT
AACAACAGCAGCCTGAAGGGCAAATCATTGGCCTTTCGTGATATGCCCAA
GGTAAACATGAGCCTGAATCTGGGCGATCGTCTGGGAGGATCTGCAGGAA
GCGGAGTAGGAGCCGGTGGCGCCGGAAGCGGGGGAGGTGGCGCTGGTTCC
GGTTCTGGAAGCGGTGGCGGCAAAAGCGCCCGCCTGATGCTGCCAGTCAG
CGACAACAAGAAGATCAACGACTATTTCAATAAGCAGCAAACGGGCGTGG
GCGTCGGTGTGCCAGGTGGTGCGGGAGGCAATACCGCTGGCCTTCGAGGA
TCACATACGGGAGGTGGCAGCAAGTCACCCTCATCCGCCCAGCAGCAGCA
AACGGCGGCACAGCAGCAGGGAAGCGGTGTTGCGACGGGAGGCAGTGCAG
GCGGTTCCGCTGGCAACCAGGTGCAAGTGCAAACGAGCAGCGCTTACGCC
CTTTACCCACCAGCTAGTCCCCAAACCCAGACGTCACAGCAACAGCAGCA
GCAGCAACCGGGATCAGACTTTCACTATGTCAACTCCAGCAAGGCGCAGC
AACAACAGCAGCGTCAACAGCAACAGACTTCCAATCAAATGGTTCCTCCA
CACGTGGTCGTTGGCCTTGGTGGTCATCCACTGAGCCTCGCGTCCATTCA
GCAGCAGACGCCCTTATCCCAGCAGCAACAGCAGCAACAACAGCAGCAGC
AACAGCAGCAACTGGGACCACCGACCACATCGACGGCCTCCGTCGTGCCA
ACGCATCCGCATCAACTCGGATCCCTGGGAGTTGTTGGGATGGTCGGTGT
GGGTGTTGGCGTGGGCGTTGGAGTAAATGTGGGTGTGGGACCACCACTGC
CACCACCACCGCCGATGGCCATGCCAGCGGCCATTATCACTTATAGTAAG
GCCACTCAAACGGAGGTGTCGCTGCATGAATTGCAGGAGCGCGAAGCGGA
GCACGAATCGGGCAAGGTGAAGCTAGACGAGATGACACGGCTGTCCGATG
AACAAAAGTCCCAAATTGTTGGCAACCAGAAGACGATTGACCAGCACAAG
TGCCACATAGCCAAGTGTATTGATGTGGTCAAGAAGCTGTTGAAGGAGAA
GAGCAGCATCGAGAAGAAGGAGGCGCGACAGAAGTGCATGCAGAATCGCC
TCAGGCTCGGACAGTTTGTTACCCAACGAGTGGGCGCCACATTCCAGGAG
AACTGGACGGACGGCTATGCGTTCCAGGAGCTGAGTCGGCGGCAAGAAGA
AATAACCGCTGAGCGTGAAGAGATAGATCGGCAGAAAAAGCAGCTGATGA
AAAAGCGTCCGGCGGAGTCCGGACGCAAGCGCAACAACAACAGTAACCAG
AACAACCAGCAGCAGCAGCAACAGCAACACCAGCAACAGCAGCAGCAACA
AAATTCCAACTCGAACGATTCCACGCAGCTGACGAGCGGAGTTGTTACCG
GTCCAGGCAGTGATCGTGTGAGCGTAAGCGTCGACAGCGGATTGGGTGGC
AATAATGCGGGCGCGATCGGTGGCGGAACCGTTGGTGGTGGCGTTGGAGG
TGGTGGTGTTGGAGGCGGTGGTGTCGGAGGCGGCGGTGGACGTGGACTTT
CTCGCAGCAATTCGACGCAGGCCAATCAGGCTCAATTGCTGCACAACGGC
GGTGGTGGTTCGGGCGGCAATGTCGGCAACTCGGGCGGCGTTGGCGACCG
CTTGTCAGATCGAGGAGGAGGAGGTGGCGGCATCGGCGGAAACGATAGCG
GCAGCTGCTCGGACTCGGGCACTTTCCTGAAGCCAGACCCCGTATCGGGT
GCCTACACAGCGCAGGAGTATTACGAGTACGATGAGATCCTCAAGTTGCG
ACAAAATGCCCTCAAAAAGGAGGACGCCGACCTGCAGCTGGAGATGGAGA
AGCTGGAGCGGGAGCGCAATCTGCACATCCGAGAGCTCAAGCGGATTCTT
AACGAGGATCAGTCCCGCTTTAACAATCATCCCGTGCTGAATGATCGCTA
TCTTCTGTTGATGCTCCTGGGCAAGGGCGGCTTCTCAGAGGTCCACAAGG
CCTTCGACCTGAAGGAGCAACGCTATGTCGCATGTAAGGTGCACCAATTA
AACAAGGATTGGAAGGAGGATAAGAAAGCTAATTATATCAAACACGCTTT
GCGGGAATACAACATTCACAAGGCACTGGATCATCCGCGGGTCGTCAAGC
TATACGATGTCTTCGAGATCGATGCGAATTCCTTTTGCACAGTGCTCGAA
TACTGTGATGGCCACGATCTGGACTTCTATTTGAAGCAACATAAGACTAT
ACCCGAGCGTGAAGCGCGCTCGATAATAATGCAGGTTGTATCTGCACTCA
AGTATCTAAATGAGATTAAGCCTCCAGTTATCCACTACGATCTGAAGCCC
GGCAACATTCTGCTTACCGAGGGCAACGTCTGCGGCGAGATTAAGATCAC
CGACTTCGGTCTGTCAAAGGTGATGGACGACGAGAATTACAATCCCGATC
ACGGCATGGATCTGACCTCTCAGGGGGCGGGAACCTACTGGTATCTGCCA
CCCGAGTGCTTTGTCGTGGGCAAAAATCCGCCGAAAATCTCCTCCAAAGT
GGACGTATGGAGTGTGGGTGTTATCTTCTACCAGTGTCTGTACGGCAAAA
AGCCCTTCGGTCACAATCAGTCGCAGGCCACGATTCTCGAGGAGAATACG
ATCCTGAAGGCCACCGAAGTGCAGTTCTCCAACAAGCCAACCGTTTCTAA
CGAGGCCAAG
(SEQ ID NO: 115)
MCVQKNMRRLKKMSPGAHLQMSPQNTSSLSQHHPHQQQQLQPPQQQQQHF
PNHHSAQQQSQQQQQQEQQNPQQQAQQQQQILPHQHLQHLHKHPHQLQLH
QQQQQQLHQQQQQHFHQQSLQGLHQGSSNPDSNMSTGSSHSEKDVNDMLS
GGAATPGAAAAAIQQQHPAFAPTLGMQQPPPPPPQHSNNGGEMGYLSAGT
TTTTSVLTVGKPRTPAERKRKRKMPPCATSADEAGSGGGSGGAGATVVNN
SSLKGKSLAFRDMPKVNMSLNLGDRLGGSAGSGVGAGGAGSGGGGAGSGS
GSGGGKSARLMLPVSDNKKINDYFNKQQTGVGVGVPGGAGGNTAGLRGSH
TGGGSKSPSSAQQQQTAAQQQGSGVATGGSAGGSAGNQVQVQTSSAYALY
PPASPQTQTSQQQQQQQPGSDFHYVNSSKAQQQQQRQQQQTSNQMVPPHV
VVGLGGHPLSLASIQQQTPLSQQQQQQQQQQQQQQLGPPTTSTASVVPTH
PHQLGSLGVVGMVGVGVGVGVGVNVGVGPPLPPPPPMAMPAAIITYSKAT
QTEVSLHELQEREAEHESGKVKLDEMTRLSDEQKSQIVGNQKTIDQHKCH
IAKCIDVVKKLLKEKSSIEKKEARQKCMQNRLRLGQFVTQRVGATFQENW
TDGYAFQELSRRQEEITAEREEIDRQKKQLMKKRPAESGRKRNNNSNQNN
QQQQQQQHQQQQQQQNSNSNDSTQLTSGVVTGPGSDRVSVSVDSGLGGNN
AGAIGGGTVGGGVGGGGVGGGGVGGGGGRGLSRSNSTQANQAQLLHNGGG
GSGGNVGNSGGVGDRLSDRGGGGGGIGGNDSGSCSDSGTFLKPDPVSGAY
TAQEYYEYDEILKLRQNALKKEDADLQLEMEKLERERNLHIRELKRILNE
DQSRFNNHPVLNDRYLLLMLLGKGGFSEVHKAFDLKEQRYVACKVHQLNK
DWKEDKKANYIKHALREYNIHKALDHPRVVKLYDVFEIDANSFCTVLEYC
DGHDLDFYLKQHKTIPEREARSIIMQVVSALKYLNEIKPPVIHYDLKPGN
ILLTEGNVCGEIKITDFGLSKVMDDENYNPDHGMDLTSQGAGTYWYLPPE
CFVVGKNPPKISSKVDVWSVGVIFYQCLYGKKPFGHNQSQATILEENTIL
KATEVQFSNKPTVSNEAK
(SEQ ID NO: 116)
AGTTTCATTCGGGGATGCTTGGCCTATCGCAAGGAGGATCGCATGGATGT
GTTCGCACTGGCCAGGCACGAGTACATTCAGCCACCGATACCGAAACATG
GGCGCGGTTCGCTCAATCAGCAACAGCAGGCGCAACAACAGCAGCAGCAA
CAACAGCAACAGCAGCAGCAACAGTCGTCGACGTCACAGGCCAATTCTAC
AGGCCAGACATCTTTCTCTGCCCACATGTTTGGCAATATGAATCAGTCGA
GTTCGTCCTAGTGGTGTCGGTGTCGTTTTGGTTTTGTCGGCGGTTGCTAA
ACACAATTTAAGTTCACTCGGTTAGCAGACATTACACACTGCCTGCTCTC
ATACATATTTACGCACTTGTATATACATGCAATGTGCCTGTGTGTGCGCA
AGAAACCAGAAAAAACGAAAAGTACAACATTCGTTGAGTCGCGTTCGGCT
TAATTTTTTTTTGTGTTACCGTGTGTGTGTTTGTGCTTTGGATTTGCCAA
TTTTAGCCGACTGGCTCTCAGTGTCGAACTTAAACTTAAAGAGCGAGCAA
CGTGACGTGTCGCCCAGTGTCGCTTAAAATTCGCGCACACAACTTCCTAC
TACAAAAAAACGAAAGAAAGAAGGAGAAAAAACGTTAAAGATGTCCCCCG
GCGCCCATTTGCAGATGTCCCCGCAGAACACTTCGTCCCTAAGTCAACAC
CATCCACATCAACAGCAACAGTTACAACCCCCACAGCAGCAACAACAGCA
TTTCCCTAACCATCACAGCGCCCAGCAACAGTCGCAGCAGCAGCAGCAAC
AGGAGCAACAGAATCCCCAGCAGCAGGCGCAACAGCAGCAGCAGATACTC
CCACATCAACATTTGCAGCACCTGCACAAGCATCCGCATCAGCTGCAACT
GCATCAGCAGCAGCAACAACAACTCCACCAGCAACAGCAGCAACACTTCC
ACCAGCAGTCGCTGCAAGGGCTGCATCAGGGTAGCAGCAATCCGGATTCG
AATATGAGCACTGGCTCCTCGCATAGCGAGAAGGATGTCAATGATATGCT
GAGTGGCGGTGCAGCAACGCCAGGAGCTGCAGCAGCAGCGATTCAACAGC
AACATCCCGCCTTTGCGCCCACACTGGGAATGCAGCAACCACCGCCGCCC
CCACCTCAACACTCCAATAATGGAGGCGAGATGGGCTACTTGTCGGCAGG
CACGACCACGACGACGTCGGTGTTAACGGTAGGCAAGCCTCGGACGCCAG
CGGAGCGGAAACGGAAGCGAAAAATGCCTCCATGTGCCACTAGTGCGGAT
GAGGCGGGGAGTGGCGGTGGCTCTGGCGGAGCAGGAGCAACCGTTGTTAA
CAACAGCAGCCTGAAGGGCAAATCATTGGCCTTTCGTGATATGCCCAAGG
TAAACATGAGCCTGAATCTGGGCGATCGTCTGGGAGGATCTGCAGGAAGC
GGAGTAGGAGCCGGTGGCGCCGGAAGCGGGGGAGGTGGCGCTGGTTCCGG
TTCTGGAAGCGGTGGCGGCAAAAGCGCCCGCCTGATGCTGCCAGTCAGCG
ACAACAAGAAGATCAACGACTATTTCAATAAGCAGCAAACGGGCGTGGGC
GTCGGTGTGCCAGGTGGTGCGGGAGGCAATACCGCTGGCCTTCGAGGATC
ACATACGGGAGGTGGCAGCAAGTCACCCTCATCCGCCCAGCAGCAGCAAA
CGGCGGCACAGCAGCAGGGAAGCGGTGTTGCGACGGGAGGCAGTGCAGGC
GGTTCCGCTGGCAACCAGGTGCAAGTGCAAACGAGCAGCGCTTACGCCCT
TTACCCACCAGCTAGTCCCCAAACCCAGACGTCACAGCAACAGCAGCAGC
AGCAACCGGGATCAGACTTTCACTATGTCAACTCCAGCAAGGCGCAGCAA
CAACAGCAGCGTCAACAGCAACAGACTTCCAATCAAATGGTTCCTCCACA
CGTGGTCGTTGGCCTTGGTGGTCATCCACTGAGCCTCGCGTCCATTCAGC
AGCAGACGCCCTTATCCCAGCAGCAACAGCAGCAACAACAGCAGCAGCAA
CAGCAGCAACTGGGACCACCGACCACATCGACGGCCTCCGTCGTGCCAAC
GCATCCGCATCAACTCGGATCCCTGGGAGTTGTTGGGATGGTCGGTGTGG
GTGTTGGCGTGGGCGTTGGAGTAAATGTGGGTGTGGGACCACCACTGCCA
CCACCACCGCCGATGGCCATGCCAGCGGCCATTATCACTTATAGTAAGGC
CACTCAAACGGAGGTGTCGCTGCATGAATTGCAGGAGCGCGAAGCGGAGC
ACGAATCGGGCAAGGTGAAGCTAGACGAGATGACACGGCTGTCCGATGAA
CAAAAGTCCCAAATTGTTGGCAACCAGAAGACGATTGACCAGCACAAGTG
CCACATAGCCAAGTGTATTGATGTGGTCAAGAAGCTGTTGAAGGAGAAGA
GCAGCATCGAGAAGAAGGAGGCGCGACAGAAGTGCATGCAGAATCGCCTC
AGGCTCGGACAGTTTGTTACCCAACGAGTGGGCGCCACATTCCAGGAGAA
CTGGACGGACGGCTATGCGTTCCAGGAGCTGAGTCGGCGGCAAGAAGAAA
TAACCGCTGAGCGTGAAGAGATAGATCGGCAGAAAAAGCAGCTGATGAAA
AAGCGTCCGGCGGAGTCCGGACGCAAGCGCAACAACAACAGTAACCAGAA
CAACCAGCAGCAGCAGCAACAGCAACACCAGCAACAGCAGCAGCAACAAA
ATTCCAACTCGAACGATTCCACGCAGCTGACGAGCGGAGTTGTTACCGGT
CCAGGCAGTGATCGTGTGAGCGTAAGCGTCGACAGCGGATTGGGTGGCAA
TAATGCGGGCGCGATCGGTGGCGGAACCGTTGGTGGTGGCGTTGGAGGTG
GTGGTGTTGGAGGCGGTGGTGTCGGAGGCGGCGGTGGACGTGGACTTTCT
CGCAGCAATTCGACGCAGGCCAATCAGGCTCAATTGCTGCACAACGGCGG
TGGTGGTTCGGGCGGCAATGTCGGCAACTCGGGCGGCGTTGGCGACCGCT
TGTCAGATCGAGGAGGAGGAGGTGGCGGCATCGGCGGAAACGATAGCGGC
AGCTGCTCGGACTCGGGCACTTTCCTGAAGCCAGACCCCGTATCGGGTGC
CTACACAGCGCAGGAGTATTACGAGTACGATGAGATCCTCAAGTTGCGAC
AAAATGCCCTCAAAAAGGAGGACGCCGACCTGCAGCTGGAGATGGAGAAG
CTGGAGCGGGAGCGCAATCTGCACATCCGAGAGCTCAAGCGGATTCTTAA
CGAGGATCAGTCCCGCTTTAACAATCATCCCGTGCTGAATGATCGCTATC
TTCTGTTGATGCTCCTGGGCAAGGGCGGCTTCTCAGAGGTCCACAAGGCC
TTCGACCTGAAGGAGCAACGCTATGTCGCATGTAAGGTGCACCAATTAAA
CAAGGATTGGAAGGAGGATAAGAAAGCTAATTATATCAAACACGCTTTGC
GGGAATACAACATTCACAAGGCACTGGATCATCCGCGGGTCGTCAAGCTA
TACGATGTCTTCGAGATCGATGCGAATTCCTTTTGCACAGTGCTCGAATA
CTGTGATGGCCACGATCTGGACTTCTATTTGAAGCAACATAAGACTATAC
CCGAGCGTGAAGCGCGCTCGATAATAATGCAGGTTGTATCTGCACTCAAG
TATCTAAATGAGATTAAGCCTCCAGTTATCCACTACGATCTGAAGCCCGG
CAACATTCTGCTTACCGAGGGCAACGTCTGCGGCGAGATTAAGATCACCG
ACTTCGGTCTGTCAAAGGTGATGGACGACGAGAATTACAATCCCGATCAC
GGCATGGATCTGACCTCTCAGGGGGCGGGAACCTACTGGTATCTGCCACC
CGAGTGCTTTGTCGTGGGCAAAAATCCGCCGAAAATCTCCTCCAAAGTGG
ACGTATGGAGTGTGGGTGTTATCTTCTACCAGTGTCTGTACGGCAAAAAG
CCCTTCGGTCACAATCAGTCGCAGGCCACGATTCTCGAGGAGAATACGAT
CCTGAAGGCCACCGAAGTGCAGTTCTCCAACAAGCCAACCGTTTCTAACG
AGGCCAAG
(SEQ ID NO: 117)
MSPGAHLQMSPQNTSSLSQHHPHQQQQLQPPQQQQQHFPNHHSAQQQSQQ
QQQQEQQNPQQQAQQQQQILPHQHLQHLHKHPHQLQLHQQQQQQLHQQQQ
QHFHQQSLQGLHQGSSNPDSNMSTGSSHSEKDVNDMLSGGAATPGAAAAA
IQQQHPAFAPTLGMQQPPPPPPQHSNNGGEMGYLSAGTTTTTSVLTVGKP
RTPAERKRKRKMPPCATSADEAGSGGGSGGAGATVVNNSSLKGKSLAFRD
MPKVNMSLNLGDRLGGSAGSGVGAGGAGSGGGGAGSGSGSGGGKSARLML
PVSDNKKINDYFNKQQTGVGVGVPGGAGGNTAGLRGSHTGGGSKSPSSAQ
QQQTAAQQQGSGVATGGSAGGSAGNQVQVQTSSAYALYPPASPQTQTSQQ
QQQQQPGSDFHYVNSSKAQQQQQRQQQQTSNQMVPPHVVVGLGGHPLSLA
SIQQQTPLSQQQQQQQQQQQQQQLGPPTTSTASVVPTHPHQLGSLGVVGM
VGVGVGVGVGVNVGVGPPLPPPPPMAMPAAIITYSKATQTEVSLHELQER
EAEHESGKVKLDEMTRLSDEQKSQIVGNQKTIDQHKCHIAKCIDVVKKLL
KEKSSIEKKEARQKCMQNRLRLGQFVTQRVGATFQENWTDGYAFQELSRR
QEEITAEREEIDRQKKQLMKKRPAESGRKRNNNSNQNNQQQQQQQHQQQQ
QQQNSNSNDSTQLTSGVVTGPGSDRVSVSVDSGLGGNNAGAIGGGTVGGG
VGGGGVGGGGVGGGGGRGLSRSNSTQANQAQLLHNGGGGSGGNVGNSGGV
GDRLSDRGGGGGGIGGNDSGSCSDSGTFLKPDPVSGAYTAQEYYEYDEIL
RLRQNALKKEDADLQLEMEKLERERNLHIRELKRILNEDQSRFNNHPVLN
DRYLLLMLLGKGGFSEVHKAFDLKEQRYVACKVHQLNKDWKEDKKANYIK
HALREYNIHKALDHPRVVKLYDVFEIDANSFCTVLEYCDGHDLDFYLKQH
KTIPEREARSIIMQVVSALKYLNEIKPPVIHYDLKPGNILLTEGNVCGEI
KITDFGLSKVMDDENYNPDHGMDLTSQGAGTYWYLPPECFVVGKNPPKIS
SKVDVWSVGVIFYQCLYGKKPFGHNQSQATILEENTILKATEVQFSNKPT
VSNEAK

Human homologue of Complete Genome candidate

AAF03095—tousled-like kinase2

(SEQ ID NO:118)
1    ccgggcgggg ggttgcggcg ctcaggagag gccccggctc cgccccgggc ctgcccaggg
61   ggagagcgga gctccgcagc cgggtcgggt cggggcccct cccgggagga gcgtggagcg
121  cggcggcggc ggcggcagca gaaatgatgg aagaattgca tagcctggac ccacgacggc
181  aggaattatt ggaggccagg tttactggag taggtgttag taagggacca cttaatagtg
241  agtcttccaa ccagagcttg tgcagcgtcg gatccttgag tgataaagaa gtagagactc
301  ccgagaaaaa gcagaatgac cagcgaaatc ggaaaagaaa agctgaacca tatgaaacta
361  gccaagggaa aggcactcct aggggacata aaattagtga ttactttgag tttgctgggg
421  gaagcgcgcc aggaaccagc cctggcagaa gtgttccacc agttgcacga tcctcaccgc
481  aacattcctt atccaatccc ttaccgcgac gagtagaaca gcccctctat ggtttagatg
541  gcagtgctgc aaaggaggca acggaggagc agtctgctct gccaaccctc atgtcagtga
601  tgctagcaaa acctcggctt gacacagagc agctggcgca aaggggagct ggcctctgct
661  tcacttttgt ttcagctcag caaaacagtc cctcatctac gggatctggc aacacagagc
721  attcctgcag ctcccaaaaa cagatctcca tccagcacag acggacccag tccgacctca
781  caatagaaaa aatatctgca ctagaaaaca gtaagaattc tgacttagag aagaaggagg
841  gaagaataga tgatttatta agagccaact gtgatttgag acggcagatt gatgaacagc
901  aaaagatgct agagaaatac aaggaacgat taaatagatg tgtgacaatg agcaagaaac
961  tccttataga aaagtcaaaa caagagaaga tggcgtgtag agataagagc atgcaagacc
1021 gcttgagact gggccacttt actactgtcc gacacggagc ctcatttact gaacagtgga
1081 cagatggtta tgcttttcag aatcttatca agcaacagga aaggataaat tcacagaggg
1141 aagagataga aagacaacgg aaaatgttag caaagcggaa acctcctgcc atgggtcagg
1201 cccctcctgc aaccaatgag cagaaacagc ggaaaagcaa gaccaatgga gctgaaaatg
1261 aaacgttaac gttagcagaa taccatgaac aagaagaaat cttcaaactc agattaggtc
1321 atcttaaaaa ggaggaagca gagatccagg cagagctgga gagactagaa agggttagaa
1381 atctacatat cagggaacta aaaaggatac ataatgaaga taattcacaa tttaaagatc
1441 atccaacgct aaatgacaga tatttgttgt tacatctttt gggtagagga ggtttcagtg
1501 aagtttacaa ggcatttgat ctaacagagc aaagatacgt agctgtgaaa attcaccagt
1561 taaataaaaa ctggagagat gagaaaaagg agaattacca caagcatgca tgtagggaat
1621 accggattca taaagagctg gatcatccca gaatagttaa gctgtatgat tacttttcac
1681 tggatactga ctcgttttgt acagtattag aatactgtga gggaaatgat ctggacttct
1741 acctgaaaca gcacaaatta atgtcggaga aagaggcccg gtccattatc atgcagattg
1801 tgaatgcttt aaagtactta aatgaaataa aacctcccat catacactat gacctcaaac
1861 caggtaatat tcttttagta aatggtacag cgtgtggaga gataaaaatt acagattttg
1921 gtctttcgaa gatcatggat gatgatagct acaattcagt ggatggcatg gagctaacat
1981 cacaaggtgc tggtacttat tggtatttac caccagagtg ttttgtggtt gggaaagaac
2041 caccaaagat ctcaaataaa gttgatgtgt ggtcggtggg tgtgatcttc tatcagtgtc
2101 tttatggaag gaagcctttt ggccataacc agtctcagca agacatccta caagagaata
2161 cgattcttaa agctactgaa gtgcagttcc cgccaaagcc agtagtaaca cctgaagcaa
2221 aggcgtttat tcgacgatgc ttggcctacc gaaagaggga ccgcattgat gtccagcagc
2281 tggcctgtga tccctacttg ttgcctcaca tccgaaagtc agtctctaca agtagccctg
2341 ctggagctgc tattgcatca acctctgggg cgtccaataa cagttcttct aattgagact
2401 gactccaagg ccacaaactg ttcaacacac acaaagtgga caaatggcgt tcagcagcgg
2461 gtttggaaca tagcgaatcc gaatggatct gatgaaacct gtaccaggtg cttttatttt
2521 cttgcttttt tcccatccat agagcatgac agcatcgatt ctcattgagg agaaaccttg
2581 ggcagctccg gccaggcctt gtaggaaaag gccccgcccg aggttccagc gtcaacggcc
2641 actgtgtgtg gctgctctga gtgaggaaaa aattaaaaag aaaaactggt tccatgtact
2701 gtgaacttga aaacttgcag actcaggggg gtccctgatg cagtgcttca gatgaagaat
2761 gtggacttga aaatacagac tgggctagtc cagtgtctat atttaaactt gttcttttct
2821 tttaataaag tttaggtaac atctcctgaa aagcttgtag cacaaaggct cagctgggga
2881 tggtgtttga cttcggagga aaaaagttgc tattgcccgt taaaggcact agagttagtg
2941 ttttatccct aaataatttc aatttttaaa aacatgcagc ttccctctcc ccttttttat
3001 ttttgaaaga atacatttgg tcataaagtg aaacccgtat tagcaagtac gaggcaatgt
3061 tcattccaat cagatgcagc tttctcctcc gtctggtctc ctgtttgcaa ttgcttccct
3121 catctcagta gggaaaaaat tgagtgggag tactgagatg tgtgggtttt tgccattgga
3181 caaagaatga ggttagaaga ctgcagcttg gagtctctct aggttttcaa ctatttcttc
3241 acaatttgaa cacttgacgg ttgtcccttt taatttattt gaagtgctat ttttttaaat
3301 aaaggttcat ctgtccatgc aaaaaaa
(SEQ ID NO:119)
1    meelhsldpr rqellearft gvgvskgpln sessnqslcs vgslsdkeve tpekkqndqr
61   nrkrkaepye tsqgkgtprg hkisdyfefa ggsapgtspg rsvppvarss pqhslsnplp
121  rrveqplygl dgsaakeate eqsalptlms vmlakprldt eqlaqrgagl cftfvsaqqn
181  spsstgsgnt ehscssqkqi siqhrrtqsd ltiekisale nsknsdlekk egriddllra
241  ncdlrrqide qqkmlekyke rlnrcvtmsk klliekskqe kmacrdksmq drlrlghftt
301  vrhgasfteq wtdgyafqnl ikqqerinsq reeierqrkm lakrkppamg qappatneqk
361  qrksktngae netltlaeyh eqeeifklrl ghlkkeeaei qaelerlerv rnlhirelkr
421  ihnednsqfk dhptlndryl llhllgrggf sevykafdlt eqryvavkih qlnknwrdek
481  kenyhkhacr eyrihkeldh privklydyf sldtdsfctv leycegndld fylkqhklms
541  ekearsiimq ivnalkylne ikppiihydl kpgnillvng tacgeikitd fglskimddd
601  synsvdgmel tsqgagtywy lppecfvvgk eppkisnkvd vwsvgvifyq clygrkpfgh
661  nqsqqdilqe ntilkatevq fppkpvvtpe akafirrcla yrkrdridvq qlacdpyllp
721  hirksvstss pagaaiasts gasnnsssn

Putative function

Serine threonine kinase involved in replication and cell cycle

Example 4 (Category 2)

Line ID—224

Phenotype—Semi-lethal male and female, cytokinesis defect. Onion stage cysts have variable sized Nebenkerns. Also has a mitotic phenotype: Tangled unevenly condensed chromosomes, anaphases with lagging chromosomes and bridges

Annotated Drosophila genome genomic segment containing P element insertion site (and map position)—AE003450 (9C)

P element insertion site—139,674

Annotated Drosophila genome Complete Genome candidate—CG2096—flapwing, phosphatase type 1

(SEQ ID NO:120)
ATCTGTAAGTGAAGTCCACTAACAACCGGTTTACTTGCAGTGCGCAGCTG
CCGAACGGGCAAACAGGTCCAGATGACGGAGGCGGAGGTGCGTGGCCTCT
GTCTCAAGTCGCGCGAGATCTTCTTGCAACAGCCCATCCTGCTGGAACTG
GAGGCACCGCTGATCATCTGCGGCGACATCCACGGCCAGTACACAGACCT
GTTGCGCCTGTTCGAGTACGGCGGATTCCCTCCGGCTGCCAACTACTTGT
TCCTCGGCGACTACGTCGATCGGGGCAAGCAGTCCCTGGAGACCATCTGT
CTGCTGCTGGCCTACAAGATCAAATATCCGGAGAACTTCTTCTTGTTGCG
CGGCAACCACGAGTGCGCCAGTATTAATAGGATTTACGGCTTCTACGATG
AGTGCAAGCGCCGATACAATGTCAAACTGTGGAAGACTTTCACAGATTGC
TTCAACTGTCTGCCGGTAGCCGCCATTATTGACGAAAAGATCTTCTGCTG
CCACGGCGGCCTCAGTCCCGATCTTCAGGGCATGGAGCAGATCCGTCGCC
TAATGCGACCCACAGATGTGCCGGATACCGGGTTACTGTGCGATCTTCTG
TGGAGTGATCCCGACAAGGATGTTCAGGGTTGGGGCGAGAATGATCGCGG
TGTGAGCTTCACCTTCGGTGTGGATGTGGTCTCCAAGTTTTTGAACCGCC
ACGAGCTGGACTTGATCTGCCGTGCACATCAGGTTGTGGAGGATGGCTAT
GAGTTCTTTGCGCGTCGGCAACTGGTCACGTTGTTCTCGGCGCCCAATTA
CTGTGGAGAGTTCGACAATGCCGGCGGAATGATGACCGTGGACGACACGC
TGATGTGCTCATTCCAGATCCTGAAACCATCCGAGAAGAAGGCCAAGTAT
CTGTACAGCGGAATGAACTCGTCGCGACCCACAACACCGCAGCGCAGCGC
CCCAATGCTTGCGACCAACAAGAAGAAATAATATATCCATCCGCTTCCAT
TTCCTTAAAGGTTCAACAAACAACAGAAATAAACTTTTACATAGATACAC
ACATATATACATATAAATATAACGAAACGATAGAAAAGGAGAGCGTTAGG
CGATAGTAGAGAAAGGGCAAATGATAAATTAAATGTGTGAGCTATTAAAG
CAAGCAAAATCGAAGTGCATGAATATCAACATCTATGTGAATCCGTCATT
ATCTGTTATCTGATGTGTCATCTGTATCCAACTTGATTACCTTATCCGTG
TACCTGCTAGTTGCAGCAGCAACATCAGGAGCAACAACACCAGCAGCAGC
AGCAGCAGAAACATCAGTGAAACACTCAGAGGCCCATAGTTAAGTCGATT
CCTGCATTTGATGATTATCTGTTGAATGGAAATTGTGACAACGTCCCCGT
AACAGCAGCTCCCAGATCCAAAACTCCCGAAACATGCAGATAAATAAATA
CATTAAAAGTACAGCGATGTTAAGCAATGAATTTATATATAGGCTTATTA
ATGTAAACT
(SEQ ID NO:121)
MTEAEVRGLCLKSREIFLQQPILLELEAPLIICGDIHGQYTDLLRLFEYG
GFPPAANYLFLGDYVDRGKQSLETICLLLAYKIKYPENFFLLRGNHECAS
INRIYGFYDECKRRYNVKLWKTFTDCFNCLPVAAIIDEKIFCCHGGLSPD
LQGMEQIRRLMRPTDVPDTGLLCDLLWSDPDKDVQGWGENDRGVSFTFGV
DVVSKFLNRHELDLICRAHQVVEDGYEFFARRQLVTLFSAPNYCGEFDNA
GGMMTVDDTLMCSFQILKPSEKKAKYLYSGMNSSRPTTPQRSAPMLATNK
KK

Human homologue of Complete Genome candidate

NP_—002700 protein phosphatase 1, catalytic subunit, beta isoform

(SEQ ID NO:122)
1    cctgggtctg acgcggccct gttcgagggg gcctctcttg tttatttatt tattttccgt
61   gggtgcctcc gagtgtgcgc gcgctctcgc tacccggcgg ggagggggtg gggggagggc
121  ccgggaaaag ggggagttgg agccggggtc gaaacgccgc gtgacttgta ggtgagagaa
181  cgccgagccg tcgccgcagc ctccgccgcc gagaagccct tgttcccgct gctgggaagg
241  agagtctgtg ccgacaagat ggcggacggg gagctgaacg tggacagcct catcacccgg
301  ctgctggagg tacgaggatg tcgtccagga aagattgtgc agatgactga agcagaagtt
361  cgaggcttat gtatcaagtc tcgggagatc tttctcagcc agcctattct tttggaattg
421  gaagcaccgc tgaaaatttg tggagatatt catggacaat atacagattt actgagatta
481  tttgaatatg gaggtttccc accagaagcc aactatcttt tcttaggaga ttatgtggac
541  agaggaaagc agtctttgga aaccatttgt ttgctattgg cttataaaat caaatatcca
601  gagaacttct ttctcttaag aggaaaccat gagtgtgcta gcatcaatcg catttatgga
661  ttctatgatg aatgcaaacg aagatttaat attaaattgt ggaagacctt cactgattgt
721  tttaactgtc tgcctatagc agccattgtg gatgagaaga tcttctgttg tcatggagga
781  ttgtcaccag acctgcaatc tatggagcag attcggagaa ttatgagacc tactgatgtc
841  cctgatacag gtttgctctg tgatttgcta tggtctgatc cagataagga tgtgcaaggc
901  tggggagaaa atgatcgtgg tgtttccttt acttttggag ctgatgtagt cagtaaattt
961  ctgaatcgtc atgatttaga tttgatttgt cgagctcatc aggtggtgga agatggatat
1021 gaattttttg ctaaacgaca gttggtaacc ttattttcag ccccaaatta ctgtggcgag
1081 tttgataatg ctggtggaat gatgagtgtg gatgaaactt tgatgtgttc atttcagata
1141 ttgaaaccat ctgaaaagaa agctaaatac cagtatggtg gactgaattc tggacgtcct
1201 gtcactccac ctcgaacagc taatccgccg aagaaaaggt gaagaaagga attctgtaaa
1261 gaaaccatca gatttgttaa ggacatactt cataatatat aagtgtgcac tgtaaaacca
1321 tccagccatt tgacaccctt tatgatgtca cacctttaac ttaaggagac gggtaaagga
1381 tcttaaattt ttttctaata gaaagatgtg ctacactgta ttgtaataag tatactctgt
1441 tatagtcaac aaagttaaat ccaaattcaa aattatccat taaagttaca tcttcatgta
1501 tcacaatttt taaagttgaa aagcatccca gttaaactag atgtgatagt taaaccagat
1561 gaaagcatga tgatccatct gtgtaatgtg gttttagtgt tgcttggttg tttaattatt
1621 ttgagcttgt tttgtttttg tttgttttca ctagaataat ggcaaatact tctaattttt
1681 ttccctaaac atttttaaaa gtgaaatatg ggaagagctt tacagacatt caccaactat
1741 tattttccct tgtttatcta cttagatatc tgtttaatct tactaagaaa actttcgcct
1801 cattacatta aaaaggaatt ttagagattg attgttttaa aaaaaaatac gcacattgtc
1861 caatccagtg attttaatca tacagtttga ctgggcaaac tttacagctg atagtgaata
1921 ttttgcttta tacaggaatt gacactgatt tggatttgtg cactctaatt tttaacttat
1981 tgatgctcta ttgtgcagta gcatttcatt taagataagg ctcatatagt attacccaac
2041 tagttggtaa tgtgattatg tggtaccttg gctttaggtt ttcattcgca cggaacacct
2101 tttggcatgc ttaacttcct ggtaacacct tcacctgcat tggttttctt tttctttttt
2161 ctttcttttt tttttttttt ttttttttga gttgttgttt gtttttagat ccacagtaca
2221 tgagaatcct tttttgacaa gccttggaaa gctgacactg tctctttttc ctccctctat
2281 acgaaggatg tatttaaatg aatgctggtc agtgggacat tttgtcaact atgggtattg
2341 ggtgcttaac tgtctaatat tgccatgtga atgttgtata cgattgtaag gcttatgtca
2401 ctaaagattt ttattctgat tttttcataa tcaaaggtca tatgatactg tatagacaag
2461 ctttgtagtg aagtatagta gcaataattt ctgtacctga tcaagtttat tgcagccttt
2521 cttttcctat ttcttttttt taagggttag tattaacaaa tggcaatgag tagaaaagtt
2581 aacatgaaga ttttagaagg agagaactta caggacacag atttgtgatt ctttgactgt
2641 gacactattg gatgtgattc taaaagcttt tattgagcat tgtcaaattt gtaagcttca
2701 tagggatgga catcatatct ataatgccct tctatatgtg ctaccataga tgtgacattt
2761 ttgaccttaa tatcgtcttt gaaaatgtta aattgagaaa cctgttaact tacattttat
2821 gaattggcac attgtattac ttactgcaag agatatttca ttttcagcac agtgcaaaag
2881 ttctttaaaa tgcatatgtc tttttttcta attccgtttt gttttaaagc acattttaaa
2941 tgtagttttc tcatttagta aaagttgtct aattgatatg aagcctgact gatttttttt
3001 ttccttacag tgagacattt aagcacacat tttattcaca tagatactat gtccttgaca
3061 tattgaaatg attcttttct gaaagtattc atgatctgca tatgatgtat taggttaggt
3121 cacaaaggtt ttatctgagg tgatttaaat aacttcctga ttggagtgtg taagctgagc
3181 gatttctaat aaaattttag ttgtacactt ttagtagtca tagtgaagca ggtctagaaa
3241 ataagccttt ggcagggaaa aagggcaatg ttgattaatc tcagtattaa accacattaa
3301 tctgtatccc attgtctggc ttttgtaaat tcatccaggt caagactaag tatgttggtt
3361 aataggaatc cttttttttt tttaaagact aaatgtgaaa aaataatcac tacttaagct
3421 aattaatatt ggtcattaaa tttaaaggat ggaaatttat catgtttaaa aattattcaa
3481 gcactcttaa aaccacttaa acagcctcca gtcataaaaa tgtgttcttt acaaatattt
3541 gcttggcaac acgacttgaa ataaataaaa ctttgtttct taggagaaaa
(SEQ ID NO:123)
1    madgelnvds litrllevrg crpgkivqmt eaevrglcik sreiflsqpi lleleaplki
61   cgdihgqytd llrlfeyggf ppeanylflg dyvdrgkqsl eticlllayk ikypenffll
121  rgnhecasin riygfydeck rrfniklwkt ftdcfnclpi aaivdekifc chgglspdlq
181  smeqirrimr ptdvpdtgll cdllwsdpdk dvqgwgendr gvsftfgadv vskflnrhdl
241  dlicrahqvv edgyeffakr qlvtlfsapn ycgefdnagg mmsvdetlmc sfqilkpsek
301  kakyqyggln sgrpvtpprt anppkkr

Putative function

Protein phosphatase

Example 5 (Category 2)

Line ID—231

Phenotype—Semi-lethal male and female, cytokinesis defect. In some cysts, variable sized Nebenkerns

Annotated Drosophila genome genomic segment containing P element insertion site (and map position)—AE003429 (3F)

P element insertion site—153,730

Annotated Drosophila genome Complete Genome candidate—CG5014—vap-33-1 vesicle associated membrane protein

(SEQ ID NO:124)
CACATCACTAGCTGACAGAATATATGGCTTTTTTACATTTTGCGTTTTCA
ACTGAAGTTTGCGAAGAAACCGAAGCGTGGTAAACCACTGAAATCGAAAA
TATCGACAGAAAAGCGACCTAAAGTCGGTGAAGAAGTCGCACGTTGATCG
TTGTGTTTTTTTCCCGAAATTTTCTGCAAAAAGCCCGTGCGTGCGTGAGT
TTCTCTGGCTCTTGCTTTTTTTTTGTCCATGCGTGTGTGTGTGGTCGCAT
AAATTTACCGATATTTCGCCTGTGAGAGCGAAACGAACGAAAAACGAAAG
AAAAAAAGAGAGACGAGTAAAGTAAAACGAAACAGGCATAAAAACAGCAG
CAGTTTTCTTGATATATTTGGCTAAAAAACGCAAACCAAACAGCCAGCAA
GAACAACAAATAGCTGGGCAAAAACAGGACGCACAAAAAATAAAATTAAA
ACGATAAGAGGCGAAAAGCGGAGAGAGTGAAATTCTCGGCAGCAACAACG
ACAAGAACAACACCAGGAGCAGCAGCAACAACAACAACAAAAGCCAGCCG
CCACAATGAGCAAATCACTCTTTGATCTTCCGTTGACCATTGAACCAGAA
CATGAGTTGCGTTTTGTGGGTCCCTTCACCCGACCCGTTGTCACAATCAT
GACTCTGCGCAACAACTCGGCTCTGCCTCTGGTCTTCAAGATCAAGACAA
CCGCCCCGAAACGCTACTGCGTACGTCCAAACATCGGCAAGATAATTCCC
TTTCGATCAACCCAGGTGGAGATCTGCCTTCAGCCATTCGTCTACGATCA
GCAGGAGAAGAACAAGCACAAGTTCATGGTGCAGAGCGTCCTGGCACCCA
TGGATGCTGATCTAAGCGATTTAAATAAATTGTGGAAGGATCTGGAGCCC
GAGCAGCTGATGGACGCCAAACTGAAGTGCGTTTTCGAGATGCCCACCGC
TGAGGCAAATGCTGAGAACACCAGCGGTGGTGGTGCCGTTGGCGGCGGAA
CCGGAGCTGCCGGAGGCGGAAGCGCGGGTGCCAATACTAGCTCAGCCAGC
GCTGAGGCGCTCGAGAGCAAGCCGAAGCTCTCCAGCGAGGATAAGTTTAA
GCCATCCAATTTGCTCGAAACGTCTGAGAGTCTGGACTTGCTGTCCGGAG
AGATCAAAGCGCTGCGTGAATGCAACATTGAATTGCGAAGAGAGAATCTT
CACTTGAAGGATCAAATCACACGTTTCCGGAGCTCGCCGGCCGTCAAACA
GGTGAATGAGCCCTATGCCCCAGTCCTGGCTGAGAAGCAGATTCCGGTCT
TTTACATTGCAGTTGCCATTGCTGCGGCCATCGTTAGCCTCCTGCTGGGC
AAATTCTTTCTCTGA
(SEQ ID NO:125)
MSKSLFDLPLTIEPEHELRFVGPFTRPVVTIMTLRNNSALPLVFKIKTTA
PKRYCVRPNIGKIIPFRSTQVEICLQPFVYDQQEKNKHKFMVQSVLAPMD
ADLSDLNKLWKDLEPEQLMDAKLKCVFEMPTAEANAENTSGGGAVGGGTG
AAGGGSAGANTSSASAEALESKPKLSSEDKFKPSNLLETSESLDLLSGEI
KALRECNIELRRENLHLKDQITRFRSSPAVKQVNEPYAPVLAEKQIPVFY
IAVAIAAAIVSLLLGKFFL

Human homologue of Complete Genome candidate

AAD13577 VAMP-associated protein B

(SEQ ID NO:126)
1    gcgcgcccac ccggtagagg acccccgccc gtgccccgac cggtccccgc ctttttgtaa
61   aacttaaagc gggcgcagca ttaacgcttc ccgccccggt gacctctcag gggtctcccc
121  gccaaaggtg ctccgccgct aaggaacatg gcgaaggtgg agcaggtcct gagcctcgag
181  ccgcagcacg agctcaaatt ccgaggtccc ttcaccgatg ttgtcaccac caacctaaag
241  cttggcaacc cgacagaccg aaatgtgtgt tttaaggtga agactacagc accacgtagg
301  tactgtgtga ggcccaacag cggaatcatc gatgcagggg cctcaattaa tgtatctgtg
361  atgttacagc ctttcgatta tgatcccaat gagaaaagta aacacaagtt tatggttcag
421  tctatgtttg ctccaactga cacttcagat atggaagcag tatggaagga ggcaaaaccg
481  gaagacctta tggattcaaa acttagatgt gtgtttgaat tgccagcaga gaatgataaa
541  ccacatgatg tagaaataaa taaaattata tccacaactg catcaaagac agaaacacca
601  atagtgtcta agtctctgag ttcttctttg gatgacaccg aagttaagaa ggttatggaa
661  gaatgtaaga ggctgcaagg tgaagttcag aggctacggg aggagaacaa gcagttcaag
721  gaagaagatg gactgcggat gaggaagaca gtgcagagca acagccccat ttcagcatta
781  gccccaactg ggaaggaaga aggccttagc acccggctct tggctctggt ggttttgttc
841  tttatcgttg gtgtaattat tgggaagatt gccttgtaga ggtagcatgc acaggatggt
901  aaattggatt ggtggatcca ccatatcatg ggatttaaat ttatcataac catgtgtaaa
961  aagaaattaa tgtatgatga catctcacag gtcttgcctt taaattaccc ctccctgcac
1021 acacatacac agatacacac acacaaatat aatgtaacga tcttttagaa agttaaaaat
1081 gtatagtaac tgattgaggg ggaaaagaat gatctttatt aatgacaagg gaaaccatga
1141 gtaatgccac aatggcatat tgtaaatgtc attttaaaca ttggtaggcc ttggtacatg
1201 atgctggatt acctctctta aaatgacacc cttcctcgcc tgttggtgct ggcccttggg
1261 gagctggagc ccagcatgct ggggagtgcg gtcagctcca cacagtagtc cccacgtggc
1321 ccactcccgg cccaggctgc tttccgtgtc ttcagttctg tccaagccat cagctccttg
1381 ggactgatga acagagtcag aagcccaaag gaattgcact gtggcagcat cagacgtact
1441 cgtcataagt gagaggcgtg tgttgactga ttgacccagc gctttggaaa taaatggcag
1501 tgctttgttc acttaaaggg accaagctaa atttgtattg gttcatgtag tgaagtcaaa
1561 ctgttattca gagatgttta atgcatattt aacttattta atgtatttca tctcatgttt
1621 tcttattgtc acaagagtac agttaatgct gcgtgctgct gaactctgtt gggtgaactg
1681 gtattgctgc tggagggctg tgggctcctc tgtctctgga gagtctggtc atgtggaggt
1741 ggggtttatt gggatgctgg agaagagctg ccaggaagtg ttttttctgg gtcagtaaat
1801 aacaactgtc ataggcaggg aaattctcag tagtgacagt caactctagg ttaccttttt
1861 taatgaagag tagtcagtct tctagattgt tcttatacca cctctcaacc attactcaca
1921 cttccagcgc ccaggtccaa gtttgagcct gacctcccct tggggaccta gcctggagtc
1981 aggacaaatg gatcgggctg caaagggtta gaagcgaggg caccagcagt tgtgggtggg
2041 gagcaaggga agagagaaac tcttcagcga atccttctag tactagttga gagtttgact
2101 gtgaattaat tttatgccat aaaagaccaa cccagttctg tttgactatg tagcatcttg
2161 aaaagaaaaa ttataataaa gccccaaaat taaga
(SEQ ID NO:127)
1    makveqvlsl epqhelkfrg pftdvvttnl klgnptdrnv cfkvkttapr rycvrpnsgi
61   idagasinvs vmlqpfdydp nekskhkfmv qsmfaptdts dmeavwkeak pedlmdsklr
121  cvfelpaend kphdveinki isttasktet pivskslsss lddtevkkvm eeckrlqgev
181  qrlreenkqf keedglrmrk tvqsnspisa laptgkeegl strllalvvl ffivgviigk
241  ial

Putative function

Membrane associated protein which may be involved in priming synaptic vesicles

Example 6 (Category 2)

Line ID—248

Phenotype—Male sterile, cytokinesis defect. Cytokinesis defect, different meiotic stages within one cyst, variable sized nuclei, 2-4 nuclei. Also has a mitotic phenotype: semi-lethal, rod-like overcondensed chromosomes, high mitotic index, lagging chromosomes and bridges.

Annotated Drosophila genome genomic segment containing P element insertion site (and map position)—AE003431 (4D 1)

P element insertion site—299,078

Annotated Drosophila genome Complete Genome candidate—CG6998—cutup (dynein light chain)

(SEQ ID NO:128)
CAAAACGTTCAGTTGTGTTTCAGTTGTCGAGAAGTCAGGGTGTTTCTACC
TTCCATTTACCGTTCCAGTGTAAAATTCAGGCGACACGCTTAGCGTTACC
AAGGAGAACCGCTAAAAAGGGCCACTTTTCAAACGGTTAGATTCCAGTGA
AGTTGTAAGCACACAGGGAACCTAAAAAAAAAAAAAACAGCCAAAATGTC
TGATCGCAAGGCCGTGATTAAAAATGCCGACATGAGCGAGGAGATGCAGC
AGGATGCCGTCGATTGTGCGACACAGGCCCTCGAGAAGTACAACATTGAA
AAGGACATTGCGGCCTACATCAAGAAGGAGTTCGACAAAAAATACAATCC
CACATGGCATTGCATTGTCGGTCGCAACTTTGGATCGTATGTCACACACG
AGACGCGCCACTTTATTTACTTCTATTTGGGCCAGGTGGCTATTTTACTG
TTTAAGAGCGGTTAAAGTATTGTCGAGTCGGATGAAGTGGTGGTGAGGAG
GCTGATGGAGATGCAGCAGCTGCCCCGCCAGCAGCAACAACAGCAGGGGC
AGCAGTCGCATTTCGGAGCATCAGAGGATGAGGATCTAGAGCAGAAACAG
CAACAACCA
(SEQ ID NO:129)
MSDRKAVIKNADMSEEMQQDAVDCATQALEKYNIEKDIAAYIKKEFDKKY
NPTWHCIVGRNFGSYVTHETRHFIYFYLGQVAILLFKSG

Human homologue of Complete Genome candidate

AAH10744 Similar to RIKEN cDNA 6720463E02 gene

(SEQ ID NO:130)
1   gctgtgaggc gccagtgcgg agcgggcggg cgggcgggcg ggcgggcggc gcgaggcgga
61  gcgcgggcgg ccggcgaaac tccaagggcg gaccgcggca gggagcgatc ggcctcgggc
121 tgcgggagcc ggagaccgcg gcggcggcgg ctgctgcagc tgcaggagga gcccagggaa
181 caccgcccct gcctgtgctc tgcctcgggc catcgctcct ccccagggcc cagtgcggac
241 tcgcctccgt gaagtgtcac accatgtctg accggaaggc agtgatcaag aacgcagaca
301 tgtctgagga catgcaacag gatgccgttg actgcgccac gcaggccatg gagaagtaca
361 atatagagaa ggacattgct gcctatatca agaaggaatt tgacaagaaa tataacccta
421 cctggcattg tatcgtgggc cgaaattttg gcagctacgt cacacacgag acaaagcact
481 tcatctattt ttacttgggt caagttgcaa tcctcctctt caagtcaggc taggtggcca
541 tggtgaaggt gtcagtggcg gcggcagcga tggcaagcag gcggcgttgc tgggactgtt
601 ttgcactgga gccagcatca ggatgtcctc tccaatggct gtgctactgc atggactgta
661 tactcgattt catgtgtatg tcgcagtaaa caaaaccaaa cctcaaaaaa aaaaaaaaaa
721 aaaaaaaaaa aaaaa
(SEQ ID NO:131)
1   msdrkavikn admsedmqqd avdcatqame kyniekdiaa yikkefdkky nptwhcivgr
61  nfgsyvthet khfiyfylgq vaillfksg

Putative function

Dynein light chain, a microtubule motor protein

Example 7 (Category 2)

Line ID—bbl-E1

Phenotype—Male sterile. Asynchronous meiotic divisions, cysts with large Nebenkern and 1-2 larger nuclei, testis from 2-3 old males become smaller. High mitotic index, colchicine type overcondensaton, many anaphases and telophases, no decondensation in telophase. Also has a mitotic phenotype: High mitotic index, colchicines-type overcondensed chromosomes, many ana- and relophases, no decondensation in telophase

Annotated Drosophila genome genomic segment containing P element insertion site (and map position)—AE003431 (4E)

P element insertion site—not determined

Annotated Drosophila genome Complete Genome candidate

CG2984—Pp2C 1 protein phosphatase

(SEQ ID NO:132)
TGTTCGCAAGTCGAGAGCAGAATCGAACGGCAAAAAATGCTGGCGAACAA
CAAATCATCAAGGTAAAACTGCGCGCCTTGGTCATTAAGTCTTTCATCGA
GGATAAAAGACCGATGTCTTTTAACGTTATTGCTGTAAGCAAAAGCAGAA
ATCACAATCTACTCATAAATCCTCGATTTGGTGCAAATTAAAGGAAATTC
ATCGGTTTTTGGCGGCCAGTTGCAAACACAAAATACTAAATACGCTAGAT
GGAGCACGCATACACGCAAGCTCGTTGGCGAACGTAAATTACATACATCA
TATAGATAGTCGTCCCGCTTGCACTGCCCGTCACAGCGAGGGCTGCGAGA
GCGAGAGCGGGAGAGAGAAAGGCCTGAGTCGCTTTTTCTTCTTGTACTTT
ATATATTTTTTATTGTTTTTTTGTGTTGTGTTGCGTTGTACGTGTGTGTG
AGAGTGCCAAATGTCAACGGAAATTACAACACTGCGAGACGGAGAAGTCT
AAAAGGCAGAAGAAGAAGAAGCAGCAGCAGGCAGCATAAACAAAACTCGG
GGGAAAAATGTTGCCCGCCAATAACAGGAGTAGCACCAGCACCCATACCA
ACACAAATGCCAACACAATCAACGCCACTACCAATACCACCAACAGATGC
CTCATCAATACGGCCATCGAAAAAACGGTAGTCCGTTTGCGAGAGACGGC
AGCGAATAGCGCACCAGCTCCAGCCACAGCCTCCGTTACTCGCCACGGCG
GCAGCAGCAGCGGCAATAACAACAATAACAGTGCATGCCATCCAGCACTG
GATGCCAGCAGTGATGTTGTTGTTGTTGAACCGGCAGCGGTAGGAGTCGC
ACAGGAGGAAGAGGAAGAGCCGGAGCAAAGGCCAGAGAGGATCAGCATAC
CCATTCCCGACCTGGCGTTCACCGAGATGGAAGCATATGCCGAGGATATA
GTCGTCGATATGGAGGGGGGATCACCAGCCAAGCCTTTAAATCCAAAGAA
ACAACGTTTAAACTCAGCAACAACCACAACAATAAATCGCTCGAGGGGCG
GCGGAGCGGCACAGAGTCGATTACGCCGGTCGGCGGCCATCGTTCCACCG
CGATCGATTCCAGAGAGCTGTGCCAGCAGCAGCAATTCCAATTCGAGCAG
CAGTTCCAACAGTAATTCCAGTTCCAGCTCCGCTACAGGAAGTAGCGCAT
CCACCGGCAATCCGTCGCCGTGCTCCTCCCTGGGCGTCAATATGCGCGTA
ACTGGACAATGCTGCCAGGGAGGCCGGAAATACATGGAGGATCAGTTCTC
GGTGGCCTACCAGGAATCACCGATCACCCACGAACTGGAATACGCATTTT
TTGGCATCTACGACGGACACGGCGGTCCCGAGGCCGCGCTCTTCGCCAAG
GAGCACCTTATGCTCGAGATCGTCAAGCAGAAGCAGTTCTGGTCTGATCA
GGATGAGGATGTCCTGCGGGCAATACGCGAGGGATACATCGCCACACATT
TCGCCATGTGGCGGGAACAAGAGAAATGGCCACGCACTGCCAATGGGCAT
CTGAGCACCGCCGGCACCACCGCCACAGTGGCCTTTATGCGTCGCGAGAA
GATCTACATTGGTCATGTGGGTGATTCTGGGATCGTTTTGGGTTACCAGA
ACAAGGGCGAACGCAACTGGCGTGCTCGTCCACTGACCACGGACCACAAG
CCGGAGTCACTGGCAGAGAAGACGAGAATCCAGCGTTCCGGCGGCAATGT
TGCCATCAAATCGGGAGTTCCGCGAGTGGTATGGAACCGACCCAGGGACC
CAATGCATCGCGGTCCCATTCGCCGCAGAACTCTGGTAGATGAAATACCC
TTTTTGGCGGTGGCTCGTTCCCTGGGCGATCTCTGGAGCTACAATTCCCG
CTTCAAGGAATTCGTTGTGAGTCCCGATCCGGATGTCAAAGTGGTTAAAA
TAAATCCCAGTACCTTTAGATGCTTAATTTTCGGCACCGATGGCCTGTGG
AATGTGGTGACCGCCCAGGAGGCGGTGGACAGTGTGCGCAAGGAGCATCT
AATCGGCGAGATACTCAACGAGCAGGACGTTATGAATCCCAGCAAGGCGC
TGGTGGATCAGGCCCTCAAAACCTGGGCCGCCAAGAAGATGCGTGCGGAC
AACACGTCCGTTGTGACTGTGATACTAACACCAGCGGCCCGCATTAATTC
GCCCACAACGCCAACACGTTCCCCATCCGCGATGGCACGCGACAATGATC
TGGAGGTGGAGCTACTGCTGGAGGAGGACGACGAGGAGCTGCCGACACTG
GATGTGGAGAACAACTACCCTGACTTTCTCATCGAGGAGCATGAGTATGT
GCTGGACCAGCCGTACAGTGCATTGGCCAAGCGACATTCGCCTCCGGAAG
CCTTCCGCAACTTCGACTACTTCGATGTGGACGAGGACGAGTTGGATGAA
GATGAGGAAACAGTGGAAGAAGACGAGGAGGAGGAGGAGGAAGAGGAGGA
AACCAAATCGGTGGGAATTCTACAGCAAAGTTTGTTCAACCCCAGAAAAA
CGTGGCGCAAGTCAACCATCAACAATTCCTGGAGTGGCGTCACCGAACCG
GAACCGGAACCCGATCCCGAACCAGATCGAATAGATGTCTTAACACTGGA
CATGTACTCCCACACCAGCATTGACAAGGGCACCAATTATGGCGGCAGCA
TAGCCCAGTCCTCAATAGATCCTGCGGAGACGGCTGAAAATCGTGAGCTG
AGTGAGTTGGAGCAGCATCTGGAGAGTAGCTACAGTTTCGCCGAGTCGTA
CAACTCCCTGTTAAACGAGCAGGAGGAGCAGGAGGCACGCTCACGTTCAG
CAGCAGCAGCAGCCGCCGCCGCAGAAGCAGCAGCAGTAGAAGCACAACAA
ACCACTGCCCATTCCGCATCCGTTGTGCTGGACCGCAGCATGTTGGAGAT
CATCCAGGAGCAGCAGCACTATCAGCAGCAAGAGGGCTATTCGCTAACGC
AACTAGAGACCAGACGTGAAAGGGAGCGGCTGACCGAATCGTGGCCACAG
CAGCCGGCTGAGCTGCTCGAGCTGGATGCTCTACTGCAGCAGGAGCGTGC
CGAGGAGGAGCAGGTAGCCCTGGAGCAGCAGCAGCAGCGCGAACAGCAAA
TGGAGCAAATGGAGGTGGAGGCCATTAGTAGTTCGGGACAGCACGAATTT
GCTTACCCAGTGACCACCGCCACAGCCAGCGAGTGGTGTGCTACATTACA
AGAAGACGAGGAGGAGTTGGACTCCACAGTAATAGACATAGTAATTCAAC
CCGAACAAGAGTTGCAGGACAATGAAGTGAGCTCCACGTTGCCCGCCACA
CCCACTCATGTGGAGCCTGAGCAGATTGTGGACAAGATGGAGCCCCTGAA
GGTTCAGGAGATGCTAACCGCGGTCGAAAAACCTCCATCCAAGCAGGAAA
AGAAGCTGCCGAAGAAGCAAGAGACCAAACAGGTTGCTGTGCTAGATACA
GTGGCCGAGATGCCCAAAGAGGATGCCCATGCCGTGCACTATATATTCCA
GCGCATTCAAAAGGTTCAGGACTCTGAGGCAACACCAGTGGCCGTGACGA
ATTCCACAATGGCTGACGCCCTGCCCACCGAATCTAGTGGACTGGGAGGA
TCTATGACCGCGCCCCGAATCCGACGCTATCGCAACGTGCCCAACGAGAA
CCATCAGCACATGCAGACGCGTCGTCGTCAGATCTTCAAGCATGTCAAGC
CAAAGTCCTTCATACAGTCCAGTGCTGCGGCGATTGTGGCCTATGGAGAC
AGCACCGAAACGGTCGGAGGAACAGCCGGAGCATCTGGCACACCTGCAGC
TGGGCGTGTAGGCGGGGGCGGTGGCGGCGGCGGCGGCAGAGGATCGGCCA
GTGGTGGGAGCAGTCCAGCGGTGGCAGCCAATAGTCGGCGGAGCGTCAAT
GTGGTGGCCAATGCGAGTGGAAACAGCGCTAGCAAAGTTGTGCCCAGCAG
CAGTTCCATGATGATGACCCGCCGCAGTCACACCTTGACGGCCAGCGGTG
GTGTGAACAAAAGGCAGCTGCGCAGCAGTCTCTGCACCTTGGGCCTGGGT
GTGGGTGTCGGTGTCGGTCTGGGCATGGACCTGGACATGACCAAGCGCAC
GCTAAGGACAAGGAATGTACCCGCTTTGTCGGGCGGTTCAGCCACGCCAT
CTAGCAATTCGTCGCCAGCCAGCGGAGGCAGCAGTCCAGCCGGTTTCACA
AGCCCAGCCAGTCCGGTCATCACGTCCAGGGGAAGCGGATCGCGTACTAC
CGCCTCGCCAGCCAGGCGCCTAAAACGCAGTCATGAGGATCGGGAGCAAA
GAATGAGCTTGCGACGGAGCACTCTGAGTGGCAGTGCCAGCGGCAGTGGG
CTGGTGGGCACTGGTGGGTCGCCCTCGAATGTGAAATCAAATCGCCTGCA
GGCCTGCAATGGAGCCATCTCTGCGCGTCCGCCGCCCTCGCCGAAGAAAC
TGAATGCAGCCGTGCCCACATTGGCAATTGGAACGCGTGCATATACGGCG
GCGTTGGCGGCGGCGGCGGATCACCTGAACAAGCGGTGGTCGTTGCGCAG
CAGCAGTGGCAACTCTGGCAATCTGATAACCGCCATCAGTTGCTACAGTG
ACAGGAGCAGGGCGGCGACTGCGGCGGGATCACCGGGATCTGGAGGCGGG
GCAGCGGGACCACCAGGAGCATCTTTGGCCGCATCCACAGTCGGCACGCG
AAGGCGCTAGGCTAGATTGTAACGAAACATGCGAGCAACTTGCAAGTACA
AATCCTAAGCAACGGAAAATTTTAGATCCTAGTATACTACTTTACTGAAA
ACGCAAAATTGCATAATTTAACCAATTTTTTTATGTGCACAACACACACA
C
(SEQ ID NO:133)
MLPANNRSSTSTHTNTNANTINATTNTTNRCLINTAIEKTVVRLRETAAN
SAPAPATASVTRHGGSSSGNNNNNSACHPALDASSDVVVVEPAAVGVAQE
EEEEPEQRPERISIPIPDLAFTEMEAYAEDIVVDMEGGSPAKPLNPKKQR
LNSATTTTINRSRGGGAAQSRLRRSAAIVPPRSIPESCASSSNSNSSSSS
NSNSSSSSATGSSASTGNPSPCSSLGVNMRVTGQCCQGGRKYMEDQFSVA
YQESPITHELEYAFFGIYDGHGGPEAALFAKEHLMLEIVKQKQFWSDQDE
DVLRAIREGYIATHFAMWREQEKWPRTANGHLSTAGTTATVAFMRREKIY
IGHVGDSGIVLGYQNKGERNWRARPLTTDHKPESLAEKTRIQRSGGNVAI
KSGVPRVVWNRPRDPMHRGPIRRRTLVDEIPFLAVARSLGDLWSYNSRFK
EFVVSPDPDVKVVKINPSTFRCLIFGTDGLWNVVTAQEAVDSVRKEHLIG
EILNEQDVMNPSKALVDQALKTWAAKKMRADNTSVVTVILTPAARNNSPT
TPTRSPSAMARDNDLEVELLLEEDDEELPTLDVENNYPDFLIEEHEYVLD
QPYSALAKRHSPPEAFRNFDYFDVDEDELDEDEETVEEDEEEEEEEEETK
SVGILQQSLFNPRKTWRKSTINNSWSGVTEPEPEPDPEPDRIDVLTLDMY
SHTSIDKGTNYGGSIAQSSIDPAETAENRELSELEQHLESSYSFAESYNS
LLNEQEEQEARSRSAAAAAAAAEAAAVEAQQTTAHSASVVLDRSMLEIIQ
EQQHYQQQEGYSLTQLETRRERERLTESWPQQPAELLELDALLQQERAEE
EQVALEQQQQREQQMEQMEVEAISSSGQHEFAYPVTTATASEWCATLQED
EEELDSTVIDIVIQPEQELQDNEVSSTLPATPTHVEPEQIVDKMEPLKVQ
EMLTAVEKPPSKQEKKLPKKQETKQVAVLDTVAEMPKEDAHAVHYIFQRI
QKVQDSEATPVAVTNSTMADALPTESSGLGGSMTAPRIRRYRNVPNENHQ
HMQTRRRQIFKHVKPKSFIQSSAAAIVAYGDSTETVGGTAGASGTPAAGR
VGGGGGGGGGRGSASGGSSPAVAANSRRSVNVVANASGNSASKVVPSSSS
MMMTRRSHTLTASGGVNKRQLRSSLCTLGLGVGVGVGLGMDLDMTKRTLR
TRNVPALSGGSATPSSNSSPASGGSSPAGFTSPASPVITSRGSGSRTTAS
PARRLKRSHEDREQRMSLRRSTLSGSASGSGLVGTGGSPSNVKSNRLQAC
NGAISARPPPSPKKLNAAVPTLAIGTRAYTAALAAAADHLNKRWSLRSSS
GNSGNLITAISCYSDRSRAATAAGSPGSGGGAAGPPGASLAASTVGTRRR

Human homologue of Complete Genome candidate

AAB61637 Wip1

(SEQ ID NO:134)
1    ctggctctgc tcgctccggc gctccggccc agctctcgcg gacaagtcca gacatcgcgc
61   gccccccctt ctccgggtcc gccccctccc ccttctcggc gtcgtcgaag ataaacaata
121  gttggccggc gagcgcctag tgtgtctccc gccgccggat tcggcgggct gcgtgggacc
181  ggcgggatcc cggccagccg gccatggcgg ggctgtactc gctgggagtg agcgtcttct
241  ccgaccaggg cgggaggaag tacatggagg acgttactca aatcgttgtg gagcccgaac
301  cgacggctga agaaaagccc tcgccgcggc ggtcgctgtc tcagccgttg cctccgcggc
361  cgtcgccggc cgcccttccc ggcggcgaag tctcggggaa aggcccagcg gtggcagccc
421  gagaggctcg cgaccctctc ccggacgccg gggcctcgcc ggcacctagc cgctgctgcc
481  gccgccgttc ctccgtggcc tttttcgccg tgtgcgacgg gcacggcggg cgggaggcgg
541  cacagtttgc ccgggagcac ttgtggggtt tcatcaagaa gcagaagggt ttcacctcgt
601  ccgagccggc taaggtttgc gctgccatcc gcaaaggctt tctcgcttgt caccttgcca
661  tgtggaagaa actggcggaa tggccaaaga ctatgacggg tcttcctagc acatcaggga
721  caactgccag tgtggtcatc attcggggca tgaagatgta tgtagctcac gtaggtgact
781  caggggtggt tcttggaatt caggatgacc cgaaggatga ctttgtcaga gctgtggagg
841  tgacacagga ccataagcca gaacttccca aggaaagaga acgaatcgaa ggacttggtg
901  ggagtgtaat gaacaagtct ggggtgaatc gtgtagtttg gaaacgacct cgactcactc
961  acaatggacc tgttagaagg agcacagtta ttgaccagat tccttttctg gcagtagcaa
1021 gagcacttgg tgatttgtgg agctatgatt tcttcagtgg tgaatttgtg gtgtcacctg
1081 aaccagacac aagtgtccac actcttgacc ctcagaagca caagtatatt atattgggga
1141 gtgatggact ttggaatatg attccaccac aagatgccat ctcaatgtgc caggaccaag
1201 aggagaaaaa atacctgatg ggtgagcatg gacaatcttg tgccaaaatg cttgtgaatc
1261 gagcattggg ccgctggagg cagcgtatgc tccgagcaga taacactagt gccatagtaa
1321 tctgcatctc tccagaagtg gacaatcagg gaaactttac caatgaagat gagttatacc
1381 tgaacctgac tgacagccct tcctataata gtcaagaaac ctgtgtgatg actccttccc
1441 catgttctac accaccagtc aagtcactgg aggaggatcc atggccaagg gtgaattcta
1501 aggaccatat acctgccctg gttcgtagca atgccttctc agagaatttt ttagaggttt
1561 cagctgagat agctcgagag aatgtccaag gtgtagtcat accctcaaaa gatccagaac
1621 cacttgaaga aaattgcgct aaagccctga ctttaaggat acatgattct ttgaataata
1681 gccttccaat tggccttgtg cctactaatt caacaaacac tgtcatggac caaaaaaatt
1741 tgaagatgtc aactcctggc caaatgaaag cccaagaaat tgaaagaacc cctccaacaa
1801 actttaaaag gacattagaa gagtccaatt ctggccccct gatgaagaag catagacgaa
1861 atggcttaag tcgaagtagt ggtgctcagc ctgcaagtct ccccacaacc tcacagcgaa
1921 agaactctgt taaactcacc atgcgacgca gacttagggg ccagaagaaa attggaaatc
1981 ctttacttca tcaacacagg aaaactgttt gtgtttgctg aaatgcatct gggaaatgag
2041 gtttttccaa acttaggata taagagggct ttttaaattt ggtgccgatg ttgaactttt
2101 tttaagggga gaaaattaaa agaaatatac agtttgactt tttggaattc agcagtttta
2161 tcctggcctt gtacttgctt gtattgtaaa tgtggatttt gtagatgtta gggtataagt
2221 tgctgtaaaa tttgtgtaaa tttgtatcca cacaaattca gtctctgaat acacagtatt
2281 cagagtctct gatacacagt aattgtgaca atagggctaa atgtttaaag aaatcaaaag
2341 aatctattag attttagaaa aacatttaaa ctttttaaaa tacttattaa aaaatttgta
2401 taagccactt gtcttgaaaa ctgtgcaact ttttaaagta aattattaag cagactggaa
2461 aagtgatgta ttttcatagt gacctgtgtt tcacttaatg tttcttagag ccaagtgtct
2521 tttaaacatt attttttatt tctgatttca taattcagaa ctaaattttt catagaagtg
2581 ttgagccatg ctacagttag tcttgtccca attaaaatac tatgcagtat ctcttacatc
2641 agtagcattt ttctaaaacc ttagtcatca gatatgctta ctaaatcttc agcatagaag
2701 gaagtgtgtt tgcctaaaac aatctaaaac aattcccttc tttttcatcc cagaccaatg
2761 gcattattag gtcttaaagt agttactccc ttctcgtgtt tgcttaaaat atgtgaagtt
2821 ttccttgcta tttcaataac agatggtgct gctaattccc aacatttctt aaattatttt
2881 atatcataca gttttcattg attatatggg tatatattca tctaataaat cagtgaactg
2941 ttcctcatgt tgctgaaaaa aaaaaaaaaa aaa
(SEQ ID NO:135)
1    maglyslgvs vfsdqggrky medvtqivve peptaeekps prrslsqplp prpspaalpg
61   gevsgkgpav aareardplp dagaspapsr ccrrrssvaf favcdghggr eaaqfarehl
121  wgfikkqkgf tssepakvca airkgflach lamwkklaew pktmtglpst sgttasvvii
181  rgmkmyvahv gdsgvvlgiq ddpkddfvra vevtqdhkpe lpkererieg lggsvmnksg
241  vnrvvwkrpr lthngpvrrs tvidqipfla varalgdlws ydffsgefvv spepdtsvht
301  ldpqkhkyii lgsdglwnmi ppqdaismcq dqeekkylmg ehgqscakml vnralgrwrq
361  rmlradntsa ivicispevd nqgnftnede lylnltdsps ynsqetcvmt pspcstppvk
421  sleedpwprv nskdhipalv rsnafsenfl evsaeiaren vqgvvipskd pepleencak
481  altlrihdsl nnslpiglvp tnstntvmdq knlkmstpgq mkaqeiertp ptnfkrtlee
541  snsgplmkkh rrnglsrssg aqpaslptts qrknsvkltm rrrlrgqkki gnpllhqhrk
601  tvcvc

Putative function

Protein phosphatase, with p53 dependent expression, so may be inhibitory to division

Example 8 (Category 2)

Line ID—ms(1)04

Phenotype—Cytokinesis defect, small testis, no meiosis observed, variable sized Nebenkerns with 2-4N nuclei

Annotated Drosophila genome genomic segment containing P element insertion site (and map position)—AE003442 (7C-D)

P element insertion site—not determined

Annotated Drosophila genome Complete Genome candidate

CG1524—RpS14A ribosomal protein (2 splice variants)

(SEQ ID NO:136)
GATATCCGGTTAACGCAAGTGTTGCTGATCGACAAACAAACCCAGAATGG
CACCCAGGAAGGCTAAAGTTCAGAAGGAGGAGGTTCAGGTCCAGCTGGGA
CCCCAAGTTCGCGACGGCGAGATCGTGTTCGGAGTGGCTCACATCTACGC
CAGCTTCAACGACACCTTCGTCCATGTCACTGATCTGTCCGGCCGTGAGA
CCATCGCTCGTGTCACCGGAGGCATGAAGGTGAAGGCCGATCGTGATGAG
GCTTCGCCCTACGCCGCTATGTTGGCCGCTCAGGATGTGGCTGAGAAGTG
CAAGACACTGGGCATTACTGCCCTGCATATTAAGCTGCGTGCCACCGGCG
GCAACAAGACCAAGACCCCCGGACCCGGCGCCCAGTCCGCTCTGCGTGCT
TTGGCCCGTTCGTCCATGAAGATTGGCCGCATCGAGGATGTGACGCCCAT
CCCATCGGACTCCACCCGCAGGAAGGGCGGTCGCCGTGGTCGTCGTCTGT
AGATGGCAGTATCTGGAAAGCAGTAGTCTATGTTTGCGGTCGAAATACAA
TACTGC
(SEQ ID NO:137)
MAPRKAKVQKEEVQVQLGPQVRDGEIVFGVAHIYASFNDTFVHVTDLSGR
ETIARVTGGMKVKADRDEASPYAAMLAAQDVAEKCKTLGITALHIKLRAT
GGNKTKTPGPGAQSALRALARSSMKIGRIEDVTPIPSDSTRRKGGRRGRR
L
(SEQ ID NO:138)
CAAGTGGTTCGTCTTTAATTTTTCCCTCTTAATTTTTGCGAAAAAAAACC
CGACTTTGAGCCCCTAAACTTAAAAAATGTGCCTTCCTCCAGAGTGTTCA
GAGCGTCGACTGAAAATGACAAACAAGCTGCCCGGCAGCTAATTTTTTTT
TACATTTTTTGTTTTGTTTGTTCGCACGCATTTGTTTTTATTTGTGAAAC
ACGTGGTATAAATGTGGAAATTCCCTTGCTATTCCCGCAGTTGCTGATCG
ACAAACAAACCCAGAATGGCACCCAGGAAGGCTAAAGTTCAGAAGGAGGA
GGTTCAGGTCCAGCTGGGACCCCAAGTTCGCGACGGCGAGATCGTGTTCG
GAGTGGCTCACATCTACGCCAGCTTCAACGACACCTTCGTCCATGTCACT
GATCTGTCCGGCCGTGAGACCATCGCTCGTGTCACCGGAGGCATGAAGGT
GAAGGCCGATCGTGATGAGGCTTCGCCCTACGCCGCTATGTTGGCCGCTC
AGGATGTGGCTGAGAAGTGCAAGACACTGGGCATTACTGCCCTGCATATT
AAGCTGCGTGCCACCGGCGGCAACAAGACCAAGACCCCCGGACCCGGCGC
CCAGTCCGCTCTGCGTGCTTTGGCCCGTTCGTCCATGAAGATTGGCCGCA
TCGAGGATGTGACGCCCATCCCATCGGACTCCACCCGCAGGAAGGGCGGT
CGCCGTGGTCGTCGTCTGTAGATGGCAGTATCTGGAAAGCAGTAGTCTAT
GTTTGCGGTCGAAATACAATACTGC
(SEQ ID NO:139)
MAPRKAKVQKEEVQVQLGPQVRDGEIVFGVAHIYASFNDTFVHVTDLSGR
ETIARVTGGMKVKADRDEASPYAAMLAAQDVAEKCKTLGITALHIKLRAT
GGNKTKTPGPGAQSALRALARSSMKIGRIEDVTPIPSDSTRRKGGRRGRR
L

Human homologue of Complete Genome candidate

A25220 ribosomal protein S14, cytosolic

(SEQ ID NO:140)
1   ctccgccctc tcccactctc tctttccggt gtggagtctg gagacgacgt gcagaaatgg
61  cacctcgaaa ggggaaggaa aagaaggaag aacaggtcat cagcctcgga cctcaggtgg
121 ctgaaggaga gaatgtattt ggtgtctgcc atatctttgc atccttcaat gacacttttg
181 tccatgtcac tgatctttct ggcaaggaaa ccatctgccg tgtgactggt gggatgaagg
241 taaaggcaga ccgagatgaa tcctcaccat atgctgctat gttggctgcc caggatgtgg
301 cccagaggtg caaggagctg ggtatcaccg ccctacacat caaactccgg gccacaggag
361 gaaataggac caagacccct ggacctgggg cccagtcggc cctcagagcc cttgcccgct
421 cgggtatgaa gatcgggcgg attgaggatg tcacccccat cccctctgac agcactcgca
481 ggaagggggg tcgccgtggt cgccgtctgt gaacaagatt cctcaaaata ttttctgtta
541 ataaattgcc ttcatgtaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaa
(SEQ ID NO:141)
1   maprkgkekk eeqvislgpq vaegenvfgv chifasfndt fvhvtdlsgk eticrvtggm
61  kvkadrdess pyaamlaaqd vaqrckelgi talhiklrat ggnrtktpgp gaqsalrala
121 rsgmkigrie dvtpipsdst rrkggrrgrr l

Putative function

Ribosomal protein

Example 9 (Category 2)

Line ID—thb-a

Phenotype—Male sterile. Cytokinesis defect, larger Nebenkerns with 2-4N nuclei

Annotated Drosophila genome genomic segment containing P element insertion site (and map position)—(10B1-2)

P element insertion site—not determined

Annotated Drosophila genome Complete Genome candidate

2 candidates:

CG1453—kinesin-like protein KIF2 homolog

(SEQ ID NO:142)
AAACTAAAAAATTGTGTTGCTGACATCTGGTCGCTTGCAAAACTATTTCT
AGCAGATTTTGTGATATTTCGTTGTGATCGGTCGATAAATCCGCCAGTTT
TTTTTTTAATGGAAAGTGCTAACACATTGTAGCGGTTGGGAAGATAGCAG
GAAAGAGCCAGCGGGCTGCCGTTTTTCCTTTTTGTTATCCGTTGCCAGAC
GCAACGAAAACGACAGTTGGCATTTGAATTCAGCACAAACACACATACTA
ACGCCGACCCGCAAGCAGCACACACACACACACTGGGACACTCGAAAAAA
AAAAAACAGACGCTGTCGGCGACCTCGACAAGCAGTTGGGTTCGATTTAG
TTGTCAATGCCTTGAATTCGGTTCGGGGCTTAGTTTCCACAAGTTTATCG
CTCGTCAAGAAACAACGAAATAAAATTATTTTCGACCTAAAAAATCTGAC
TAAATTGTGTTTTTTGTTTATGTATTTATTTAGGCACATTTTGCACACCA
CAACGTAGTTACTACATCTACGACTAACGGAACTCCTCCTGCAAGCAGTG
GAAGTTGCTGTCCATCAAGCAGTACTCGGAGTTAACGCAGGATAAGCCGG
GAGAAAGAGAAAGAGATCGGTGGAGAATAGAGATATACAGGTGGAGTCAA
AGAGGAAGGATCATGGACATGATTACGGTGGGGCAGAGCGTCAAGATCAA
GCGGACGGATGGCCGCGTCCACATGGCCGTGGTGGCGGTGATCAACCAGT
CGGGCAAGTGCATCACAGTCGAATGGTACGAGCGCGGCGAAACGAAGGGC
AAGGAGGTAGAACTGGACGCCATACTCACGCTCAATCCGGAGCTAATGCA
AGATACTGTCGAACAGCACGCCGCCCCGGAGCCCAAGAAACAAGCCACCG
CGCCGATGAACCTCTCGCGTAATCCCACACAATCGGCTATCGGTGGCAAT
CTCACCAGCCGTATGACCATGGCCGGAAACATGCTGAACAAGATCCAGGA
AAGCCAGTCGATTCCCAATCCGATTGTCAGCAGCAATAGCGTGAATACAA
ACAGCAACTCCAACACTACGGCCGGCGGAGGTGGTGGCACCACAACGTCG
ACGACCACTGGATTACAGCGTCCACGGTACTCGCAAGCTGCTACCGGCCA
GCAGCAGACAAGGATCGCCTCGGCGGTGCCTAATAACACATTGCCCAATC
CCAGCGCGGCAGCCAGTGCTGGTCCGGCGGCACAAGGAGTCGCCACTGCG
GCCACAACCCAGGGAGCTGGCGGCGCTAGTACCCGGCGATCGCACGCATT
GAAAGAGGTGGAGCGACTGAAGGAGAATCGCGAGAAGCGACGCGCCCGAC
AGGCCGAGATGAAGGAGGAGAAGGTGGCGCTGATGAACCAGGATCCGGGC
AATCCAAACTGGGAGACGGCGCAAATGATACGCGAATATCAGAGCACGCT
GGAATTTGTGCCGCTGCTCGATGGCCAGGCCGTCGATGACCATCAGATCA
CAGTGTGCGTGCGCAAGCGTCCCATTAGCCGCAAGGAGGTCAATCGCAAG
GAGATCGATGTCATTTCGGTGCCGCGCAAGGACATGCTCATCGTGCACGA
GCCGCGCAGCAAGGTCGACCTCACCAAGTTCCTGGAGAACCACAAGTTTC
GCTTCGACTACGCCTTCAACGACACGTGCGACAATGCCATGGTATACAAA
TACACAGCCAAGCCGTTGGTGAAAACCATTTTCGAGGGCGGAATGGCGAC
GTGCTTCGCCTACGGCCAGACGGGATCGGGCAAAACGCACACCATGGGCG
GTGAGTTTAATGGAAAGGTGCAGGACTGCAAGAACGGCATCTACGCCATG
GCGGCCAAGGATGTCTTTGTGACCCTGAATATGCCGCGTTACCGCGCCAT
GAATCTAGTCGTCTCGGCCAGTTTCTTTGAGATTTACAGTGGCAAGGTCT
TCGATCTTCTGTCCGACAAGCAGAAACTGCGCGTCCTGGAGGATGGTAAA
CAGCAAGTGCAGGTGGTGGGACTCACCGAGAAGGTGGTCGATGGCGTCGA
GGAGGTACTGAAGCTCATCCAGCACGGCAATGCTGCCCGAACATCCGGCC
AGACGTCGGCCAACTCCAATTCGTCGCGTTCGCACGCCGTTTTCCAGATT
GTGCTGCGGCCGCAGGGCTCGACGAAGATCCATGGCAAGTTCTCGTTCAT
CGATCTGGCGGGCAATGAGCGGGGCGTGGACACTTCCTCGGCCGATCGGC
AGACGCGTATGGAGGGTGCCGAGATTAACAAATCGCTGCTGGCCCTCAAG
GAGTGCATTCGTGCGTTGGGCAAACAGTCGGCCCACTTGCCCTTCCGTGT
CTCCAAACTCACCCAGGTGCTGCGCGACTCGTTCATTGGCGAGAAGAGCA
AGACGTGCATGATAGCCATGATCTCGCCGGGACTTAGCTCCTGCGAGCAC
ACGCTCAACACGCTGCGCTATGCGGATCGTGTCAAGGAGCTGGTGGTCAA
GGATATCGTCGAAGTTTGCCCTGGCGGCGACACCGAGCCCATCGAGATCA
CGGACGACGAGGAGGAGGAGGAGCTCAACATGGTGCATCCGCACTCGCAT
CAGCTGCATCCCAATTCGCATGCACCGGCCAGCCAGTCGAATAATCAGCG
TGCTCCGGCCTCTCATCACTCGGGGGCGGTCATTCACAACAATAATAATA
ACAACAACAAGAACGGAAACGCCGGCAACATGGACCTGGCCATGCTGAGT
TCGCTGAGCGAACACGAGATGTCCGACGAGCTGATTGTGCAGCACCAGGC
CATCGACGACCTGCAGCAGACGGAGGAGATGGTGGTGGAGTATCATCGCA
CCGTTAATGCCACACTGGAGACCTTCCTCGCCGAGTCGAAGGCGCTGTAC
AATCTGACCAACTATGTGGACTACGACCAGGACTCGTACTGCAAACGGGG
CGAGTCGATGTTCTCGCAGCTGCTGGACATCGCCATCCAGTGCCGCGACA
TGATGGCCGAATATCGCGCCAAGTTGGCCAAGGAGGAGATGCTGTCGTGC
AGCTTCAATTCGCCGAATGGCAAGCGTTAGT
(SEQ ID NO:143)
1   mitvgqsvki krtdgrvhma vvavinqsgk citvewyerg etkgkeveld ailtlnpelm
61  qdtveqhaap epkkqatapm nlsrnptqsa iggnltsrmt magnmlnkiq esqsipnpiv
121 ssnsvntnsn snttaggggg tttstttglq rprysqaatg qqqtriasav pnntlpnpsa
181 aasagpaaqg vataattqga ggastrrsha lkeverlken rekrrarqae mkeekvalmn
241 qdpgnpnwet aqmireyqst lefvplldgq avddhqitvc vrkrpisrke vnrkeidvis
301 vprkdmlivh eprskvdltk flenhkfrfd yafndtcdna mvykytakpl vktifeggma
361 tcfaygqtgs gkthtmggef ngkvqdckng iyamaakdvf vtlnmpryra mnlvvsasff
421 eiysgkvfdl lsdkqklrvl edgkqqvqvv gltekvvdgv eevlkliqhg naartsgqts
481 ansnssrsha vfqivlrpqg stkihgkfsf idlagnergv dtssadrqtr megaeinksl
541 lalkeciral gkqsahlpfr vskltqvlrd sfigeksktc miamispgls scehtlntlr
601 yadrvkelvv kdivevcpgg dtepieitdd eeeeelnmvh phshqlhpns hapasqsnnq
661 rapashhsga vihnnnnnnn kngnagnmdl amlsslsehe msdelivqhq aiddlqqtee
721 mvveyhrtvn atletflaes kalynltnyv dydqdsyckr gesmfsqlld iaiqcrdmma
781 eyraklakee mlscsfnspn gkr
CG18292 - novel
(SEQ ID NO:144)
CGTAATAACGCCTCCTGATATCGATATCGATATCATATCACAAAAAACAA
TAAACCAAAAAAGAAACGCTAAAAACTAGTAGTTTTGTGTGCCAGGAAAA
CGGAAAGGTGGACATAGTTAAGTTACCACAACAACCGACGGATATCGACT
CCAGACACCACATCGCCCAGCGCCACCATGGACATCATGGATATCCAGGC
CGTAGAGTCCAAGCTGAGTGACGTCACGGTGACACCGATACCGCGCAGCC
AAGTGCAGAATTTCTACAATTACCAGCAGCAGCGGGAGCAGCGCGAGCAG
CAGCCCCAAATCCAGATATCGGCCATCCACCACTCGCGTGGATCCGTTGG
CGGAGGAGGCGGATCCAACTCATCCAACGCTGCCACCGACTACTCCACGA
GCAGCGGTGGCAAGCGGGAGCGGGACCGCTCCTCCGCCAGCGACTACAGC
AGCTCGTCCAGCAAGCAGAGCTCCGCTGCAGCGGCCAATGCAGCAGCAGC
TGCCGCCGCCGTCGCTGCCCTCCAATACTCCCCGCAGTTCCTCCAGGCCC
AGCTGGCGCTACTCCAGCAGCAGTCGAACACGACGGCCACGCCGGCAGCC
GTCGCCGCTGCGGCCCTCTCGCTGGCCAACATGTGCTCCAGCAATGGTGG
TCAGCGGAATTCCGGTGCCGGCGTTTCCTCCACCTCCTCTGGCAGCAATG
GCCAGAGCATGGGCCTGAATCTGAGCTCATCGCAGCTAAAGTACCCGCCA
CCCTCCACCTCGCCCGTGGTGGTGACCACCCAAACTTCGGCCAATATCAC
CACGCCGCTGACCTCCACGGCCAGCCTGCCCTCAGTGGGCCCGGGCAATG
GGCTGACCAAGTACGCCCAGCTGCTGGCCGTCATTGAGGAGATGGGCCGC
GATATCCGGCCCACGTACACGGGCTCGCGCAGCTCCACGGAGCGTCTCAA
GCGGGGCATTGTCCATGCCCGCATCCTGGTGCGCGAATGCCTCATGGAAA
CGGAGCGTGCGGCGCGCCAATGA
(SEQ ID NO:145)
1   mdiqaveskl sdvtvtpipr sqvqnfynyq qqreqreqqp qiqisaihhs rgsvgggggs
61  nssnaatdys tssggkrerd rssasdysss sskqssaaaa naaaaaaava alqyspqflq
121 aqlallqqqs nttatpaava aaalslanmc ssnggqrnsg agvsstssgs ngqsmglnls
181 ssqlkyppps tspvvvttqt sanittplts taslpsvgpg ngltkyaqll avieemgrdi
241 rptytgsrss terlkrgivh arilvreclm eteraarq

Human homologue of Complete Genome candidate

(CG1453)—CAA69621—kinesin-2

(SEQ ID NO:146)
1    ggccgaatac atcaagcaat ggtaacatct ttaaatgaag ataatgaaag tgtaactgtt
61   gaatggatag aaaatggaga tacaaaaggc aaagagattg acctggagag catcttttca
121  cttaaccctg accttgttcc tgatgaagaa attgaaccca gtccagaaac acctccacct
181  ccagcatcct cagccaaagt aaacaaaatt gtaaagaatc gacggactgt agcttctatt
241  aagaatgacc ctccttcaag agataataga gtggttggtt cagcacgtgc acggcccagt
301  caatttcctg aacagtcttc ctctgcacaa cagaatggta gtgtttcaga tatatctcca
361  gttcaagctg caaaaaagga atttggaccc ccttcacgta gaaaatctaa ttgtgtgaaa
421  gaagtagaaa aactgcaaga aaaacgagag aaaaggagat tgcaacagca agaacttaga
481  gaaaaaagag cccaggacgt tgatgctaca aacccaaatt atgaaattat gtgtatgatc
541  agagacttta gaggaagttt ggattataga ccattaacaa cagcagatcc tattgatgaa
601  cataggatat gtgtgtgtgt aagaaaacga ccactcaata aaaaagaaac tcaaatgaaa
661  gatcttgatg taatcacaat tcctagtaaa gatgttgtga tggtacatga accaaaacaa
721  aaagtagatt taacaaggta cctagaaaac caaacatttc gttttgatta tgcctttgat
781  gactcagctc ctaatgaaat ggtttacagg tttactgcta aaccactagt ggaaactata
841  tttgaaaggg gaatggctac atgctttgct tatgggcaga ctggaagtgg aaaaactcat
901  actatgggtg gtgacttttc aggaaagaac caagattgtt ctaaaggaat ttatgcatta
961  gcagctcgag atgtcttttt aatgctaaag aagccaaact ataagaagct agaacttcaa
1021 gtatatgcaa ccttctttga aatttatagt ggaaaggtgt ttgacttgct aaacaggaaa
1081 acaaaattaa gagttctaga agatggaaaa cagcaggttc aagtggtggg attacaggaa
1141 cgggaggtca aatgtgttga agatgtactg aaactcattg acataggcaa cagttgcaga
1201 acatccggtc aaacatctgc aaatgcacat tcatctcgga gccatgcagt gtttcagatt
1261 attcttagaa ggaaaggaaa actacatggc aaattttctc tcattgattt ggctggaaat
1321 gaaagaggag ctgatacttc cagtgcggac aggcaaacta ggcttgaagg tgctgaaatt
1381 aataaaagcc ttttagcact caaggagtgc atcagagcct taggtagaaa taaacctcat
1441 actcctttcc gtgcaagtaa actcactcag gtgttaagag attctttcat aggtgaaaac
1501 tctcgtacct gcatgattgc cacaatctct ccaggaatgg catcctgtga aaatactctt
1561 aatacattaa gatatgcaaa tagggtcaaa gaattgactg tagatccaac tgctgctggt
1621 gatgttcgtc caataatgca ccatccacca aaccagattg atgacttaga gacacagtgg
1681 ggtgtgggga gttcccctca gagagatgat ctaaaacttc tttgtgaaca aaatgaagaa
1741 gaagtctctc cacagttgtt tactttccac gaagctgttt cacaaatggt agaaatggaa
1801 gaacaagttg tagaagatca cagggcagtg ttccaggaat ctattcggtg gttagaagat
1861 gaaaaggccc tcttagagat gactgaagaa gtagattatg atgtcgattc atatgctaca
1921 caacttgaag ctattcttga gcaaaaaata gacattttaa ctgaactgcg ggataaagtg
1981 aaatctttcc gtgcagctct acaagaggag gaacaagcca gcaagcaaat caacccgaag
2041 agaccccgtg ccctttaaac cggcatttgc tgctaaagga tacccagaac cctcactact
2101 gtaacataca acggttcagc tgtaagggcc atttgaaagt ttggaatttt aagtgtctgt
2161 ggaaaatgtt ttgtccttca cctgaattac atttcaattt tgtgaaacac tcttttgtct
2221 acaaaatgct tctagtccag gaggcacaac caagaactgg gattaatgaa gcattttgtt
2281 tcatttacac aaatagtgat ttacttttgg agatccttgt cagttttatt ttctatttga
2341 tgaagtaaga ctgtggactc aatccagagc cagatagtag gggaagccac agcatttcct
2401 tttaactcag ttcaattttt gtagtgagac tgagcagttt taaatccttt gcgtgcatgc
2461 atacctcatc agtgattgta cataccttgc ccactcctag agacagctgt gctcactttt
2521 cctgctttgt gccttgatta aggctactga ccctaaattt ctgaagcaca gccaagaaaa
2581 attacattcc ttgtcattgt aaattacctt tgtgtgtaca tttttactgt atttgagaca
2641 ttttttgtgt gtgactagtt aattttgcag gatgtgccat atcattgaac ggaactaaag
2701 tctgtgacag tggatatagc tgctggacca ttccatctta tatgtaaaga aatctggaat
2761 tattatttta aaaccatata acatgtgatt ataatttttc ttagcatttt ctttgtaaag
2821 aactacaata taaactagtt ggtgtataat aaaaagtaat gaaattctga agaaaaaaaa
2881 aaaaaaaaaa aaaaaaaaaa aaaaa
(SEQ ID NO:147)
1    mvtslnedne svtvewieng dtkgkeidle sifslnpdlv pdeeiepspe tppppassak
61   vnkivknrrt vasikndpps rdnrvvgsar arpsqfpeqs ssaqqngsvs dispvqaakk
121  efgppsrrks ncvkeveklq ekrekrrlqq qelrekraqd vdatnpnyei mcmirdfrgs
181  ldyrplttad pidehricvc vrkrplnkke tqmkdldvit ipskdvvmvh epkqkvdltr
241  ylenqtfrfd yafddsapne mvyrftakpl vetifergma tcfaygqtgs gkthtmggdf
301  sgknqdcskg iyalaardvf lmlkkpnykk lelqvyatff eiysgkvfdl lnrktklrvl
361  edgkqqvqvv glqerevkcv edvlklidig nscrtsgqts anahssrsha vfqiilrrkg
421  klhgkfslid lagnergadt ssadrqtrle gaeinkslla lkeciralgr nkphtpfras
481  kltqvlrdsf igensrtcmi atispgmasc entlntlrya nrvkeltvdp taagdvrpim
541  hhppnqiddl etqwgvgssp qrddlkllce qneeevspql ftfheavsqm vemeeqvved
601  hravfqesir wledekalle mteevdydvd syatqleail eqkidiltel rdkvksfraa
661  lqeeeqaskq inpkrpral
(CG18292) - BAA22937 - cdk2-associated protein 1; cdk2ap1, deleted in
oral cancer 1 (doc-1, alias DORC1)
(SEQ ID NO:148)
1    accgcccggc ctcgccgccg ccgccgccgc cctcgcggcc tggccccgcc gcgcccggcg
61   cgcccgccgc ccggggggat gtcttacaaa ccgaacttgg ccgcgcacat gcccgccgcc
121  gccctcaacg ccgctgggag tgtccactcg ccttccacca gcatggcaac gtcttcacag
181  taccgccagc tgctcagtga ctacgggcca ccgtccctag gctacaccca gggaactggg
241  aacagccagg tgccccaaag caaatacgcg gagctgctgg ccatcattga agagctgggg
301  aaggagatca gacccacgta cgcagggagc aagagtgcca tggagaggct gaagcgcggc
361  atcattcacg ctagaggact ggttcgggag tgcttggcag aaacggaacg gaatgccaga
421  tcctagctgc cttgttggtt ttgaaggatt tccatctttt tacaagatga gaagttacag
481  ttcatctccc ctgttcagat gaaacccttg ttttcaaaat ggttacagtt tcgtttttcc
541  tcccatggtt cacttggctc tgaacctaca gtctcaaaga ttgagaaaag attttgcagt
601  taattaggat ttgcatttta agtagttagg aactgcccag gttttttttg ttttttaagc
661  attgatttaa aagatgcacg gaaagttatc ttacagcaaa ctgtagtttg cctccaagac
721  accattgtct ccctttaatc ttctcttttg tatacatttg ttacccatgg tgttctttgt
781  tccttttcat aagctaatac cactgtaggg attttgtttt gaacgcatat tgacagcacg
841  ctttacttag tagccggttc ccatttgcca tacaatgtag gttctgctta atgtaacttc
901  ttttttgctt aagcatttgc atgactatta gtgcttcaaa gtcaattttt aaaaatgcac
961  aagttataaa tacagaagaa agagcaaccc accaaaccta acaaggaccc ccgaacactt
1021 tcatactaag actgtaagta gatctcagtt ctgcgtttat tgtaagttga taaaaacatc
1081 tgggaggaaa tgactaaaac tgtttgcatc tttgtatgta tttattactt gatgtaataa
1141 agcttatttt cattaacc
(SEQ ID NO:149)
1    msykpnlaah mpaaalnaag svhspstsma tssqyrqlls dygppslgyt qgtgnsqvpq
61   skyaellaii eelgkeirpt yagsksamer lkrgiiharg lvreclaete rnars

Putative function

(CG1453)—Motor protein

(CG18292)—Cdk2 associated, candidate tumour supressor

Example 9A (Category 2)

Line ID—ms(1) 13

Phenotype—Male sterile, Cytokinesis defect: variable sized Nebenkerns with 4N nuclei, some nuclei detached from Nebenkern

Annotated Drosophila genome genomic segment containing P element insertion site (and map position)—AE003436 (5D1)

P element insertion site sequence

(SEQ ID NO:150)
CATCATGTATCATACATTGAAGACGGATTAGCACCGTCGACCACGAAAAA
AGAACGCAAGGAAATCGTGCAAAATGTTCAAAAAGTACGTATGGCATGAG
TTAGATGGGGACATCAGACTAACCATAGCAATTCGATCTGTGCAGATTCG
AAGAGAAGGACAGCATTTCCAGCATTCAGCAGCTGAAGTCGTCTGTGCAG
AAGGGCATACGTGCCAAGTTGCTGGAGGCCTATCCCAAGTTGGAGAGTCA
CATCGACCTGATCCTGCCCAAGAAGGACTCGTACCGCATCGCCAAGTGGT
AGGATGGCTCAGTTCTTGCCACAGCACATAACTCCATTCATATTCCCGAT
CCCTACTCCTCCACCAGCCATGACCACATCGAACTGCTGCTAAACGGAGC
CGGCGACCAGGTGTTCTTTCGCCACCGCGATGGCCCCTGGATGCCTACCC
TGCGCAACTGTTGGGAAGGGCGATCGGTGCGGGCCTCTTCGCTATTACGC
CAGCTGGCGAAAGGGGGGATGTGCTGCAAGGCGATTAAGTTGGGTAACGC
CAGGGTTTTCCCAGNCACGACGTTGNAAAACGACGGNCANNGCCAAGCTC
TGCTGCT

Annotated Drosophila genome Complete Genome candidate—CG5941—novel protein with a PUA domain

(SEQ ID NO:151)
CGGATTAGCACCGTCGACCACGAAAAAAGAACGCAAGGAAATCGTGCAAA
ATGTTCAAAAAATTCGAAGAGAAGGACAGCATTTCCAGCATTCAGCAGCT
GAAGTCGTCTGTGCAGAAGGGCATACGTGCCAAGTTGCTGGAGGCCTATC
CCAAGTTGGAGAGTCACATCGACCTGATCCTGCCCAAGAAGGACTCGTAC
CGCATCGCCAAGTGCCATGACCACATCGAACTGCTGCTAAACGGAGCCGG
CGACCAGGTGTTCTTTCGCCACCGCGATGGCCCCTGGATGCCTACCCTGC
GCCTCCTGCACAAGTTCCCCTACTTCGTGACCATGCAGCAAGTGGACAAA
GGCGCCATCCGCTTCGTCCTGAGCGGAGCGAACGTCATGTGTCCCGGCCT
CACATCGCCAGGCGCCTGTATGACGCCGGCCGACAAGGACACCGTGGTGG
CCATCATGGCTGAGGGCAAGGAGCACGCCCTGGCCGTTGGACTCCTCACG
TTATCCACACAGGAAATTCTGGCGAAGAACAAAGGCATCGGTATCGAGAC
GTACCACTTCCTCAACGACGGCCTGTGGAAGTCGAAGCCCGTGAAGTAGG
CGAAATAGGAATCTGCACTTGCACTTTTTA
(SEQ ID NO:152)
MFKKFEEKDSISSIQQLKSSVQKGIRAKLLEAYPKLESHIDLILPKKDSY
RIAKCHDHIELLLNGAGDQVFFRHRDGPWMPTLRLLHKFPYFVTMQQVDK
GAIRFVLSGANVMCPGLTSPGACMTPADKDTVVAIMAEGKEHALAVGLLT
LSTQEILAKNKGIGIETYHFLNDGLWKSKPVK

Human homologue of Complete Genome candidate

MCT-1 (multiple copies in a T-cell malignancies) (BAA86055), a novel candidate oncogene involved in cell cycle which has a domain similar to cyclin H

(SEQ ID NO:153)
1   gctacctcca actgctgagg aaccggttgc ctaaaaggag ccggcaaaag cgcctacgtg
61  gagtccagag gagcggaagt agtcagattt gactgagagc cgtaaagcgc ggctggctct
121 cgttttccgg ataacgacta cagctccgac tgtcagtgcc ggccttcctc gtgtgagggg
181 atctgccgga cccctgcaaa ttcaatttct ttcccattcc gggcccttcc ctatcgtcgc
241 ccccttcacc ttggatcatg ttcaagaaat ttgatgaaaa agaaaatgtg tccaactgca
301 tccagttgaa aacttcagtt attaagggta ttaagaatca attgatagag caatttccag
361 gtattgaacc atggcttaat caaatcatgc ctaagaaaga tcctgtcaaa atagtccgat
421 gccatgaaca tatagaaatc cttacagtaa atggagaatt actctttttt agacaaagag
481 aagggccttt ttatccaacc ctaagattac ttcacaaata tccttttatc ctgccacacc
541 agcaggttga taaaggagcc atcaaatttg tactcagtgg agcaaatatc atgtgtccag
601 gcttaacttc tcctggagct aagctttacc ctgctgcagt agataccatt gttgctatca
661 tggcagaagg aaaacagcat gctctatgtg ttggagtcat gaagatgtct gcagaagaca
721 ttgagaaagt caacaaagga attggcattg aaaatatcca ttatttaaat gatgggctgt
781 ggcatatgaa gacatataaa tgagcctcag aaggaatgca cttgggctaa atatggatat
841 tgtgctgtat ctgtgtttgt gtctgtgtgt gacagcatga agataatgcc tgtggttatg
901 ctgaataaat tcaccagatg ctaaaaaaaa aaaaaaaaaa aaa
(SEQ ID NO:154)
1   mfkkfdeken vsnciqlkts vikgiknqli eqfpgiepwl nqimpkkdpv kivrchehie
61  iltvngellf frqregpfyp tlrllhkypf ilphqqvdkg aikfvlsgan imcpgltspg
121 aklypaavdt ivaimaegkq halcvgvmkm saediekvnk gigienihyl ndglwhmkty
181 k

Putative function

Role in cell cycle progression

Category 3—Mitotic (Neuroblast) Phenotypes

Example 10 (Category 3)

Line ID—187

Phenotype—lethal phase between pupil and pharate adult (P-pA). High mitotic index, rod-like overcondensed chromosomes, a few circular metaphases, many overcondensed anaphases and telophases, a few tetraploid cells

Annotated Drosophila genome genomic segment containing P element insertion site (and map position)—AE003445 (8B3-7)

P element insertion site—174,362

Annotated Drosophila genome Complete Genome candidate—CG10701 moesin, cytoskeletal binding protein (4 splice variants)

(SEQ ID NO:155)
ACGCCGCATGCACTTTTTTATCTATGATATTATGTTTATTATTTCATTAT
TGAATCGGGAAAACCAAACGTTTTTTTTTTTTTCGTATACAAATCCATTT
GCAGTTTGTAAACTTTAGCGTGCATTCGCATCTAATAGTGATATGTTTTC
GCTTTTCACAGGTGATGAACCAGGACGTGAAGAAGGAGAATCCCTTGCAG
TTTAGGTTCCGTGCCAAATTCTATCCCGAGGATGTGGCCGAGGAGCTGAT
CCAGGACATTACACTGCGTCTGTTCTACCTGCAGGTGAAGAATGCCATAC
TGACCGACGAGATCTATTGTCCGCCAGAGACATCCGTGCTGCTCGCCTCG
TACGCCGTCCAGGCGCGTCATGGTGACCACAATAAGACCACCCACACAGC
CGGCTTTCTGGCCAACGATCGCCTGCTGCCGCAGCGCGTCATCGACCAGC
ACAAGATGTCCAAGGACGAGTGGGAGCAGTCGATTATGACCTGGTGGCAG
GAGCATCGCAGCATGCTGCGCGAGGATGCCATGATGGAGTATCTGAAGAT
CGCCCAAGACCTGGAGATGTACGGCGTTAACTACTTTGAGATCCGCAACA
AGAAGGGCACGGATCTTTGGCTGGGCGTAGACGCACTGGGTCTGAACATT
TACGAGCAGGACGATAGGTTGACGCCGAAAATTGGTTTCCCATGGTCCGA
GATTCGCAACATTTCGTTCTCGGAGAAGAAGTTCATCATCAAGCCGATCG
ACAAGAAGGCTCCGGACTTTATGTTCTTTGCGCCACGTGTCCGCATCAAC
AAGCGCATTCTGGCCCTCTGCATGGGCAACCACGAGCTGTACATGCGTCG
CCGCAAGCCGGACACCATCGATGTGCAGCAGATGAAGGCGCAGGCGCGCG
AGGAGAAGAATGCCAAACAGCAGGAACGTGAGAAGCTGCAGCTGGCGCTG
GCCGCACGCGAACGCGCTGAAAAGAAGCAGCAGGAGTACGAGGATCGGCT
AAAGCAGATGCAGGAGGACATGGAGCGTTCGCAGCGCGATCTGCTTGAGG
CGCAGGACATGATCCGCCGGCTGGAGGAGCAGCTGAAGCAGCTGCAGGCC
GCCAAGGATGAGCTGGAGCTGCGCCAGAAGGAGCTGCAGGCGATGCTGCA
GCGCCTCGAGGAGGCCAAGAATATGGAGGCCGTCGAGAAGCTCAAGCTCG
AGGAGGAGATCATGGCCAAGCAGATGGAGGTGCAGCGCATTCAGGACGAG
GTCAACGCCAAGGATGAGGAGACAAAGCGTCTGCAGGACGAAGTGGAAGA
CGCCCGACGCAAGCAGGTCATTGCGGCTGAAGCCGCTGCCGCTCTGCTGG
CCGCGTCGACAACGCCGCAGCATCACCACGTGGCCGAGGATGAGAACGAG
AACGAGGAGGAGCTGACGAACGGCGATGCCGGTGGCGATGTGTCGCGCGA
CCTGGACACCGACGAGCATATCAAGGACCCCATCGAGGACAGACGCACGC
TGGCCGAGCGCAACGAACGCTTGCACGATCAGCTCAAGGCTCTGAAACAA
GATTTGGCGCAGTCTCGCGACGAGACGAAAGAGACGGCAAACGATAAGAT
TCATCGCGAGAACGTTCGCCAGGGACGTGACAAGTACAAGACGCTCCGCG
AGATTCGTAAGGGCAACACAAAGCGTCGCGTCGATCAGTTTGAGAACATG
TAAAAGCTATCAAAGATCAGAGATCGATAGTGCGCGGGAAAGAGAGAGGG
AGCGGTGAGACTCCAGAAAGA
(SEQ ID NO:156)
MNQDVKKENPLQFRFRAKFYPEDVAEELIQDITLRLFYLQVKNAILTDEI
YCPPETSVLLASYAVQARHGDHNKTTHTAGFLANDRLLPQRVIDQHKMSK
DEWEQSIMTWWQEHRSMLREDAMMEYLKIAQDLEMYGVNYFEIRNKKGTD
LWLGVDALGLNIYEQDDRLTPKIGFPWSEIRNISFSEKKFIIKPIDKKAP
DFMFFAPRVRINKRILALCMGNHELYMRRRKPDTIDVQQMKAQAREEKNA
KQQEREKLQLALAARERAEKKQQEYEDRLKQMQEDMERSQRDLLEAQDMI
RRLEEQLKQLQAAKDELELRQKELQAMLQRLEEAKNMEAVEKLKLEEEIM
AKQMEVQRIQDEVNAKDEETKRLQDEVEDARRKQVIAAEAAAALLAASTT
PQHHHVAEDENENEEELTNGDAGGDVSRDLDTDEHIKDPIEDRRTLAERN
ERLHDQLKALKQDLAQSRDETKETANDKIHRENVRQGRDKYKTLREIRKG
NTKRRVDQFENM
(SEQ ID NO:157)
GACAACAGAATCGAATCGTCGCTTTTCCGCTTTTAACCATCGTGTCGCGT
TGGTCGGTTGGTTTTCCCGCGTAGCTTGTGGCTGCTCAAGAATATATATA
TATTTCCCAGACGGAGATTTGCATTGAAAAGGCGTAATAATTCAAAAGCT
ACTGCGCAATCCGTTTTCGGTGCCCAAAATGGTCGTCGTCTCCGACAGCC
GCGTCCGTTTGCCGCGTTACGGCGGAGTCAGCGTCAAACGGAAAACGCTA
AATGTGCGCGTCACGACAATGGACGCGGAACTGGAGTTCGCCATTCAGTC
GACGACGACGGGCAAGCAATTGTTTGACCAGGTGGTGAAGACGATCGGCC
TGCGAGAGGTTTGGTTCTTTGGACTCCAGTACACCGACTCCAAGGGCGAC
TCCACATGGATCAAGCTGTACAAAAAGCCCGAATCGCCGGCCATAAAGAC
AATAAAATATTTAAAGCGTGTAAAGAAGTATGTGGACAAAAAGACAGCCG
ACAGCAATGGAGTAAATCATTTAGAGACGAGCGAAGAGGATGACGACGCC
GATGATATGACTGGATCAATGCCGTTTTCGACATGGGTGATGAACCAGGA
CGTGAAGAAGGAGAATCCCTTGCAGTTTAGGTTCCGTGCCAAATTCTATC
CCGAGGATGTGGCCGAGGAGCTGATCCAGGACATTACACTGCGTCTGTTC
TACCTGCAGGTGAAGAATGCCATACTGACCGACGAGATCTATTGTCCGCC
AGAGACATCCGTGCTGCTCGCCTCGTACGCCGTCCAGGCGCGTCATGGTG
ACCACAATAAGACCACCCACACAGCCGGCTTTCTGGCCAACGATCGCCTG
CTGCCGCAGCGCGTCATCGACCAGCACAAGATGTCCAAGGACGAGTGGGA
GCAGTCGATTATGACCTGGTGGCAGGAGCATCGCAGCATGCTGCGCGAGG
ATGCCATGATGGAGTATCTGAAGATCGCCCAAGACCTGGAGATGTACGGC
GTTAACTACTTTGAGATCCGCAACAAGAAGGGCACGGATCTTTGGCTGGG
CGTAGACGCACTGGGTCTGAACATTTACGAGCAGGACGATAGGTTGACGC
CGAAAATTGGTTTCCCATGGTCCGAGATTCGCAACATTTCGTTCTCGGAG
AAGAAGTTCATCATCAAGCCGATCGACAAGAAGGCTCCGGACTTTATGTT
CTTTGCGCCACGTGTCCGCATCAACAAGCGCATTCTGGCCCTCTGCATGG
GCAACCACGAGCTGTACATGCGTCGCCGCAAGCCGGACACCATCGATGTG
CAGCAGATGAAGGCGCAGGCGCGCGAGGAGAAGAATGCCAAACAGCAGGA
ACGTGAGAAGCTGCAGCTGGCGCTGGCCGCACGCGAACGCGCTGAAAAGA
AGCAGCAGGAGTACGAGGATCGGCTAAAGCAGATGCAGGAGGACATGGAG
CGTTCGCAGCGCGATCTGCTTGAGGCGCAGGACATGATCCGCCGGCTGGA
GGAGCAGCTGAAGCAGCTGCAGGCCGCCAAGGATGAGCTGGAGCTGCGCC
AGAAGGAGCTGCAGGCGATGCTGCAGCGCCTCGAGGAGGCCAAGAATATG
GAGGCCGTCGAGAAGCTCAAGCTCGAGGAGGAGATCATGGCCAAGCAGAT
GGAGGTGCAGCGCATTCAGGACGAGGTCAACGCCAAGGATGAGGAGACAA
AGCGTCTGCAGGACGAAGTGGAAGACGCCCGACGCAAGCAGGTCATTGCG
GCTGAAGCCGCTGCCGCTCTGCTGGCCGCGTCGACAACGCCGCAGCATCA
CCACGTGGCCGAGGATGAGAACGAGAACGAGGAGGAGCTGACGAACGGCG
ATGCCGGTGGCGATGTGTCGCGCGACCTGGACACCGACGAGCATATCAAG
GACCCCATCGAGGACAGACGCACGCTGGCCGAGCGCAACGAACGCTTGCA
CGATCAGCTCAAGGCTCTGAAACAAGATTTGGCGCAGTCTCGCGACGAGA
CGAAAGAGACGGCAAACGATAAGATTCATCGCGAGAACGTTCGCCAGGGA
CGTGACAAGTACAAGACGCTCCGCGAGATTCGTAAGGGCAACACAAAGCG
TCGCGTCGATCAGTTTGAGAACATGTAAAAGCTATCAAAGATCAGAGATC
GATAGTGCGCGGGAAAGAGAGAGGGAGCGGTGAGACTCCAGAAAGA
(SEQ ID NO:158)
MVVVSDSRVRLPRYGGVSVKRKTLNVRVTTMDAELEFAIQSTTTGKQLFD
QVVKTIGLREVWFFGLQYTDSKGDSTWIKLYKKPESPAIKTIKYLKRVKK
YVDKKTADSNGVNHLETSEEDDDADDMTGSMPFSTWVMNQDVKKENPLQF
RFRAKFYPEDVAEELIQDITLRLFYLQVKNAILTDEIYCPPETSVLLASY
AVQARHGDHNKTTHTAGFLANDRLLPQRVIDQHKMSKDEWEQSIMTWWQE
HRSMLREDAMMEYLKIAQDLEMYGVNYFEIRNKKGTDLWLGVDALGLNIY
EQDDRLTPKIGFPWSEIRNISFSEKKFIIKPIDKKAPDFMFFAPRVRINK
RILALCMGNHELYMRRRKPDTIDVQQMKAQAREEKNAKQQEREKLQLALA
ARERAEKKQQEYEDRLKQMQEDMERSQRDLLEAQDMIRRLEEQLKQLQAA
KDELELRQKELQAMLQRLEEAKNMEAVEKLKLEEEIMAKQMEVQRIQDEV
NAKDEETKRLQDEVEDARRKQVIAAEAAAALLAASTTPQHHHVAEDENEN
EEELTNGDAGGDVSRDLDTDEHIKDPIEDRRTLAERNERLHDQLKALKQD
LAQSRDETKETANDKIHRENVRQGRDKYKTLREIRKGNTKRRVDQFENM
(SEQ ID NO:159)
CCAAAGCGAAACGGGAGCTCTTGGCACGTGCCCTGCTCACATCCCGTTAA
TCCATCGACCCCTAAACAAATCGTGGGGGATTCTCCTCTGCACGCCACCT
TCATCGATGGGTGTCAATTTTTTACTCTTTTTTTTTTCTATTTGGCTTCT
AAATGTGCGCGTCACGACAATGGACGCGGAACTGGAGTTCGCCATTCAGT
CGACGACGACGGGCAAGCAATTGTTTGACCAGGTGGTGAAGACGATCGGC
CTGCGAGAGGTTTGGTTCTTTGGACTCCAGTACACCGACTCCAAGGGCGA
CTCCACATGGATCAAGCTGTACAAAAAGCCCGAATCGCCGGCCATAAAGA
CAATAAAATATTTAAAGCGTGTAAAGAAGTATGTGGACAAAAAGACAGCC
GACAGCAATGGAGTAAATCATTTAGAGACGAGCGAAGAGGATGACGACGC
CGATGATATGACTGGATCAATGCCGTTTTCGACATGGGTGATGAACCAGG
ACGTGAAGAAGGAGAATCCCTTGCAGTTTAGGTTCCGTGCCAAATTCTAT
CCCGAGGATGTGGCCGAGGAGCTGATCCAGGACATTACACTGCGTCTGTT
CTACCTGCAGGTGAAGAATGCCATACTGACCGACGAGATCTATTGTCCGC
CAGAGACATCCGTGCTGCTCGCCTCGTACGCCGTCCAGGCGCGTCATGGT
GACCACAATAAGACCACCCACACAGCCGGCTTTCTGGCCAACGATCGCCT
GCTGCCGCAGCGCGTCATCGACCAGCACAAGATGTCCAAGGACGAGTGGG
AGCAGTCGATTATGACCTGGTGGCAGGAGCATCGCAGCATGCTGCGCGAG
GATGCCATGATGGAGTATCTGAAGATCGCCCAAGACCTGGAGATGTACGG
CGTTAACTACTTTGAGATCCGCAACAAGAAGGGCACGGATCTTTGGCTGG
GCGTAGACGCACTGGGTCTGAACATTTACGAGCAGGACGATAGGTTGACG
CCGAAAATTGGTTTCCCATGGTCCGAGATTCGCAACATTTCGTTCTCGGA
GAAGAAGTTCATCATCAAGCCGATCGACAAGAAGGCTCCGGACTTTATGT
TCTTTGCGCCACGTGTCCGCATCAACAAGCGCATTCTGGCCCTCTGCATG
GGCAACCACGAGCTGTACATGCGTCGCCGCAAGCCGGACACCATCGATGT
GCAGCAGATGAAGGCGCAGGCGCGCGAGGAGAAGAATGCCAAACAGCAGG
AACGTGAGAAGCTGCAGCTGGCGCTGGCCGCACGCGAACGCGCTGAAAAG
AAGCAGCAGGAGTACGAGGATCGGCTAAAGCAGATGCAGGAGGACATGGA
GCGTTCGCAGCGCGATCTGCTTGAGGCGCAGGACATGATCCGCCGGCTGG
AGGAGCAGCTGAAGCAGCTGCAGGCCGCCAAGGATGAGCTGGAGCTGCGC
CAGAAGGAGCTGCAGGCGATGCTGCAGCGCCTCGAGGAGGCCAAGAATAT
GGAGGCCGTCGAGAAGCTCAAGCTCGAGGAGGAGATCATGGCCAAGCAGA
TGGAGGTGCAGCGCATTCAGGACGAGGTCAACGCCAAGGATGAGGAGACA
AAGCGTCTGCAGGACGAAGTGGAAGACGCCCGACGCAAGCAGGTCATTGC
GGCTGAAGCCGCTGCCGCTCTGCTGGCCGCGTCGACAACGCCGCAGCATC
ACCACGTGGCCGAGGATGAGAACGAGAACGAGGAGGAGCTGACGAACGGC
GATGCCGGTGGCGATGTGTCGCGCGACCTGGACACCGACGAGCATATCAA
GGACCCCATCGAGGACAGACGCACGCTGGCCGAGCGCAACGAACGCTTGC
ACGATCAGCTCAAGGCTCTGAAACAAGATTTGGCGCAGTCTCGCGACGAG
ACGAAAGAGACGGCAAACGATAAGATTCATCGCGAGAACGTTCGCCAGGG
ACGTGACAAGTACAAGACGCTCCGCGAGATTCGTAAGGGCAACACAAAGC
GTCGCGTCGATCAGTTTGAGAACATGTAAAAGCTATCAAAGATCAGAGAT
CGATAGTGCGCGGGAAAGAGAGAGGGAGCGGTGAGACTCCAGAAAGA
(SEQ ID NO:160)
MGVNFLLFFFSIWLLNVRVTTMDAELEFAIQSTTTGKQLFDQVVKTIGLR
EVWFFGLQYTDSKGDSTWIKLYKKPESPAIKTIKYLKRVKKYVDKKTADS
NGVNHLETSEEDDDADDMTGSMPFSTWVMNQDVKKENPLQFRFRAKFYPE
DVAEELIQDITLRLFYLQVKNAILTDEIYCPPETSVLLASYAVQARHGDH
NKTTHTAGFLANDRLLPQRVIDQHKMSKDEWEQSIMTWWQEHRSMLREDA
MMEYLKIAQDLEMYGVNYFEIRNKKGTDLWLGVDALGLNIYEQDDRLTPK
IGFPWSEIRNISFSEKKFIIKPIDKKAPDFMFFAPRVRINKRILALCMGN
HELYMRRRKPDTIDVQQMKAQAREEKNAKQQEREKLQLALAARERAEKKQ
QEYEDRLKQMQEDMERSQRDLLEAQDMIRRLEEQLKQLQAAKDELELRQK
ELQAMLQRLEEAKNMEAVEKLKLEEEIMAKQMEVQRIQDEVNAKDEETKR
LQDEVEDARRKQVIAAEAAAALLAASTTPQHHHVAEDENENEEELTNGDA
GGDVSRDLDTDEHIKDPIEDRRTLAERNERLHDQLKALKQDLAQSRDETK
ETANDKIHRENVRQGRDKYKTLREIRKGNTKRRVDQFENM
(SEQ ID NO:161)
AAAGCTCACGAAAAACACGCGGCAATTGGATAAGAAACGAAATTGTTGAT
CCAACGCGAGGAAGAAGAAGAATTGTGAAGCAAGAAGAAGCGAAAACAAA
CTGCGATTGCAGCACAAAAACAATAAAGAGTTCAGACGATAATATCCTGG
AAAGAAAACATTTCGTTTCGATAAGTACGACAAGACACGAAACAACAAAA
TGTCTCCAAAAGCGCTAAATGTGCGCGTCACGACAATGGACGCGGAACTG
GAGTTCGCCATTCAGTCGACGACGACGGGCAAGCAATTGTTTGACCAGGT
GGTGAAGACGATCGGCCTGCGAGAGGTTTGGTTCTTTGGACTCCAGTACA
CCGACTCCAAGGGCGACTCCACATGGATCAAGCTGTACAAAAAGGTGATG
AACCAGGACGTGAAGAAGGAGAATCCCTTGCAGTTTAGGTTCCGTGCCAA
ATTCTATCCCGAGGATGTGGCCGAGGAGCTGATCCAGGACATTACACTGC
GTCTGTTCTACCTGCAGGTGAAGAATGCCATACTGACCGACGAGATCTAT
TGTCCGCCAGAGACATCCGTGCTGCTCGCCTCGTACGCCGTCCAGGCGCG
TCATGGTGACCACAATAAGACCACCCACACAGCCGGCTTTCTGGCCAACG
ATCGCCTGCTGCCGCAGCGCGTCATCGACCAGCACAAGATGTCCAAGGAC
GAGTGGGAGCAGTCGATTATGACCTGGTGGCAGGAGCATCGCAGCATGCT
GCGCGAGGATGCCATGATGGAGTATCTGAAGATCGCCCAAGACCTGGAGA
TGTACGGCGTTAACTACTTTGAGATCCGCAACAAGAAGGGCACGGATCTT
TGGCTGGGCGTAGACGCACTGGGTCTGAACATTTACGAGCAGGACGATAG
GTTGACGCCGAAAATTGGTTTCCCATGGTCCGAGATTCGCAACATTTCGT
TCTCGGAGAAGAAGTTCATCATCAAGCCGATCGACAAGAAGGCTCCGGAC
TTTATGTTCTTTGCGCCACGTGTCCGCATCAACAAGCGCATTCTGGCCCT
CTGCATGGGCAACCACGAGCTGTACATGCGTCGCCGCAAGCCGGACACCA
TCGATGTGCAGCAGATGAAGGCGCAGGCGCGCGAGGAGAAGAATGCCAAA
CAGCAGGAACGTGAGAAGCTGCAGCTGGCGCTGGCCGCACGCGAACGCGC
TGAAAAGAAGCAGCAGGAGTACGAGGATCGGCTAAAGCAGATGCAGGAGG
ACATGGAGCGTTCGCAGCGCGATCTGCTTGAGGCGCAGGACATGATCCGC
CGGCTGGAGGAGCAGCTGAAGCAGCTGCAGGCCGCCAAGGATGAGCTGGA
GCTGCGCCAGAAGGAGCTGCAGGCGATGCTGCAGCGCCTCGAGGAGGCCA
AGAATATGGAGGCCGTCGAGAAGCTCAAGCTCGAGGAGGAGATCATGGCC
AAGCAGATGGAGGTGCAGCGCATTCAGGACGAGGTCAACGCCAAGGATGA
GGAGACAAAGCGTCTGCAGGACGAAGTGGAAGACGCCCGACGCAAGCAGG
TCATTGCGGCTGAAGCCGCTGCCGCTCTGCTGGCCGCGTCGACAACGCCG
CAGCATCACCACGTGGCCGAGGATGAGAACGAGAACGAGGAGGAGCTGAC
GAACGGCGATGCCGGTGGCGATGTGTCGCGCGACCTGGACACCGACGAGC
ATATCAAGGACCCCATCGAGGACAGACGCACGCTGGCCGAGCGCAACGAA
CGCTTGCACGATCAGCTCAAGGCTCTGAAACAAGATTTGGCGCAGTCTCG
CGACGAGACGAAAGAGACGGCAAACGATAAGATTCATCGCGAGAACGTTC
GCCAGGGACGTGACAAGTACAAGACGCTCCGCGAGATTCGTAAGGGCAAC
ACAAAGCGTCGCGTCGATCAGTTTGAGAACATGTAAAAGCTATCAAAGAT
CAGAGATCGATAGTGCGCGGGAAAGAGAGAGGGAGCGGTGAGACTCCAGA
AAGA
(SEQ ID NO:162)
MSPKALNVRVTTMDAELEFAIQSTTTGKQLFDQVVKTIGLREVWFFGLQY
TDSKGDSTWIKLYKKVMNQDVKKENPLQFRFRAKFYPEDVAEELIQDITL
RLFYLQVKNAILTDEIYCPPETSVLLASYAVQARHGDHNKTTHTAGFLAN
DRLLPQRVIDQHKMSKDEWEQSIMTWWQEHRSMLREDAMMEYLKIAQDLE
MYGVNYFEIRNKKGTDLWLGVDALGLNIYEQDDRLTPKIGFPWSEIRNIS
FSEKKFIIKPIDKKAPDFMFFAPRVRINKRILALCMGNHELYMRRRKPDT
IDVQQMKAQAREEKNAKQQEREKLQLALAARERAEKKQQEYEDRLKQMQE
DMERSQRDLLEAQDMIRRLEEQLKQLQAAKDELELRQKELQAMLQRLEEA
KNMEAVEKLKLEEEIMAKQMEVQRIQDEVNAKDEETKRLQDEVEDARRKQ
VIAAEAAAALLAASTTPQHHHVAEDENENEEELTNGDAGGDVSRDLDTDE
HIKDPIEDRRTLAERNERLHDQLKALKQDLAQSRDETKETANDKIHRENV
RQGRDKYKTLREIRKGNTKRRVDQFENM

Human homologue of Complete Genome candidate

A41289 human moesin

(SEQ ID NO:163)
1    ggcacgaggc cagccgaatc caagccgtgt gtactgcgtg ctcagcactg cccgacagtc
61   ctagctaaac ttcgccaact ccgctgcctt tgccgccacc atgcccaaaa cgatcagtgt
121  gcgtgtgacc accatggatg cagagctgga gtttgccatc cagcccaaca ccaccgggaa
181  gcagctattt gaccaggtgg tgaaaactat tggcttgagg gaagtttggt tctttggtct
241  gcagtaccag gacactaaag gtttctccac ctggctgaaa ctcaataaga aggtgactgc
301  ccaggatgtg cggaaggaaa gccccctgct ctttaagttc cgtgccaagt tctaccctga
361  ggatgtgtcc gaggaattga ttcaggacat cactcagcgc ctgttctttc tgcaagtgaa
421  agagggcatt ctcaatgatg atatttactg cccgcctgag accgctgtgc tgctggcctc
481  gtatgctgtc cagtctaagt atggcgactt caataaggaa gtgcataagt ctggctacct
541  ggccggagac aagttgctcc cgcagagagt cctggaacag cacaaactca acaaggacca
601  gtgggaggag cggatccagg tgtggcatga ggaacaccgt ggcatgctca gggaggatgc
661  tgtcctggaa tatctgaaga ttgctcaaga tctggagatg tatggtgtga actacttcag
721  catcaagaac aagaaaggct cagagctgtg gctgggggtg gatgccctgg gtctcaacat
781  ctatgagcag aatgacagac taactcccaa gataggcttc ccctggagtg aaatcaggaa
841  catctctttc aatgataaga aatttgtcat caagcccatt gacaaaaaag ccccggactt
901  cgtcttctat gctccccggc tgcggattaa caagcggatc ttggccttgt gcatggggaa
961  ccatgaacta tacatgcgcc gtcgcaagcc tgataccatt gaggtgcagc agatgaaggc
1021 acaggcccgg gaggagaagc accagaagca gatggagcgt gctatgctgg aaaatgagaa
1081 gaagaagcgt gaaatggcag agaaggagaa agagaagatt gaacgggaga aggaggagct
1141 gatggagagg ctgaagcaga tcgaggaaca gactaagaag gctcagcaag aactggaaga
1201 acagacccgt agggctctgg aacttgagca ggaacggaag cgtgcccaga gcgaggctga
1261 aaagctggcc aaggagcgtc aagaagctga agaggccaag gaggccttgc tgcaggcctc
1321 ccgggaccag aaaaagactc aggaacagct ggccttggaa atggcagagc tgacagctcg
1381 aatctcccag ctggagatgg cccgacagaa gaaggagagt gaggctgtgg agtggcagca
1441 gaaggcccag atggtacagg aagacttgga gaagacccgt gctgagctga agactgccat
1501 gagtacacct catgtggcag agcctgctga gaatgagcag gatgagcagg atgagaatgg
1561 ggcagaggct agtgctgacc tacgggctga tgctatggcc aaggaccgca gtgaggagga
1621 acgtaccact gaggcagaga agaatgagcg tgtgcagaag cacctgaagg ccctcacttc
1681 ggagctggcc aatgccagag atgagtccaa gaagactgcc aatgacatga tccatgctga
1741 gaacatgcga ctgggccgag acaaatacaa gaccctgcgc cagatccggc agggcaacac
1801 caagcagcgc attgacgaat ttgagtctat gtaatgggca cccagcctct agggacccct
1861 cctccctttt tccttgtccc cacactccta cacctaactc acctaactca tactgtgctg
1921 gagccactaa ctagagcagc cctggagtca tgccaagcat ttaatgtagc catgggacca
1981 aacctagccc cttagccccc acccacttcc ctgggcaaat gaatggctca ctatggtgcc
2041 aatggaacct cctttctctt ctctgttcca ttgaatctgt atggctagaa tatcctactt
2101 ctccagccta gaggtacttt ccacttgatt ttgcaaatgc ccttacactt actgttgtcc
2161 tatgggagtc aagtgtggag taggttggaa gctagctccc ctcctctccc ctccactgtc
2221 ttcttcaggt cctgagatta cacggtggag tgtatgcggt ctaggaatga gacaggacct
2281 agatatcttc tccagggatg tcaactgacc taaaatttgc cctcccatcc cgtttagagt
2341 tatttaggct ttgtaacgat tgggggaata aaaagatgtt cagtcatttt tgtttctacc
2401 tcccagatcg gatctgttgc aaactcagcc tcaataagcc ttgtcgttga ctttagggac
2461 tcaatttctc cccagggtgg atgggggaaa tggtgccttc aagaccttca ccaaacatac
2521 tagaagggca ttggccattc tattgtggca aggctgagta gaagatccta ccccaattcc
2581 ttgtaggagt ataggccggt ctaaagtgag ctctatgggc agatctaccc cttacttatt
2641 attccagatc tgcagtcact tcgtgggatc tgcccctccc tgcttcaata cccaaatcct
2701 ctccagctat aacagtaggg atgagtaccc aaaagctcag ccagccccat caggactctt
2761 gtgaaaagag aggatatgtt cacacctagc gtcagtattt tccctgctag gggttttagg
2821 tctcttcccc tctcagagct acttgggcca tagctcctgc tccacagcca tcccagcctt
2881 ggcatctaga gcttgatgcc agtaggctca actagggagt gagtgcaaaa agctgagtat
2941 ggtgagagaa gcctgtgccc tgatccaagt ttactcaacc ctctcaggtg accaaaatcc
3001 ccttctcatc actcccctca aagaggtgac tgggccctgc ctctgtttga caaacctcta
3061 acccaggtct tgacaccagc tgttctgtcc cttggagctg taaaccagag agctgctggg
3121 ggattctggc ctagtccctt ccacaccccc accccttgct ctcaacccag gagcatccac
3181 ctccttctct gtctcatgtg tgctcttctt ctttctacag tattatgtac tctactgata
3241 tctaaatatt gatttctgcc ttccttgcta atgcaccatt agaagatatt agtcttgggg
3301 caggatgatt ttggcctcat tactttacca cccccacacc tggaaagcat atactatatt
3361 acaaaatgac attttgccaa aattattaat ataagaagct ttcagtatta gtgatgtcat
3421 ctgtcactat aggtcataca atccattctt aaagtacttg ttatttgttt ttattattac
3481 tgtttgtctt ctccccaggg ttcagtccct caaggggcca tcctgtccca ccatgcagtg
3541 ccccctagct tagagcctcc ctcaattccc cctggccacc accccccact ctgtgcctga
3601 ccttgaggag tcttgtgtgc attgctgtga attagctcac ttggtgatat gtcctatatt
3661 ggctaaattg aaacctggaa ttgtggggca atctattaat agctgcctta aagtcagtaa
3721 cttaccctta gggaggctgg gggaaaaggt tagattttgt attcaggggt tttttgtgta
3781 ctttttgggt ttttaaaaaa ttgtttttgg aggggtttat gctcaatcca tgttctattt
3841 cagtgccaat aaaatttagg tgacttcaaa aaaaaaaaa
(SEQ ID NO:164)
1    mpktisvrvt tmdaelefai qpnttgkqlf dqvvktiglr evwffglqyq dtkgfstwlk
61   lnkkvtaqdv rkespllfkf rakfypedvs eeliqditqr lfflqvkegi lnddiycppe
121  tavllasyav qskygdfnke vhksgylagd kllpqrvleq hklnkdqwee riqvwheehr
181  gmlredavle ylkiaqdlem ygvnyfsikn kkgselwlgv dalglniyeq ndrltpkigf
241  pwseirnisf ndkkfvikpi dkkapdfvfy aprlrinkri lalcmgnhel ymrrrkpdti
301  evqqmkaqar eekhqkqmer amlenekkkr emaekekeki erekeelmer lkqieeqtkk
361  aqqeleeqtr raleleqerk raqseaekla kerqeaeeak eallqasrdq kktqeqlale
421  maeltarisq lemarqkkes eavewqqkaq mvqedlektr aelktamstp hvaepaeneq
481  deqdengaea sadlradama kdrseeertt eaeknervqk hlkaltsela nardeskkta
541  ndmihaenmr lgrdkyktlr qirqgntkqr idefesm

Putative function

Cytoskeletal binding protein linking to plama membrane, involved in cytokinesis and cell shape

Example 11 (Category 3)

Line ID—226

Phenotype—Lethal phase pharate adult. High mitotic index, rod-like overcondensed chromosomes, lagging chromosomes and bridges in anaphase, highly condensed

Annotated Drosophila genome genomic segment containing P element insertion site (and map position)—AE003423 (2F1-2)

P element insertion site—226,527

Annotated Drosophila genome Complete Genome candidate—CG2865—EG:25E8.4

(SEQ ID NO:165)
AGAAAACCACATAAACAAGCCAGCAAACAAGGCACACACTTGCTTGAAAA
ACGCACAATGACCTTGCCCACAAACACACACGCATCTGCAAACGACGGCG
GCAGCGGCAACAACAACCACAGCAATATCAGCAGTAACAACAGCAGCAGC
AGCGACGAAGACTCAGACATGTTTGGACCACCCCGCTGCTCCCCGCCCAT
CGGCTATCACCATCACCGTTCCCGTGTGCCCATGATCTCGCCAAAGCTGC
GGCAGCGCGAGGAGCGCAAGCGGATCCTCCAGCTCTGCGCCCACAAGATG
GAGAGGATCAAGGACTCGGAGGCGAACCTGCGGCGCAGCGTCTGCATCAA
CAACACCTACTGCCGCCTGAATGACGAACTGCGGCGCGAGAAGCAGATGC
GCTACCTCCAGAATCTGCCCAGAACCAGCGACAGCGGCGCAAGCACCGAA
CTGGCGCGTGAGAATCTCTTCCAGCCGAACATGGACGACGCCAAGCCGGC
CGGCAATAGCACTAGCAATAATATCAACGCCAACGGCAAGCCTTCATCCT
CTTTTGGCGATGCCTTTGGCTCCTCAAACGGATCATCGTCGGGTCGCGGC
GGAATTTGCTCCCTGGAGAATCAACCGCCCGAGCGTCAGCAGTTGGGGAC
GCCCGCTGGTGCCTCCGCTCCCGAGGCGGCCAATTCGGCGCCCCTTTCCG
TTTCGGGCTCGGCATCGGAACGCGTGAATAACCGAAAACGCCACCTGTCC
AGCTGCAACTTGGTCAACGATCTGGAAATACTGGACAGGGAGCTGAGCGC
CATCAATGCACCCATGCTGCTAATCGATCCAGAGATTACCCAAGGAGCCG
AACAGCTGGAGAAGGCCGCCTTGTCCGCCAGCAGGAAGAGATTGAGGAGC
AATAGCGGCAGCGAGGACGAAAGTGATCGCCTGGTGCGCGAGGCTCTGTC
CCAGTTCTACATACCGCCACAGCGCCTCATCTCCGCCATTGAGGAGTGTC
CCCTGGATGTGGTTGGCTTGGGTATGGGAATGAATGTGAATGTGAATGTG
GGAGGAATTAGTGGAATCGGTGGCATCGGAGGAGCTGCAGGCGCTGGCGT
CGAAATGCCCGGAGGCAAACGGATGAAGCTGAATGACCATCACCATCTCA
ATCACCATCACCATTTGCACCATCATCTGGAGCTGGTCGATTTCGACATG
AACCAAAACCAAAAGGATTTCGAGGTGATCATGGACGCCTTGAGGCTGGG
AACGGCGACACCGCCGAGCGGCGCCAGCAGCGATTCTTGCGGACAGGCGG
CGATGATGAGCGAGTCGGCCAGCGTGTTCCACAATCTGGTGGTCACCTCG
TTGGAGACATGA
(SEQ ID NO:166)
MTLPTNTHASANDGGSGNNNHSNISSNNSSSSDEDSDMFGPPRCSPPIGY
HHHRSRVPMISPKLRQREERKRILQLCAHKMERIKDSEANLRRSVCINNT
YCRLNDELRREKQMRYLQNLPRTSDSGASTELARENLFQPNMDDAKPAGN
STSNNINANGKPSSSFGDAFGSSNGSSSGRGGICSLENQPPERQQLGTPA
GASAPEAANSAPLSVSGSASERVNNRKRHLSSCNLVNDLEILDRELSAIN
APMLLIDPEITQGAEQLEKAALSASRKRLRSNSGSEDESDRLVREALSQF
YIPPQRLISAIEECPLDVVGLGMGMNVNVNVGGISGIGGIGGAAGAGVEM
PGGKRMKLNDHHHLNHHHHLHHHLELVDFDMNQNQKDFEVIMDALRLGTA
TPPSGASSDSCGQAAMMSESASVFHNLVVTSLET

Human homologue of Complete Genome candidate

CG2865—none

Putative function

Putative phosphatidylinositol 3-kinase

Example 12 (Category 3)

Line ID—269

Phenotype—Lethal phase pupal-pharate adult. High mitotic index, colchicines-type overcondensation, high frequency of polyploids

Annotated Drosophila genome genomic segment containing P element insertion site (and map position)—AE003568 (19F)

P element insertion site—197,805

Annotated Drosophila genome Complete Genome candidate—CG 1696—novel protein

(SEQ ID NO:167)
AAAACTCATCGATGCTGCGAAAGTGCGATAGTATCGAATAAACATGAGTG
TGTGCATGAGTGTGGGAATTTATTAAACAAAAACGAAACGCGGACAAACT
ATATTTATGTAATAAACACTAAGCCGCAGCGCCAACGAGTAATGAACAGT
CCACGGCCAGGTCGTACTATTCAGGCGAACGCACCTCGCAATCGACTGCA
ATCAAAGTGCAATAGCTCAATCAATTGATTCGTTTTGCTCAACCAAAAAC
AAAATCTATTCCCAAATCGGTGCGATAGTTGCCAAAATATAAAAACTACA
CTACGCTAAAAAAAAAACAATACACTCACACACTGGCGTACAAGACAACA
AAAGAGAAGAAGAAGAGCAGACGCCAGATATAAAAAGCCCCCAAAAGAAT
TGGAAATAAGACCATACCCCTCCTTCTCCCTTGAAAAGGGACCTTAAAAC
TAGGCGACACCGAATAATTGAACTCAAGTAAAAAACCGGGAAAAGAGAAA
AACACTTTCAACAAAATATCTAGAAGCCTTGTTATCGATTTTGTTCCGGG
TTTTTTTTGTGTGAGTGTGTGTTGTGTGAAGCGCGCCCGCGGGTGTGTGG
GTGAGTGTGCGTGTGGCTCTCGGCGCGTTATCAAAAACAACAACAATTCG
TTGCAAAAGAAAAAATAAAGTAGAGGAGGCGGAAGAAGAAGAGGAATCTG
CTCGCACCGCGGTCAATCGCGGATCGTGGTCGATTTATCGAATTAATCGC
CCCGAACAAAAAAAACACCGTACAAGGACTTGCACTATTTCCAATGATTT
CGCTGCTGCAAATGAAATTCCGTGCGCTTTTGTTGTTGCTATCAAAAGTA
TGGACATGCATTTGTTTCATGTTCAATCGCCAAGTGCGAGCTTTTATCCA
GTATCAACCGGTTAAATACGAACTCTTCCCGTTGTCACCCGTCTCGCGGC
ACCGCCTGAGCCTGGTGCAGCGCAAGACCCTCGTTCTGGACCTGGACGAA
ACGCTAATCCACTCCCATCACAATGCGATGCCCCGGAATACGGTGAAGCC
GGGCACGCCGCACGATTTCACTGTCAAAGTGACCATCGATCGGAATCCAG
TGCGCTTTTTCGTGCACAAGCGACCGCATGTGGACTACTTCCTGGACGTG
GTCTCGCAGTGGTACGATCTGGTGGTCTTCACGGCCAGCATGGAGATTTA
CGGAGCGGCGGTGGCAGACAAGCTGGACAACGGACGAAACATCCTCCGGA
GGCGATACTACAGACAGCACTGCACGCCCGACTACGGATCCTACACCAAA
GACCTGTCGGCCATCTGCAGTGACCTAAATAGGATATTTATCATCGACAA
TTCGCCCGGCGCCTATCGCTGTTTTCCCAACAACGCCATACCCATCAAGA
GTTGGTTCTCGGACCCGATGGACACGGCGCTGCTGTCGCTGCTGCCCATG
CTGGATGCGCTGAGGTTCACGAACGACGTGAGATCGGTGCTGTCGAGGAA
CTTGCACCTGCACCGCCTCTGGTAGCAGGTGGGCCGCCTGTCGCTAGTTT
AGTTTA
(SEQ ID NO:168)
MISLLQMKFRALLLLLSKVWTCICFMFNRQVRAFIQYQPVKYELFPLSPV
SRHRLSLVQRKTLVLDLDETLIHSHHNAMPRNTVKPGTPHDFTVKVTIDR
NPVRFFVHKRPHVDYFLDVVSQWYDLVVFTASMEIYGAAVADKLDNGRNI
LRRRYYRQHCTPDYGSYTKDLSAICSDLNRIFIIDNSPGAYRCFPNNAIP
IKSWFSDPMDTALLSLLPMLDALRFTNDVRSVLSRNLHLHRLW

Human homologue of Complete Genome candidate

NP_—056158 hypothetical protein

(SEQ ID NO:169)
1    gccggggccg gcggtgccgg ggtcatcggg atgatgcgga
     cgcagtgtct gctggggctg
61   cgcgcgttcg tggccttcgc cgccaagctc tggagcttct
     tcatttacct tttgcggagg
121  cagatccgca cggtaattca gtaccaaact gttcgatatg
     atatcctccc cttatctcct
181  gtgtcccgga atcggctagc ccaggtgaag aggaagatcc
     tggtgctgga tctggatgag
241  acacttattc actcccacca tgatggggtc ctgaggccca
     cagtccggcc tggtacgcct
301  cctgacttca tcctcaaggt ggtaatagac aaacatcctg
     tccggttttt tgtacataag
361  aggccccatg tggatttctt cctggaagtg gtgagccagt
     ggtacgagct ggtggtgttt
421  acagcaagca tggagatcta tggctctgct gtggcagata
     aactggacaa tagcagaagc
481  attcttaaga ggagatatta cagacagcac tgcactttgg
     agttgggcag ctacatcaag
541  gacctctctg tggtccacag tgacctctcc agcattgtga
     tcctggataa ctccccaggg
601  gcttacagga gccatccaga caatgccatc cccatcaaat
     cctggttcag tgaccccagc
661  gacacagccc ttctcaacct gctcccaatg ctggatgccc
     tcaggttcac cgctgatgtt
721  cgttccgtgc tgagccgaaa ccttcaccaa catcggctct
     ggtgacagct gctccccctc
781  cacctgagtt ggggtggggg ggaaagggag ggcgagccct
     tgggatgccg tctgatgccc
841  tgtccaatgt gaggactgcc tgggcagggt ctgcccctcc
     cacccctctc tgccctggga
901  gccctacact ccacttggag tctggatgga cacatgggcc
     aggggctctg aagcagcctc
961  actcttaact tcgtgttcac actccatgga aaccccagac
     tgggacacag gcggaagcct
1021 aggagagccg aatcagtgtt tgtgaagagg caggactggc
     cagagtgaca gacatacggt
1081 gatccaggag gctcaaagag aagccaagtc agctttgttg
     tgatttgatt ttttttaaaa
1141 aactcttgta caaaactgat ctaattcttc actcctgctc
     caagggctgg gctgtgggtg
1201 ggatactggg attttgggcc actggatttt ccctaaattt
     gtcccccctt tactctccct
1261 ctatttttct ctccttagac tccctcagac ctgtaaccag
     ctttgtgtct tttttccttt
1321 tctctctttt aaaccatgca ttataacttt gaaacc
(SEQ ID NO:170)
1    mmrtqcllgl rafvafaakl wsffiyllrr qirtviqyqt
     vrydilplsp vsrnrlaqvk
61   rkilvldlde tlihshhdgv lrptvrpgtp pdfilkvvid
     khpvrffvhk rphvdfflev
121  vsqwyelvvf tasmeiygsa vadkldnsrs ilkrryyrqh
     ctlelgsyik dlsvvhsdls
181  sivildnspg ayrshpdnai pikswfsdps dtallnllpm
     ldalrftadv rsvlsrnlhq
241  hrlw

Putative function

unknown

Example 13 (Category 3)

Line ID—291

Phenotype—Lethal phase pupal-pharate adult. High mitotic index, colchicines-type overcondensed chromosomes, many strongly stained nuclei

Annotated Drosophila genome genomic segment containing P element insertion site (and map position)—AE003427 (3D5)

P element insertion site—131,166

Annotated Drosophila genome Complete Genome candidate—CG10798—dm diminutive, dMyc1

(SEQ ID NO:171)
GTCGCGTGTTCAGTTCACCGCGGGTAATTCAGAGAATCGCTTTGTGGATT
GGATTTTTGCCTGTTTTCCGCCCGATACAAAAAAAAAAAACCAAACGCTA
TATAAATAGTTCTGTAGTAAAACCTGAAGCAACACGTTTTAAAATATACA
ACTACTACTAACAACTGTCACAGCCAAGTTACAAAAGTGCTAAATCCCAG
AAATAACCTAAGAGCCGACTTAAAACCGCGCAAATACATAAAAAAAAATC
TTCTCCAAAGCAGAAACAAAAACTTGTGAAAAACTAGAATTAAAAAAAGA
TTTTTTAAAAAAAATCAGCTAGTGCAAAATAAACGGGAAGAATTTTTTTT
TGTGTCCCTTTTTTTGGTGTTTTTTCTCCGTCTTTCCCCTTCTTTGACGC
AAAAAAAAAAGTGCCCAACTTGCTGGCGGCACGGGAACGGGATAGAAATA
GATATAGCCGAAAGCGACTGGAAAGCAAAGGAAGCTAACTAAATTGGATT
ACAATCAATTAAATAGAGACGGATACGGAAACTATGTTCAGCGAGACAGG
CATATAACTCAGGAACTTAAGATATATAGAAAGAAAAAAAAACCCAGACA
ACATAATCGCAATGGCCCTTTACCGCTCTGATCCGTATTCCATAATGGAC
GACCAACTTTTTTCAAATATTTCAATATTCGATATGGATAATGATCTGTA
CGATATGGACAAACTCCTTTCGTCGTCCACCATTCAGAGTGATCTCGAGA
AGATCGAGGACATGGAAAGTGTATTTCAAGACTATGACTTAGAGGAGGAT
ATGAAGCCAGAGATCCGCAACATCGACTGCATGTGGCCGGCGATGTCCAG
CTGTTTGACCAGCGGTAACGGTAATGGAATAGAGAGCGGAAACAGTGCAG
CCTCGTCGTACAGCGAAACCGGTGCCGTATCCCTGGCGATGGTTTCCGGC
TCTACGAATCTCTACAGCGCGTATCAACGATCGCAGACGACAGATAACAC
CCAGTCAAATCAACAGCATGTCGTCAACAGTGCCGAGAACATGCCGGTGA
TCATCAAGAAGGAGCTCGCAGATCTGGACTACACGGTCTGTCAGAAGCGC
CTCCGTTTGAGCGGCGGTGACAAGAAGTCACAGATCCAGGACGAGGTCCA
TTTAATACCGCCCGGCGGAAGTTTGCTCCGCAAGCGGAACAACCAGGACA
TTATCCGCAAATCGGGCGAATTGAGCGGCAGCGATAGCATAAAATACCAG
AGACCAGACACACCTCACAGTCTTACCGACGAGGTGGCCGCCTCAGAGTT
TAGACATAACGTCGACTTGCGTGCCTGCGTGATGGGCAGCAATAATATCT
CGCTGACCGGCAATGATAGCGATGTCAACTACATTAAGCAAATCAGCAGG
GAGCTTCAGAATACCGGCAAGGATCCGTTGCCGGTGCGTTACATCCCGCC
GATCAACGATGTCCTCGATGTGCTCAACCAGCATTCCAATTCGACGGGTG
GCCAACAGCAGTTGAACCAACAGCAACTGGACGAGCAACAACAGGCCATC
GATATAGCCACTGGACGCAACACAGTGGATTCTCCGCCGACGACCGGCTC
TGATAGTGACTCCGATGACGGTGAACCCCTCAACTTTGACCTGCGCCATC
ATCGCACTAGCAAAAGCGGCAGCAATGCCAGCATCACCACCAACAACAAC
AACAGCAACAACAAAAACAACAAATTGAAGAACAACAGCAACGGCATGCT
GCACATGATGCACATCACCGATCACAGCTACACGCGCTGCAACGATATGG
TGGACGATGGTCCCAATTTGGAGACCCCCTCAGATTCCGATGAGGAAATC
GATGTCGTTTCATATACGGACAAGAAGCTACCCACAAATCCCTCGTGCCA
CTTGATGGGCGCCCTACAGTTCCAGATGGCCCATAAGATCTCGATTGATC
ACATGAAGCAAAAACCGCGCTACAATAACTTCAATCTGCCGTACACACCG
GCCAGCAGCAGTCCAGTGAAATCGGTGGCCAACTCGCGTTATCCATCACC
GTCGAGCACACCGTATCAGAACTGCTCCTCCGCTTCGCCGTCCTACTCGC
CGCTATCCGTGGACTCTTCAAATGTCAGCTCGAGCAGCTCCAGTTCCAGT
TCGCAGTCAAGCTTCACCACCTCCAGTTCGAACAAGGGACGCAAACGATC
CAGTCTGAAGGATCCAGGCTTGTTGATCTCCTCCAGCAGCGTTTATCTGC
CGGGAGTCAATAACAAAGTGACGCATAGCTCCATGATGAGCAAAAAGAGT
CGTGGCAAGAAGGTGGTTGGCACCTCGTCTGGCAATACATCTCCGATATC
GTCTGGCCAGGATGTGGATGCCATGGATCGTAATTGGCAGCGGCGCAGTG
GTGGAATTGCCACTAGCACAAGCTCCAACAGCAGTGTCCATCGGAAGGAC
TTTGTTTTGGGCTTTGATGAGGCCGATACGATCGAGAAGCGCAATCAGCA
CAATGATATGGAGCGTCAGCGACGCATTGGACTCAAGAACCTCTTTGAGG
CTCTAAAGAAACAGATTCCCACAATTAGGGACAAGGAGCGGGCTCCCAAG
GTAAATATCCTGCGAGAGGCGGCCAAGCTATGCATCCAGCTGACCCAGGA
GGAGAAGGAGCTTAGTATGCAGCGCCAGCTTTTGTCGCTGCAGCTGAAGC
AACGTCAGGACACTCTGGCCAGTTACCAAATGGAGTTGAACGAATCGCGC
TCGGTTAGTGGATAGTGTTGTCTCATACTATCGGCTTAAAGCGGCGGCGT
AGGGCTAGGATAACCCCCAATGTATATGCAAGATTTGTATATCCTCCTAC
TTTTTTTTTTTTGCAATTTACTTTGATTTAGCTTCGATCCTTTCTTGACA
TTAAGCCCTAAATATGATTTTTTTCTGGAGAACTTCAATATCAGTTAGTA
GGTTATGTTTAACGATTTGCTTGCGCTTTTTCCGCTTTTTTTTTTGTTTT
TTTACCATACCATACCATAC
(SEQ ID NO:172)
MDDQLFSNISIFDMDNDLYDMDKLLSSSTIQSDLEKIEDMESVFQDYDLE
EDMKPEIRNIDCMWPAMSSCLTSGNGNGIESGNSAASSYSETGAVSLAMV
SGSTNLYSAYQRSQTTDNTQSNQQHVVNSAENMPVIIKKELADLDYTVCQ
KRLRLSGGDKKSQIQDEVHLIPPGGSLLRKRNNQDIIRKSGELSGSDSIK
YQRPDTPHSLTDEVAASEFRHNVDLRACVMGSNNISLTGNDSDVNYIKQI
SRELQNTGKDPLPVRYIPPINDVLDVLNQHSNSTGGQQQLNQQQLDEQQQ
AIDIATGRNTVDSPPTTGSDSDSDDGEPLNFDLRHHRTSKSGSNASITTN
NNNSNNKNNKLKNNSNGMLHMMHITDHSYTRCNDMVDDGPNLETPSDSDE
EIDVVSYTDKKLPTNPSCHLMGALQFQMAHKISIDHMKQKPRYNNFNLPY
TPASSSPVKSVANSRYPSPSSTPYQNCSSASPSYSPLSVDSSNVSSSSSS
SSSQSSFTTSSSNKGRKRSSLKDPGLLISSSSVYLPGVNNKVTHSSMMSK
KSRGKKVVGTSSGNTSPISSGQDVDAMDRNWQRRSGGIATSTSSNSSVHR
KDFVLGFDEADTIEKRNQHNDMERQRRIGLKNLFEALKKQIPTIRDKERA
PKVNILREAAKLCIQLTQEEKELSMQRQLLSLQLKQRQDTLASYQMELNE
SRSVSG

Human homologue of Complete Genome candidate

CAA23831 c-myc oncogene

(SEQ ID NO:173)
1    ctgctcgcgg ccgccaccgc cgggccccgg ccgtccctgg
     ctcccctcct gcctcgagaa
61   gggcagggct tctcagaggc ttggcgggaa aaaagaacgg
     agggagggat cgcgctgagt
121  ataaaagccg gttttcgggg ctttatctaa ctcgctgtag
     taattccagc gagaggcaga
181  gggagcgagc gggcggccgg ctagggtgga agagccgggc
     gagcagagct gcgctgcggg
241  cgtcctggga agggagatcc ggagcgaata gggggcttcg
     cctctggccc agccctcccg
301  cttgatcccc caggccagcg gtccgcaacc cttgccgcat
     ccacgaaact ttgcccatag
361  cagcgggcgg gcactttgca ctggaactta caacacccga
     gcaaggacgc gactctcccg
421  acgcggggag gctattctgc ccatttgggg acacttcccc
     gccgctgcca ggacccgctt
481  ctctgaaagg ctctccttgc agctgcttag acgctggatt
     tttttcgggt agtggaaaac
541  cagcagcctc ccgcgacgat gcccctcaac gttagcttca
     ccaacaggaa ctatgacctc
601  gactacgact cggtgcagcc gtatttctac tgcgacgagg
     aggagaactt ctaccagcag
661  cagcagcaga gcgagctgca gcccccggcg cccagcgagg
     atatctggaa gaaattcgag
721  ctgctgccca ccccgcccct gtcccctagc cgccgctccg
     ggctctgctc gccctcctac
781  gttgcggtca cacccttctc ccttcgggga gacaacgacg
     gcggtggcgg gagcttctcc
841  acggccgacc agctggagat ggtgaccgag ctgctgggag
     gagacatggt gaaccagagt
901  ttcatctgcg acccggacga cgagaccttc atcaaaaaca
     tcatcatcca ggactgtatg
961  tggagcggct tctcggccgc cgccaagctc gtctcagaga
     agctggcctc ctaccaggct
1021 gcgcgcaaag acagcggcag cccgaacccc gcccgcggcc
     acagcgtctg ctccacctcc
1081 agcttgtacc tgcaggatct gagcgccgcc gcctcagagt
     gcatcgaccc ctcggtggtc
1141 ttcccctacc ctctcaacga cagcagctcg cccaagtcct
     gcgcctcgca agactccagc
1201 gccttctctc cgtcctcgga ttctctgctc tcctcgacgg
     agtcctcccc gcagggcagc
1261 cccgagcccc tggtgctcca tgaggagaca ccgcccacca
     ccagcagcga ctctgaggag
1321 gaacaagaag atgaggaaga aatcgatgtt gtttctgtgg
     aaaagaggca ggctcctggc
1381 aaaaggtcag agtctggatc accttctgct ggaggccaca
     gcaaacctcc tcacagccca
1441 ctggtcctca agaggtgcca cgtctccaca catcagcaca
     actacgcagc gcctccctcc
1501 actcggaagg actatcctgc tgccaagagg gtcaagttgg
     acagtgtcag agtcctgaga
1561 cagatcagca acaaccgaaa atgcaccagc cccaggtcct
     cggacaccga ggagaatgtc
1621 aagaggcgaa cacacaacgt cttggagcgc cagaggagga
     acgagctaaa acggagcttt
1681 tttgccctgc gtgaccagat cccggagttg gaaaacaatg
     aaaaggcccc caaggtagtt
1741 atccttaaaa aagccacagc atacatcctg tccgtccaag
     cagaggagca aaagctcatt
1801 tctgaagagg acttgttgcg gaaacgacga gaacagttga
     aacacaaact tgaacagcta
1861 cggaactctt gtgcgtaagg aaaagtaagg aaaacgattc
     cttctaacag aaatgtcctg
1921 agcaatcacc tatgaacttg tttcaaatgc atgatcaaat
     gcaacctcac aaccttggct
1981 gagtcttgag actgaaagat ttagccataa tgtaaactgc
     ctcaaattgg actttgggca
2041 taaaagaact tttttatgct taccatcttt tttttttctt
     taacagattt gtatttaaga
2101 attgttttta aaaaatttta a
(SEQ ID NO:174)
1    mplnvsftnr nydldydsvq pyfycdeeen fyqqqqqsel
     qppapsediw kkfellptpp
61   lspsrrsglc spsyvavtpf slrgdndggg gsfstadqle
     mvtellggdm vnqsficdpd
121  detfikniii qdcmwsgfsa aaklvsekla syqaarkdsg
     spnparghsv cstsslylqd
181  lsaaasecid psvvfpypln dssspkscas qdssafspss
     dsllsstess pqgspeplvl
241  heetppttss dseeeqedee eidvvsvekr qapgkrsesg
     spsagghskp phsplvlkrc
301  hvsthqhnya appstrkdyp aakrvkldsv rvlrqisnnr
     kctsprssdt eenvkrrthn
361  vlerqrrnel krsffalrdq ipelenneka pkvvilkkat
     ayilsvqaee qkliseedll
421  rkrreqlkhk leqlrnsca

Putative function

C-myc oncogene, transcription factor

Example 14 (Category 3)

Line ID—316

Phenotype—Lethal phase larval stage 3—Pre-pupal-pupal. Small optic lobes, missing or small imaginal discs, badly defined chromosomes.

Annotated Drosophila genome genomic segment containing P element insertion site (and map position)—AE003506 (16B-C)

P element insertion site—27,868

Annotated Drosophila genome Complete Genome candidate—CG8465—novel protein (3 splice variants)

(SEQ ID NO:175)
TGACAGTCCGCCTCTAATTTAATTTCGTTTGTGCACATTTTGTTTGAAAG
ACGCTTAAGATTATTGGGTTTTGTTTCATGTATTGTGCCCTTTGTGCTAA
AAGTGCATCCGCCATTTTACGCAGAGATGTCGACCTATTTCGGGGTCTAT
ATCCCGACCTCCAAAGCGGGCTGTTTTGAGGGATCGGTGTCGCAGTGCAT
CGGCTCCATAGCCGCGGTGAACATAAAGCCATCCAATCCGGCGTCTGGAT
CGGCATCAGTAGCATCGGGATCGCCATCCGGCTCGGCGGCATCCGTGCAA
ACGGGCAACGCAGACGATGGCAGTGCTGCCACCAAGTACGAGGATCCCGA
CTATCCACCGGACTCGCCACTGTGGCTGATCTTCACGGAGAAATCCAAGG
CGCTGGACATCCTGCGACACTACAAGGAGGCGCGCCTCCGCGAGTTTCCC
AATCTGGAGCAGGCGGAGAGTTACGTTCAGTTTGGGTTCGAGAGCATCGA
GGCGCTCAAGAGATTTTGCAAGGCAAAGCCCGAAAGCAAGCCCATTCCGA
TAATCAGCGGTAGCGGTTACAAGAGCTCACCGACCTCGACGGACAATTCG
TGCTCCTCCTCGCCGACGGGTAACGGCAGTGGCTTCATCATTCCCCTGGG
AAGCAATTCCTCAATGTCGAATTTACTGCTCAGTGACTCACCGACTTCCT
CGCCGAGCAGCTCCAGCAACGTCATTGCCAATGGGCGACAGCAGCAGATG
CAGCAGCAACAGCAGCAGCAGCCGCAGCAGCCGGATGTGTCCGGAGAAGG
CCCTCCTTTCCGGGCGCCCACCAAACAGGAACTGGTAGAGTTTCGCAAGC
AAATCGAAGGTGGTCACATAGACCGGGTGAAGAGGATTATATGGGAGAAT
CCACGATTTTTGATCAGCAGCGGTGATACGCCCACCAGTTTGAAGGAGGG
CTGTCGCTATAATGCCATGCACATCTGCGCCCAGGTCAATAAGGCCAGGA
TCGCTCAGTTGCTGTTAAAGACCATTTCGGATCGGGAGTTCACTCAGCTT
TACGTTGGCAAGAAGGGCAGTGGCAAGATGTGTGCTGCCCTCAACATCAG
TCTCCTGGACTATTACCTGAACATGCCGGACAAGGGGCGCGGCGAAACAC
CGCTCCACTTTGCCGCAAAGAACGGTCATGTGGCCATGGTCGAGGTTCTC
GTTTCCTATCCGGAGTGCAAATCGCTGCGGAATCATGAGGGCAAGGAGCC
CAAGGAAATCATCTGCCTGCGTAATGCTAATGCTACACATGTGACCATCA
AGAAGCTGGAGCTGCTCTTGTACGATCCGCATTTTGTGCCCGTACTAAGA
TCCCAGTCAAATACACTGCCGCCAAAAGTGGGTCAACCGTTCTCGCCCAA
AGATCCACCGAACCTGCAACACAAAGCGGACGATTACGAGGGCCTCAGCG
TGGACCTGGCAATCAGTGCGCTGGCGGGACCCATGTCCCGCGAAAAGGCC
ATGAACTTCTATCGCCGTTGGAAGACACCACCGCGGGTCAGCAACAATGT
GATGTCGCCGCTGGCTGGTTCACCATTTAGCTCGCCGGTGAAAGTAACCC
CAAGCAAGTCGATCTTTGACCGAAGTGCTGGAAACTCGAGTCCAGTCCAC
TCAGGACGCAGAGTGCTCTTTAGTCCATTGGCGGAGGCGACCAGCTCACC
AAAACCGACGAAAAACGTGCCCAATGGCACCAATGAGTGCGAGCACAACA
ATAATAATGTGAAGCCAGTGTATCCGTTGGAGTTCCCGGCGACACCCATT
CGAAAAATGAAACCGGATTTATTCATGGCCTATCGCAATAACAATAGCTT
TGATTCGCCATCTTTGGCCGATGACTCCCAAATCCTGGACATGAGCCTAA
GCCGCAGCCTGAATGCGTCGCTAAATGACAGCTTCCGTGAGCGGCACATC
AAGAACACTGATATCGAGAAGGGTCTGGAGGTGGTCGGCCGCCAACTGGC
ACGACAGGAGCAGTTAGAGTGGCGCGAGTACTGGGATTTTCTCGATTCAT
TTTTGGACATTGGTACGACCGAAGGCCTGGCCCGTCTTGAAGCGTATTTC
CTGGAAAAGACCGAACAGCAGGCGGATAAATCAGAAACGGTCTGGAACTT
TGCCCATCTGCATCAGTATTTCGATTCGATGGCCGGCGAGCAACAGCAGC
AACTCCGAAAGGATAAAAATGAGGCTGCGGGAGCAACTTCGCCATCCGCC
GGAGTCATGACTCCGTACACATGCGTAGAGAAGTCGCTGCAAGTGTTCGC
CAAGCGCATCACTAAAACGTTGATCAACAAAATCGGCAACATGGTGTCCA
TCAACGACACGCTGCTCTGTGAGCTCAAAAGACTGAAATCGCTGATTGTC
AGCTTCAAGGATGATGCCCGCTTCATTAGCGTGGACTTTAGCAAGGTGCA
TTCACGTATCGCCCACCTGGTGGCCAGCTATGTGACCCACTCGCAGGAGG
TCAGCGTAGCCATGCGTCTACAATTGTTGCAGATGCTCCGAAGTTTGCGG
CAACTGCTGGCCGACGAGCGTGGTCGAGAACAGCATTTGGGCTGCGTGTG
CGCTAGTCTATTGCTGATGCTGGAACAGGCGCCGACATCCGCCGTGCATC
TACCAGACACTCTGAAGACCGAGGAGCTATGTTGCGCCGCCTGGGAGACG
GAGCAGTGTTGCGCCTGTCTGTGGGACGCAAATCTCAGCCGTAAGACCAG
TCGTCGAAAGCGCACTAAGTCGCTGCGGGCAGCTGCTGTTGTTCAGTCTC
AGGGTCAGCTTCAGGATACTTCGGGATCGACAGGGTCGTCCGCCTTGCAC
GCTTCGCTTGGTGTGGGATCGACCAGTTTGGGAGCATCGAGGGTCGTGGC
GTCCGCTTCGAAAGATGCTTGGCGCCGTCAACAAAGCGACGACGAGGACT
ACGACAGCGATGAGCAAGTAATCTTTTTCGACTGCACTAATGTTACGCTG
CCTTATGGAAGCAGCAGCGAGGACGAGGAAAACTTCCGTACGCCGCCGCA
AAGCTTGTCGCCAGGTATTTCCATGGATTTGGAGCCGCGTTACGAGTTGT
TTATTTTTGGAAACGAGCCAACCAAGCGAGATTTGGATGTGCTGAATGCC
CTTTCCAATGTCGACATTGATAAGGAAACACTGCCGCATGTCTACGCCTG
GAAGACTGCCATGGAGAGCTACTCCTGTGCTGAAATGAATCTGAACGTCA
AGGTTCAAAAGCCGGAGCCTTGGTATTCTGGAACCAGTTCTAGCCACAAC
AGCCAACCATTGTTGCATCCCAAGCGTCTGCTTGCCACGCCAAAGCTGAA
TGCCGTGGTCAGCGGCAGACGCGGATCCGGACCATTGACGGCGCCAGTTA
CACCGCGTCTGGCGCGAACTCCGTCCGCCGCCAGTATTCAAGTTGCATCC
GAGACGAATGGCGAGTCGGTCGGAACTGCTGTGACTCCGGCATCGCCGAT
TTTGAGTTTTGCCGCCTTGACGGCAGCGACGCAGTCATTCCAAACACCAT
TGAACAAGGTGCGCGGCTTGTTCAGCCAATATCGGGATCAACGGTCCTAT
AACGAGGGGGACACGCCGCTGGGCAATCGGAACTGAAACGGAATCGGCCC
GGAAACAGAAACAGAAACAGCGACTGATTGATGAAAGGCCGACTGCATAC
TTACCCCCCTGAATAGCCGGTGTCGTCCATTGTCCCTTTTAATGTTAATC
GCATGTATATTA
(SEQ ID NO:176)
MSTYFGVYIPTSKAGCFEGSVSQCIGSIAAVNIKPSNPASGSASVASGSP
SGSAASVQTGNADDGSAATKYEDPDYPPDSPLWLIFTEKSKALDILRHYK
EARLREFPNLEQAESYVQFGFESIEALKRFCKAKPESKPIPIISGSGYKS
SPTSTDNSCSSSPTGNGSGFIIPLGSNSSMSNLLLSDSPTSSPSSSSNVI
ANGRQQQMQQQQQQQPQQPDVSGEGPPFRAPTKQELVEFRKQIEGGHIDR
VKRIIWENPRFLISSGDTPTSLKEGCRYNAMHICAQVNKARIAQLLLKTI
SDREFTQLYVGKKGSGKMCAALNISLLDYYLNMPDKGRGETPLHFAAKNG
HVAMVEVLVSYPECKSLRNHEGKEPKEIICLRNANATHVTIKKIELLLYD
PHFVPVLRSQSNTLPPKVGQPFSPKDPPNLQHKADDYEGLSVDLAISALA
GPMSREKAMNFYRRWKTPPRVSNNVMSPLAGSPFSSPVKVTPSKSIFDRS
AGNSSPVHSGRRVLFSPLAEATSSPKPTKNVPNGTNECEHNNNNVKPVYP
LEFPATPIRKMKPDLFMAYRNNNSFDSPSLADDSQILDMSLSRSLNASLN
DSFRERHIKNTDIEKGLEVVGRQLARQEQLEWREYWDFLDSFLDIGTTEG
LARLEAYFLEKTEQQADKSETVWNFAHLHQYFDSMAGEQQQQLRKDKNEA
AGATSPSAGVMTPYTCVEKSLQVFAKRITKTLINKIGNMVSINDTLLCEL
RRLKSLIVSFKDDARFISVDFSKVHSRIAHLVASYVTHSQEVSVAMRLQL
LQMLRSLRQLLADERGREQHLGCVCASLLLMLEQAPTSAVHLPDTLKTEE
LCCAAWETEQCCACLWDANLSRKTSRRKRTKSLRAAAVVQSQGQLQDTSG
STGSSALHASLGVGSTSLGASRVVASASKDAWRRQQSDDEDYDSDEQVIF
FDCTNVTLPYGSSSEDEENFRTPPQSLSPGISMDLEPRYELFIFGNEPTK
RDLDVLNALSNVDIDKETLPHVYAWKTAMESYSCAEMNLNVKVQKPEPWY
SGTSSSHNSQPLLHPKRLLATPKLNAVVSGRRGSGPLTAPVTPRLARTPS
AASIQVASETNGESVGTAVTPASPILSFAALTAATQSFQTPLNKVRGLFS
QYRDQRSYNEGDTPLGNRN
(SEQ ID NO:177)
TTGATGTTACCCTATTTTTACCGTTGCCTTCGCTTGCCATCAGCGGAACT
TTACATTTTTTCACGGAGTTGTGAAGAAGTTGCCTGTTATTTGGTGTTGA
TGTCAAACCATTTTAACCGCTTACCTTGCAGTGCATCCGCCATTTTACGC
AGAGATGTCGACCTATTTCGGGGTCTATATCCCGACCTCCAAAGCGGGCT
GTTTTGAGGGATCGGTGTCGCAGTGCATCGGCTCCATAGCCGCGGTGAAC
ATAAAGCCATCCAATCCGGCGTCTGGATCGGCATCAGTAGCATCGGGATC
GCCATCCGGCTCGGCGGCATCCGTGCAAACGGGCAACGCAGACGATGGCA
GTGCTGCCACCAAGTACGAGGATCCCGACTATCCACCGGACTCGCCACTG
TGGCTGATCTTCACGGAGAAATCCAAGGCGCTGGACATCCTGCGACACTA
CAAGGAGGCGCGCCTCCGCGAGTTTCCCAATCTGGAGCAGGCGGAGAGTT
ACGTTCAGTTTGGGTTCGAGAGCATCGAGGCGCTCAAGAGATTTTGCAAG
GCAAAGCCCGAAAGCAAGCCCATTCCGATAATCAGCGGTAGCGGTTACAA
GAGCTCACCGACCTCGACGGACAATTCGTGCTCCTCCTCGCCGACGGGTA
ACGGCAGTGGCTTCATCATTCCCCTGGGAAGCAATTCCTCAATGTCGAAT
TTACTGCTCAGTGACTCACCGACTTCCTCGCCGAGCAGCTCCAGCAACGT
CATTGCCAATGGGCGACAGCAGCAGATGCAGCAGCAACAGCAGCAGCAGC
CGCAGCAGCCGGATGTGTCCGGAGAAGGCCCTCCTTTCCGGGCGCCCACC
AAACAGGAACTGGTAGAGTTTCGCAAGCAAATCGAAGGTGGTCACATAGA
CCGGGTGAAGAGGATTATATGGGAGAATCCACGATTTTTGATCAGCAGCG
GTGATACGCCCACCAGTTTGAAGGAGGGCTGTCGCTATAATGCCATGCAC
ATCTGCGCCCAGGTCAATAAGGCCAGGATCGCTCAGTTGCTGTTAAAGAC
CATTTCGGATCGGGAGTTCACTCAGCTTTACGTTGGCAAGAAGGGCAGTG
GCAAGATGTGTGCTGCCCTCAACATCAGTCTCCTGGACTATTACCTGAAC
ATGCCGGACAAGGGGCGCGGCGAAACACCGCTCCACTTTGCCGCAAAGAA
CGGTCATGTGGCCATGGTCGAGGTTCTCGTTTCCTATCCGGAGTGCAAAT
CGCTGCGGAATCATGAGGGCAAGGAGCCCAAGGAAATCATCTGCCTGCGT
AATGCTAATGCTACACATGTGACCATCAAGAAGCTGGAGCTGCTCTTGTA
CGATCCGCATTTTGTGCCCGTACTAAGATCCCAGTCAAATACACTGCCGC
CAAAAGTGGGTCAACCGTTCTCGCCCAAAGATCCACCGAACCTGCAACAC
AAAGCGGACGATTACGAGGGCCTCAGCGTGGACCTGGCAATCAGTGCGCT
GGCGGGACCCATGTCCCGCGAAAAGGCCATGAACTTCTATCGCCGYFGGA
AGACACCACCGCGGGTCAGCAACAATGTGATGTCGCCGCTGGCTGGTTCA
CCATTTAGCTCGCCGGTGAAAGTAACCCCAAGCAAGTCGATCTTTGACCG
AAGTGCTGGAAACTCGAGTCCAGTCCACTCAGGACGCAGAGTGCTCTTTA
GTCCATTGGCGGAGGCGACCAGCTCACCAAAACCGACGAAAAACGTGCCC
AATGGCACCAATGAGTGCGAGCACAACAATAATAATGTGAAGCCAGTGTA
TCCGTTGGAGTTCCCGGCGACACCCATTCGAAAAATGAAACCGGATTTAT
TCATGGCCTATCGCAATAACAATAGCTTTGATTCGCCATCTTTGGCCGAT
GACTCCCAAATCCTGGACATGAGCCTAAGCCGCAGCCTGAATGCGTCGCT
AAATGACAGCTTCCGTGAGCGGCACATCAAGAACACTGATATCGAGAAGG
GTCTGGAGGTGGTCGGCCGCCAACTGGCACGACAGGAGCAGTTAGAGTGG
CGCGAGTACTGGGATTTTCTCGATTCATTTTTGGACATTGGTACGACCGA
AGGCCTGGCCCGTCTTGAAGCGTATTTCCTGGAAAAGACCGAACAGCAGG
CGGATAAATCAGAAACGGTCTGGAACTTTGCCCATCTGCATCAGTATTTC
GATTCGATGGCCGGCGAGCAACAGCAGCAACTCCGAAAGGATAAAAATGA
GGCTGCGGGAGCAACTTCGCCATCCGCCGGAGTCATGACTCCGTACACAT
GCGTAGAGAAGTCGCTGCAAGTGTTCGCCAAGCGCATCACTAAAACGTTG
ATCAACAAAATCGGCAACATGGTGTCCATCAACGACACGCTGCTCTGTGA
GCTCAAAAGACTGAAATCGCTGATTGTCAGCTTCAAGGATGATGCCCGCT
TCATTAGCGTGGACTTTAGCAAGGTGCATTCACGTATCGCCCACCTGGTG
GCCAGCTATGTGACCCACTCGCAGGAGGTCAGCGTAGCCATGCGTCTACA
ATTGTTGCAGATGCTCCGAAGTTTGCGGCAACTGCTGGCCGACGAGCGTG
GTCGAGAACAGCATTTGGGCTGCGTGTGCGCTAGTCTATTGCTGATGCTG
GAACAGGCGCCGACATCCGCCGTGCATCTACCAGACACTCTGAAGACCGA
GGAGCTATGTTGCGCCGCCTGGGAGACGGAGCAGTGTTGCGCCTGTCTGT
GGGACGCAAATCTCAGCCGTAAGACCAGTCGTCGAAAGCGCACTAAGTCG
CTGCGGGCAGCTGCTGTTGTTCAGTCTCAGGGTCAGCTTCAGGATACTTC
GGGATCGACAGGGTCGTCCGCCTTGCACGCTTCGCTTGGTGTGGGATCGA
CCAGTTTGGGAGCATCGAGGGTCGTGGCGTCCGCTTCGAAAGATGCTTGG
CGCCGTCAACAAAGCGACGACGAGGACTACGACAGCGATGAGCAAGTAAT
CTTTTTCGACTGCACTAATGTTACGCTGCCTTATGGAAGCAGCAGCGAGG
ACGAGGAAAACTTCCGTACGCCGCCGCAAAGCTTGTCGCCAGGTATTTCC
ATGGATTTGGAGCCGCGTTACGAGTTGTTTATTTTTGGAAACGAGCCAAC
CAAGCGAGATTTGGATGTGCTGAATGCCCTTTCCAATGTCGACATTGATA
AGGAAACACTGCCGCATGTCTACGCCTGGAAGACTGCCATGGAGAGCTAC
TCCTGTGCTGAAATGAATCTGAACGTCAAGGTTCAAAAGCCGGAGCCTTG
GTATTCTGGAACCAGTTCTAGCCACAACAGCCAACCATTGTTGCATCCCA
AGCGTCTGCTTGCCACGCCAAAGCTGAATGCCGTGGTCAGCGGCAGACGC
GGATCCGGACCATTGACGGCGCCAGTTACACCGCGTCTGGCGCGAACTCC
GTCCGCCGCCAGTATTCAAGTTGCATCCGAGACGAATGGCGAGTCGGTCG
GAACTGCTGTGACTCCGGCATCGCCGATTTTGAGTTTTGCCGCCTTGACG
GCAGCGACGCAGTCATTCCAAACACCATTGAACAAGGTGCGCGGCTTGTT
CAGCCAATATCGGGATCAACGGTCCTATAACGAGGGGGACACGCCGCTGG
GCAATCGGAACTGAAACGGAATCGGCCCGGAAACAGAAACAGAAACAGCG
ACTGATTGATGAAAGGCCGACTGCATACTTACCCCCCTGAATAGCCGGTG
TCGTCCATTGTCCCTTTTAATGTTAATCGCATGTATATTA
(SEQ ID NO:178)
MSTYFGVYIPTSKAGCFEGSVSQCIGSIAAVNIKPSNPASGSASVASGSP
SGSAASVQTGNADDGSAATKYEDPDYPPDSPLWLIFTEKSKALDILRHYK
EARLREFPNLEQAESYVQFGFESIEALKRFCKARPESKPIPIISGSGYKS
SPTSTDNSCSSSPTGNGSGFIIPLGSNSSMSNLLLSDSPTSSPSSSSNVI
ANGRQQQMQQQQQQQPQQPDVSGEGPPFRAPTKQELVEFRKQIEGGHIDR
VKRIIWENPRFLISSGDTPTSLKEGCRYNAMHICAQVNKARIAQLLLKTI
SDREFTQLYVGKKGSGKMCAALNISLLDYYLNMPDKGRGETPLHFAAKNG
HVAMVEVLVSYPECKSLRNHEGKEPKEIICLRNANATHVTIKKLELLLYD
PHFVPVLRSQSNTLPPKVGQPFSPKDPPNLQHKADDYEGLSVDLAISALA
GPMSREKAMNFYRRWKTPPRVSNNVMSPLAGSPFSSPVKVTPSKSIFDRS
AGNSSPVHSGRRVLFSPLAEATSSPKPTKNVPNGTNECEHNNNNVKPVYP
LEFPATPIRKMKPDLFMAYRNNNSFDSPSLADDSQILDMSLSRSLNASLN
DSFRERHIKNTDIEKGLEVVGRQLARQEQLEWREYWDFLDSFLDIGTTEG
LARLEAYFLEKTEQQADKSETVWNFAHLHQYFDSMAGEQQQQLRKDKNEA
AGATSPSAGVMTPYTCVEKSLQVFAKRITKTLINKIGNMVSINDTLLCEL
KRLKSLIVSFKDDARFISVDFSKVHSRIAHLVASYVTHSQEVSVAMRLQL
LQMLRSLRQLLADERGREQHLGCVCASLLLMLEQAPTSAVHLPDTLKTEE
LCCAAWETEQCCACLWDANLSRKTSRRKRTKSLRAAAVVQSQGQLQDTSG
STGSSALHASLGVGSTSLGASRVVASASKDAWRRQQSDDEDYDSDEQVIF
FDCTNVTLPYGSSSEDEENFRTPPQSLSPGISMDLEPRYELFIFGNEPTK
RDLDVLNALSNVDIDKETLPHVYAWKTAMESYSCAEMNLNVKVQKPEPWY
SGTSSSHNSQPLLHPKRLLATPKLNAVVSGRRGSGPLTAPVTPRLARTPS
AASIQVASETNGESVGTAVTPASPILSFAALTAATQSFQTPLNKVRGLFS
QYRDQRSYNEGDTPLGNRN
(SEQ ID NO:179)
AAAACAGCCAGCTCATTTATTAATGGTTTATCCCTCTCGATGCCCACACA
TCAACATTGCCATCGCCACGACGGAGCAGCGGACTCGCCACTGTGGCTGA
TCTTCACGGAGAAATCCAAGGCGCTGGACATCCTGCGACACTACAAGGAG
GCGCGCCTCCGCGAGTTTCCCAATCTGGAGCAGGCGGAGAGTTACGTTCA
GTTTGGGTTCGAGAGCATCGAGGCGCTCAAGAGATTTTGCAAGGCAAAGC
CCGAAAGCAAGCCCATTCCGATAATCAGCGGTAGCGGTTACAAGAGCTCA
CCGACCTCGACGGACAATTCGTGCTCCTCCTCGCCGACGGGTAACGGCAG
TGGCTTCATCATTCCCCTGGGAAGCAATTCCTCAATGTCGAATTTACTGC
TCAGTGACTCACCGACTTCCTCGCCGAGCAGCTCCAGCAACGTCATTGCC
AATGGGCGACAGCAGCAGATGCAGCAGCAACAGCAGCAGCAGCCGCAGCA
GCCGGATGTGTCCGGAGAAGGCCCTCCTTTCCGGGCGCCCACCAAACAGG
AACTGGTAGAGTTTCGCAAGCAAATCGAAGGTGGTCACATAGACCGGGTG
AAGAGGATTATATGGGAGAATCCACGATTTTTGATCAGCAGCGGTGATAC
GCCCACCAGTTTGAAGGAGGGCTGTCGCTATAATGCCATGCACATCTGCG
CCCAGGTCAATAAGGCCAGGATCGCTCAGTTGCTGTTAAAGACCATTTCG
GATCGGGAGTTCACTCAGCTTTACGTTGGCAAGAAGGGCAGTGGCAAGAT
GTGTGCTGCCCTCAACATCAGTCTCCTGGACTATTACCTGAACATGCCGG
ACAAGGGGCGCGGCGAAACACCGCTCCACTTTGCCGCAAAGAACGGTCAT
GTGGCCATGGTCGAGGTTCTCGTTTCCTATCCGGAGTGCAAATCGCTGCG
GAATCATGAGGGCAAGGAGCCCAAGGAAATCATCTGCCTGCGTAATGCTA
ATGCTACACATGTGACCATCAAGAAGCTGGAGCTGCTCTTGTACGATCCG
CATTTTGTGCCCGTACTAAGATCCCAGTCAAATACACTGCCGCCAAAAGT
GGGTCAACCGTTCTCGCCCAAAGATCCACCGAACCTGCAACACAAAGCGG
ACGATTACGAGGGCCTCAGCGTGGACCTGGCAATCAGTGCGCTGGCGGGA
CCCATGTCCCGCGAAAAGGCCATGAACTTCTATCGCCGTTGGAAGACACC
ACCGCGGGTCAGCAACAATGTGATGTCGCCGCTGGCTGGTTCACCATTTA
GCTCGCCGGTGAAAGTAACCCCAAGCAAGTCGATCTTTGACCGAAGTGCT
GGAAACTCGAGTCCAGTCCACTCAGGACGCAGAGTGCTCTTTAGTCCATT
GGCGGAGGCGACCAGCTCACCAAAACCGACGAAAAACGTGCCCAATGGCA
CCAATGAGTGCGAGCACAACAATAATAATGTGAAGCCAGTGTATCCGTTG
GAGTTCCCGGCGACACCCATTCGAAAAATGAAACCGGATTTATTCATGGC
CTATCGCAATAACAATAGCTTTGATTCGCCATCTTTGGCCGATGACTCCC
AAATCCTGGACATGAGCCTAAGCCGCAGCCTGAATGCGTCGCTAAATGAC
AGCTTCCGTGAGCGGCACATCAAGAACACTGATATCGAGAAGGGTCTGGA
GGTGGTCGGCCGCCAACTGGCACGACAGGAGCAGTTAGAGTGGCGCGAGT
ACTGGGATTTTCTCGATTCATTTTTGGACATTGGTACGACCGAAGGCCTG
GCCCGTCTTGAAGCGTATTTCCTGGAAAAGACCGAACAGCAGGCGGATAA
ATCAGAAACGGTCTGGAACTTTGCCCATCTGCATCAGTATTTCGATTCGA
TGGCCGGCGAGCAACAGCAGCAACTCCGAAAGGATAAAAATGAGGCTGCG
GGAGCAACTTCGCCATCCGCCGGAGTCATGACTCCGTACACATGCGTAGA
GAAGTCGCTGCAAGTGTTCGCCAAGCGCATCACTAAAACGTTGATCAACA
AAATCGGCAACATGGTGTCCATCAACGACACGCTGCTCTGTGAGCTCAAA
AGACTGAAATCGCTGATTGTCAGCTTCAAGGATGATGCCCGCTTCATTAG
CGTGGACTTTAGCAAGGTGCATTCACGTATCGCCCACCTGGTGGCCAGCT
ATGTGACCCACTCGCAGGAGGTCAGCGTAGCCATGCGTCTACAATTGTTG
CAGATGCTCCGAAGTTTGCGGCAACTGCTGGCCGACGAGCGTGGTCGAGA
ACAGCATTTGGGCTGCGTGTGCGCTAGTCTATTGCTGATGCTGGAACAGG
CGCCGACATCCGCCGTGCATCTACCAGACACTCTGAAGACCGAGGAGCTA
TGTTGCGCCGCCTGGGAGACGGAGCAGTGTTGCGCCTGTCTGTGGGACGC
AAATCTCAGCCGTAAGACCAGTCGTCGAAAGCGCACTAAGTCGCTGCGGG
CAGCTGCTGTTGTTCAGTCTCAGGGTCAGCTTCAGGATACTTCGGGATCG
ACAGGGTCGTCCGCCTTGCACGCTTCGCTTGGTGTGGGATCGACCAGTTT
GGGAGCATCGAGGGTCGTGGCGTCCGCTTCGAAAGATGCTTGGCGCCGTC
AACAAAGCGACGACGAGGACTACGACAGCGATGAGCAAGTAATCTTTTTC
GACTGCACTAATGTTACGCTGCCTTATGGAAGCAGCAGCGAGGACGAGGA
AAACTTCCGTACGCCGCCGCAAAGCTTGTCGCCAGGTATTTCCATGGATT
TGGAGCCGCGTTACGAGTTGTTTATTTTTGGAAACGAGCCAACCAAGCGA
GATTTGGATGTGCTGAATGCCCTTTCCAATGTCGACATTGATAAGGAAAC
ACTGCCGCATGTCTACGCCTGGAAGACTGCCATGGAGAGCTACTCCTGTG
CTGAAATGAATCTGAACGTCAAGGTTCAAAAGCCGGAGCCTTGGTATTCT
GGAACCAGTTCTAGCCACAACAGCCAACCATTGTTGCATCCCAAGCGTCT
GCTTGCCACGCCAAAGCTGAATGCCGTGGTCAGCGGCAGACGCGGATCCG
GACCATTGACGGCGCCAGTTACACCGCGTCTGGCGCGAACTCCGTCCGCC
GCCAGTATTCAAGTTGCATCCGAGACGAATGGCGAGTCGGTCGGAACTGC
TGTGACTCCGGCATCGCCGATTTTGAGTTTTGCCGCCTTGACGGCAGCGA
CGCAGTCATTCCAAACACCATTGAACAAGGTGCGCGGCTTGTTCAGCCAA
TATCGGGATCAACGGTCCTATAACGAGGGGGACACGCCGCTGGGCAATCG
GAACTGAAACGGAATCGGCCCGGAAACAGAAACAGAAACAGCGACTGATT
GATGAAAGGCCGACTGCATACTTACCCCCCTGAATAGCCGGTGTCGTCCA
TTGTCCCTTTTAATGTTAATCGCATGTATATTA
(SEQ ID NO:180)
MPTHQHCHRHDGAADSPLWLIFTEKSKALDILRHYKEARLREFPNLEQAE
SYVQFGFESIEALKRFCKAKPESKPIPIISGSGYKSSPTSTDNSCSSSPT
GNGSGFIIPLGSNSSMSNLLLSDSPTSSPSSSSNVIANGRQQQMQQQQQQ
QPQQPDVSGEGPPFRAPTKQELVEFRKQIEGGHIDRVKRIIWENPRFLIS
SGDTPTSLKEGCRYNAMHICAQVNKARIAQLLLKTISDREFTQLYVGKKG
SGKMCAALNISLLDYYLNMPDKGRGETPLHFAAKNGHVAMVEVLVSYPEC
KSLRNHEGKEPKEIICLRNANATHVTIKKLELLLYDPHFVPVLRSQSNTL
PPKVGQPFSPKDPPNLQHKADDYEGLSVDLAISALAGPMSREKAMNFYRR
WKTPPRVSNNVMSPLAGSPFSSPVKVTPSKSIFDRSAGNSSPVHSGRRVL
FSPLAEATSSPKPTKNVPNGTNECEHNNNNVKPVYPLEFPATPIRKMKPD
LFMAYRNNNSFDSPSLADDSQILDMSLSRSLNASLNDSFRERHIKNTDIE
KGLEVVGRQLARQEQLEWREYWDFLDSFLDIGTTEGLARLEAYFLEKTEQ
QADKSETVWNFAHLHQYFDSMAGEQQQQLRKDKNEAAGATSPSAGVMTPY
TCVEKSLQVFAKRITKTLINKIGNMVSINDTLLCELKRLKSLIVSFKDDA
RFISVDFSKVHSRIAHLVASYVTHSQEVSVAMRLQLLQMLRSLRQLLADE
RGREQHLGCVCASLLLMLEQAPTSAVHLPDTLKTEELCCAAWETEQCCAC
LWDANLSRKTSRRKRTKSLRAAAVVQSQGQLQDTSGSTGSSALHASLGVG
STSLGASRVVASASKDAWRRQQSDDEDYDSDEQVIFFDCTNVTLPYGSSS
EDEENFRTPPQSLSPGISMDLEPRYELFIFGNEPTKRDLDVLNALSNVDI
DKETLPHVYAWKTAMESYSCAEMNLNVKVQKPEPWYSGTSSSHNSQPLLH
PKRLLATPKLNAVVSGRRGSGPLTAPVTPRLARTPSAASIQVASETNGES
VGTAVTPASPILSFAALTAATQSFQTPLNKVRGLFSQYRDQRSYNEGDTP
LGNRN

Human Homologue of Complete Genome candidate

BAA31667 KIAA0692 protein

(SEQ ID NO:181)
1    gagattttgg ttacagtgtg ggcctgaatc ctccagagga
     ggaagctgtg acatccaaga
61   cctgctcggt gccccctagt gacaccgaca cctacagagc
     tggagcgact gcgtctaagg
121  agccgcccct gtactatggg gtgtgtccag tgtatgagga
     cgtcccagcg agaaatgaaa
181  ggatctatgt ttatgaaaat aaaaaggaag cattgcaagc
     tgtcaagatg atcaaagggt
241  cccgatttaa agctttttct accagagaag acgctgagaa
     atttgctaga ggaatttgtg
301  attatttccc ttctccaagc aaaacgtcct taccactgtc
     tcctgtgaaa acagctccac
361  tctttagcaa tgacaggttg aaagatggtt tgtgcttgtc
     ggaatcagaa acagtcaaca
421  aagagcgagc gaacagttac aaaaatcccc gcacgcagga
     cctcaccgcc aagcttcgga
481  aagctgtgga gaagggagag gaggacacct tttctgacct
     tatctggagc aacccccggt
541  atctgatagg ctcaggagac aaccccacta tcgtgcagga
     agggtgcagg tacaacgtga
601  tgcatgttgc tgccaaagag aaccaggctt ccatctgcca
     gctgactctg gacgtcctgg
661  agaaccctga cttcatgagg ctgatgtacc ctgatgacga
     cgaggccatg ctgcagaagc
721  gtatccgtta cgtggtggac ctgtacctca acacccccga
     caagatgggc tatgacacac
781  cgttgcattt tgcttgtaag tttggaaatg cagatgtagt
     caacgtgctt tcgtcacacc
841  atttgattgt aaaaaactca aggaataaat atgataaaac
     acctgaagat gtaatttgtg
901  aaagaagcaa aaataaatct gtggaactga aggagcggat
     cagagagtat ttaaagggcc
961  actactacgt gcccctcctg agagcggaag agacttcttc
     tccagtcatc ggggagctgt
1021 ggtccccaga ccagacggct gaggcctctc acgtcagccg
     ctatggaggc agccccagag
1081 acccggtact gaccctgaga gccttcgcag ggcccctgag
     tccagccaag gcagaagatt
1141 ttcgcaagct ctggaaaact ccacctcgag agaaagcagg
     cttccttcac cacgtcaaga
1201 agtcggaccc ggaaagaggc tttgagagag tgggaaggga
     gctagctcat gagctggggt
1261 atccctgggt tgaatactgg gaatttctgg gctgttttgt
     tgatctgtct tcccaggaag
1321 gcctgcaaag actagaagaa tatctcacac agcaggaaat
     aggcaaaaag gctcaacaag
1381 aaacaggaga acgggaagcc tcctgccgag ataaagccac
     cacgtctggc agcaattcca
1441 tttccgtgag ggcgtttcta gatgaagatg acatgagctt
     ggaagaaata aaaaatcggc
1501 aaaatgcagc tcgaaataac agcccgccca cagtcggtgc
     ttttggacat acgaggtgca
1561 gcgccttccc cttggagcag gaggcagacc tcatagaagc
     cgccgagccg ggaggtccac
1621 acagcagcag aaatgggctc tgccatcctc tgaatcacag
     caggaccctg gcgggcaaga
1681 gaccaaaggc cccccatggg gaggaagccc atctgccacc
     tgtctcggat ttgactgttg
1741 agtttgataa actgaatttg caaaatatag gacgtagcgt
     ttccaagaca ccagatgaaa
1801 gtacaaaaac taaagatcag atcctgactt caagaatcaa
     tgcagtagaa agagacttgt
1861 tagagccttc tcccgcagac caactcggga atggccacag
     gaggacagaa agtgaaatgt
1921 cagccaggat cgctaaaatg tccttgagtc ccagcagccc
     caggcacgag gatcagctcg
1981 aggtcaccag ggaaccggcc aggcggctct tcctttttgg
     agaggagcca tcaaaactcg
2041 atcaggatgt tttggccgct cttgaatgtg cagacgtcga
     cccccatcag ttcccggccg
2101 tgcacagatg gaagagtgct gtcctgtgct actcaccctc
     ggacagacag agttggccca
2161 gtcccgcggt gaaaggaagg ttcaagtctc agctgccaga
     tctcagtggc cctcacagct
2221 acagtccggg gagaaacagc gtggctggaa gcaaccccgc
     aaagccaggc ctgggcagtc
2281 ctgggcgcta cagccccgtg cacgggagcc agctccgcag
     gatggcgcgc ctggctgagc
2341 ttgccgccct gtaggcttgg cgctgggctc tcggtttgtt
     cttcattttt aaagaaggaa
2401 gggtcatatg tttattgcta aactgtcaaa aaggaatata
     ttctgattaa attattactc
2461 ctcactttga gggtgtgaga attttagaag atttaaatgt
     tctatataac acttagattt
2521 ctgatatttt ggaagaagtt agaagttaat gaaagcaaac
     tcagttacca attttctgga
2581 aaatatccat gtggtaatgt agacttttta ggtggcaatt
     tctaggtctg aaatatagca
2641 gaggaaaggg cgctgaggca gttgcaggca ggcagccctg
     tacttaccct gtactcacct
2701 catccgacag acgctgtgga tgaggagggg cttggcggag
     gcgtgagcac cgatgtccct
2761 ttgataacct gcactcacca agatgaacta tttgccgccc
     tgtcttttcc tgggttgggg
2821 ggtggcatct gatggtggca gagtgcctgt tggttcgccc
     gtgggtctca tggttcagac
2881 agagggaggt ggacggcagg gatcagggag ccaggagcgc
     gcctcagact tgcagcaacc
2941 attgtgattt gggttgttcg gaatatttaa attactgatc
     agaagatgaa agtagctttt
3001 ctcttgggaa gtcttgcagc ccgtgggagt gataccagga
     gcaacacaga gctcagcagc
3061 ggcgccaagg tgttccctgt ttcctcagca cgtgagcctt
     caccgcctgc ttcattcagg
3121 agccagtgca gcagtaatac agtctataca ttgttctgtt
     ttcaaattta tcctgaggct
3181 ttgttgagca taaatgatta tacgataaag gtatccgtta
     ttttggaact catttcagtt
3241 gggatctcct gtatgcagag tgttgcattt agaggtttga
     gtcccatctt ggtttcttgc
3301 cgtgctgact gtagccttca ccttgacttg aatgaaggtc
     tgtggttgga atgtgtgagg
3361 agccgctgag gtgttcagga ggtgctgcct ggaggtcggt
     ttcttcctgg gtgttacggg
3421 caactgctca cacagttgtt tctctgtgaa catttccagt
     gtttaatcca aaatgaaaac
3481 ccaccaatgc ttttgctaac ttcagtgcct tttataaatc
     atttttaaat ttcctgaact
3541 tgctttttga ggatatacag ggatattaag tagacgcagg
     attgtttttg tttgtaaaaa
3601 ttctgaattg aaactttgtt ttaaaaaaag gcttctttct
     ttcatatgac aagagatagg
3661 tcaggaatat tggaatcaag atttaaatgt taaaattcga
     ttttgttaca cagggtgtgt
3721 tcatttgttt tgtagcagac aagatctaga tcccagacag
     aaacaacaca tgctattcta
3781 aaaagccgca ttttaaaagg caccttggtt ctcaaaagaa
     atcagaatat ggatattcgt
3841 agtgatgatc tgttttctct aaaatcttac catattgtct
     gtatatggtt gtaaattcaa
3901 atggaaagta aaacgttttg gccctgattt tgtatgtgga
     ccactgctcc tgatttccca
3961 ggtcttaggc cacctttgac tgtttctccg tttgtttgtg
     ggcagcgatt ccagtcccaa
4021 cggaggcatt ctcgtgtgtc ccggggggtt atgtccttca
     caaaacactt aatgaaatga
4081 attacttc
(SEQ ID NO:182)
1    dfgysvglnp peeeavtskt csvppsdtdt yragataske
     pplyygvcpv yedvparner
61   iyvyenkkea lqavkmikgs rfkafstred aekfargicd
     yfpspsktsl plspvktapl
121  fsndrlkdgl clsesetvnk eransyknpr tqdltaklrk
     avekgeedtf sdliwsnpry
181  ligsgdnpti vqegcrynvm hvaakenqas icqitidvle
     npdfmrlmyp dddeamlqkr
241  iryvvdlyln tpdkmgydtp lhfackfgna dvvnvlsshh
     livknsrnky dktpedvice
301  rsknksvelk erireylkgh yyvpllraee tsspvigelw
     spdqtaeash vsryggsprd
361  pvltlrafag plspakaedf rklwktppre kagflhhvkk
     sdpergferv grelahelgy
421  pwveyweflg cfvdlssqeg lqrleeyltq qeigkkaqqe
     tgereascrd kattsgsnsi
481  svrafldedd msleeiknrq naarnnsppt vgafghtrcs
     afpleqeadl ieaaepggph
541  ssrnglchpl nhsrtlagkr pkaphgeeah lppvsdltve
     fdklnlqnig rsvsktpdes
601  tktkdqilts rinaverdll epspadqlgn ghrrtesems
     ariakmslsp ssprhedqle
661  vtreparrlf lfgeepskld qdvlaaleca dvdphqfpav
     hrwksavlcy spsdrqswps
721  pavkgrfksq lpdlsgphsy spgrnsvags npakpglgsp
     gryspvhgsq lrrmarlael
781  aal

Putative function

Unknown

Example 15 (Category 3)

Line ID—379

Category—Lethal phase pharate adult, Dot and rod-like overcondensed chromosomes, high mitotic index, overcondensed anaphases some with lagging chromosomes, a few tetraploid cells with overcondensed chromosomes, XYY males.

Annotated Drosophila genome genomic segment containing P element insertion site (and map position)—AE003443 (7D14-E2)

P element insertion site—130,532

Annotated Drosophila genome Complete Genome candidate—2 candidates:

CG10964—novel, similarity to dehydrogenases

(SEQ ID NO:183)
AACGAAACAGCCGGCCGTCAAAATTTTTCCTAACATTTCACTATTTTCAC
GCTTGTGTTACGGCAATAAAGTCGATTGATAAGCACGGAAAGATCTGGCT
GCGGGTCTGGTGAAATCCACAGAACACACGGAACCCGTATAGTAGTGCCG
CCCTTTATTGGTTTTATCTCAAGTACGACGCGATAAGATTTCGAGCAACT
CGATCGCGGATCTTCGGAAAAAAAAAACATGAACTCCATCCTGATAACCG
GCTGCAATCGAGGATTGGGTCTGGGCCTGGTCAAGGCGCTGCTCAATCTT
CCCCAGCCGCCGCAGCATCTATTTACCACCTGCCGGAATCGCGAGCAGGC
AAAGGAGCTGGAGGATCTAGCCAAGAACCACTCGAACATACACATACTTG
AGATTGATTTGAGAAATTTCGATGCCTATGACAAGCTAGTCGCCGACATC
GAGGGCGTGACCAAGGACCAAGGCCTCAATGTGCTCTTCAACAATGCCGG
CATAGCGCCCAAATCGGCCAGGATAACGGCCGTTCGATCGCAGGAGCTGC
TCGACACCTTGCAGACCAACACGGTTGTGCCCATCATGCTGGCCAAGGCG
TGTCTGCCGCTCCTTAAGAAGGCAGCCAAAGCGAACGAATCCCAGCCGAT
GGGCGTGGGCCGTGCCGCCATTATTAACATGTCCTCGATCCTTGGCTCCA
TCCAGGGCAACACGGACGGCGGAATGTACGCCTATCGCACCTCTAAGTCG
GCCTTGAATGCGGCCACCAAGTCGTTGAGCGTGGATCTGTATCCGCAACG
CATCATGTGCGTCAGTCTGCATCCTGGCTGGGTGAAAACCGACATGGGTG
GCTCCAGTGCCCCCTTGGACGTGCCCACCAGCACGGGACAAATTGTGCAG
ACCATCAGCAAGCTGGGCGAGAAACAGAACGGCGGTTTTGTCAACTACGA
CGGCACTCCGCTGGCCTGGTAA
(SEQ ID NO:184)
MNSILITGCNRGLGLGLVKALLNLPQPPQHLFTTCRNREQAKELEDLAKN
HSNIHILEIDLRNFDAYDKLVADIEGVTKDQGLNVLFNNAGIAPKSARIT
AVRSQELLDTLQTNTVVPIMLAKACLPLLKKAAKANESQPMGVGRAAIIN
MSSILGSIQGNTDGGMYAYRTSKSALNAATKSLSVDLYPQRIMCVSLHPG
WVKTDMGGSSAPLDVPTSTGQIVQTISKLGEKQNGGFVNYDGTPLAW
CG2151-Trxr-1 thoredoxin reductase-1 (2 splice
variants)
(SEQ ID NO:185)
CGACAAGCCAATCGACGTCTCCCTTTCGCACGCTCGTACGAAAGTACAAA
AGCTATTGCAAAAGTTGGCTCCGCTTATTCGTTTCGTGCTTTCGCGAGTG
CCGAGAGCCGCTACAATACACGCTTAGCAGTTTTTACATTTCCGCTTCGA
CTACAACAACATTCACTACCCGCCGTTGATCCTTGTTTTCTGTCTGATTT
ACGTGGAGCACCTACCAACAAGCAACAAAATAATGGCGCCCGTGCAAGGA
TCCTACGACTACGACCTTATTGTGATTGGAGGCGGCTCAGCTGGCCTGGC
CTGCGCCAAGGAGGCAGTCCTCAATGGAGCCCGTGTGGCCTGTCTGGATT
TCGTTAAGCCCACGCCCACTCTGGGCACCAAGTGGGGCGTTGGCGGCACC
TGCGTGAACGTGGGCTGCATTCCCAAGAAGCTGATGCACCAGGCCTCCCT
TCTGGGCGAGGCTGTCCATGAGGCGGCCGCCTACGGCTGGAACGTGGACG
AAAAGATCAAGCCAGACTGGCACAAGCTGGTGCAGTCCGTACAGAACCAC
ATCAAGTCCGTCAACTGGGTGACCCGTGTGGATCTGCGCGACAAGAAAGT
GGAGTACATCAATGGACTGGGCTCCTTCGTGGACTCGCACACACTGCTGG
CCAAGCTGAAGAGCGGCGAGCGCACAATCACCGCCCAGACCTTCGTCATT
GCCGTTGGCGGCCGACCACGTTATCCGGATATTCCCGGTGCTGTCGAGTA
TGGCATCACCAGCGATGATCTGTTCAGTTTGGACCGCGAGCCCGGCAAGA
CCCTGGTGGTGGGAGCTGGCTACATTGGCTTGGAGTGCGCTGGATTCCTG
AAGGGTCTCGGCTACGAGCCCACTGTGATGGTGCGTTCTATTGTGCTGCG
TGGCTTCGACCAGCAGATGGCCGAGCTGGTGGCAGCCTCGATGGAGGAGC
GTGGCATTCCCTTCCTCCGCAAGACGGTGCCGCTGTCCGTGGAAAAGCAG
GATGATGGCAAGCTGCTCGTGAAGTACAAGAACGTGGAGACCGGCGAGGA
GGCCGAGGATGTTTACGACACCGTTCTGTGGGCCATCGGCCGCAAGGGTC
TGGTGGACGATCTGAACCTGCCCAATGCCGGCGTGACTGTGCAGAAGGAC
AAGATTCCAGTGGACTCCCAGGAGGCTACCAATGTGGCAAACATCTACGC
TGTCGGCGATATCATCTATGGCAAGCCAGAGCTGACGCCCGTCGCCGTTT
TGGCTGGCCGTTTGCTGGCCCGCCGCCTGTACGGAGGATCTACCCAGCGC
ATGGACTACAAGGATGTGGCCACCACCGTTTTCACGCCCCTGGAGTACGC
CTGCGTCGGCCTGAGCGAGGAGGATGCCGTCAAGCAGTTCGGAGCCGATG
AGATCGAGGTGTTCCACGGCTACTACAAGCCCACGGAGTTCTTCATTCCC
CAGAAGAGCGTGCGCTACTGCTACTTGAAGGCTGTGGCCGAGCGCCATGG
TGACCAGCGCGTCTATGGACTGCACTATATTGGCCCGGTGGCCGGTGAGG
TTATCCAGGGATTCGCTGCCGCTTTGAAGTCTGGCCTGACTATTAACACG
CTGATCAACACCGTGGGCATCCATCCCACTACCGCCGAAGAATTCACCCG
GCTGGCCATCACCAAGCGCTCCGGACTGGACCCCACGCCGGCCAGCTGCT
GCAGCTAAAGCGGGAACGCAGCTCAGCCGCCTGGGACGTGTCGAAGCCGC
TTGCTCCACCCGAAATCCCGTAGATGAATGGTTGTTGTCGCGGCCCAGCG
ATCGATGAGTTCAATAGTTCCGTTTCGTTTCCACAATTAACACCCAACAC
AATAGCTCTGCGCAAGGGAGGGGCACTGGGCAGCGATGGCGGGTGGAACG
ACACCAGTGGAACTACCCGCGCGACCAGCCCAACCCACGACTGCTGCGCC
GCCGACATGCACTCAAAATTTTGAATTTGTTTGAACCTATGAAATTAACT
ATGAAATCCCCTAAATGTACGGTTGAAGAATATAATTTTTCACC
(SEQ ID NO:186)
MAPVQGSYDYDLIVIGGGSAGLACAKEAVLNGARVACLDFVKPTPTLGTK
WGVGGTCVNVGCIPKKLMHQASLLGEAVHEAAAYGWNVDEKIKPDWHKLV
QSVQNHIKSVNWVTRVDLRDKKVEYINGLGSFVDSHTLLAKLKSGERTIT
AQTFVIAVGGRPRYPDIPGAVEYGITSDDLFSLDREPGKTLVVGAGYIGL
ECAGFLKGLGYEPTVMVRSIVLRGFDQQMAELVAASMEERGIPFLRKTVP
LSVEKQDDGKLLVKYKNVETGEEAEDVYDTVLWAIGRKGLVDDLNLPNAG
VTVQKDKIPVDSQEATNVANIYAVGDIIYGKPELTPVAVLAGRLLARRLY
GGSTQRMDYKDVATTVFTPLEYACVGLSEEDAVKQFGADEIEVFHGYYKP
TEFFIPQKSVRYCYLKAVAERHGDQRVYGLHYIGPVAGEVIQGFAAALKS
GLTINTLINTVGIHPTTAEEFTRLAITKRSGLDPTPASCCS
(SEQ ID NO:187)
CCCGGCCGAACCAGCGAACGTGTTTGTGTTGTGTGTTCCGCCGTCATTTT
TCTGCACCCTTTTCGCGAATAGTTTCGTTTCGCCTCCAGCTGGTAGAGTG
AAACGCCAAACGTTGAAGAAGGGGAAAGGCCAACAAGATGAACTTGTGCA
ATTCGAGATTCTCCGTTACGTTCGTGCGGCAGTGCTCGACGATTTTAACG
TCTCCTTCGGCTGGCATTATACAAAACAGAGGCTCACTGACAACAAAGGT
TCCCCATTGGATTTCCAGTAGTCTCAGCTGTGCCCATCACACGTTTCAGC
GAACTATGAACTTGACGGGACAGCGAGGATCACGCGACAGTACTGGAGCT
ACCGGTGGGAATGCTCCAGCCGGATCCGGTGCCGGCGCACCACCACCCTT
CCAGCATCCACATTGCGACAGGGCGGCCATGTACGCGCAACCGGTGCGAA
AGATGAGCACCAAAGGAGGATCCTACGACTACGACCTTATTGTGATTGGA
GGCGGCTCAGCTGGCCTGGCCTGCGCCAAGGAGGCAGTCCTCAATGGAGC
CCGTGTGGCCTGTCTGGATTTCGTTAAGCCCACGCCCACTCTGGGCACCA
AGTGGGGCGTTGGCGGCACCTGCGTGAACGTGGGCTGCATTCCCAAGAAG
CTGATGCACCAGGCCTCCCTTCTGGGCGAGGCTGTCCATGAGGCGGCCGC
CTACGGCTGGAACGTGGACGAAAAGATCAAGCCAGACTGGCACAAGCTGG
TGCAGTCCGTACAGAACCACATCAAGTCCGTCAACTGGGTGACCCGTGTG
GATCTGCGCGACAAGAAAGTGGAGTACATCAATGGACTGGGCTCCYFCGT
GGACTCGCACACACTGCTGGCCAAGCTGAAGAGCGGCGAGCGCACAATCA
CCGCCCAGACCTTCGTCATTGCCGTTGGCGGCCGACCACGTTATCCGGAT
ATTCCCGGTGCTGTCGAGTATGGCATCACCAGCGATGATCTGTTCAGTTT
GGACCGCGAGCCCGGCAAGACCCTGGTGGTGGGAGCTGGCTACATTGGCT
TGGAGTGCGCTGGATTCCTGAAGGGTCTCGGCTACGAGCCCACTGTGATG
GTGCGTTCTATTGTGCTGCGTGGCTTCGACCAGCAGATGGCCGAGCTGGT
GGCAGCCTCGATGGAGGAGCGTGGCATTCCCTTCCTCCGCAAGACGGTGC
CGCTGTCCGTGGAAAAGCAGGATGATGGCAAGCTGCTCGTGAAGTACAAG
AACGTGGAGACCGGCGAGGAGGCCGAGGATGTTTACGACACCGTTCTGTG
GGCCATCGGCCGCAAGGGTCTGGTGGACGATCTGAACCTGCCCAATGCCG
GCGTGACTGTGCAGAAGGACAAGATTCCAGTGGACTCCCAGGAGGCTACC
AATGTGGCAAACATCTACGCTGTCGGCGATATCATCTATGGCAAGCCAGA
GCTGACGCCCGTCGCCGTTTTGGCTGGCCGTTTGCTGGCCCGCCGCCTGT
ACGGAGGATCTACCCAGCGCATGGACTACAAGGATGTGGCCACCACCGTT
TTCACGCCCCTGGAGTACGCCTGCGTCGGCCTGAGCGAGGAGGATGCCGT
CAAGCAGTTCGGAGCCGATGAGATCGAGGTGTTCCACGGCTACTACAAGC
CCACGGAGTTCTTCATTCCCCAGAAGAGCGTGCGCTACTGCTACTTGAAG
GCTGTGGCCGAGCGCCATGGTGACCAGCGCGTCTATGGACTGCACTATAT
TGGCCCGGTGGCCGGTGAGGTTATCCAGGGATTCGCTGCCGCTTTGAAGT
CTGGCCTGACTATTAACACGCTGATCAACACCGTGGGCATCCATCCCACT
ACCGCCGAAGAATTCACCCGGCTGGCCATCACCAAGCGCTCCGGACTGGA
CCCCACGCCGGCCAGCTGCTGCAGCTAAAGCGGGAACGCAGCTCAGCCGC
CTGGGACGTGTCGAAGCCGCTTGCTCCACCCGAAATCCCGTAGATGAATG
GTTGTTGTCGCGGCCCAGCGATCGATGAGTTCAATAGTTCCGTTTCGTTT
CCACAATTAACACCCAACACAATAGCTCTGCGCAAGGGAGGGGCACTGGG
CAGCGATGGCGGGTGGAACGACACCAGTGGAACTACCCGCGCGACCAGCC
CAACCCACGACTGCTGCGCCGCCGACATGCACTCAAAATTTTGAATTTGT
TTGAACCTATGAAATTAACTATGAAATCCCCTAAATGTACGGTTGAAGAA
TATAATTTTTCACC
(SEQ ID NO:188)
MSTKGGSYDYDLIVIGGGSAGLACAKEAVLNGARVACLDFVKPTPTLGTK
WGVGGTCVNVGCIPKKLMHQASLLGEAVHEAAAYGWNVDEKIKPDWHKLV
QSVQNHIKSVNWVTRVDLRDKKVEYINGLGSFVDSHTLLAKLKSGERTIT
AQTFVIAVGGRPRYPDIPGAVEYGITSDDLFSLDREPGKTLVVGAGYIGL
ECAGFLKGLGYEPTVMVRSIVLRGFDQQMAELVAASMEERGIPFLRKTVP
LSVEKQDDGKLLVKYKNVETGEEAEDVYDTVLWAIGRKGLVDDLNLPNAG
VTVQKDKIPVDSQEATNVANIYAVGDIIYGKPELTPVAVLAGRLLARRLY
GGSTQRMDYKDVATTVFTPLEYACVGLSEEDAVKQFGADEIEVFHGYYKP
TEFFIPQKSVRYCYLKAVAERHGDQRVYGLHYIGPVAGEVIQGFAAALKS
GLTINTLINTVGIHPTTAEEFTRLAITKRSGLDPTPASCCS

Human homologue of Complete Genome candidate

(CG10965)—AAC50725 11-cis retinol dehydrogenase

(SEQ ID NO: 189)
1    taagcttcgg gcgctgtagt acctgccagc tttcgccaca
     ggaggctgcc acctgtaggt
61   cacttgggct ccagctatgt ggctgcctct tctgctgggt
     gccttactct gggcagtgct
121  gtggttgctc agggaccggc agagcctgcc cgccagcaat
     gcctttgtct tcatcaccgg
181  ctgtgactca ggctttgggc gccttctggc actgcagctg
     gaccagagag gcttccgagt
241  cctggccagc tgcctgaccc cctccggggc cgaggacctg
     cagcgggtgg cctcctcccg
301  cctccacacc accctgttgg atatcactga tccccagagc
     gtccagcagg cagccaagtg
361  ggtggagatg cacgttaagg aagcagggct ttttggtctg
     gtgaataatg ctggtgtggc
421  tggtatcatc ggacccacac catggctgac ccgggacgat
     ttccagcggg tgctgaatgt
481  gaacacaatg ggtcccatcg gggtcaccct tgccctgctg
     cctctgctgc agcaagcccg
541  gggccgggtg atcaacatca ccagcgtcct gggtcgcctg
     gcagccaatg gtgggggcta
601  ctgtgtctcc aaatttggcc tggaggcctt ctctgacagc
     ctgaggcggg atgtagctca
661  ttttgggata cgagtctcca tcgtggagcc tggcttcttc
     cgaacccctg tgaccaacct
721  ggagagtctg gagaaaaccc tgcaggcctg ctgggcacgg
     ctgcctcctg ccacacaggc
781  ccactatggg ggggccttcc tcaccaagta cctgaaaatg
     caacagcgca tcatgaacct
841  gatctgtgac ccggacctaa ccaaggtgag ccgatgcctg
     gagcatgccc tgactgctcg
901  acacccccga acccgctaca gcccaggttg ggatgccaag
     ctgctctggc tgcctgcctc
961  ctacctgcca gccagcctgg tggatgctgt gctcacctgg
     gtccttccca agcctgccca
1021 agcagtctac tgaatccagc cttccagcaa gagattgttt
     ttcaaggaca aggactttga
1081 tttatttctg cccccaccct ggtactgcct ggtgcctgcc
     acaaaata
(SEQ ID NO:190)
1    mwlplllgal lwaviwllrd rqslpasnaf vfitgcdsgf
     grllalqldq rgfrvlascl
61   tpsgaedlqr vassrlhttl lditdpqsvq qaakwvemhv
     keaglfglvn nagvagiigp
121  tpwltrddfq rvlnvntmgp igvtlallpl lqqargrvin
     itsvlgrlaa ngggycvskf
181  gleafsdslr rdvahfgirv sivepgffrt pvtnleslek
     tlqacwarlp patqahygga
241  fltkylkmqq rimnlicdpd ltkvsrcleh altarhprtr
     yspgwdakll wlpasylpas
301  lvdavltwvl pkpaqavy
(CG2151)-XP_033135 thioredoxin reductase beta
(SEQ ID NO:191)
1    ccggacctca ggcccagttc agtgtacttc ccctctctac
     ttcctccctc cagtcccttc
61   tccatccctc ccttttttgg ctgccccttg cctgccttcc
     tcgccagtag cttgcagagt
121  agacacgatg acaccttttg caggctaaaa aggctgagag
     tggcactatg tgcagtgagc
181  caccatggag gaccaagcag gtcagcggga ctatgatctc
     ctggtggtcg gcgggggatc
241  tggtggcctg gcttgtgcca aggaggccgc ccagctggga
     aggaaggtgg ccgtggtgga
301  ctacgtggaa ccttctcccc aaggcacccg gtggggcctc
     ggcggcacct gcgtcaacgt
361  gggctgcatc cccaagaagc tgatgcacca ggcggcactg
     ctgggaggcc tgatccaaga
421  tgcccccaac tatggctggg aggtggccca gcccgtgccg
     catgactgga ggaagatggc
481  agaagctgtt caaaatcacg tgaaatcctt gaactggggc
     caccgtgtcc agcttcagga
541  cagaaaagtc aagtacttta acatcaaagc cagctttgtt
     gacgagcaca cggtttgcgg
601  cgttgccaaa ggtgggaaag agattctgct gtcagccgat
     cacatcatca ttgctactgg
661  agggcggccg agatacccca cgcacatcga aggtgccttg
     gaatatggaa tcacaagtga
721  tgacatcttc tggctgaagg aatcccctgg aaaaacgttg
     gtggtcgggg ccagctatgt
781  ggccctggag tgtgctggct tcctcaccgg gattgggctg
     gacaccacca tcatgatgcg
841  cagcatcccc ctccgcggct tcgaccagca aatgtcctcc
     atggtcatag agcacatggc
901  atctcatggc acccggttcc tgaggggctg tgccccctcg
     cgggtcagga ggctccctga
961  tggccagctg caggtcacct gggaggacag caccaccggc
     aaggaggaca cgggcacctt
1021 tgacaccgtc ctgtgggcca taggtcgagt cccagacacc
     agaagtctga atttggagaa
1081 ggctggggta gatactagcc ccgacactca gaagatcctg
     gtggactccc gggaagccac
1141 ctctgtgccc cacatctacg ccattggtga cgtggtggag
     gggcggcctg agctgacacc
1201 catagcgatc atggccggga ggctcctggt gcagcggctc
     ttcggcgggt cctcagatct
1261 gatggactac gacaatgttc ccacgaccgt cttcaccccg
     ctggagtatg gctgtgtggg
1321 gctgtccgag gaggaggcag tggctcgcca cgggcaggag
     catgttgagg tctatcacgc
1381 ccattataaa ccactggagt tcacggtggc tggacgagat
     gcatcccagt gttatgtaaa
1441 gatggtgtgc ctgagggagc ccccacagct ggtgctgggc
     ctgcatttcc ttggccccaa
1501 cgcaggcgaa gttactcaag gatttgctct ggggatcaag
     tgtggggctt cctatgcgca
1561 ggtgatgcgg accgtgggta tccatcccac atgctctgag
     gaggtagtca agctgcgcat
1621 ctccaagcgc tcaggcctgg accccacggt gacaggctgc
     tgagggtaag cgccatccct
1681 gcaggccagg gcacacggtg cgcccgccgc cagctcctcg
     gaggccagac ccaggatggc
1741 tgcaggccag gtttgggggg cctcaaccct ctcctggagc
     gcctgtgaga tggtcagcgt
1801 ggagcgcaag tgctggacag gtggcccgtg tgccccacag
     ggatggctca ggggactgtc
1861 cacctcaccc ctgcacctct cagcctctgc cgccgggcac
     ccccccccag gctcctggtg
1921 ccagatgatg acgacctggg tggaaaccta ccctgtgggc
     acccatgtcc gagccccctg
1981 gcatttctgc aatgcaaata aagagggtac tttttctgaa
     gtgtg
(SEQ ID NO:192)
1    medqagqrdy dllvvgggsg glacakeaaq lgrkvavvdy
     vepspqgtrw glggtcvnvg
61   cipkklmhqa allggliqda pnygwevaqp vphdwrkmae
     avqnhvksln wghrvqlqdr
121  kvkyfnikas fvdehtvcgv akggkeills adhiiiatgg
     rprypthieg aleygitsdd
181  ifwlkespgk tlvvgasyva lecagfltgi gldttimmrs
     iplrgfdqqm ssmviehmas
241  hgtrflrgca psrvrrlpdg qlqvtwedst tgkedtgtfd
     tvlwaigrvp dtrslnleka
301  gvdtspdtqk ilvdsreats vphiyaigdv vegrpeltpi
     aimagrllvq rlfggssdlm
361  dydnvpttvf tpleygcvgl seeeavarhg qehvevyhah
     ykpleftvag rdasqcyvkm
421  vclreppqlv lglhflgpna gevtqgfalg ikcgasyaqv
     mrtvgihptc seevvklris
481  krsgldptvt gcxg

Putative function

(CG 10964)—unknown, similarity to dehydrogenases

(CG2151)—thioredoxin reductase

Example 16 (Category 3)

Line ID—418

Phenotype—Lethal phase embryonic larval phase3-pre-pupal-pupal. High mitotic index, dot-like chromosomes, strong metaphase arrest

Annotated Drosophila genome genomic segment containing P element insertion site (and map position)—AE003431 (4C 1-16)

P element insertion site—289,752

Annotated Drosophila genome Complete Genome candidate

CG3000—rap, fizzy related

(SEQ ID NO:193)
CTTTGGCTTGTTTGCTTGAAAAAACGTAACTTTTTTTGTTGTAATGAAGG
AAGCAGCACGGGCAGTAGACCAACTCGAAATCGCGCATTGCCAACACGTA
ACGTACCAGCCCGTGTAATAACAGAAGAAACCCCGAGCCGCAACAACAAC
CCCCGAAAAGCGGTAGTTGTAAGAGTTTTCCCAAAGTGGCAGCGGCAATT
ACACGGCGAGAAACGAGTTCGCGTCGCGTCCAGCTGTTTGAAAATCAAAA
TTAACCGTTTTTAGCGCGTGAAACAAGACGTTTAGAACCGTGTTCAAAAT
CCCTCGTACATAAATTGTGTGTACATTTATATATATATATATTTTCTACG
CCACGTTAACCAGACTTTTTAAGTTTTAAATTAAAACTAAAGACGTATTA
TTTTTTTTTTTTTGAGTGTTTATATTTTTTTTTTTGCAAGTTTTGTTTGG
TTACATTTGAGTTTGTGTTGAGTTTTTGCCAGCCAAAGGCGCTTAAGATG
TTTAGTCCCGAGTACGAGAAGCGCATCCTGAAGCACTACAGTCCTGTGGC
ACGGAATCTGTTCAACAACTTCGAGTCGTCCACTACGCCCACATCTCTCG
ACCGCTTCATACCCTGCAGAGCGTACAACAACTGGCAGACGAACTTTGCG
TCAATCAACAAGTCCAATGACAACTCGCCGCAGACGAGTAAGAAGCAGCG
GGACTGCGGGGAAACGGCACGCGATAGTCTCGCCTACTCCTGCCTACTGA
AGAACGAGCTCCTCGGATCGGCAATCGACGACGTGAAGACCGCCGGCGAG
GAGCGGAATGAGAATGCCTACACGCCGGCCGCAAAGCGGAGTCTCTTCAA
GTACCAGTCACCCACCAAGCAGGACTACAATGGCGAGTGTCCGTACTCGT
TGTCACCCGTCAGCGCCAAAAGTCAGAAGCTGTTGCGATCGCCGCGCAAG
GCTACGCGCAAAATCTCTCGCATTCCCTTCAAGGTGCTAGACGCGCCCGA
GTTGCAGGACGACTTCTATCTGAACCTGGTCGACTGGTCGTCGCAGAACG
TACTGGCTGTAGGCCTGGGCAGCTGTGTCTATCTGTGGAGCGCGTGCACC
AGTCAGGTTACCCGCCTGTGTGATCTCAGTCCGGATGCGAATACGGTGAC
CTCGGTGTCGTGGAACGAGCGTGGCAACACCGTGGCCGTGGGCACACATC
ACGGCTACGTGACCGTCTGGGATGTGGCGGCCAATAAGCAGATCAACAAA
CTGAATGGCCATTCGGCGCGTGTGGGCGCCTTGGCATGGAACAGTGACAT
CCTGTCGAGCGGGTCGCGAGACCGTTGGATCATACAGCGGGATACGAGAA
CGCCGCAACTGCAATCGGAGCGCAGATTGGCCGGACATCGGCAGGAGGTG
TGCGGACTGAAATGGTCACCGGATAATCAATACTTGGCCAGTGGCGGCAA
CGATAATCGGTTGTATGTGTGGAATCAGCAITCCGTGAATCCCGTACAAT
CATACACGGAGCATATGGCGGCTGTAAAGGCGATCGCGTGGTCGCCGCAT
CACCACGGACTCCTGGCCAGCGGCGGTGGAACGGCGGATAGGTGTATCCG
TTTCTGGAATACGCTGACGGGCCAGCCCATGCAGTGCGTGGACACGGGCT
CGCAGGTTTGCAATCTGGCCTGGTCCAAGCACTCCTCGGAGCTGGTCTCC
ACGCACGGCTACTCGCAGAACCAGATACTCGTGTGGAAATATCCCTCCCT
GACGCAAGTGGCCAAGCTGACGGGCCATTCGTATCGTGTGCTCTATCTGG
CGCTGAGTCCCGATGGTGAGGCTATTGTTACGGGCGCCGGCGACGAGACG
CTGCGATTTTGGAACGTATTCAGCAAGGCGCGCAGTCAGAAGGAGAACAA
GTCCGTTCTGAATCTGTTTGCCAATATCAGATAAGGACAATAACTCCAAG
CGAGCGAAGACTGAGCGAGCGCCAAAGGCAAACACAACACAACACAAAAC
AAAACAAAACAAAGCAAAGTATAATATAAATAAAATGGATACTTGAAACC
GAAAAACAAAGCCAACCAACCAATCAGCAAAAACCAAGCTGAAGCTAACA
AACTAATCGAGCCTATATGCTATATATATACAAACGATTCTTGTTCAGCA
GTCGTTTTGTAAATTGTTGTGTGACCCCACAGCAGCAATAGATTAAATAA
ATTTAAGTTAAGCAATCTGTATAGAACGGTAATTAGCAACATTTACGTAG
GTAAACACATGCAATTTATGAAGGAATAACATCAAGAGAGATGGCTGAAA
CAAGAACTGAAAATGAAACTAAGTCTATGGAAATTGTAAGTAATTGGAAA
ATCAACAACACCACACTCACACACTATCTTTAATCGACATTTTTTGTTGC
TGCTTTTTTAAATGTATTGTTTTTTTTTTGTGGTACACCTACACTACACC
TAAGAAAATTGGATACCCCTACATATACATTTATACGTTTATATATATAT
ATTTTTTTGCTAGCCTCTAAGTAACTAACTTTATTTCAAGCAAACATTTA
TACACATATTTCGCTCACTAGAAACACTCATACCCCCGAAAACACAATGT
ATATTAAATAAACTTATACAATTTCAAAATGTGCCCCAAAAAGTA
(SEQ ID NO:194)
MFSPEYEKRILKHYSPVARNLFNNFESSTTPTSLDRFIPCRAYNNWQTNF
ASINKSNDNSPQTSKKQRDCGETARDSLAYSCLLKNELLGSAIDDVKTAG
EERNENAYTPAAKRSLFKYQSPTKQDYNGECPYSLSPVSAKSQKLLRSPR
KATRKISRIPFKVLDAPELQDDFYLNLVDWSSQNVLAVGLGSCVYLWSAC
TSQVTRLCDLSPDANTVTSVSWNERGNTVAVGTHHGYVTVWDVAANKQIN
KLNGHSARVGALAWNSDILSSGSRDRWIIQRDTRTPQLQSERRLAGHRQE
VCGLKWSPDNQYLASGGNDNRLYVWNQHSVNPVQSYTEHMAAVKAIAWSP
HHHGLLASGGGTADRCIRFWNTLTGQPMQCVDTGSQVCNLAWSKHSSELV
STHGYSQNQILVWKYPSLTQVAKLTGHSYRVLYLALSPDGEAIVTGAGDE
TLRFWNVFSKARSQKENKSVLNLFANIR

Human homologue of Complete Genome candidate

XP_—009259 Fzr1 protein

(SEQ ID NO:195)
1    ggccgcggcc gggcctgcgg gagctgcgga ggccggaggc
     gggcgctgtg cggtgccagg
61   agaggcgggg tcggcgggag ccagcgagcc acgggagcga
     gccaggctaa ccttgccgcg
121  ggccgagccc tgcctcgcca tggaccagga ctatgagcgg
     cgcctgcttc gccagatcgt
181  catccagaat gagaacacga tgccacgcgt cacagagatg
     cggcggaccc tgacgcctgc
241  cagctcccca gtgtcctcgc ccagcaagca cggagaccgc
     ttcatcccct ccagagccgg
301  agccaactgg agcgtgaact tccacaggat taacgagaat
     gagaagtctc ccagtcagaa
361  ccggaaagcc aaggacgcca cctcagacaa cggcaaagac
     ggcctggcct actctgccct
421  gctcaagaat gagctgctgg gtgccggcat cgagaaggtg
     caggacccgc agactgagga
481  ccgcaggctg cagccctcca cgcctgagaa gaagggtctg
     ttcacgtatt cccttagcac
541  caagcgctcc agccccgatg acggcaacga tgtgtctccc
     tactccctgt ctcccgtcag
601  caacaagagc cagaagctgc tccggtcccc ccggaaaccc
     acccgcaaga tctccaagat
661  ccccttcaag gtgctggacg cgcccgagct gcaggacgac
     ttctacctca atctggtgga
721  ctggtcgtcc ctcaatgtgc tcagcgtggg gctaggcacc
     tgcgtgtacc tgtggagtgc
781  ctgtaccagc caggtgacgc ggctctgtga cctctcagtg
     gaaggggact cagtgacctc
841  cgtgggctgg tctgagcggg ggaacctggt ggcggtgggc
     acacacaagg gcttcgtgca
901  gatctgggac gcagccgcag ggaagaagct gtccatgttg
     gagggccaca cggcacgcgt
961  cggggcgctg gcctggaatg ctgagcagct gtcgtccggg
     agccgcgacc gcatgatcct
1021 gcagagggac atccgcaccc cgccactgca gtcggagcgg
     cggctgcagg gccaccggca
1081 ggaggtgtgc gggctcaagt ggtccacaga ccaccagctc
     ctcgcctcgg ggggcaacga
1141 caacaagctg ctggtctgga atcactcgag cctgagcccc
     gtgcagcagt acacggagca
1201 cctggcggcc gtgaaggcca tcgcctggtc cccacatcag
     cacgggctgc tggcctcggg
1261 gggcggcaca gctgaccgct gtatccgctt ctggaacacg
     ctgacaggac aaccactgca
1321 gtgtatcgac acgggctccc aagtgtgcaa tctggcctgg
     tccaagcacg ccaacgagct
1381 ggtgagcacg cacggctact cacagaacca gatccttgtc
     tggaagtacc cctccctgac
1441 ccaggtggcc aagctgaccg ggcactccta ccgcgtgctg
     tacctggcaa tgtcccctga
1501 tggggaggcc atcgtcactg gtgctggaga cgagaccctg
     aggttctgga acgtctttag
1561 caaaacccgt tcgacaaagg agtctgtgtc tgtgctcaac
     ctcttcacca ggatccggta
1621 aacctgccgg gcaggaccgt gccacaccag ctgtccagag
     tcggaggacc ccagctcctc
1681 agcttgcatg gactctgcct tcccagcgct tgtcccccga
     ggaaggcggc tgggcgggcg
1741 gggagctggg cctggaggat cctggagtct cattaaatgc
     ctgattgtga accatgtcca
1801 ccagtatctg gggtgggcac gtggtcgggg accctcagca
     gcaggggctc tgtctccctt
1861 cccaaagggc gagaaccaca ttggacggtc ccggctcaga
     ccgtctgtac tcagagcgac
1921 ggatgccccc tgggaccctc actgcctccg tctgttcatc
     acctgcccac cggagccgca
1981 tgctcttcct ggaactgccc acgtctgcac agaacagacc
     accagacgcc agggctgatt
2041 ggtgggggcc tgagaccccg gttgcccatt catggctgca
     ccccaccatg tcaaacccaa
2101 gaccagcccc aaggccagac caaggcatgt aggcctgggc
     aggtggctcg gggccactgg
2161 cggagccagc ctgtggatcc aagagacagt ccccacctgg
     gcttcacggc atccttgcag
2221 ccacctctgc tgtcactgct cgaagcagca gtctctctgg
     aagcatctgt gtcatggcca
2281 tcgcccggcg gtcagtgggc ttcagatggg cctgtgcatc
     ctggccaagc gtcaccctca
2341 cactggagga ggatgtctgc tctggactta tcaccccagg
     agaactgaac ccggacctgc
2401 tcactgccct ggctggagag gagcacaaca gatgccacgt
     cttcgtgcat tcgccaacac
2461 gtgccctcac agggccagcg tcctccttcc ctgcgcaaga
     cttgcgtccc ccatgcctgc
2521 tgggtggctg ggtcctgtgg aggccagcag cggtgtggcc
     cccgccccca ggctgcctgt
2581 gtcttcacct gtcctgtcca ccagcgccaa cagccgtggg
     gaagccaagg agacccaagg
2641 ggtccaggag gtgggcgccc tccatccttc gagaagcttc
     ccaggctcct ctgcttctct
2701 gtctcatgct cccaggctgc acagcaggca gggagggagg
     caaggcaggg gagtggggcc
2761 tgagctgagc actgccccct caccccccca ccaccccttc
     ccatttcatc ggtggggacg
2821 tggagagggt ggggcgggct ggggttggag ggtcccaccc
     accaccctgc tgtgcttggg
2881 aacccccact ccccactccc cacatcccaa catcctggtg
     tctgtcccca gtggggttgg
2941 cgtgcatgtg tacatatgta tttgtgactt ttctttgg
(SEQ ID NO:196)
1    mdqdyerrll rqiviqnent mprvtemrrt ltpasspvss
     pskhgdrfip sraganwsvn
61   fhrineneks psqnrkakda tsdngkdgla ysallknell
     gagiekvqdp qtedrrlqps
121  tpekkglfty slstkrsspd dgndvspysl spvsnksqkl
     lrsprkptrk iskiptkvld
181  apelqddfyl nlvdwsslnv lsvglgtcvy lwsactsqvt
     rlcdlsvegd svtsvgwser
241  gnlvavgthk gfvqiwdaaa gkklsmlegh tarvgalawn
     aeqlssgsrd rmilqrdirt
301  pplqserrlq ghrqevcglk wstdhqllas ggndnkllvw
     nhsslspvqq ytehlaavka
361  iawsphqhgl lasgggtadr cirfwntltg qplqcidtgs
     qvcnlawskh anelvsthgy
421  sqnqilvwky psltqvaklt ghsyrvlyla mspdgeaivt
     gagdetlrfw nvfsktrstk
481  esvsvlnlft rir

Putative function

Cell cycle regulator involved in cyclin degradation

Example 17 (Category 3)

Line ID—121

Phenotype—Lethal phase larval phase 3-prepupal-pupal-pharate adult-adult. High mitotic index, dot and rod-like overcondensed chromosomes, high frequency of polyploids

Annotated Drosophila genome genomic segment containing P element insertion site (and map position)—AE003493 (12B7)

P element insertion site—not determined

Annotated Drosophila genome Complete Genome candidate

CG10988—1(1)dd4 gamma tubulin ring complex

(SEQ ID NO:197)
TAACACTGCACTAAATAATTTTAATAAATTATTTGTATGAAGTACGCGCC
AATTGGATGCGTTTTTGTCCTATCTGTCGAAGATTTCACGCATCCCGAAC
AATTGCCAGTGACTGCACGCCGTATTATAGCCAGGGAACAGCTGTGCGTT
TGCCATTGGCCAACAGTTGTTGTCCACTTCGCAATTACCAAGCCATCCAA
AATCGGCTGTTTAACGCGCGCTTGATTGGATATTTATGAACAATTCAGTG
CACCAGGATGTCGCAGGACAGGATCGCCGGCATCGATGTGGCAACCAATT
CCACTGATATATCGAATATCATTAACGAGATGATCATCTGCATCAAGGGC
AAGCAGATGCCCGAAGTTCACGAAAAAGCAATGGATCATTTAAGCAAAAT
GATTGCCGCCAATAGTCGGGTCATTCGGGACTCAAATATGTTGACTGAGC
GCGAATGTGTCCAGAAGATAATGAAACTGCTGAGCGCCCGGAATAAGAAG
GAGGAGGGCAAAACTGTGTCGGATCACTTCAATGAGCTGTACAGGAAACT
CACGTTGACCAAGTGCGATCCGCACATGAGGCACTCGCTAATGACCCATC
TACTTACGATGACCGACAATTCGGATGCCGAAAAGGCAGTTGCCAGCGAA
GATCCACGTACTCAGTGCGATAATCTCACTCAGATTCTGGTCAGTCGTCT
TAACTCAATAAGTTCCTCCATAGCCAGTCTGAATGAGATGGGAGTGGTCA
ACGGAAATGGAGTAGGAGCAGCAGCGGTAACAGGAGCAGCAGCGGTAACA
GGAGCAGCAGCGGTAACAGGAGCAGCAGCGGTAACAGGAGCAGCAGCAAG
CCACAGTTATGATGCCACACAGTCCAGCATCGGATTGAGAAAACAGTCCT
TGCCCAACTACCTGGATGCAACAAAGATGTTGCCCGAGTCTCGACATGAT
ATAGTGATGAGTGCCATTTACTCCTTCACCGGCGTTCAAGGGAAGTATTT
GAAGAAGGATGTGGTAACGGGCCGTTTCAAGCTGGATCAGCAGAACATCA
AGTTCCTGACCACCGGCCAAGCGGGCATGTTGCTGCGGCTCTCCGAACTT
GGCTACTACCACGATCGAGTGGTCAAGTTTTCGGATGTATCGACCGGTTT
CAATGCCATTGGCAGCATGGGCCAGGCCCTGATTTCCAAACTCAAGGAGG
AGCTGGCGAATTTTCACGGGCAAGTGGCAATGCTTCACGATGAAATGCAG
CGTTTTCGGCAGGCCTCGGTGAATGGAATTGCAAACAAGGGGAAAAAGGA
TAGTGGGCCCGATGCTGGCGATGAAATGACGCTATTCAAGCTGCTCGCCT
GGTATATAAAGCCACTGCACCGGATGCAGTGGTTAACCAAGATTGCCGAC
GCCTGCCAGGTAAAGAAGGGCGGTGATTTGGCATCGACCGTTTATGATTT
CCTTGACAACGGTAACGATATGGTCAATAAATTGGTGGAGGATCTCCTAA
CTGCCATTTGTGGCCCACTGGTGCGCATGATCTCCAAATGGATTCTGGAG
GGCGGCATTAGCGATATGCATAGAGAGTTCTTTGTGAAGTCCATTAAAGA
TGTGGGCGTTGATCGGCTATGGCACGATAAATTCCGCCTACGATTGCCAA
TGCTGCCCAAGTTTGTGCCCATGGATATGGCCAATAAGATACTCATGACG
GGCAAATCCATTAATTTTCTAAGAGAAATCTGCGAGGAGCAGGGTATGAT
GAAGGAGCGCGACGAACTAATGAAGGTCATGGAATCTAGTGCCTCTCAAA
TCTTTTCGTACACACCGGACACCAGTTGGCATGCGGCCGTGGAAACGTGC
TACCAGCAGACCTCCAAACATGTCCTCGACATTATGGTGGGCCCACACAA
GCTGCTGGATCATTTGCACGGAATGCGGCGCTACTTGCTGTTGGGCCAGG
GCGATTTTATTAGCATTCTGATTGAAAACATGAAGAACGAACTGGAGCGA
CCGGGCCTTGATATATATGCTAACGATCTCACCTCCATGTTGGATTCCGC
TCTGCGCTGTACGAATGCCCAGTACGATGATCCTGATATTCTAAACCATC
TCGATGTGATTGTTCAACGACCGTTCAACGGTGATATTGGCTGGAACATC
ATCTCGCTGCAGTACATTGTCCACGGACCACTGGCCGCCATGCTGGAGTC
GACCATGCCAACGTACAAGGTGCTCTTCAAGCCACTCTGGCGCATGAAGC
ACATGGAGTTTGTGCTCTCGATGAAGATCTGGAAGGAGCAGATGGGCAAC
GCAAAGGCCCTTCGTACAATGAAGTCCGAAATCGGCAAGGCGTCACACCG
CCTCAACCTTTTCACTTCCGAGATCATGCACTTTATCCACCAAATGCAGT
ACTATGTGCTATTTGAGGTCATCGAGTGCAACTGGGTGGAGCTACAGAAG
AAGATGCAGAAGGCTACTACGTTGGACGAAATCCTGGAAGCTCACGAGAA
GTTTCTGCAAACGATTTTGGTGGGCTGTTTTGTCAGCAACAAAGCGAGTG
TGGAGCATTCGCTGGAGGTGGTGTACGAGAACATTATCGAATTGGAGAAG
TGGCAGTCGAGCTTTTACAAGGACTGCTTTAAGGAGCTAAATGCCCGCAA
GGAACTGTCCAAAATTGTGGAGAAATCGGAAAAGAAGGGTGTCTACGGAC
TGACCAACAAGATGATCCTGCAGCGCGACCAGGAGGCGAAGATATTTGCC
GAAAAGATGGACATCGCCTGCCGCGGCTTAGAAGTCATAGCAACCGATTA
CGAAAAGGCTGTCAGCACTTTCCTAATGTCTCTCAACTCTAGCGACGATC
CGAATTTGCAGCTCTTTGGCACTCGGCTGGACTTCAACGAGTACTACAAG
AAGAGGGACACCAATTTGAGCAAACCCCTGACCTTCGAGCACATGCGCAT
GAGCAATGTGTTCGCCGTGAACAGTCGCTTCGTGATATGTACGCCGTCCA
CTCAGGAATAGCGACCAATGTCCATGCAATCGGTTTATCCCAGTGTCCAT
ACATCATACCAAATCCCAAATCCCATACAGCATCAGCACTCCATTCAGTT
CAATTGCTGCTAAATATTTGAGATATCTCGATATCATTGGAGCCAATCCA
ACCAAACAAACTAATCCAATTATTAACTAAGCCTTCGAATCGAAAACAAC
CTCTATACATATATATCTCAAGCTTTGCCGTCAATCGCCTGGCTGCAAGC
CATCAACTTAAGATATCTCCAATACAAAATTATTGAGTAGTTGTAACGAA
AGTATTAAGCGACAATTTGTTTGTCGAAAAACGCAACGTTCTATTTTGTT
TGCGAATCCCATAATTTTTTTTACATCGAAGCTTAGTTGAAATAGATTTT
CGTAAGTGCATTTGCCAATTGCCATGTTGTAATTAAAGAGAATAAGAGAA
TGTTACGTACTTTAAAAGAATGTTTTAAAAAAGTTAATGTTTTGAACAGT
TTTAAACCGTAATGCGAG
(SEQ ID NO:198)
MSQDRIAGIDVATNSTDISNIINEMIICIKGKQMPEVHEKAMDHLSKMIA
ANSRVIRDSNMLTERECVQKIMKLLSARNKKEEGKTVSDHFNELYRKLTL
TKCDPHMRHSLMTHLLTMTDNSDAEKAVASEDPRTQCDNLTQILVSRLNS
ISSSIASLNEMGVVNGNGVGAAAVTGAAAVTGAAAVTGAAAVTGAAASHS
YDATQSSIGLRKQSLPNYLDATKMLPESRHDIVMSAIYSFTGVQGKYLKK
DVVTGRFKLDQQNIKFLTTGQAGMLLRLSELGYYHDRVVKFSDVSTGFNA
IGSMGQALISKLKEELANFHGQVAMLHDEMQRFRQASVNGIANKGKKDSG
PDAGDEMTLFKLLAWYIKPLHRMQWLTKIADACQVKKGGDLASTVYDFLD
NGNDMVNKLVEDLLTAICGPLVRMISKWILEGGISDMHREFFVKSIKDVG
VDRLWHDKFRLRLPMLPKFVPMDMANKILMTGKSINFLREICEEQGMMKE
RDELMKVMESSASQIFSYTPDTSWHAAVETCYQQTSKHVLDIMVGPHKLL
DHLHGMRRYLLLGQGDFISILIENMKNELERPGLDIYANDLTSMLDSALR
CTNAQYDDPDILNHLDVIVQRPFNGDIGWNIISLQYIVHGPLAAMLESTM
PTYKVLFKPLWRMKHMEFVLSMKIWKEQMGNAKALRTMKSEIGKASHRLN
LFTSEIMHFIHQMQYYVLFEVIECNWVELQKKMQKATTLDEILEAHEKFL
QTILVGCFVSNKASVEHSLEVVYENIIELEKWQSSFYKDCFKELNARKEL
SKIVEKSEKKGVYGLTNKMILQRDQEAKIFAEKMDIACRGLEVIATDYEK
AVSTFLMSLNSSDDPNLQLFGTRLDFNEYYKKRDTNLSKPLTFEHMRMSN
VFAVNSRFVICTPSTQE

Human homologue of Complete Genome candidate

AAC39727—spindle pole body protein spc98 homolog GCP3

(SEQ ID NO:199)
1    caggaagggc gcgggccgcg gtccctgcgc gtgcggcggc agtggcggct ctgcccggac
61   caccgtgcac ggctccgggc gaggatggcg accccggacc agaagtcgcc gaacgttctg
121  ctgcagaacc tgtgctgcag gatcctgggc aggagcgaag ctgatgtagc ccagcagttc
181  cagtatgctg tgcgggtgat tggcagcaac ttcgccccaa ctgttgaaag agatgaattt
241  ttagtagctg aaaaaatcaa gaaagagctt attcgacaac gaagagaagc agatgctgca
301  ttattttcag aactccacag aaaacttcat tcacagggag ttttgaaaaa taaatggtca
361  atactctacc tcttgctgag cctcagtgag gacccacgca ggcagccaag caaggtttct
421  agctatgcta cgttatttgc tcaggcctta ccaagagatg cccactcaac cccttactac
481  tatgccaggc ctcagaccct tcccctgagc taccaagatc ggagtgccca gtcagcccag
541  agctccggca gcgtgggcag cagtggcatc agcagcattg gcctgtgtgc cctcagtggc
601  cccgcgcctg cgccacaatc tctcctccca ggacagtcta atcaagctcc aggagtagga
661  gattgccttc gacagcagtt ggggtcacga ctcgcatgga ctttaactgc aaatcagcct
721  tcttcacaag ccactacctc aaaaggtgtc cccagtgctg tgtctcgcaa catgacaagg
781  tccaggagag aaggggatac gggtggtact atggaaatta cagaagcagc tctggtaagg
841  gacattttgt acgtctttca gggcatagat ggcaaaaaca tcaaaatgaa caacactgaa
901  aattgttaca aagtagaagg aaaggcaaat ctaagtaggt ctttgagaga cacagcagtc
961  aggctttctg agttgggatg gttgcataat aaaatcagaa gatacacgga ccagaggagc
1021 ctggaccgct cattcggact cgtcgggcag agcttttgtg ctgccttgca ccaggaactc
1081 agagaatact atcgattgct ctctgtttta cattctcagc tacaactaga ggatgaccag
1141 ggtgtgaatt tgggacttga gagtagttta acacttcggc gcctcctggt ttggacctat
1201 gatcccaaaa tacgactgaa gacccttgcg gccctagtgg accactgcca aggaaggaaa
1261 ggaggtgagc tggcctcagc tgtccacgcc tacacaaaaa caggagaccc gtacatgcgg
1321 tctctggtgc agcacatcct cagcctcgtg tctcatcctg ttttgagctt cctgtaccgc
1381 tggatatatg atggggagct tgaggacact taccacgaat tttttgtagc atcagatcca
1441 acagttaaaa cagatcgact gtggcacgac aagtatactt tgaggaaatc gatgattcct
1501 tcgtttatga cgatggatca gtctaggaag gtccttttga taggaaaatc aataaatttc
1561 ttgcaccaag tttgtcatga tcagactccc actacaaaga tgatagctgt gaccaagtct
1621 gcagagtcac cccaggacgc tgcagaccta ttcacagact tggaaaatgc atttcagggg
1681 aagattgatg ctgcttattt tgagaccagc aaatacctgt tggatgttct caataaaaag
1741 tacagcttgc tggaccacat gcaggcaatg aggcggtacc tgcttcttgg tcaaggagac
1801 tttataaggc acttaatgga cttgctaaaa ccagaacttg tccgtccagc tacgactttg
1861 tatcagcata acttgactgg aattctagaa accgctgtca gagccaccaa cgcacagttt
1921 gacagtcctg agatcctgcg aaggctggac gtgcggctgc tggaggtctc tccaggtgac
1981 actggatggg atgtcttcag cctcgattat catgttgacg gaccaattgc aactgtgttt
2041 actcgagaat gtatgagcca ctacctaaga gtatttaact tcctctggag ggcgaagcgg
2101 atggaataca tcctcactga catacggaag ggacacatgt gcaatgcaaa gctcctgaga
2161 aacatgccag agttctccgg ggtgctgcac cagtgtcaca ttttggcctc tgagatggtc
2221 catttcattc atcagatgca gtattacatc acatttgagg tgcttgaatg ttcttgggat
2281 gagctttgga acaaagtcca gcaggcccag gatttggatc acatcattgc tgcacacgag
2341 gtgttcttag acaccatcat ctcccgctgc ctgctggaca gtgactccag ggcactttta
2401 aatcaactta gagctgtgtt tgatcaaatt attgaacttc agaatgctca agatgcaata
2461 tacagagctg ctctggaaga attgcagaga cgattacagt ttgaagagaa aaagaaacag
2521 cgtgaaattg agggccagtg gggagtgacg gcagcagagg aagaggagga aaataagagg
2581 attggagaat ttaaagaatc tataccaaaa atgtgctcac agttgcgaat attgacccat
2641 ttctaccagg gtatcgtgca gcagtttttg gtgttactga cgaccagctc tgacgagagt
2701 cttcggtttc ttagcttcag gctggacttc aacgagcatt acaaagccag ggagcccagg
2761 ctccgtgtgt ctctgggtac cagggggcgg cgcagctccc acacgtgaag ctcgcggtcc
2821 tcccagggag ctgcgggtga tgttcgttgc actgctagac acgaaattcc cattgacgtc
2881 ctgcaggaac tgcatgctgc aggtgtcctg cccttccgcc cacgagtgcg ccatgtttca
2941 gcggagcggc gtgtgggaga agccacgtcg tgtttcacat gtcggagtcg aatgcatttg
3001 taaatcccta agtcaagtag gctggctgca ctgttcacat ttgtctctaa aagtcttcat
3061 cgctaaaaga taccataatt tgctgaggct tcttaagctt tctatgttat aatttatatt
3121 tgtcacttta aaaaatccat ttcttttaga aaaaattagg gtgataggat attcattagt
3181 taagatggta acgtcattgc tattttttta acatcctctt tagaggtaat ttttgttaac
3241 ataaccaaaa attaaattga aacaaaatgt cccaactaag aaaatatata gagcatttta
3301 ttttttttta gtgttgtaaa atattaacct ctgtgagatc ctttgtatct taatgcatta
3361 cctttacaca tatttattct tattttctct cctttcagag tttacatttt tatatttaat
3421 ttactatttc agatttttaa aatagtatag aaaaaagtag gagtgataga gaacaaaaat
3481 actcttatac agtgcaaccc aaataccgcg aatgcatcag ctaaagcagc gtgtaaatag
3541 gagtgatgag aaagttaatg gagtatttta ttttcaaagt tcctgataag cattggaaag
3601 aaatcgacat ggataatgaa gatttccttt ttccttgcct attttttcat tgtaaatatt
3661 tatatactac tgaccaagat gttggggtgg gggggattgt tttttgtaaa aatgtcatta
3721 tcaggtcaca taaatctgcc tttatgttgc ataagtgaaa atttagaaaa ttaaaagcaa
3781 ttatctttca aaaaa
(SEQ ID NO:200)
1    matpdqkspn vllqnlccri lgrseadvaq qfqyavrvig snfaptverd eflvaekikk
61   elirqrread aalfselhrk lhsqgvlknk wsilylllsl sedprrqpsk vssyatlfaq
121  alprdahstp yyyarpqtlp lsyqdrsaqs aqssgsvgss gissiglcal sgpapapqsl
181  lpgqsnqapg vgdclrqqlg srlawtltan qpssqattsk gvpsavsrnm trsrregdtg
241  gtmeiteaal vrdilyvfqg idgknikmnn tencykvegk anlsrslrdt avrlselgwl
301  hnkirrytdq rsldrsfglv gqsfcaalhq elreyyrlls vlhsqlqled dqgvnlgles
361  sltlrrllvw tydpkirlkt laalvdhcqg rkggelasav haytktgdpy mrslvqhils
421  lvshpvlsfl yrwiydgele dtyheffvas dptvktdrlw hdkytlrksm ipsfmtmdqs
481  rkvlligksi nflhqvchdq tpttkmiavt ksaespqdaa dlftdlenaf qgkidaayfe
541  tskylldvln kkyslldhmq amrrylllgq gdfirhlmdl lkpelvrpat tlyqhnltgi
601  letavratna qfdspeilrr ldvrllevsp gdtgwdvfsl dyhvdgpiat vftrecmshy
661  lrvfnflwra krmeyiltdi rkghmcnakl lrnmpefsgv lhqchilase mvhfihqmqy
721  yitfevlecs wdelwnkvqq aqdldhiiaa hevfldtiis rclldsdsra llnqlravfd
781  qiielqnaqd aiyraaleel qrrlqfeekk kqreiegqwg vtaaeeeeen krigefkesi
841  pkmcsqlril thfyqgivqq flvllttssd eslrflsfrl dfnehykare prlrvslgtr
901  grrssht

Putative function

Component of the centrosome

Example 18 (Category 3)

Line ID—237

Phenotype—Lethal phase larval stage 3 (few pupae). High mitotic index, colchicine-type overcondensation of chromosomes, polyploid cells, ‘mininuclei’ formation

Annotated Drosophila genome genomic segment containing P element insertion site (and map position)—AE0086 (10C4-5)

P element insertion site—182,487

Annotated Drosophila genome Complete Genome candidate

2 candidates:

CG1558—novel protein

(SEQ ID NO:201)
ATGGAGCCAGCCGAAAGTCCAGAAAAATTAATGAAATTCGTACGCCGCAG
TGACGTACTGGAATACGTGGGCAACACGAGTGCCGTCGATCTATCGAGCG
GTGATCTCTCCGACATCGATCTCAAGGACGTGCCGGCCCAACTGGAGGCC
ACTTTGAAACCGCGTCGCTATGAAGCAAGCACTTTGTTTAACATTGACCT
GGACGATATCTGGGATCCTAGCTGTCAGGAGGACGAGGTGCAGCAGTACA
AGGAGCGCGCCCAGAAGGAGCAGCAAAAGTTCTTCGACTTTGTAATGCAT
GCGGCACTGGACACGGACAATCGCAAGGTTAGCTTCAAGCCAAACAAGGA
GCAGCAGCGTTACCTAGATCAGGGACCCAATTTGCAAAACTTCGTGCGAA
GCTCGTTGGCTTTCACAAACGCGGCCATCCGATTTCAGGCGGAGCACGAG
GACATGATGGAGCTGCAGTGCAATATGGACGATCACTACCTATTCATGCG
GAACACCATGATCAACAACGCTATACACCAGAATATGGCCAACCAACGGT
GACCCTAAGCTATGCATAAATATACATATGTGAATTGTAGATATTGATAA
ATTAAATTAAGACTCAGAGATTGTAAGACGGTTTGCTTTTGGCTTATACA
GTATAATTCGCTTAGCTGCCTCGAGTACTTTGCACAATGCCTCGATGCAG
GTAACTTAAAAATGCAGCTAACTTAATTTTTTTTTTTCTATTTTCTATTT
TCTATTCACAC
(SEQ ID NO:202)
MEPAESPEKLMKFVRRSDVLEYVGNTSAVDLSSGDLSDIDLKDVPAQLEA
TLKPRRYEASTLFNIDLDDIWDPSCQEDEVQQYKERAQKEQQKFFDFVMH
AALDTDNRKVSFKPNKEQQRYLDQGPNLQNFVRSSLAFTNAAIRFQAEHE
DMMELQCNMDDHYLFMRNTMINNAIHQNMANQR

CG11697—novel protein

(SEQ ID NO:203)
ATGATTTATGCGATCGTGATACACATACTGTCCCTTCTGGTGGGCTGTTT
CTATCCAGCATTCGCGTCCTACAAGATCCTGAAAAGTCAGAATTGTAGCG
TCAATGATCTTCGCGGATGGTTAATCTACTGGATTGCCTATGGAGTTTAT
GTGGCCTTTGATTATTTCACAGCGGGTCTGCTGGCATTTATTCCATTGCT
AAGTGAGTTCAAGGTGCTTCTCCTGTTCTGGATGTTGCCCTCTGTGGGCG
GCGGCAGTGAGGTGATCTACGAGGAGTTCCTGCGATCCTTTAGCTGTAAC
GAATCCTTCGACCAGGTCCTGGGACGTATCACCTTGGAATGGGGCGAATT
GGTGTGGCAACAAGTTTGCTCCGTTCTTAGCCATTTGATGGTTTTGGCAG
ATCGCTATCTCCTGCCCAGCGGTCATCGTCCTGCCCTCCAAATAACGCCC
AGCATCGAGGATCTGGTCAACGATGCCATAGCCAAAAGGCAGTTGGAAGA
GAAGCGGAAACAGATGGGTAACTTATCTGATACCATCAACGAGGTTTTGG
GAGAAAATATCGATTTAAATATGGATCTGCTGCACGGATCCGAATCTGAT
TTATTGGTTATTAAGGAGCCTATTTCCAAGCCCAAGGAGAGACCAATACC
GCCGCCGAAGCCAATGCGTCAGCCATCATCAAGCAACCAGCAAGAAATGA
ATCTTTCGTCGCAGTTTATGTGA
(SEQ ID NO:204)
MIYAIVIHILSLLVGCFYPAFASYKILKSQNCSVNDLRGWLIYWIAYGVY
VAFDYFTAGLLAFIPLLSEFKVLLLFWMLPSVGGGSEVIYEEFLRSFSCN
ESFDQVLGRITLEWGELVWQQVCSVLSHLMVLADRYLLPSGHRPALQITP
SIEDLVNDAIAKRQLEEKRKQMGNLSDTINEVLGENIDLNMDLLHGSESD
LLVIKEPISKPKERPIPPPKPMRQPSSSNQQEMNLSSQFM

Human homologue of Complete Genome candidate

(CG1558)—none

(CG11697)—BAB14444 unamed protein—similar to a hypothetical protein in the region deleted in human familial adenomatous polyposis 1

(SEQ ID NO:205)
1    aacgccgggc agggcggcgg gcgcgctcag tctggcggcg gctgccgtga gctgactgac
61   gttccgggaa cgccgcagca gcccgcgccg cccgcagcct agccgagccg cgccgcccgg
121  gcctcgcccg cccgcctgcc cgccatggtg tcatggatca tctccaggct ggtggtgctt
181  atatttggca ccctttaccc tgcgtattat tcctacaagg ctgtgaaatc aaaggacatt
241  aaggaatatg tcaaatggat gatgtactgg attatatttg cacttttcac cacagcagag
301  acattcacag acatcttcct ttgttggttt ccattctatt atgaactaaa aatagcattt
361  gtagcctggc tgctgtctcc ctacacaaaa ggctccagcc tcctgtacag gaagtttgta
421  catcccacac tatcttcaaa agaaaaggaa atcgatgatt gtctggtcca agcaaaagac
481  cgaagttacg atgcccttgt gcacttcggg aagcggggct tgaacgtggc cgccacagcg
541  gctgtgatgg ctgcttccaa gggacagggt gccttatcgg agagactgcg gagcttcagc
601  atgcaggacc tcaccaccat caggggagac ggcgcccctg ctccctcggg ccccccacca
661  ccggggtctg ggcgggccag cggcaaacac ggccagccta agatgtccag gagtgcttct
721  gagagcgcta gcagctcagg caccgcctag aatccttcga tctcgcttca ggaagaaaag
781  tacctcatcc tcggccaccg aaaccacgtg agtgagatga gccaacagca ccggatccac
841  agaatgtttc ttctctgcct taaagagcta ttcactaata acatagaaat ccgcaagctg
901  ggtgtgcttt gagtgtgcag cctcacaaac atggcctttt ctctctcccc ttccactttt
961  aaggatttat ttttttcccc cttttcttta ttttgctggg gagaggctaa agggaaaggt
1021 agtaggggcg ggggtggtga cctttaagtc ttctgaggtt ggtaattttc cacaattgga
1081 ttgtcattat agacagcagt gtgtttttta gaaagataag agaatcaccc ctatgctgct
1141 gagatgtaca tttgtaattt atctgttgca tacttagttt ttagtcctgt aaatgcaaac
1201 acagcatttt ttacaacttt ctttgttctt ggtacttata ctttgaacta tgatgtacat
1261 atttatggct tttggctttt aatataatgg acttgcaagg gctgccagag gttctgatat
1321 gtaagaaaac tgcaaaaaca aatatagaca aatattttga ttctagagaa cgtctcagat
1381 gtgcttataa agcttccaaa tacaactcca gtaagacatc cctttccctg caggagtgtg
1441 gtctatattc tttagatagt tgtttagtca aaagaccaga caagttacaa actaagagaa
1501 acaatatttc acaacacagt aaagtgtgat gagaggtcag gggaacatcc cagtaaaaga
1561 gaagagtcac aggaagctca tctcctccct ggattctgga ttaggagctt ctgaatcttt
1621 tccagggata ggcaggtagc tcactcttgg tgcaatttct tgaggatggg aacatgtaga
1681 gctgctggaa ggagtaattc tgtgcttgac aaaggacgat ttctccttta tcgtgaccag
1741 tgctgccgat ttcctgacag aggagcttac actctgagca ccttgtttta gcgaactcta
1801 gcaaaacttg tttagcttag caaaaacaaa cacacaaaaa actgagaact ctgctgtttc
1861 agatatgcca taacatacat ctgaaacaca tgtgtaacaa tcaaaatggt gggctctaga
1921 atggttttgg agctcgagat cttcatgggt tagacttgct ggtcagaccc aggagcacct
1981 gtggctcaca ccttctgttc ccctcctggc ctgtgcagaa tgtaaacagc agactcatac
2041 tcaatgggca ctacaggcct tatcagacgt tttatacaag cctggattgc ttagtagggg
2101 aataaggcat tctctgaggg ggctttccac ttagattgag aattttattt gaaaagaatc
2161 tggtttaaat ggcattgtgg tccgaggtag ctgctctccc cactgagagc tgagccgaaa
2221 tataagaata atatatttgt gcttcgagtt ggtgtttctt tcagtgtaat gcatgcagtg
2281 gtcacaaccc agttactcat aatatttgga ttgtatttgt tcgtagatat gcccagaaga
2341 ctagagaatt agtgttatat accatataga acttactgtc agtcaactat aaacaggccc
2401 aattaaaaac tgttccatta ctacgcaaac acatattaga ggcctttgct gatgacacat
2461 tagctggatc ttagccaccc cagaaagggt ttgatttgaa gctgattgtt gccagatatg
2521 catattggaa tcccatctac ccatagttcc tctgaaggtg attttgtaat ttgcaaaagg
2581 gtataggaaa atatacctaa aagcgaattt gtggctgaga ggataaacag aagctgtttg
2641 ctcatgttct gtgccccaca cccaccaata cctaaatctg ttaaggaaga cagaaaatgt
2701 tttctttgtg ctcattgagt agttccagac agaagaagaa tatactcttt aaaatgtatt
2761 tacctgttag ttggaagtac ccagaattat cagaaacgaa tgcaaaaaaa aaaaaaaaaa
2821 aaaaaagctt acacagcttc ttagcaattt tttttttttt tgccgaaaca ataaattgcc
2881 tttagcagca gtttaaaatc ctatcgtgaa caacctatat tttcgccatt ttacaatgga
2941 gagttgtgac aagtacaggt tatcaagttt gcacttaact atgccaaaaa aagtttgaag
3001 cgctctattc tcagacatgc tgtattatta cttctcattc aagattgaaa aatataaagg
3061 tatccaaact ctgtcttaat gtaaatgtaa ctatttttcc ttcaagtgtt gactagggag
3121 tcggtttctc tcttaaagac actcactgta caactgaaag cagctgtcat atttctggca
3181 aaatgtgttt acgtatctga caagttgtac atttgtgtat gaactgacat aaaatgtgaa
3241 agcctgtaag tgtacatgta gtggtgtggt gttctgtcta gaggatacaa ctgaatgttt
3301 ttaatttgct gacttacaga cacaggctgt ttacaaaatg ctagctggaa agtctgtaat
3361 gttcatgtca taacttttag ttaattgcca ttgagcacct gttctgagga ggtgagatgt
3421 ggacttgtgc ttataaactg gagagtttag tcataatccc tcctggcttt gtgtgaatag
3481 cttgctcact ttgctggcct ttgaaatgtg ttctccgtga taagctatcc atgtgtttgt
3541 gataagagtg cttgtcaacc atgaccatct ttgagccttc ctagtcctcc acctggcaca
3601 gtatttgaaa tggcaaagga tgtgcttcat cctctaacaa acagtgtaca ctcccagagc
3661 tgatattctg gattgtgact gtgcacattt cctctagttc atgtctgtag tccctataga
3721 atgatctgta ataaaatagt atactggact gtgcatcaaa gggatgtaaa attacagtat
3781 tccaaaggtt gaagttctgc tgttttgtta taatgcctga tacacatctt gaataaagtc
3841 ttaacatttt tctttt
(SEQ ID NO:206)
1    miyaivihil sllvgcfypa fasykilksq ncsvndlrgw liywiaygvy vafdyftagl
61   lafipllsef kvlllfwmlp svgggseviy eeflrsfscn esfdqvlgri tlewgelvwq
121  qvcsvlshlm vladryllps ghrpalqitp siedlvndai akrqleekrk qmgnlsdtin
181  evlgenidln mdllhgsesd llvikepisk pkerpipppk pmrqpsssnq qemnlssqfm
241

Putative function

(CG1558)—unknown

(CG11697)—may be deleted in human cancers, possibly a receptor.

Example 19

Corkscrew/Shp2 (Category 3)

Corkscrew (CG3954) as a candidate gene is detected in a screen of a P-element insertion library covering the X chromosome of Drosophila melanogaster (Peter et al. 2001) as mutant phenotype in fly line 171 , as described above.

Mitotic defects are observed in brain squashes: low mitotic index, few cells in mitosis and metaphases with separated chromosomes, and is placed in Category 3 as described above.

Rescue and sequencing of genomic DNA flanking the P-element insertion site indicates that the P-element is inserted into the 5′ region of two genes: CG3954 corkscrew and CG16903 cyclin/non-specific RNA polymersae II transcription factor.

Line ID—171

Phenotype—Lethal phase larval stage 1-2. Low mitotic index, few cells in mitosis, metaphase with separated chromosomes

Annotated Drosophila genome genomic segment containing P element insertion site (and map position)—AE003423 (2D 1-2)

P element insertion site—42,253

Annotated Drosophila genome Complete Genome candidate

2 candidates: CG3954—corkscrew. Protein tyrosine phosphatase required for cell signaling in eye development (2 splice variants) and CG16903—cyclin/non-specific RNA polymersae II transcription factor

CG3954—corkscrew. Protein tyrosine phosphatase required for cell signaling in eye splice variant 1

(SEQ ID NO:207)
ATGCTGTTCAACAAATGTCTGGAAAAGTTGTCCAGCTCGCTGGGCAATGT
GGTCAATCACAAGCTGCAAGAGAAACAAGTCTACAACAACAACAATATCA
ACAATAACAATAACAATACGCTAAACAACAACAATGCCTACAACAATCAG
CGAAACTTTGAGTACGAAAGAGCCATACAGGCGCACTACGGAAGCAAGGG
AAGACGCTCGGAGGAGCGCGAAAGGAGCGGCAAGTTCAAGGCCAGCAAGG
GTCGGAAAGCAAAGGTCACCCCACCAACGGAGACACCCGAGGCCCAGGAG
CCGGCCTGCAAGAACTGTATGACCCACGACGAGCTGGCCCAGATCATAAA
GGGCGTGGCCAAGGGCGCTGACGCGCAACGTAATCGAGACAACCGACTGC
AGCGCAGACGTCGTCCTCTCTCCGCCCAACCCTCCGCCGCTGCCTCCGCC
TCCACATCGACGGAATCTCTGCACCGTCTTACACCCAGCCCGCAGGCTTC
CTACCCGGCCACGCCCACCTCCTGGACAGCCACACCGCCCCAGTTCCCAG
CCGCCTTCGGCGGCGCCAGCTGCTCCAACAGCACACTGTCCCTCTTGGCC
ACCATGCGCGTCCAGCTCCATGGTTACACATGGTTTCATGGCAATCTTTC
CGGAAAGGAAGCGGAAAAATTGATCCTGGAGCGGGGCAAGAATGGTTCGT
TTCTCGTCCGTGAATCTCAGAGCAAGCCTGGCGACTTCGTCCTTTCCGTG
CGCACGGACGACAAAGTAACGCATGTCATGATTCGATGGCAGGACAAGAA
GTACGACGTCGGCGGCGGGGAATCCTTTGGCACCTTGTCGGAACTGATCG
ATCACTACAAGCGTAATCCCATGGTGGAGACGTGCGGAACCGTGGTGCAT
CTGCGACAGCCATTCAACGCCACACGAATCACGGCGGCCGGCATCAATGC
CCGGGTGGAACAGCTGGTCAAGGGAGGTTTCTGGGAGGAATTCGAATCGC
TGCAACAGGACAGTCGGGACACATTCTCGCGCAACGAGGGCTACAAACAG
GAGAACCGCCTCAAGAATCGCTACCGCAACATATTGCCATACGACCACAC
GCGCGTCAAGCTGCTGGACGTGGAGCATAGCGTGGCCGGAGCCGAGTACA
TCAATGCCAACTACATACGGCTGCCCACCGACGGCGACCTGTACAACATG
AGCAGCTCGTCGGAGAGCCTGAACAGCTCGGTGCCCTCGTGCCCCGCCTG
CACGGCTGCCCAGACACAGCGGAACTGCTCCAACTGCCAGCTGCAAAACA
AGACGTGCGTGCAGTGCGCCGTGAAGAGCGCCATTCTGCCGTATAGCAAC
TGTGCCACCTGCAGCCGCAAGTCAGACTCCCTGAGCAAGCACAAGCGGAG
CGAATCCTCGGCCTCTTCATCGCCCTCCTCCGGCTCTGGGTCCGGACCAG
GATCGTCGGGCACCAGCGGAGTGAGCAGCGTCAATGGACCCGGCACACCC
ACCAATCTCACGAGCGGCACAGCCGGATGTCTGGTCGGCCTGCTGAAGAG
ACACTCGAACGACTCGTCCGGAGCTGTTTCTATATCGATGGCCGAACGGG
AACGCGAGAGGGAGCGCGAGATGTTTAAGACCTACATCGCCACCCAGGGC
TGTCTGCTCACCCAGCAAGTGAACACGGTGACGGACTTCTGGAACATGGT
CTGGCAGGAGAACACGCGGGTGATCGTCATGACCACCAAGGAGTACGAGC
GCGGCAAAGAAAAGTGCGCCCGCTACTGGCCGGACGAGGGTAGATCGGAG
CAGTTCGGCCACGCGCGGATACAGTGCGTCTCGGAGAACTCGACCAGTGA
CTATACGCTGCGCGAGTTCCTCGTCTCGTGGCGGGATCAGCCGGCGCGCC
GGATCTTTCACTACCATTTCCAGGTGTGGCCGGATCACGGAGTGCCCGCC
GATCCGGGCTGTGTGCTCAACTTCCTGCAAGATGTCAACACGCGTCAGAG
TCACCTGGCTCAAGCGGGCGAGAAGCCGGGTCCGATCTGCGTGCACTGCT
CTGCGGGCATCGGTCGCACTGGCACCTTTATTGTGATCGATATGATTCTC
GATCAGATTGTGCGCAATGGATTGGATACTGAAATCGACATCCAGCGCAC
CATTCAGATGGTCCGATCGCAGCGTTCCGGTCTTGTGCAAACCGAGGCGC
AATACAAGTTCGTCTACTATGCGGTGCAGCACTATATACAGACCCTGATC
GCCCGGAAACGAGCTGAGGAGCAGAGCCTGCAGGTTGGCCGCGAGTACAC
CAATATAAAGTACACGGGCGAAATTGGAAACGATTCACAAAGATCTCCAT
TACCACCAGCAATTTCTAGCATAAGTTTAGTTCCGAGTAAGACGCCACTG
ACGCCGACATCGGCGGATTTGGGCACTGGGATGGGCCTAAGCATGGGCGT
GGGCATGGGCGTCGGCAACAAGCACGCATCGAAGCAGCAGCCGCCGTTGC
CGGTGGTCAACTGCAACAATAATAACAACGGCATTGGCAATAGCGGCTGC
AGCAACGGCGGCGGGAGCAGCACCACCAGCAGCAGCAACGGCAGCAGCAA
CGGTAACATCAACGCCCTACTGGGCGGCATCGGCTTGGGGCTGGGCGGCA
ATATGCGCAAGTCGAACTTTTACAGCGACTCGCTGAAGCAGCAACAGCAG
CGCGAGGAGCAGGCTCCGGCGGGAGCAGGTAAGATGCAGCAGCCGGCGCC
GCCGCTGCGACCGCGTCCTGGAATACTCAAGTTGCTCACCAGTCCCGTCA
TCTTTCAGCAAAATTCAAAAACATTCCCAAAGACATGA
(SEQ ID NO:208)
MLFNKCLEKLSSSLGNVVNHKLQEKQVYNNNNINNNNNNTLNNNNAYNNQ
RNFEYERAIQAHYGSKGRRSEERERSGKFKASKGRKAKVTPPTETPEAQE
PACKNCMTHDELAQIIKGVAKGADAQRNRDNRLQRRRRPLSAQPSAAASA
STSTESLHRLTPSPQASYPATPTSWTATPPQFPAAFGGASCSNSTLSLLA
TMRVQLHGYTWFHGNLSGKEAEKLILERGKNGSFLVRESQSKPGDFVLSV
RTDDKVTHVMIRWQDKKYDVGGGESFGTLSELIDHYKRNPMVETCGTVVH
LRQPFNATRITAAGINARVEQLVKGGFWEEFESLQQDSRDTFSRNEGYKQ
ENRLKNRYRNILPYDHTRVKLLDVEHSVAGAEYINANYIRLPTDGDLYNM
SSSSESLNSSVPSCPACTAAQTQRNCSNCQLQNKTCVQCAVKSAILPYSN
CATCSRKSDSLSKHKRSESSASSSPSSGSGSGPGSSGTSGVSSVNGPGTP
TNLTSGTAGCLVGLLKRHSNDSSGAVSISMAEREREREREMFKTYIATQG
CLLTQQVNTVTDFWNMVWQENTRVIVMTTKEYERGKEKCARYWPDEGRSE
QFGHARIQCVSENSTSDYTLREFLVSWRDQPARRIFHYHFQVWPDHGVPA
DPGCVLNFLQDVNTRQSHLAQAGEKPGPICVHCSAGIGRTGTFIVIDMIL
DQIVRNGLDTEIDIQRTIQMVRSQRSGLVQTEAQYKFVYYAVQHYIQTLI
ARKRAEEQSLQVGREYTNIKYTGEIGNDSQRSPLPPAISSISLVPSKTPL
TPTSADLGTGMGLSMGVGMGVGNKHASKQQPPLPVVNCNNNNNGIGNSGC
SNGGGSSTTSSSNGSSNGNINALLGGIGLGLGGNMRKSNFYSDSLKQQQQ
REEQAPAGAGKMQQPAPPLRPRPGILKLLTSPVIFQQNSKTFPKT

CG3954—corkscrew. Protein tyrosine phosphatase required for cell signaling in eve splice variant 2

(SEQ ID NO:209)
AGTAAAAAAATAGTTTTTTTTTTGTATCCAACCAACCAACTGTAAAAATA
AGTTTAAACAAAGCATCTACTCATAAGTTTCATTTTTTTCCGTTAAGTGT
CAACATTATTTATTTTTTAAGTGTGCATTCAATAAGAAAATGTCATCGCG
AAGATGGTTCCACCCAACGATATCTGGCATCGAAGCTGAGAAACTGCTGC
AGGAGCAGGGATTCGACGGCTCCTTCCTCGCCCGCCTCTCCTCCTCGAAT
CCGGGCGCCTTCACGCTCTCCGTGCGCCGCGGCAACGAGGTGACCCACAT
CAAAATCCAAAACAATGGCGACTTCTTTGATCTCTACGGTGGTGAAAAGT
TCGCCACACTGCCGGAACTGGTACAATACTACATGGAGAATGGCGAGCTA
AAGGAGAAGAACGGCCAGGCCATCGAACTCAAGCAGCCGCTGATCTGCGC
CGAGCCCACCACGGAAAGATGGTTTCATGGCAATCTTTCCGGAAAGGAAG
CGGAAAAATTGATCCTGGAGCGGGGCAAGAATGGTTCGTTTCTCGTCCGT
GAATCTCAGAGCAAGCCTGGCGACTTCGTCCTTTCCGTGCGCACGGACGA
CAAAGTAACGCATGTCATGATTCGATGGCAGGACAAGAAGTACGACGTCG
GCGGCGGGGAATCCTTTGGCACCTTGTCGGAACTGATCGATCACTACAAG
CGTAATCCCATGGTGGAGACGTGCGGAACCGTGGTGCATCTGCGACAGCC
ATTCAACGCCACACGAATCACGGCGGCCGGCATCAATGCCCGGGTGGAAC
AGCTGGTCAAGGGAGGTTTCTGGGAGGAATTCGAATCGCTGCAACAGGAC
AGTCGGGACACATTCTCGCGCAACGAGGGCTACAAACAGGAGAACCGCCT
CAAGAATCGCTACCGCAACATATTGCCATACGACCACACGCGCGTCAAGC
TGCTGGACGTGGAGCATAGCGTGGCCGGAGCCGAGTACATCAATGCCAAC
TACATACGGCTGCCCACCGACGGCGACCTGTACAACATGAGCAGCTCGTC
GGAGAGCCTGAACAGCTCGGTGCCCTCGTGCCCCGCCTGCACGGCTGCCC
AGACACAGCGGAACTGCTCCAACTGCCAGCTGCAAAACAAGACGTGCGTG
CAGTGCGCCGTGAAGAGCGCCATTCTGCCGTATAGCAACTGTGCCACCTG
CAGCCGCAAGTCAGACTCCCTGAGCAAGCACAAGCGGAGCGAATCCTCGG
CCTCTTCATCGCCCTCCTCCGGCTCTGGGTCCGGACCAGGATCGTCGGGC
ACCAGCGGAGTGAGCAGCGTCAATGGACCCGGCACACCCACCAATCTCAC
GAGCGGCACAGCCGGATGTCTGGTCGGCCTGCTGAAGAGACACTCGAACG
ACTCGTCCGGAGCTGTTTCTATATCGATGGCCGAACGGGAACGCGAGAGG
GAGCGCGAGATGTTTAAGACCTACATCGCCACCCAGGGCTGTCTGCTCAC
CCAGCAAGTGAACACGGTGACGGACTTCTGGAACATGGTCTGGCAGGAGA
ACACGCGGGTGATCGTCATGACCACCAAGGAGTACGAGCGCGGCAAAGAA
AAGTGCGCCCGCTACTGGCCGGACGAGGGTAGATCGGAGCAGTTCGGCCA
CGCGCGGATACAGTGCGTCTCGGAGAACTCGACCAGTGACTATACGCTGC
GCGAGTTCCTCGTCTCGTGGCGGGATCAGCCGGCGCGCCGGATCTTTCAC
TACCATTTCCAGGTGTGGCCGGATCACGGAGTGCCCGCCGATCCGGGCTG
TGTGCTCAACTTCCTGCAAGATGTCAACACGCGTCAGAGTCACCTGGCTC
AAGCGGGCGAGAAGCCGGGTCCGATCTGCGTGCACTGCTCTGCGGGCATC
GGTCGCACTGGCACCTTTATTGTGATCGATATGATTCTCGATCAGATTGT
GCGCAATGGATTGGATACTGAAATCGACATCCAGCGCACCATTCAGATGG
TCCGATCGCAGCGTTCCGGTCTTGTGCAAACCGAGGCGCAATACAAGTTC
GTCTACTATGCGGTGCAGCACTATATACAGACCCTGATCGCCCGGAAACG
AGCTGAGGAGCAGAGCCTGCAGGTTGGCCGCGAGTACACCAATATAAAGT
ACACGGGCGAAATTGGAAACGATTCACAAAGATCTCCATTACCACCAGCA
ATTTCTAGCATAAGTTTAGTTCCGAGTAAGACGCCACTGACGCCGACATC
GGCGGATTTGGGCACTGGGATGGGCCTAAGCATGGGCGTGGGCATGGGCG
TCGGCAACAAGCACGCATCGAAGCAGCAGCCGCCGTTGCCGGTGGTCAAC
TGCAACAATAATAACAACGGCATTGGCAATAGCGGCTGCAGCAACGGCGG
CGGGAGCAGCACCACCAGCAGCAGCAACGGCAGCAGCAACGGTAACATCA
ACGCCCTACTGGGCGGCATCGGCTTGGGGCTGGGCGGCAATATGCGCAAG
TCGAACTTTTACAGCGACTCGCTGAAGCAGCAACAGCAGCGCGAGGAGCA
GGCTCCGGCGGGAGCAGGTAAGATGCAGCAGCCGGCGCCGCCGCTGCGAC
CGCGTCCTGGAATACTCAAGTTGCTCACCAGTCCCGTCATCTTTCAGCAA
AATTCAAAAACATTCCCAAAGACATGA
(SEQ ID NO:210)
MSSRRWFHPTISGIEAEKLLQEQGFDGSFLARLSSSNPGAFTLSVRRGNE
VTHIKIQNNGDFFDLYGGEKFATLPELVQYYMENGELKEKNGQAIELKQP
LICAEPTTERWFHGNLSGKEAEKLILERGKNGSFLVRESQSKPGDFVLSV
RTDDKVTHVMIRWQDKKYDVGGGESFGTLSELIDHYKRNPMVETCGTVVH
LRQPFNATRITAAGINARVEQLVKGGFWEEFESLQQDSRDTFSRNEGYKQ
ENRLKNRYRNILPYDHTRVKLLDVEHSVAGAEYINANYIRLPTDGDLYNM
SSSSESLNSSVPSCPACTAAQTQRNCSNCQLQNKTCVQCAVKSAILPYSN
CATCSRKSDSLSKHKRSESSASSSPSSGSGSGPGSSGTSGVSSVNGPGTP
TNLTSGTAGCLVGLLKRHSNDSSGAVSISMAEREREREREMFKTYIATQG
CLLTQQVNTVTDFWNMVWQENTRVIVMTTKEYERGKEKCARYWPDEGRSE
QFGHARIQCVSENSTSDYTLREFLVSWRDQPARRIFHYHFQVWPDHGVPA
DPGCVLNFLQDVNTRQSHLAQAGEKPGPICVHCSAGIGRTGTFIVIDMIL
DQIVRNGLDTEIDIQRTIQMVRSQRSGLVQTEAQYKFVYYAVQHYIQTLI
ARKRAEEQSLQVGREYTNIKYTGEIGNDSQRSPLPPAISSISLVPSKTPL
TPTSADLGTGMGLSMGVGMGVGNKHASKQQPPLPVVNCNNNNNGIGNSGC
SNGGGSSTTSSSNGSSNGNINALLGGIGLGLGGNMRKSNFYSDSLKQQQQ
REEQAPAGAGKMQQPAPPLRPRPGILKLLTSPVIFQQNSKTFPKT

CG16903—cyclin/non-specific RNA polymersae II transcription factor

(SEQ ID NO:211)
ATTTAGTATAAAAGCACGCCTGTTATCGGCTAAATTTACAAAAAAAAAGG
GAAAATTAAAAAATTAAAACACTTAAATAAACGCTTTCCTGGGTTAACCG
CGCACGAATGGCCACCCGTGGGGCCGGCTCGACTGTGGTCCACACGACGG
TGACAGCGCTGACGGTGGAGACGATCACCAATGTCCTGACCACGGTGACT
TCGTTCCATTCGAACAGCGTCAACATTTCGAACAACAACAGCAGCAGTGG
AGCGGCCCCGGGGGCGGATGCAGCTGGCGGCGATGCAGGGGGCGTGGCAG
CGGCTCAGGCGGACGCCAACAAGCCTATCTATCCTCGGCTCTTTAACCGC
ATCGTGCTGACGCTGGAGAACAGCCTCATTCCGGAGGGCAAAATCGATGT
GACGCCATCCAGCCAGGATGGACTGGACCATGAGACGGAGAAGGACCTGC
GCATACTGGGCTGCGAGCTTATTCAGACAGCCGGAATTTTGCTGCGCTTG
CCGCAGGTTGCCATGGCCACCGGCCAGGTGCTGTTCCAGCGCTTCTTCTA
CTCGAAGAGCTTTGTGCGGCACAACATGGAGACTGTGGCCATGAGCTGCG
TGTGCCTGGCGTCCAAGATCGAGGAGGCGCCGCGCCGCATTAGAGACGTG
ATCAATGTGTTCCATCACATCAAGCAAGTGCGGGCCCAAAAGGAAATCTC
GCCCATGGTGCTAGATCCTTACTACACGAACCTCAAGATGCAGGTGATCA
AGGCCGAGCGGCGCGTCCTCAAGGAACTGGGCTTCTGTGTACACGTGAAG
CATCCGCACAAGCTGATCGTGATGTATCTGCAGGTGCTTCAGTACGAGAA
GCACGAGAAGCTGATGCAGCTCTCCTGGAACTTCATGAATGACTCGCTGA
GGACGGACGTTTTTATGCGCTACACACCAGAGGCGATTGCATGCGCCTGC
ATCTACCTGAGTGCCCGCAAGCTCAACATACCTCTGCCCAACAGCCCGCC
GTGGTTCGGCATTTTTCGGGTGCCCATGGCGGACATTACGGATATCTGCT
ACCGTGTGATGGAGCTGTACATGCGTTCCAAGCCGGTGGTGGAGAAACTG
GAGGCGGCCGTGGACGAGCTGAAAAAGCGGTACATTGATGCGCGCAACAA
AACGAAGGAGGCAAACACACCGCCGGCTGTAATCACCGTGGATCGGAACA
ATGGCTCGCACAATGCGTGGGGTGGCTTCATCCAGCGTGCTATCCCACTG
CCCTTGCCATCGGAAAAGTCGCCGCAAAAGGATTCGAGGTCACGCTCGCG
ATCCAGGACGCGCACCCATTCGCGGACACCTCGCTCCCGATCACCCAGGT
CCAGGTCGCCTAGTCGCGAGCGCACTAAGAAGACCCACCGCAGTCGATCC
TCCCGCTCGCGCTCCCGTTCGCCGCCGAAGCATAAGAAAAAGTCACGTCA
CTACTCGAGGTCGCCCACGCGCTCCAATTCGCCGCACAGCAAGCACAGGA
AGTCGAAATCCTCGCGAGAACGCTCTGAATACTACTCCAAGAAAGATCGG
TCTGGAAACCCAGGCAGTAGCAATAATCTAGGTGATGGCGACAAGTATCG
CAACTCCGTCTCCAATTCCGGCAAGCACAGTCGGTACTCCTCCTCCTCGT
CGCGTCGGAACAGCGGTGGTGGTGGAGACGGAAGAAGCGGAGGAGGAGGT
GGTGGCGGCGGTGGAGGCAACGGGAACCACGGCAGCCGAGGGGGGCACAA
GCATCGGGATGGCGATCGCTCCAGGGATCGCAAGCGCTAGTGATTGATAG
ACAAGCGAGACAAACACTCCCTTATATTTAATTGCTCTTTATTTTACAAA
TTTACAGATTATTTCTACCGATTTAGTAATGCTAATGTGTATTGAAAAAA
CGAACGCGGGTAAACAATAAATGTAACTCTTCAATC
(SEQ ID NO:212)
MATRGAGSTVVHTTVTALTVETITNVLTTVTSFHSNSVNISNNNSSSGAA
PGADAAGGDAGGVAAAQADANKPIYPRLFNRIVLTLENSLIPEGKIDVTP
SSQDGLDHETEKDLRILGCELIQTAGILLRLPQVAMATGQVLFQRFFYSK
SFVRHNMETVAMSCVCLASKIEEAPRRIRDVINVFHHIKQVRAQKEISPM
VLDPYYTNLKMQVIKAERRVLKELGFCVHVKHPHKLIVMYLQVLQYEKHE
KLMQLSWNFMNDSLRTDVFMRYTPEAIACACIYLSARKLNIPLPNSPPWF
GIFRVPMADITDICYRVMELYMRSKPVVEKLEAAVDELKKRYIDARNKTK
EANTPPAVITVDRNNGSHNAWGGFIQRAIPLPLPSEKSPQKDSRSRSRSR
TRTHSRTPRSRSPRSRSPSRERTKKTHRSRSSRSRSRSPPKHKKKSRHYS
RSPTRSNSPHSKHRKSKSSRERSEYYSKKDRSGNPGSSNNLGDGDKYRNS
VSNSGKHSRYSSSSSRRNSGGGGDGRSGGGGGGGGGGNGNHGSRGGHKHR
DGDRSRDRKR

Human homologue of Complete Genome candidate

CG3954 homologue is Homo sapiens protein tyrosine phosphatase, non-receptor type 11 (PTPN11), also known as Shp2. Shp2 has 2 alternative transcripts having accession numbers NM_—002834 and NM_—080601.

NM_—002834 Homo sapiens protein tyrosine phosphatase, non-receptor type 11 (PTPN11) transcript variant 1, mRNA also known as Shp2.

(SEQ ID NO:213)
1    cggccgcggt ttccaggagg aagcaaggat gctttggaca ctgtgcgtgg cgcctccgcg
61   gagcccccgc gctgccattc ccggccgtcg ctcggtcctc cgctgacggg aagcaggaag
121  tggcggcggg cgtcgcgagc ggtgacatca cgggggcgac ggcggcgaag ggcgggggcg
181  gaggaggagc gagccgggcc ggggggcagc tgcacagtct ccgggatccc caggcctgga
241  ggggggtctg tgcgcggccg gctggctctg ccccgcgtcc ggtcccgagc gggcctccct
301  cgggccagcc cgatgtgacc gagcccagcg gagcctgagc aaggagcggg tccgtcgcgg
361  agccggaggg cgggaggaac atgacatcgc ggagatggtt tcacccaaat atcactggtg
421  tggaggcaga aaacctactg ttgacaagag gagttgatgg cagttttttg gcaaggccta
481  gtaaaagtaa ccctggagac ttcacacttt ccgttagaag aaatggagct gtcacccaca
541  tcaagattca gaacactggt gattactatg acctgtatgg aggggagaaa tttgccactt
601  tggctgagtt ggtccagtat tacatggaac atcacgggca attaaaagag aagaatggag
661  atgtcattga gcttaaatat cctctgaact gtgcagatcc tacctctgaa aggtggtttc
721  atggacatct ctctgggaaa gaagcagaga aattattaac tgaaaaagga aaacatggta
781  gttttcttgt acgagagagc cagagccacc ctggagattt tgttctttct gtgcgcactg
841  gtgatgacaa aggggagagc aatgacggca agtctaaagt gacccatgtt atgattcgct
901  gtcaggaact gaaatacgac gttggtggag gagaacggtt tgattctttg acagatcttg
961  tggaacatta taagaagaat cctatggtgg aaacattggg tacagtacta caactcaagc
1021 agccccttaa cacgactcgt ataaatgctg ctgaaataga aagcagagtt cgagaactaa
1081 gcaaattagc tgagaccaca gataaagtca aacaaggctt ttgggaagaa tttgagacac
1141 tacaacaaca ggagtgcaaa cttctctaca gccgaaaaga gggtcaaagg caagaaaaca
1201 aaaacaaaaa tagatataaa aacatcctgc cctttgatca taccagggtt gtcctacacg
1261 atggtgatcc caatgagcct gtttcagatt acatcaatgc aaatatcatc atgcctgaat
1321 ttgaaaccaa gtgcaacaat tcaaagccca aaaagagtta cattgccaca caaggctgcc
1381 tgcaaaacac ggtgaatgac ttttggcgga tggtgttcca agaaaactcc cgagtgattg
1441 tcatgacaac gaaagaagtg gagagaggaa agagtaaatg tgtcaaatac tggcctgatg
1501 agtatgctct aaaagaatat ggcgtcatgc gtgttaggaa cgtcaaagaa agcgccgctc
1561 atgactatac gctaagagaa cttaaacttt caaaggttgg acaagggaat acggagagaa
1621 cggtctggca ataccacttt cggacctggc cggaccacgg cgtgcccagc gaccctgggg
1681 gcgtgctgga cttcctggag gaggtgcacc ataagcagga gagcatcatg gatgcagggc
1741 cggtcgtggt gcactgcagt gctggaattg gccggacagg gacgttcatt gtgattgata
1801 ttcttattga catcatcaga gagaaaggtg ttgactgcga tattgacgtt cccaaaacca
1861 tccagatggt gcggtctcag aggtcaggga tggtccagac agaagcacag taccgattta
1921 tctatatggc ggtccagcat tatattgaaa cactacagcg caggattgaa gaagagcaga
1981 aaagaaagag gaaagggcac gaatatacaa atattaagta ttctctagcg gaccagacga
2041 gtggagatca gagccctctc ccgccttgta ctccaacgcc accctgtgca gaaatgagag
2101 aagacagtgc tagagtctat gaaaacgtgg gcctgatgca acagcagaaa agtttcagat
2161 gagaaaacct gccaaaactt cagcacagaa atagatgtgg actttcaccc tctccctaaa
2221 aagatcaaga acagacgcaa gaaagtttat gtgaagacag aatttggatt tggaaggctt
2281 gcaatgtggt tgactacctt ttgataagca aaatttgaaa ccatttaaag accactgtat
2341 tttaactcaa caatacctgc ttcccaatta ctcatttcct cagataagaa gaaatcatct
2401 ctacaatgta gacaacatta tattttatag aatttgtttg aaattgagga agcagttaaa
2461 ttgtgcgctg tattttgcag attatgggga ttcaaattct agtaataggc ttttttattt
2521 ttatttttat acccttaacc agtttaattt tttttttcct cattgttggg gatgatgaga
2581 agaaatgatt tgggaaaatt aagtaacaac gacctagaaa agtgagaaca atctcattta
2641 ccatcatgta tccagtagtg gataattcat tttgatggct tctatttttg gccaaatgag
2701 aattaagcca gtgcctgaga ctgtcagaag ttgacctttg cactggcatt aaagagtcat
2761 agaaaaaa
(SEQ ID NO:214)
MTSRRWFHPNITGVEAENLLLTRGVDGSFLARPSKSNPGDFTLS
VRRNGAVTHIKIQNTGDYYDLYGGEKFATLAELVQYYMEHHGQLKEKNGDVIELKYPL
NCADPTSERWFHGHLSGKEAEKLLTEKGKHGSFLVRESQSHPGDFVLSVRTGDDKGES
NDGKSKVTHVMIRCQELKYDVGGGERFDSLTDLVEHYKKNPMVETLGTVLQLKQPLNT
TRINAAEIESRVRELSKLAETTDKVKQGFWEEFETLQQQECKLLYSRKEGQRQENKNK
NRYKNILPFDHTRVVLHDGDPNEPVSDYINANIIMPEFETKCNNSKPKKSYIATQGCL
QNTVNDFWRMVFQENSRVIVMTTKEVERGKSKCVKYWPDEYALKEYGVMRVRNVKESA
AHDYTLRELKLSKVGQGNTERTVWQYHFRTWPDHGVPSDPGGVLDFLEEVHHKQESIM
DAGPVVVHCSAGIGRTGTFIVIDILIDIIREKGVDCDIDVPKTIQMVRSQRSGMVQTE
AQYRFIYMAVQHYIETLQRRIEEEQKRKRKGHEYTNIKYSLADQTSGDQSPLPPCTPT
PPCAEMREDSARVYENVGLMQQQKSFR

NM_—080601 Homo sapiens protein tyrosine phosphatase, non-receptor type 11 (PTPN11), transcript variant 2, mRNA (version 1)

(SEQ ID NO:215)
1    gcggaggagg agcgagccgg gccggggggc agctgcacag tctccgggat ccccaggcct
61   ggaggggggt ctgtgcgcgg ccggctggct ctgccccgcg tccggtcccg agcgggcctc
121  cctcgggcca gcccgatgtg accgagccca gcggagcctg agcaaggagc gggtccgtcg
181  cggagccgga gggcgggagg aacatgacat cgcggagatg gtttcaccca aatatcactg
241  gtgtggaggc agaaaaccta ctgttgacaa gaggagttga tggcagtttt ttggcaaggc
301  ctagtaaaag taaccctgga gacttcacac tttccgttag aagaaatgga gctgtcaccc
361  acatcaagat tcagaacact ggtgattact atgacctgta tggaggggag aaatttgcca
421  ctttggctga gttggtccag tattacatgg aacatcacgg gcaattaaaa gagaagaatg
481  gagatgtcat tgagcttaaa tatcctctga actgtgcaga tcctacctct gaaaggtggt
541  ttcatggaca tctctctggg aaagaagcag agaaattatt aactgaaaaa ggaaaacatg
601  gtagttttct tgtacgagag agccagagcc accctggaga ttttgttctt tctgtgcgca
661  ctggtgatga caaaggggag agcaatgacg gcaagtctaa agtgacccat gttatgattc
721  gctgtcagga actgaaatac gacgttggtg gaggagaacg gtttgattct ttgacagatc
781  ttgtggaaca ttataagaag aatcctatgg tggaaacatt gggtacagta ctacaactca
841  agcagcccct taacacgact cgtataaatg ctgctgaaat agaaagcaga gttcgagaac
901  taagcaaatt agctgagacc acagataaag tcaaacaagg cttttgggaa gaatttgaga
961  cactacaaca acaggagtgc aaacttctct acagccgaaa agagggtcaa aggcaagaaa
1021 acaaaaacaa aaatagatat aaaaacatcc tgccctttga tcataccagg gttgtcctac
1081 acgatggtga tcccaatgag cctgtttcag attacatcaa tgcaaatatc atcatgcctg
1141 aatttgaaac caagtgcaac aattcaaagc ccaaaaagag ttacattgcc acacaaggct
1201 gcctgcaaaa cacggtgaat gacttttggc ggatggtgtt ccaagaaaac tcccgagtga
1261 ttgtcatgac aacgaaagaa gtggagagag gaaagagtaa atgtgtcaaa tactggcctg
1321 atgagtatgc tctaaaagaa tatggcgtca tgcgtgttag gaacgtcaaa gaaagcgccg
1381 ctcatgacta tacgctaaga gaacttaaac tttcaaaggt tggacaaggg aatacggaga
1441 gaacggtctg gcaataccac tttcggacct ggccggacca cggcgtgccc agcgaccctg
1501 ggggcgtgct ggacttcctg gaggaggtgc accataagca ggagagcatc atggatgcag
1561 ggccggtcgt ggtgcactgc aggtgacagc tcctgctgcc cctctaggcc acagcctgtc
1621 cctgtctcct agcgcccagg gcttgctttt acctacccac tcctagctct ttaactgtag
1681 gaagaattta atatctgttt gaggcataga gcaactgcat tgagggacat tttgatccca
1741 aggcatattt ctcctagacc ctacagcact gccattggcc atggccatgg caacatgctc
1801 agttaaaaca gcaaagacta agtcagcatt atctctgagt ccaccagaag ttgtgcatta
1861 aacaacttca tcctggaaaa aaaaaaaaaa aa
(SEQ ID NO:216)
1    mtsrrwfhpn itgveaenll ltrgvdgsfl arpsksnpgd ftlsvrrnga vthikiqntg
61   dyydlyggek fatlaelvqy ymehhgqlke kngdvielky plncadptse rwfhghlsgk
121  eaeklltekg khgsflvres qshpgdfvls vrtgddkges ndgkskvthv mircqelkyd
181  vgggerfdsl tdlvehykkn pmvetlgtvl qlkqplnttr inaaeiesrv relsklaett
241  dkvkqgfwee fetlqqqeck llysrkegqr qenknknryk nilpfdhtrv vlhdgdpnep
301  vsdyinanii mpefetkcnn skpkksyiat qgclqntvnd fwrmvfqens rvivmttkev
361  ergkskcvky wpdeyalkey gvmrvrnvke saahdytlre lklskvgqgn tertvwqyhf
421  rtwpdhgvps dpggvldfle evhhkqesim dagpvvvhcr

NM_—080601 Homo sapiens protein tyrosine phosphatase non-receptor type 11 (PTPN11), transcript variant 2, mRNA (version 2)

(SEQ ID NO:217)
1    cggccgcggt ttccaggagg aagcaaggat gctttggaca
     ctgtgcgtgg cgcctccgcg
61   gagcccccgc gctgccattc ccggccgtcg ctcggtcctc
     cgctgacggg aagcaggaag
121  tggcggcggg cgtcgcgagc ggtgacatca cgggggcgac
     ggcggcgaag ggcgggggcg
181  gaggaggagc gagccgggcc ggggggcagc tgcacagtct
     ccgggatccc caggcctgga
241  ggggggtctg tgcgcggccg gctggctctg ccccgcgtcc
     ggtcccgagc gggcctccct
301  cgggccagcc cgatgtgacc gagcccagcg gagcctgagc
     aaggagcggg tccgtcgcgg
361  agccggaggg cgggaggaac atgacatcgc ggagatggtt
     tcacccaaat atcactggtg
421  tggaggcaga aaacctactg ttgacaagag gagttgatgg
     cagttttttg gcaaggccta
481  gtaaaagtaa ccctggagac ttcacacttt ccgttagaag
     aaatggagct gtcacccaca
541  tcaagattca gaacactggt gattactatg acctgtatgg
     aggggagaaa tttgccactt
601  tggctgagtt ggtccagtat tacatggaac atcacgggca
     attaaaagag aagaatggag
661  atgtcattga gcttaaatat cctctgaact gtgcagatcc
     tacctctgaa aggtggtttc
721  atggacatct ctctgggaaa gaagcagaga aattattaac
     tgaaaaagga aaacatggta
781  gttttcttgt acgagagagc cagagccacc ctggagattt
     tgttctttct gtgcgcactg
841  gtgatgacaa aggggagagc aatgacggca agtctaaagt
     gacccatgtt atgattcgct
901  gtcaggaact gaaatacgac gttggtggag gagaacggtt
     tgattctttg acagatcttg
961  tggaacatta taagaagaat cctatggtgg aaacattggg
     tacagtacta caactcaagc
1021 agccccttaa cacgactcgt ataaatgctg ctgaaataga
     aagcagagtt cgagaactaa
1081 gcaaattagc tgagaccaca gataaagtca aacaaggctt
     ttgggaagaa tttgagacac
1141 tacaacaaca ggagtgcaaa cttctctaca gccgaaaaga
     gggtcaaagg caagaaaaca
1201 aaaacaaaaa tagatataaa aacatcctgc cctttgatca
     taccagggtt gtcctacacg
1261 atggtgatcc caatgagcct gtttcagatt acatcaatgc
     aaatatcatc atgcctgaat
1321 ttgaaaccaa gtgcaacaat tcaaagccca aaaagagtta
     cattgccaca caaggctgcc
1381 tgcaaaacac ggtgaatgac ttttggcgga tggtgttcca
     agaaaactcc cgagtgattg
1441 tcatgacaac gaaagaagtg gagagaggaa agagtaaatg
     tgtcaaatac tggcctgatg
1501 agtatgctct aaaagaatat ggcgtcatgc gtgttaggaa
     cgtcaaagaa agcgccgctc
1561 atgactatac gctaagagaa cttaaacttt caaaggttgg
     acaagggaat acggagagaa
1621 cggtctggca ataccacttt cggacctggc cggaccacgg
     cgtgcccagc gaccctgggg
1681 gcgtgctgga cttcctggag gaggtgcacc ataagcagga
     gagcatcatg gatgcagggc
1741 cggtcgtggt gcactgcagg tgacagctcc tgctgcccct
     ctaggccaca gcctgtccct
1801 gtctcctagc gcccagggct tgcttttacc tacccactcc
     tagctcttta actgtaggaa
1861 gaatttaata tctgtttgag gcatagagca actgcattga
     gggacatttt gatcccaagg
1921 catatttctc ctagacccta cagcactgcc attggccatg
     gccatggcaa catgctcagt
1981 taaaacagca aagactaagt cagcattatc tctgagtcca
     ccagaagttg tgcattaaac
2041 aacttcatcc tggaaaaaaa aaaaaaaaa
(SEQ ID NO:218)
MTSRRWFHPNITGVEAENLLLTRGVDGSFLARPSKSNPGDFTLSVRRNGA
VTHIKIQNTGDYYDLYGGEKFATLAELVQYYMEHHGQLKEKNGDVIELKY
PLNCADPTSERWFHGHLSGKEAEKLLTEKGKHGSFLVRESQSHPGDFVLS
VRTGDDKGESNDGKSKVTHVMIRCQELKYDVGGGERFDSLTDLVEHYKKN
PMVETLGTVLQLKQPLNTTRINAAEIESRVRELSKLAETTDKVKQGFWEE
FETLQQQECKLLYSRKEGQRQENKNKNRYKNILPFDHTRVVLHDGDPNEP
VSDYINANIIMPEFETKCNNSKPKKSYIATQGCLQNTVNDFWRMVFQENS
RVIVMTTKEVERGKSKCVKYWPDEYALKEYGVMRVRNVKESAAHDYTLRE
LKLSKVGQGNTERTVWQYHFRTWPDHGVPSDPGGVLDFLEEVHHKQESIM
DAGPVVVHCR

Putative function

(CG3954)—protein tyrosine phosphatase

(CG16903)—cyclin, potentially involved in differentiation and neural plasticity

Example 19B

Validation of GENE Function by RNA Interference (RNAi) Knockdown in Drosophila Cultured Cells

To confirm the mitotic role of the target protein, knockdown of Corkscrew (CG3954) expression is performed in cultured Drosophila Dmel-2 cells using a double stranded RNA (dsRNA) from within the Corkscrew (CG3954) CDS corresponding to the following CDS sequence:

(SEQ ID NO:219)
GCCGAGTACATCAATGCCAACTACATACGGCTGCCCACCGACGGCGACCT
GTACAACATGAGCAGCTCGTCGGAGAGCCTGAACAGCTCGGTGCCCTCGT
GCCCCGCCTGCACGGCTGCCCAGACACAGCGGAACTGCTCCAACTGCCAG
CTGCAAAACAAGACGTGCGTGCAGTGCGCCGTGAAGAGCGCCATTCTGCC
GTATAGCAACTGTGCCACCTGCAGCCGCAAGTCAGACTCCCTGAGCAAGC
ACAAGCGGAGCGAATCCTCGGCCTCTTCATCGCCCTCCTCCGGCTCTGGG
TCCGGACCAGGATCGTCGGGCACCAGCGGAGTGAGCAGCGTCAATGGACC
CGGCACACCCACCAATCTCACGAGCGGCACAGCCGGATGTCTGGTCGGCC
TGCTGAAGAGACACTCGAACGACTCGTCCGGAGCTGTTTCTATATCGATG
GCCGAACGGGAACGCGAGAGGGAGCGCGAGATGTTTAAGACCTACATCGC
CACCCA

dsRNA is prepared by annealing complimentary RNAs made by in vitro transcription from a PCR fragment created with the following PCR primers:

(SEQ ID NO:220)
TAATACGACTCACTATAGGGAGAGCCGAGTACATCAATGCCAACTACAT
(SEQ ID NO:221)
TAATACGACTCACTATAGGGAGATGGGTGGCGATGTAGGTCTTAAACAT

Cells are transfected with double stranded RNA in the presence of ‘Transfast’ transfection reagent. A control transfection of a non-endogenous RNA corresponding to RFP (red fluorescent protein) is carried out in parallel.

Analysis of Corkscrew CG3954 Knockdown by RNAi in D-Mel2 cells by Cellomics Mitotic Index Assay

For the transfection, 1 μg dsRNA is added to a well of a 96-well Packard viewplate and 35 μl of logarithmically growing DMel-2 cells diluted to 2.3×10⁵ cells/ml in fresh Drosophila-SFM/glutamine/Pen-Strep are added. Cells are incubated with the dsRNA (60 nM) in a humid chamber at 28° C. for 1 hr before addition of 100 μl Drosophila-SFM/glutamine/Pen-Strep. Cells are incubated at 28° C. for 72 hours before analysis. For the assay, cells were fixed and stained using the Cellomics Mitotic Index HitKit following manufacturers instructions. The mitotic index of cells in each well was determined using the ArrayScan HCS System, running the Application protocol Mike_—250502_Polgen_MitoticIndex_—10×_p2.0 with the 10× objective and the DualBGlp filter set. This automated screening system detects the levels of a specific antigen (phosphorylated histone H3) which is only detectable during mitosis while the chromosomes are condensed.

Results for Corkscrew (CG3954) are shown in FIG. 1. A reproducible and significant reduction in mitotic index is observed in this assay indicating a reduction in the number of cells able to exit S-phase and enter mitosis after RNAi

Analysis of Corkscrew CG3954 Knockdown by RNAi in D-Mel2 Cells by Microscopy

For transfection 9 μl of Transfast reagent (Promega) is added to 3 μg gene specific dsRNA in 500 μl Drosophila Schneiders medium (no additives) and incubated at room temperature for 15 min. For control wells an equivalent amount of RFP dsRNA is used. This mix is added to a well of a 6-well tissue culture plate containing a glass coverslip and 500 μl of a Dmel-2 cells at 1×10⁶ cells/ml in shneiders medium. After a 1 hour incubation at 28° C., 2 mls Schneiders medium+10% FCS and pen/strep solution is added and cells are incubated at 28° C. for 48 hours. Cells on the coverslip are fixed in formaldehyde and stained with antibodies which detect α-tubulin and γ-tubulin (centrosomes), and are co-stained with DAPI to detect DNA.

An increase in the number of cells with chromosomal defects (see Table 1 below) was observed upon RNAi. The phenotypes seen were aneuploidy (65% of mitoses compared to 30% in control cells), misaligned chromosomes (80% compared to 40% in control cells), and polyploidy, however no spindle defects were observed.

	Number	Number of	% of chromosomal
	cells with	cells with	defects (no
	chromosomal	normal	defects/total
dsRNA	defects	mitosis	cells in mitosis)
No RNA	135	314	39.47
RFP	137	309	40.29
CG1725	186	87	68.13

Table 1 shows mitotic defects observed by microscopy after RNAi knockdown of Corkscrew (CG3954) in Dmel2 Drosophila cultured cells.

Example 19C

Shp2 is a Human Homologue of Drosophila Corkscrew CG3954

BLASTP with Drosophila Corkscrew CG3954 reveals 46% (327/700) sequence identity with the human Shp2 gene (genbank accession D13540), indicating that they are homologues. The BLASTP results are shown in FIG. 2.

The sequence of the human Shp2 gene mRNA (2 splice variants is shown in Example 19 above).

Example 19D

Validation of the Mitotic Role of the Human Homologue by siRNA Knockdown of Shp2 Expression in Human Cultured Cells

Generation of Shp2 siRNA Knockdowns

Knockdown of human Shp2 gene expression is achieved by siRNA (short interfering RNA, Elbashir et al, Nature 2001 May 24; 411(6836):494-8). We used synthetic double stranded RNAs corresponding to two different regions of the Shp2 mRNA. siRNAs are obtained from Dharmacon (our supplier). The siRNA sequences are:

COD1650	shp2-1	AACGUCAAAGAAAGCGCCGCU	Corresponds to
	siRNA	(SEQ ID NO:222)	nucleotides 1539-1559 in
			human Shp2 splice
			variants 1 and 2 see
			example 19 above)
COD1651	shp2-2	AAUUGGCCGGACAGGGACGUU	Corresponds to
	siRNA	(SEQ ID NO:223)	nucleotides 1766-1786 in
			human Shp2 splice
			variants 1 and 2 see
			example 19 above)

Analysis of siRNA Hu Shp2 Knockdowns in U2OS Cells by Flow Cytometry Analysis

Cells are seeded in 6-well tissue culture dishes at 1×10⁵ cells/well in 2 ml Dulbecco's Modified Eagle's Medium (DMEM) (Sigma)+10% Foetal Bovine Serum (FBS) (Perbio), and incubated overnight (37° C./5% CO₂).

For each well, 12 μl of 20 μM siRNA duplex (Dharmacon, Inc) (in RNAse-free H₂O) is mixed with 200 μl of Optimem (Invitrogen). In a separate tube 8 μl of oligofectamine reagent (Invitrogen) was mixed with 52 μl of Optimem, and incubated at room temperature for 7-10 mins. The oligofectamine/Optimem mix is then added dropwise to the siRNA/Optimem mix, and this is then mixed gently, before being incubated for 15-20 mins at room temperature. During this incubation the cells are washed once with DMEM (with no FBS or antibiotics added). 600 μl of DMEM (no FBS or antibiotics) is then added to each well.

Following the 15-20 min incubation, 128 μl of Optimem is added to the siRNA/oligofectamine/optimem mix, and this was added to the cells (in 600 μl DMEM). The transfection mix is added at the edge of each well to assist dilution before contact is made with the cells. Cells are then incubated with the transfection mix for 4 h (37° C./5% CO₂). Subsequently 1 ml DMEM+20% FBS is added to each well. Cells are then incubated at 37° C./5% CO₂ for 72 h. Cells are harvested by trypsinisation, washed in PBS, fixed in ice-cold 70% EtOH and stained with propidium iodide before Facs analysis.

siRNA Hu Shp2 knockdowns are conducted in U2OS. As shown in FIG. 3 major changes in the distribution of cells between cell cycle compartments (G1, S, G2/M) are seen with Shp2 siRNA COD1650 which is directed to both alternative transcripts of Shp2. An accumulation of cells in the S2 compartment cell cycle, is observed with a concomitant reduction in the G1 compartment population. This indicates that a proportion of cells may unable complete S-phase and enter mitosis.

Subsequent microscopic analysis is performed in order to look at phenotypes resulting from the Shp2 siRNA induced defect and check for the presence of large multinucleate cells which may, due to their size and ploidy, be excluded from the FACS analysis.

Analysis of Hu Shp2 siRNA Knockdowns in U2OS Cells by Microscopy

The transfection method for samples for microscopy is identical to that for Facs except that cells are plated in wells containing a sterile glass coverslip. Cells are incubated with siRNA for 48 hours before formaldehyde fixation and co-staining with Dapi to reveal DNA (blue) and antibodies to reveal microtubules (red) and centrosomes (green). Antibodies used are: rat anti-alpha tubulin (YL12) (supplier Serotec) with secondary antibody goat anti-rat IgG-TRITC (supplier Jackson Immunoresearch) and mouse anti-gamma-tubulin (GTU88) with secondary antibody Alexagreen488-goat anti-mouseIgG (supplier Sigma).

Phenotype analysis by microscopy is conducted on U2OS cells. Results from duplicate experiments in U2OS cells are shown in FIG. 4, and Table 2 below. After siRNA no mitotic defects were seen, only a small increase in binucleate and apoptotic cells. These results are consistent with the Facs analysis, and in conjunction with the results of Corkscrew siRNA in Dmel-2 cells, they confirm that Shp2 is involved in cell cycle progression, in particular, in completing S-phase. Accordingly, modulators of Shp2 activity (as identified by the assays described above) may be used to treat any proliferative disease.

TABLE 2
Description of significant cell division
defects after Shp2 siRNA in U2OS cells.
Gene/siRNA              Shp2/COD1650
Cell Type               U2OS
Polyploidy              Normal
Mitotic Defects         Normal
Main knockout phenotype No mitotic phenotype observed
Additional observations Increased number of binuclear cells
                        (0.6/field compared to 0.2/field in
                        untreated)
                        Increase in apoptotic cells

Example 19E

Expression of Recombinant Hu Shp2 Protein in Insect Cells

A cDNA encoding the Human Shp2 coding region derived by RT-PCR is inserted into the baculovirus expression vector pFastbacHTc (Life Technologies). A baculovirus stock is generated and western blot of subsequent infections of Sf9 insect cells demonstrates expression of N-terminal 6-His tagged proteins of approximately 68 kD. The recombinant protein is purified by Ni-NTA resin affinity chromatography.

Similarly 6-His tagged Dlg proteins are expressed in bacteria by inserting cDNAs into bacterial expression plamids pDest17 or pET series. Protein expression in cultures of host E. coli cells transformed with recombinant plasmid is induced by addition of inducer chemical IPTG. The recombinant protein is purified by Ni-NTA resin affinity chromatography

Example 19F

Assay for Modulators of Shp2 Activity

Shp2 is a non-transmembrane-type protein tyrosine phosphatase that participates in the signal transduction pathways of a variety of growth factors and cytokines. Shp2 binds directly to the PDGF receptor, EGF receptor, and c-KIT in response to stimulation of cells with the corresponding receptor ligand and undergoes tyrosine phosphorylation. Shp2 is implicated in PDGF-induced RAS activation and EGF stimulation of the RAS-MAP kinase cascade that leads to DNA synthesis. Corkscrew (the putative Drosophila homolog of Shp2) is thought to be required for Ras1 activation or to function in conjunction with Ras1 during signaling by the Sevenless receptor tyrosine kinase. In addition Shp2 is implicated in insulin dependent signaling. Shp2 does not interact directly with the insulin receptor, but it binds through its SH2 domains to tyrosine-phosphorylated docking proteins such as IRS1, IRS2, and GAB 1 in response to insulin. Overall Shp2 appears to play a role in growth factor-induced cell proliferation, through activation of the RAS-MAP kinase cascade. In addition to its role in receptor tyrosine kinase-mediated MAP kinase activation, Shp2 may play an important role, partly through its interaction with the membrane glycoprotein SHPS-1, in the activation of MAP kinase in response to the engagement of integrins by the extracellular matrix.

phosphotyrosyl proteins or peptides derived from SHPS-1, IRS1 or PDGF. An assay for modulators of Shp2 activity would consist of detection of dephosphorylation of ligand proteins, or phosphotyrosyl peptides derived from ligand proteins, described above e.g. phosphotyrosyl proteins or peptides derived from SHPS-1, IRS1 or PDGF (Takada et al 1998). Dephosphorylation of the substrate would be detected by quantifying the released inorganic phosphate, or by detecting loss of phosphate using an anti-phosphotyrosine antibody.

Example 20 (Category 3)

Line ID—500

Phenotype—Viable, High mitotic index, colchicines-type overcondensed chromosomes, a few polyploid cells

Annotated Drosophila genome genomic segment containing P element insertion site (and map position)—AE003422 (2C)

P element insertion site—247,403

Annotated Drosophila genome Complete Genome candidate CG4399—EAST

(SEQ ID NO:224)
ATGTCTAGCCGGAAGGTGCCAGGAGGCTCTGGAGGAGCTGACGAATCCAC
AGCAGCAGCTGCCCCCCTGGATGATAATGCCAATGCCAGTGTGGAGATTC
CAGACAGCAGCGAGGAGCCAGCAATGGGCGTCGGCGAAGAGATGTCTATC
ATAAGCAAAACACGCACCTCAACTTTGTCAGTGGAGCCCGCTAAGGAGCC
AACAGTAACAGCAGAGCTGGAAGGCGAAAAAGAGCTGGAATCGAATCCAG
TCTCCAAAACTCCTAGGTCCACGCCTACGCCAACCCTTACGCCAGCCGTC
ACGCCTACCGCCAGTGATGGAGTGGCGGCCAAGAGCGTGAGGGTTACCCG
GCACTCGTCGCCACTGCTTCTGATCATCTCGCCCACGACAAGTAGACGTG
AGGTCGGCGACGGAGAGCTAGACACCGAGGAACCAACGGGATCGGGTGGC
CAAAGAAAGAGCTCCGTGGAGCGATCTTTGGCGCCCGTTATACGCGGACG
AAAGTCCATCAAGGATCTGAAAGAAGCCAAAGAAGTCAAGTCCGAGGAGC
CGCCTGCCGCAGCATCAGAGTCACGAGCTGCAAGTGGAGTGACGCCTGGC
CAGGTCAAGGAACAGCATGTCGCGGATGGCAACGAAATGGAATCCTTGCC
AATCACAGACAAGAAAGACCACAAAGACACAAAAGACAAGGGAGATGAGC
GGGAAACCGATCAGGAGGAAGAGAAGGAAAAATCAGCTGATACAGAAATA
ATTGCAGATACAGAAAAAACTTCGGAGAAACAAAAGTATACAGAGAAGGA
CAAAGCTGCCGATAAAGATGGAGGAAAAGAAAAAGATATTGATGCAAATA
AGGATATAGATAAGGAGAAGGAAAAGGTCAAGGAAGTACTTCCGCCAGTG
GTGCCTATAGCACCAGTGACACCCACTTGTAACCGTGTCACACGTAAATC
ACATGCCCAGGAGCAGGCGATTAACACGCGGGTCACTCGCAATCGTCGCC
AGTCCTCTACAGTTGGAGCCAACTCCACCGCGTCTTTGGTAGCTGCATCC
TCCTCAGTAACAGAGCAACCCCCTCCATCTCGCGGTCGACGGAAGAAGCC
AGTGGTGGTGGCTCCTCCCTTGGAGCCTGCGGTAAAACGGAAGCGATCGC
AAGATGTTGAAGCCGACTCAGACGCCAACAACAGCACGAAATACAGCAAG
GTGGAAGTGGTAAAGTCTGAGGAAGCTGAGGCACCAGAGGAGGACTCCAG
TGCCGTGCCCATTAAGCAGGAATCTGTTGATGGCAACGAGGTCAGTTCTA
TTTCTCCAACAGTCACGCCCACACCCACACCTGCGCCAACACCAGCTCCA
GTCCCGGGCAGTCGACGGGGTCGTGGGCGCCCGCAGAACAGGAACTCCTC
TTCGCCTGCAACCACAACGCGGGCAACGCGGCTAAGCAAGGCGGGATCAC
CGGTTATCCTGACGCCAGTAGCCCAGGAACCGGCGCCACCGAAACGGCGG
CGAGTCGGCTCCAGCACACGGAAGACTGTCTCGGCCAGCTCGCTGGCACC
CAGCTCGCAGGGCGGCGCCGGGGATGAGGACTCCAAGGACAGTATGGCCT
CGTCCATGGACGACCTGCTGATGGCCGCAGCAGATATCAAGCAGGAGAAG
CTGACGCCCGATTTCGACGATAGTTTGATGCCAGAAGGCCTGCCCTCTAC
TTCTGGTGCGTCGAGTGCCAATGGTCATTCCTGCACCGAACCGCTTACTG
TGGACACGGAAATTAATGTTAAGCCCGCTGATTCCAAAGTAAAACCAAAG
GAGTCACCGGTGGTAGCAGTCGAGGAATCTCCATCACAATCCGAAACGCA
ATCTGCAAAGGTGTCAGCGCATGCGGGGAAGGCTCCATCTCTTAGTCCAG
ATATGATAAGTGAAGGCGTGAGCGCGGTCAGTGTTCGAAAGTTTTATAAG
AAGCCTGAGTTCCTGGAAAACAATCTGGGCATTGAAAAGGATCCGGAGCT
AGGTGAAATCGTTCAGACGGTTAGTAACAATGACACGGAAACAGATGTGG
AGATGGCTGTTGATGGCGAGGTGAATCAACCGTCAACTCCCAAGTCGCAG
GATAAAAAGAAAGAGGAGCAGGAAAAGAATCAGAAATCAGGGCTAAAGGC
AGCAAAGAAGGCTCCTGCTAAGTTAGAACCTAAAGCTGAAGACATTTCTG
AAATTCTTACTGACGTTCCTGTTGATATTTCGACTGAGGCAGTAGAAATT
ATAGAAGAAGCAGAGGAAGACACTTGTTCAAATAGCTCAATCAAACCAGG
TGAGCTCCGACTGGACGAGAGCAACGATGAACCTGAACTGCTTCTTGAAG
ACGCCCTCATAGTCAATGGTGATGAGAATGAGACACCAGATCAACCGGAG
GAAAAGGAGGACCAGGTGGAGTTCTTCCATACAGGAGAATACGACGACTT
TGAGCACGAGATTATGGTGGAGCTGGCGAAGGAGGGGGTGCTAGATGCCA
GCGGCAATGCATTAAGTCAGCAAAAGGTAGAACTTGAGCATCCCGAGGAT
GTAACTCTACACGAATCAAAAAATGACATAGAAGCCGAAGAATCGGTTGA
ACGTAAGCCTCTTAAGGACCCGTCGGTTGCGGACGAAATGGAGGACATGA
ATGAGGAATCCTATATTGACATTAAGGACCAGACAAATCAACTGTTAGTT
GAACACTTGGCAGAAGAGGCCATGGAAGCGGACTGCGGTCCCGAGGATAA
CAAGGAGAACTTGTCCACGTCTGCTTCGAGCACCGCTGCCGATGGTCTAG
ATATTCAGTTGGCCATCAAGGAGGATGACGACGAGGAGAAACCGCTTGCA
GTTATCGCTGACGAACAGAAGCCTGGGCTGCTGTTGACCAATGACATGAA
AGTGGATGAGAAACCAAATGGCAAGCAGGAATCGGTCTGTGATGAGCACG
TTCAGCTGGTGCCAAACCTTCGTCAAGAACAGGAAATTCACTTACAAAAT
CTGGGCCTACTCACGCACCAGGCCGCTGAACATAGGCGCAAGTGTCTGCT
TGAGGCACAGGCCCGCCAGGCGCAAATGCAGCTCCAGCAACATCACCACC
ATCAGCACAAGCGACAAGGAGCGCGCGGAGGAGGCAGTGCCACTCATGTG
GAATCCAGCGGTACTTTGAAGACAGTCATCAAGCTGAACAGGAGCAGCAA
CGGAGGAGTAAGCGGTAGTGGCGGCCTGCCTACTGGTACAGTTATCCATG
GAGGCTGTGGCTCCTCTTCAGCTTCTTCCACGTCCTCCTCCTCGGTGGGC
AGTGCCACACGTAAGTCAAGCGGGACCTTGGGCTCAGGAGCGGGAGCAGG
AGCTGGCGTTCGCCGGCAGTCGCTTAAGATGACATTCCAGAAGGGTCGGG
CTCGTGGTCACGGTGCTGCGGATCGATCCGCCGATCAGTATGGCGCCCAC
GCCGAGGACTCCTACTACACCATTCAAAACGAGAACGAAGGTGCGAAAAA
GTTTGTTGTAACTACTGGTAATACCGGCCGCAAGACTAATAACCGTTTCA
GCTCAACTAACAACTACCACTCGACGGTAGCCTTGCACGGTAGCAACTCT
GCGCTCCAGTACTATTCGTCCCACTCGGAAAGTCAGGGACAGACGGACCA
CGGCTTCTATCAGATGGTCAAAAAGGACGAAAAGGAGAAGATCCTCATTC
CGGAAAAGGCCTCCTCGTTTAAGTTTCACCCAGGGAGACTGTGCGAAGAC
CAGTGCTACTACTGTAGCGGAAAGTTTGGCCTCTATGACACCCCCTGCCA
TGTTGGACAAATAAAGTCCGTGGAGCGCCAGCAGAAGATCCTAGCCAACG
AGGAGAAGCTCACCGTGGATAACTGCTTGTGCGACGCATGTTTTCGACAC
GTGGACCGCCGGGCAAATGTGCCATCCTATAAGAAGCGTCTTTCCGCTTC
AGGTCACTTGGAGATGGGGTCTGCAGCGGGATCTGCACTAGAGAAACAGT
TTGCTGGCGACAGCGGCGTCATTACGGAATCGGGTGGCGAAGCTGGTTCT
ACGGCAGCTGTGGCCGTGCAGCAACGATCTTGTGGCGTGAAGGACTGCGT
CGAAGCGGCACGACACTCGCTGCGGCGCAAGTGCATACGCAAGAGAGTAA
AGAAGTATCAGCTCAGCCTGGAGATTCCCGCAGGCTCGTCGAACGTGGGG
CTGTGTGAGGCACATTACAATACGGTCATCCAATTTTCCGGCTGCGTTCT
TTGCAAGCGTAGATTAGGCAAGAACCATATGTACAACATAACCACGCAGG
ACACAATTCGACTGGAAAAGGCGCTGTCCGAGATGGGCATCCCAGTTCAG
CTTGGCATGGGCACTGCAGTCTGCAAGCTGTGTCGCTATTTTGCCAACCT
TTTGATAAAGCCACCGGATAGCACCAAGGCACAAAAGGCGGAATTCGTGA
AGAACTACAGAAAGAGGCTCCTCAAGGTGCATAATCTGCAGGATGGCAGT
CATGAGCTGTCCGAAGCGGATGAAGAAGAGGCACCTAATGCAACGGAGAC
AGAAAGGCCAACCTCAGACGGACACGAAGATCCCGAGATGCCCATGGTAG
CGGACTATGATGGACCTACCGACTCCAATTCCAGTAGTTCTTCGACTGCA
GCCCTGGACACCAGCAAACAAATGTCCAAGCTTCAGGCCATCCTGCAGCA
AAATGTGGGAGCGGATGCGGCAGGAGCTGCGGGAACAGGAACTGTTGCAG
CAAGTCCCGGAGGAAGCGGATCTGGGGCAGATATCTCTAACGTATTGCGA
GGGAATCCGAACATTTCCATGCGCGAACTTTTCCACGGCGAGGAAGAGCT
GGGTGTGCAGTTCAAGGTGCCGTTCGGATGCAGCAGCAGCCAGCGTACTC
CGGAGGGCTGGACACGAGTGCAGACTTTCCTACAATACGATGAGCCGACG
CGCCGCCTCTGGGAGGAGTTGCAAAAGCCGTACGGAAATCAGAGCTCATT
TCTGCGCCACTTGATACTATTAGAGAAGTACTACCGAAACGGAGATCTCG
TCCTAGCACCGCATGCTTCCTCCAATGCCACGGTTTACACAGAGACTGTT
CGTCAGCGGCTGAATTCGTTTGATCACGGTCACTGCGGTGGATTGAACAT
CGCAGGCAGCCCTTCTTCTTCGGGTTCCGGCAAGCGCAGTGGAGTTCCTC
AACCTACGGGTGCCAGTGTGCTGGCCACCGCCCTCACAACACCCTTGACA
AGCCATTCATCCTCCTCTGCATCCATTTCCTCCGAACAGCATTCGTCGGT
TGATCCTGTCATTCCGCTGGTAGACCTCAATGATGACGATGAAGGCGAAG
ATGGGGCAGGAGGAGCGGGCGAAAGGGAGTCGACAAATAGGCAGCAGGAC
GTAATCTTGGAATGCCTTAGAACTGCCTCTGTGGACAAGCTGACTAAGCA
GCTCAGCTCGAATGCGGTGACGATTATCGCCCGGCCCAAAGACAAATCGC
AGCTCTCCTGCAACAGCGGATCCTCCACGTCCATTTCCAGCTCCTCGTCC
GCTATTTCCTCGCCGGAGGAAGTGGCCGTCACTAAGGTTACAGCAGTCGC
ACCAGTCCAGTCCAAGGATGCACCGCCACTGGCGCCAGCAAGTAGCGGTG
TTAGCAACAGTCGTAGTATCCTTAAAACCAACCTCTTGGGCATGAACAAG
GCCGTGGAACTCGTGCCCTTAACGACTGCCCCCCACGCTTACAAGCCAAC
TGGATGCCATAAGCCTGAGAAACAGCAAAAGATTCTTGACGTGGCCAATA
AGCAGCCCGGTAGCCAGGGGGAACCGGTACCATCAAGCGCCTTGCTTGGC
CTGCAGTCAAAGCTAAAGCCTCCAACGCATCAGCAGCAGGTCAGCGGATC
AGGAGCGGGAACTAGTGGTTCTCAGAAGCCATCTAATGTGGCGCAATTGC
TTAGCTCTCCACCGGAGCTAATCAGCTTGCATCGACGGCAGACCAGCGGA
GCAGCAGCGGGGTCCAGCAGCTTCCTTCAGGGCAAGAGGCTTCAACTTCC
ACGATCTGGAGCAGGGCCTTCAGGAGCGGGAACGGGAACAGGCGCTGGAG
CAGCAGGAAGCCGCAGTGCGGGTGGACCACCACCGCCCAATGTGGTCATA
CTGCCGGACGCCTTAACCCCCCAGGAGCGACACGAGAGCAAGAGCTGGAA
GCCAACGCTGATACCGCTGGAGGATCAGCACAAGGTGCCGAACAAATCAC
ATGCTCTTTATCAGACCGCCGACGGTCGAAGGTTGCCCGCCCTGGTGCAA
GTGCAGTCTGGTGGCAAGCCATACCTCATCTCTATCTTCGACTATAACCG
CATGTGCATCTTGCGAAGGGAAAAGCTGATGCGGGACCAGTTGCTCAAGA
GTAACGCCAAGCCAAAGCCGCAGAACCAGCAACAGCAGCAGGGCCAAACG
CACCAGCAGCAGCAGAATTCCGCCGCATCGGCGGCTGCCTTCTCCAACAT
GGTGAAGTTGGCCCAGCAACACACGGCGCGACAGCAGCTTCAGCAGCTGC
AACAGAAGCCACAACAGCAGCAACAATTGCCCACTTTGCAGCCAGGTGGG
GTGCGACTTGCCCGGCTGCCGCAAAAACTACTGATGCCACCACTGACTAA
TCCGCAGATTGGCAGTCAAGCACCCAACTTACAGCCGTTGCTGTCTAGTA
CGCTGGATAACAGCAACAACTGCTGGCTGTGGAAAAACTTTCCTGATCCC
AATCAGTATCTGCTAAATGGAAACGGAGGGGGTGCCGGGAGCTCCTCCAG
CAAGTTGCCACATCTCACGGCCAAACCAGCCACGGCAACTAGTAGCTCCG
GAGCGGCCAACAAATCAGCAGGAAGCCTATTTACCCTCAAGCAGCAGCAG
CACCAGCAGAAACTCATCGACAACGCTATCATGTCAAAGATACCCAAAAG
TCTGACAGTAATACCGCAGCAGATGGGTGGTAATACCGGTGGCGATATGG
GGGGCAGCAGCTCCTCCGGCAAGGACTGATGACGGCGAAGGAGGGCGCCA
TGGCCATTAGCCGTAGCGCCGGAGGTAACCCGGCGAAGTAGTAGGATCAA
CAAGCAGGCGACGTGCAGCTTAAGCGGCGATCTTCAGAACAAGAGGTGAC
CAGCGGCGGCTCCATGGATATCACAAACTCCACAATTCCATGGCTGCAGT
AGAATAAGTGATACACT
(SEQ ID NO:225)
MSSRKVPGGSGGADESTAAAAPLDDNANASVEIPDSSEEPAMGVGEEMSI
ISKTRTSTLSVEPAKEPTVTAELEGEKELESNPVSKTPRSTPTPTLTPAV
TPTASDGVAAKSVRVTRHSSPLLLIISPTTSRREVGDGELDTEEPTGSGG
QRKSSVERSLAPVIRGRKSIKDLKEAKEVKSEEPPAAASESRAASGVTPG
QVKEQHVADGNEMESLPITDKKDHKDTKDKGDERETDQEEEKEKSADTEI
IADTEKTSEKQKYTEKDKAADKDGGKEKDIDANKDIDKEKEKVKEVLPPV
VPIAPVTPTCNRVTRKSHAQEQAINTRVTRNRRQSSTVGANSTASLVAAS
SSVTEQPPPSRGRRKKPVVVAPPLEPAVKRKRSQDVEADSDANNSTKYSK
VEVVKSEEAEAPEEDSSAVPIKQESVDGNEVSSISPTVTPTPTPAPTPAP
VPGSRRGRGRPQNRNSSSPATTTRATRLSKAGSPVILTPVAQEPAPPKRR
RVGSSTRKTVSASSLAPSSQGGAGDEDSKDSMASSMDDLLMAAADIKQEK
LTPDFDDSLMPEGLPSTSGASSANGHSCTEPLTVDTEINVKPADSKVKPK
ESPVVAVEESPSQSETQSAKVSAHAGKAPSLSPDMISEGVSAVSVRKFYK
KPEFLENNLGLEKDPELGEIVQTVSNNDTETDVEMAVDGEVNQPSTPKSQ
DKKKEEQEKNQKSGLKAAKKAPAKLEPKAEDISEILTDVPVDISTEAVEI
IEEAEEDTCSNSSIKPGELRLDESNDEPELLLEDALIVNGDENETPDQPE
EKEDQVEFFHTGEYDDFEHEIMVELAKEGVLDASGNALSQQKVELEHPED
VTLHESKNDIEAEESVERKPLKDPSVADEMEDMNEESYIDIKDQTNQLLV
EHLAEEAMEADCGPEDNKENLSTSASSTAADGLDIQLAIKEDDDEEKPLA
VIADEQKPGLLLTNDMKVDEKPNGKQESVCDEHVQLVPNLRQEQEIHLQN
LGLLTHQAAEHRRKCLLEAQARQAQMQLQQHHHHQHKRQGARGGGSATHV
ESSGTLKTVIKLNRSSNGGVSGSGGLPTGTVIHGGCGSSSASSTSSSSVG
SATRKSSGTLGSGAGAGAGVRRQSLKMTFQKGRARGHGAADRSADQYGAH
AEDSYYTIQNENEGAKKFVVTTGNTGRKTNNRFSSTNNYHSTVALHGSNS
ALQYYSSHSESQGQTDHGFYQMVKKDEKEKILIPEKASSFKFHPGRLCED
QCYYCSGKFGLYDTPCHVGQIKSVERQQKILANEEKLTVDNCLCDACFRH
VDRRANVPSYKKRLSASGHLEMGSAAGSALEKQFAGDSGVITESGGEAGS
TAAVAVQQRSCGVKDCVEAARHSLRRKCIRKRVKKYQLSLEIPAGSSNVG
LCEAHYNTVIQFSGCVLCKRRLGKNHMYNITTQDTIRLEKALSEMGIPVQ
LGMGTAVCKLCRYFANLLIKPPDSTKAQKAEFVKNYRKRLLKVHNLQDGS
HELSEADEEEAPNATETERPTSDGHEDPEMPMVADYDGPTDSNSSSSSTA
ALDTSKQMSKLQAILQQNVGADAAGAAGTGTVAASPGGSGSGADISNVLR
GNPNISMRELFHGEEELGVQFKVPFGCSSSQRTPEGWTRVQTFLQYDEPT
RRLWEELQKPYGNQSSFLRHLILLEKYYRNGDLVLAPHASSNATVYTETV
RQRLNSFDHGHCGGLNIAGSPSSSGSGKRSGVPQPTGASVLATALTTPLT
SHSSSSASISSEQHSSVDPVIPLVDLNDDDEGEDGAGGAGERESTNRQQD
VILECLRTASVDKLTKQLSSNAVTIIARPKDKSQLSCNSGSSTSISSSSS
AISSPEEVAVTKVTAVAPVQSKDAPPLAPASSGVSNSRSILKTNLLGMNK
AVELVPLTTAPHAYKPTGCHKPEKQQKILDVANKQPGSQGEPVPSSALLG
LQSKLKPPTHQQQVSGSGAGTSGSQKPSNVAQLLSSPPELISLHRRQTSG
AAAGSSSFLQGKRLQLPRSGAGPSGAGTGTGAGAAGSRSAGGPPPPNVVI
LPDALTPQERHESKSWKPTLIPLEDQHKVPNKSHALYQTADGRRLPALVQ
VQSGGKPYLISIFDYNRMCILRREKLMRDQLLKSNAKPKPQNQQQQQGQT
HQQQQNSAASAAAFSNMVKLAQQHTARQQLQQLQQKPQQQQQLPTLQPGG
VRLARLPQKLLMPPLTNPQIGSQAPNLQPLLSSTLDNSNNCWLWKNFPDP
NQYLLNGNGGGAGSSSSKLPHLTAKPATATSSSGAANKSAGSLFTLKQQQ
HQQKLIDNAIMSKIPKSLTVIPQQMGGNTGGDMGGSSSSGKD

Human homologue of Complete Genome candidate

AAF13722—neurofilament protein

(SEQ ID NO:226)
1    atgatgagct tcggcggcgc ggacgcgctg ctgggcgccc
     cgttcgcgcc gctgcatggc
61   ggcggcagcc tccactacgc gctagcccga aagggtggcg
     caggcgggac gcgctccgcc
121  gctggctcct ccagcggctt ccactcgtgg acacggacgt
     ccgtgagctc cgtgtccgcc
181  tcgcccagcc gcttccgtgg cgcaggcgcc gcctcaagca
     ccgactcgct ggacacgctg
241  agcaacgggc cggagggctg catggtggcg gtggccacct
     cacgcagtga gaaggagcag
301  ctgcaggcgc tgaacgaccg cttcgccggg tacatcgaca
     aggtgcggca gctggaggcg
361  cacaaccgca gcctggaggg cgaggctgcg gcgctgcggc
     agcagcaggc gggccgctcc
421  gctatgggcg agctgtacga gcgcgaggtc cgcgagatgc
     gcggcgcggt gctgcgcctg
481  ggcgcggcgc gcggtcagct acgcctggag caggagcacc
     tgctcgagga catcgcgcac
541  gtgcgccagc gcctagacga cgaggcccgg cagcgagagg
     aggccgaggc ggcggcccgc
601  gcgctggcgc gcttcgcgca ggaggccgag gcggcgcgcg
     tggacctgca gaagaaggcg
661  caggcgctgc aggaggagtg cggctacctg cggcgccacc
     accaggaaga ggtgggcgag
721  ctgctcggcc agatccaggg ctccggcgcc gcgcaggcgc
     agatgcaggc cgagacgcgc
781  gacgccctga agtgcgacgt gacgtcggcg ctgcgcgaga
     ttcgcgcgca gcttgaaggc
841  cacgcggtgc agagcacgct gcagtccgag gagtggttcc
     gagtgaggct ggaccgactg
901  tcggaggcag ccaaggtgaa cacagacgct atgcgctcag
     cgcaggagga gataactgag
961  taccggcgtc agctgcaggc caggaccaca gagctggagg
     cactgaaaag caccaaggac
1021 tcactggaga ggcagcgctc tgagctggag gaccgtcatc
     aggccgacat tgcctcctac
1081 caggaagcca ttcagcagct ggacgctgag ctgaggaaca
     ccaagtggga gatggccgcc
1141 cagctgcgag aataccagga cctgctcaat gtcaagatgg
     ctctggatat agagatagcc
1201 gcttacagaa aactcctgga aggtgaagag tgtcggattg
     gctttggccc aattcctttc
1261 tcgcttccag aaggactccc caaaattccc tctgtgtcca
     ctcacataaa ggtgaaaagc
1321 gaagagaaga tcaaagtggt ggagaagtct gagaaagaaa
     ctgtgattgt ggaggaacag
1381 acagaggaga cccaagtgac tgaagaagtg actgaagaag
     aggagaaaga ggccaaagag
1441 gaggagggca aggaggaaga agggggtgaa gaagaggagg
     cagaaggggg agaagaagaa
1501 acaaagtctc ccccagcaga agaggctgca tccccagaga
     aggaagccaa gtcaccagta
1561 aaggaagagg caaagtcacc ggctgaggcc aagtccccag
     agaaggagga agcaaaatcc
1621 ccagccgaag tcaagtcccc tgagaaggcc aagtctccag
     caaaggaaga ggcaaagtca
1681 ccgcctgagg ccaagtcccc agagaaggag gaagcaaaat
     ctccagctga ggtcaagtcc
1741 cccgagaagg ccaagtcccc agcaaaggaa gaggcaaagt
     caccggctga ggccaagtct
1801 ccagagaagg ccaagtcccc agtgaaggaa gaagcaaagt
     caccggctga ggccaagtcc
1861 ccagtgaagg aagaagcaaa atctccagct gaggtcaagt
     ccccggaaaa ggccaagtct
1921 ccaacgaagg aggaagcaaa gtcccctgag aaggccaagt
     cccctgagaa ggccaagtcc
1981 ccagagaagg aagaggccaa gtcccctgag aaggccaagt
     ccccagtgaa ggcagaagca
2041 aagtcccctg agaaggccaa gtccccagtg aaggcagaag
     caaagtcccc tgagaaggcc
2101 aagtccccag tgaaggaaga agcaaagtcc cctgagaagg
     ccaagtcccc agtgaaggaa
2161 gaagcaaagt cccctgagaa ggccaagtcc ccagtgaagg
     aagaagcaaa gacccccgag
2221 aaggccaagt ccccagtgaa ggaagaagcc aagtccccag
     agaaggccaa gtccccagag
2281 aaggccaaga ctcttgatgt gaagtctcca gaagccaaga
     ctccagcgaa ggaggaagca
2341 aggtcccctg cagacaaatt ccctgaaaag gccaaaagcc
     ctgtcaagga ggaggtcaag
2401 tccccagaga aggcgaaatc tcccctgaag gaggatgcca
     aggcccctga gaaggagatc
2461 ccaaaaaagg aagaggtgaa gtccccagtg aaggaggagg
     agaagcccca ggaggtgaaa
2521 gtcaaagagc ccccaaagaa ggcagaggaa gagaaagccc
     ctgccacacc aaaaacagag
2581 gagaagaagg acagcaagaa agaggaggca cccaagaagg
     aggctccaaa gcccaaggtg
2641 gaggagaaga aggaacctgc tglcgaaaag cccaaagaat
     ccaaagttga agccaagaag
2701 gaagaggctg aagataagaa aaaagtcccc accccagaga
     aggaggctcc tgccaaggtg
2761 gaggtgaagg aagacgctaa acccaaagaa aagacagagg
     tggccaagaa ggaaccagat
2821 gatgccaagg ccaaggaacc cagcaaacca gcagagaaga
     aggaggcagc accggagaaa
2881 aaagacacca aggaggagaa ggccaagaag cctgaggaga
     aacccaagac agaggccaaa
2941 gccaaggaag atgacaagac cctctcaaaa gagcctagca
     agcctaaggc agaaaaggct
3001 gaaaaatcct ccagcacaga ccaaaaagac agcaagcctc
     cagagaaggc cacagaagac
3061 aaggccgcca aggggaagta aggcagggag aaaggaacat
     ccggaacagc caaagaaact
3121 cagaagagtc ccggagctca aggatcagag taacacaatt
     ttcacttttt ctgtctttat
3181 gtaagaagaa actgcttaga tgacggggcc tccttcttca
     aacaggaatt tctgttagca
3241 atatgttagc aagagagggc actcccaggc ccctgccccc
     atgccctccc caggcgatgg
3301 acaattatga tagcttatgt agctgaatgt gatacatgcc
     gaatgccaca cgtaaacact
3361 tgactataaa aactgccccc ctcctttcca aataagtgca
     tttattgcct ctatgtgcaa
3421 ctgacagatg accgcaataa tgaatgagca gttagaaata
     cattatgctt gagatgtctt
3481 aacctattcc caaatgcctt ctgttttcca aaggagtggt
     caagcccttg cccagagctc
3541 tctattctgg aagagcggtc caggtggggc cgggcactgg
     ccactgaatt atgccagggc
3601 gcactttcca ctggagttca ctttcaattg cttctgtgca
     ataaaaccaa gtgcttataa
3661 aatgaaaaaa aaaaaaaaaa tgctgttatt ctctttccct
     gggaaggctg ggggcagggc
3721 aggggaggtc tggatgtgac accccagact gcatgggact
     gagcaagcat cagt
(SEQ ID NO:227)
1    mmsfggadal lgapfaplhg ggslhyalar kggaggtrsa
     agsssgfhsw trtsvssvsa
61   spsrfrgaga asstdsldtl sngpegcmva vatsrsekeq
     lqalndrfag yidkvrqlea
121  hnrslegeaa alrqqqagrs amgelyerev remrgavlrl
     gaargqlrle qehllediah
181  vrqrlddear qreeaeaaar alarfaqeae aarvdlqkka
     qalqeecgyl rrhhqeevge
241  llgqiqgsga aqaqmqaetr dalkcdvtsa lreiraqleg
     havqstlqse ewfrvrldrl
301  seaakvntda mrsaqeeite yrrqlqartt elealkstkd
     slerqrsele drhqadiasy
361  qeaiqqldae lrntkwemaa qlreyqdlln vkmaldieia
     ayrkllegee crigfgpipf
421  slpeglpkip svsthikvks eekikvveks eketviveeq
     teetqvteev teceekeake
481  eegkeeegge eeeaeggeee tksppaeeaa spekeakspv
     keeakspaea kspekeeaks
541  paevkspeka kspakeeaks ppeakspeke eakspaevks
     pekakspake eakspaeaks
601  pekakspvke eakspaeaks pvkeeakspa evkspekaks
     ptkeeakspe kakspekaks
661  pekeeakspe kakspvkaea kspekakspv kaeakspeka
     kspvkeeaks pekakspvke
721  eakspekaks pvkeeaktpe kakspvkeea kspekakspe
     kaktldvksp eaktpakeea
781  rspadkfpek akspvkeevk spekaksplk edakapekei
     pkkeevkspv keeekpqevk
841  vkeppkkaee ekapatpkte ekkdskkeea pkkeapkpkv
     eekkepavek pkeskveakk
901  eeaedkkkvp tpekeapakv evkedakpke ktevakkepd
     dakakepskp aekkeaapek
961  kdtkeekakk peekpkteak akeddktlsk epskpkaeka
     ekssstdqkd skppekated
1021 kaakgk

Putative function

unknown

Example 21 (Category 3)

Line ID—265

Phenotype—Lethal phase pharate adult. High mitotic index, rod like overcondensed chromosomes, few anaphases with lagging chromosomes

Annotated Drosophila genome genomic segment containing P element insertion site (and map position)—AE003509 (17B4-5)

P element insertion site—52,563

Annotated Drosophila genome Complete Genome candidate

CG6407—Wnt5

(SEQ ID NO:228)
CAGTTGTTTACAATTTGTCGTTGAGGGTGGATTACTTCGTCGCGAGTTTC
GTTCGTGCATGATGCGGTTGTGGTTGATTGTATACATACATACTATGCAC
AAATCCAGTTCTCATTTTGTTATTTTACAAATTCTCAGCGAGCGCATGAA
CTGGCAGCCTATAGCGAGCAGCTAATCACAATATTTACGGCAGATTCGTG
GACTCAAGGAAATTCAGCCAGCAGCCAATCGATTTTCTAGTGTTATCGAA
AAACATTTTTCATTCCTTCATTTCGTTCAACTAACAATACTAGTTACTAC
TAACAATACTCTGTAATAGTAATAGTAAGAGGAACAGGAATAGGAATACA
CATACTCCAAAGCGATAATGAGTTGCTACAGAAAAAGGCACTTTCTATTG
TGGCTCTTGCGTGCTGTGTGTATGTTGCACTTAACCGCGAGAGGGGCATA
TGCCACAGTTGGGTTGCAAGGAGTGCCGACATGGATATATCTCGGCCTCA
AGTCCCCCTTCATCGAGTTTGGCAACCAGGTGGAGCAGCTGGCCAATTCC
AGCATACCACTGAACATGACCAAGGACGAGCAGGCCAATATGCATCAAGA
GGGCCTACGCAAGCTCGGTACGTTCATAAAGCCAGTGGACCTGCGGGACT
CGGAGACTGGCTTCGTCAAGGCCGATCTCACCAAGAGACTGGTATTCGAT
AGACCGAACAACATTACATCTCGCCCTATTCACCCGATACAGGAGGAGAT
GGATCAGAAGCAGATAATCCTGCTCGACGAGGATACCGACGAGAATGGCC
TGCCAGCCAGTCTCACCGACGAGGATCGCAAGTTTATAGTGCCGATGGCG
CTCAAGAATATATCGCCCGATCCACGCTGGGCGGCCACTACACCGAGTCC
CTCCGCTTTGCAGCCGAACGCTAAAGCCATCTCGACCATTGTGCCCTCGC
CTCTGGCCCAGGTCGAGGGGGATCCCACGTCCAACATCGATGACCTGAAG
AAGCACATACTCTTCTTGCACAACATGACCAAGACCAATTCGAACTTCGA
GTCGAAATTCGTTAAATTCCCGAGCCTGCAAAAGGACAAGGCCAAGACAT
CGGGAGCTGGCGGTTCGCCGCCCAATCCCAAGCGGCCCCAGCGGCCGATT
CATCAGTATTCCGCGCCCATAGCCCCACCAACACCCAAGGTGCCCGCGCC
AGATGGCGGCGGCGTAGGAGGAGCAGCTTACAATCCCGGAGAGCAGCCAA
TTGGTGGCTACTATCAGAACGAGGAACTAGCGAATAATCAATCCCTTCTT
AAACCAACAGATACCGACTCCCATCCAGCGGCCGGCGGTAGCAGCCATGG
CCAGAAGAATCCCAGCGAGCCCCAGGTGATACTGCTCAACGAGACACTCT
CCACGGAGACCTCAATCGAAGCGGATCGCAGTCCATCGATAAACCAGCCC
AAGGCGGGATCGCCTGCGCGCACAACAAAGCGACCACCTTGCCTGCGCAA
TCCCGAGTCCCCGAAATGCATACGTCAGCGTCGGCGGGAGGAGCAACAGC
GGCAGCGGGAGCGGGACGAGTGGTTCCGCGGTCAGTCGCAGTACATGCAG
CCCCGGTTCGAGCCGATCATACAGACGATTAACAATACGAAGAGATTTGC
CGTATCAATCGAGATTCCAGACTCCTTTAAAGTATCCTCCGAGGGATCGG
ATGGGGAGTTGCTTTCGCGAGTCGAACGCTCGCAGCCCAGCATTAGTAGT
AGTAGTAGTAGCAGTAGTAGCAGTAGTAGGAAAATCATGCCAGACTATAT
TAAGGTATCCATGGAGAACAACACATCCGTCACGGATTATTTTAAGCACG
ACGTTGTGATGACATCGGCAGATGTCGCCAGCGATAGGGAATTCCTTATC
AAGAACATGGAGGAGCACGGAGGCGCTGGCTCCGCGAACAGTCATCACAA
TGATACGACTCCAACTGCAGACGCATATTCGGAGACAATCGATCTTAATC
CCAATAACTGCTATAGCGCAATAGGTCTAAGCAACAGCCAAAAGAAGCAA
TGTGTTAAGCACACCAGCGTGATGCCGGCCATAAGTCGTGGTGCCCGTGC
CGCCATCCAGGAGTGCCAGTTTCAGTTCAAGAATCGCCGCTGGAACTGCA
GCACAACGAACGACGAGACCGTATTTGGTCCCATGACCAGCCTGGCTGCT
CCCGAAATGGCCTTCATCCACGCCCTGGCCGCGGCCACGGTGACCAGCTT
CATAGCTCGCGCCTGCCGGGATGGCCAACTGGCCTCCTGCAGCTGCTCCC
GCGGCAGTCGACCCAAACAGCTCCACGACGACTGGAAGTGGGGCGGCTGT
GGCGACAACCTGGAGTTCGCCTACAAGTTCGCCACGGACTTCATCGATTC
GCGGGAGAAGGAAACCAATCGCGAGACGCGTGGCGTTAAGAGAAAACGCG
AGGAGATCAACAAGAATCGCATGCATTCCGATGACACGAATGCTTTTAAC
ATAGGTATTAAACGTAACAAAAACGTAGATGCTAAAAACGATACAAGTTT
GGTAGTGAGAAACGTTAGGAAAAGCACTGAGGCTGAAAACAGTCACATAC
TCAATGAGAACTTTGATCAGCACCTATTGGAACTAGAGCAGCGCATTACG
AAGGAGATACTTACATCCAAGATAGACGAGGAGGAGATGATTAAGCTGCA
GGAGAAGATCAAACAGGAGATTGTCAACACCAAGTTCTTCAAGGGTGAGC
AGCAGCCGCGCAAGAAGAAGCGAAAAAACCAGAGAGCCGCCGCCGATGCG
CCCGCCTATCCGAGGAACGGCATCAAGGAGAGCTACAAGGATGGCGGCAT
ATTGCCGCGCAGCACGGCCACTGTCAAGGCCAGGAGCCTGATGAACTTGC
ACAACAACGAGGCCGGACGTCGGGCGGTGATCAAGAAGGCCAGGATAACG
TGCAAGTGCCACGGCGTGTCCGGCTCCTGCAGCCTGATCACCTGCTGGCA
GCAATTGTCCTCCATCCGGGAGATTGGCGACTATCTGCGCGAGAAGTACG
AGGGCGCCACCAAGGTGAAGATCAACAAGCGTGGCCGCCTCCAGATCAAG
GACTTGCAATTCAAGGTGCCGACCGCTCACGATCTTATTTACCTAGACGA
AAGTCCCGACTGGTGCCGCAATAGCTATGCGCTGCATTGGCCGGGAACGC
ACGGACGTGTGTGCCACAAAAACTCGTCGGGATTGGAGAGCTGTGCCATC
CTCTGCTGCGGCCGGGGCTATAATACGAAGAACATTATAGTTAACGAACG
CTGCAATTGCAAATTTCACTGGTGTTGCCAGGTTAAATGTGAAGTTTGTA
CGAAGGTACTCGAGGAGCACACATGTAAATAGAGCGTTGATTGAATTCGA
ATGTCTTAATGTTTGTGACTAAGCCATGAAGGAAATAATCGTATTTAAAC
AGTCCTCTCCATTTTAATTGCCATTACCATACACCATCATATTGCTTCTT
CTTAAAATGCT
(SEQ ID NO:229)
MSCYRKRHFLLWLLRAVCMLHLTARGAYATVGLQGVPTWIYLGLKSPFIE
FGNQVEQLANSSIPLNMTKDEQANMHQEGLRKLGTFIKPVDLRDSETGFV
KADLTKRLVFDRPNNITSRPIHPIQEEMDQKQIILLDEDTDENGLPASLT
DEDRKFIVPMALKNISPDPRWAATTPSPSALQPNAKAISTIVPSPLAQVE
GDPTSNIDDLKKHILFLHNMTKTNSNEESKFVKFPSLQKDKAKTSGAGGS
PPNPKRPQRPIHQYSAPIAPPTPKVPAPDGGGVGGAAYNPGEQPIGGYYQ
NEELANNQSLLKPTDTDSHPAAGGSSHGQKNPSEPQVILLNETLSTETSI
EADRSPSINQPKAGSPARTTKRPPCLRNPESPKCIRQRRREEQQRQRERD
EWFRGQSQYMQPRFEPIIQTINNTKRFAVSIEIPDSFKVSSEGSDGELLS
RVERSQPSISSSSSSSSSSSRKIMPDYIKVSMENNTSVTDYFKHDVVMTS
ADVASDREFLIKNMEEHGGAGSANSHHNDTTPTADAYSETIDLNPNNCYS
AIGLSNSQKKQCVKHTSVMPAISRGARAAIQECQFQFKNRRWNCSTTNDE
TVFGPMTSLAAPEMAFIHALAAATVTSFIARACRDGQLASCSCSRGSRPK
QLHDDWKWGGCGDNLEFAYKFATDFIDSREKETNRETRGVKRKREEINKN
RMHSDDTNAFNIGIKRNKNVDAKNDTSLVVRNVRKSTEAENSHILNENFD
QHLLELEQRITKEILTSKIDEEEMIKLQEKIKQEIVNTKFFKGEQQPRKK
KRKNQRAAADAPAYPRNGIKESYKDGGILPRSTATVKARSLMNLHNNEAG
RRAVIKKARITCKCHGVSGSCSLITCWQQLSSIREIGDYLREKYEGATKV
KINKRGRLQIKDLQFKVPTAHDLIYLDESPDWCRNSYALHWPGTHGRVCH
KNSSGLESCAILCCGRGYNTKNIIVNERCNCKFHWCCQVKCEVCTKVLEE
HTCK

Human homologue of Complete Genome candidate

AAA16842—hWNT5A

(SEQ ID NO:230)
1    attaattctg gctccacttg ttgctcggcc caggttgggg
     agaggacgga gggtggccgc
61   agcgggttcc tgagtgaatt acccaggagg gactgagcac
     agcaccaact agagaggggt
121  cagggggtgc gggactcgag cgagcaggaa ggaggcagcg
     cctggcacca gggctttgac
181  tcaacagaat tgagacacgt ttgtaatcgc tggcgtgccc
     cgcgcacagg atcccagcga
241  aaatcagatt tcctggtgag gttgcgtggg tggattaatt
     tggaaaaaga aactgcctat
301  atcttgccat caaaaaactc acggaggaga agcgcagtca
     atcaacagta aacttaagag
361  acccccgatg ctcccctggt ttaacttgta tgcttgaaaa
     ttatctgaga gggaataaac
421  atcttttcct tcttccctct ccagaagtcc attggaatat
     taagcccagg agttgctttg
481  gggatggctg gaagtgcaat gtcttccaag ttcttcctag
     tggctttggc catatttttc
541  tccttcgccc aggttgtaat tgaagccaat tcttggtggt
     cgctaggtat gaataaccct
601  gttcagatgt cagaagtata tattatagga gcacagcctc
     tctgcagcca actggcagga
661  ctttctcaag gacagaagaa actgtgccac ttgtatcagg
     accacatgca gtacatcgga
721  gaaggcgcga agacaggcat caaagaatgc cagtatcaat
     tccgacatcg acggtggaac
781  tgcagcactg tggataacac ctctgttttt ggcagggtga
     tgcagatagg cagccgcgag
841  acggccttca catacgccgt gagcgcagca ggggtggtga
     acgccatgag ccgggcgtgc
901  cgcgagggcg agctgtccac ctgcggctgc agccgcgccg
     cgcgccccaa ggacctgccg
961  cgggactggc tctggggcgg ctgcggcgac aacatcgact
     atggctaccg ctttgccaag
1021 gagttcgtgg acgcccgcga gcgggagcgc atccacgcca
     agggctccta cgagagtgct
1081 cgcatcctca tgaacctgca caacaacgag gccggccgca
     ggacggtgta caacctggct
1141 gatgtggcct gcaagtgcca tggggtgtcc ggctcatgta
     gcctgaagac atgctggctg
1201 cagctggcag acttccgcaa ggtgggtgat gccctgaagg
     agaagtacga cagcgcggcg
1261 gccatgcggc tcaacagccg gggcaagttg gtacaggtca
     acagccgctt caactcgccc
1321 accacacaag acctggtcta catcgacccc agccctgact
     actgcgtgcg caatgagagc
1381 accggctcgc tgggcacgca gggccgcctg tgcaacaaga
     cgtcggaggg catggatggc
1441 tgcgagctca tgtgctgcgg ccgtgggtac gaccagttca
     agaccgtgca gacggagcgc
1501 tgccactgca agttccactg gtgctgctac gtcaagtgca
     agaagtgcac ggagatcgtg
1561 gaccagtttg tgtgcaagta gtgggtgcca cccagcactc
     agccccgctc ccaggacccg
1621 cttatttata gaaagtacag tgattctggt ttttggtttt
     tagaaatatt ttttattttt
1681 ccccaagaat tgcaaccgga accatttttt ttcctgttac
     catctaagaa ctctgtggtt
1741 tattattaat attataatta ttatttggca ataatggggg
     tgggaaccac gaaaaatatt
1801 tattttgtgg atctttgaaa aggtaataca agacttcttt
     tggatagtat agaatgaagg
1861 gggaaataac acatacccta acttagctgt gtgggacatg
     gtacacatcc agaaggtaaa
1921 gaaatacatt ttctttttct caaatatgcc atcatatggg
     atgggtaggt tccagttgaa
1981 agagggtggt agaaatctat tcacaattca gcttctatga
     ccaaaatgag ttgtaaattc
2041 tctggtgcaa gataaaaggt cttgggaaaa caaaacaaaa
     caaaacaaac ctcccttccc
2101 cagcagggct gctagcttgc tttctgcatt ttcaaaatga
     taatttacaa tggaaggaca
2161 agaatgtcat attctcaagg aaaaaaggta tatcacatgt
     ctcattctcc tcaaatattc
2221 catttgcaga cagaccgtca tattctaata gctcatgaaa
     tttgggcagc agggaggaaa
2281 gtccccagaa attaaaaaat ttaaaactct tatgtcaaga
     tgttgatttg aagctgttat
2341 aagaattggg attccagatt tgtaaaaaga cccccaatga
     ttctggacac tagatttttt
2401 gtttggggag gttggcttga acataaatga aatatcctgt
     attttcttag ggatacttgg
2461 ttagtaaatt ataatagtag aaataataca tgaatcccat
     tcacaggttt ctcagcccaa
2521 gcaacaaggt aattgcgtgc cattcagcac tgcaccagag
     cagacaacct atttgaggaa
2581 aaacagtgaa atccaccttc ctcttcacac tgagccctct
     ctgattcctc cgtgttgtga
2641 tgtgatgctg gccacgtttc caaacggcag ctccactggg
     tcccctttgg ttgtaggaca
2701 ggaaatgaaa cattaggagc tctgcttgga aaacagttca
     ctacttaggg atttttgttt
2761 cctaaaactt ttattttgag gagcagtagt tttctatgtt
     ttaatgacag aacttggcta
2821 atggaattca cagaggtgtt gcagcgtatc actgttatga
     tcctgtgttt agattatcca
2881 ctcatgcttc tcctattgta ctgcaggtgt accttaaaac
     tgttcccagt gtacttgaac
2941 agttgcattt ataagggggg aaatgtggtt taatggtgcc
     tgatatctca aagtcttttg
3001 tacataacat atatatatat atacatatat ataaatataa
     atataaatat atctcattgc
3061 agccagtgat ttagatttac agcttactct ggggttatct
     ctctgtctag agcattgttg
3121 tccttcactg cagtccagtt gggattattc caaaagtttt
     ttgagtcttg agcttgggct
3181 gtggccccgc tgtgatcata ccctgagcac gacgaagcaa
     cctcgtttct gaggaagaag
3241 cttgagttct gactcactga aatgcgtgtt gggttgaaga
     tatctttttt tcttttctgc
3301 ctcacccctt tgtctccaac ctccatttct gttcactttg
     tggagagggc attacttgtt
3361 cgttatagac atggacgtta agagatattc aaaactcaga
     agcatcagca atgtttctct
3421 tttcttagtt cattctgcag aatggaaacc catgcctatt
     agaaatgaca gtacttatta
3481 attgagtccc taaggaatat tcagcccact acatagatag
     cttttttttt tttttttttt
3541 ttttaataag gacacctctt tccaaacagg ccatcaaata
     tgttcttatc tcagacttac
3601 gttgttttaa aagtttggaa agatacacat cttttcatac
     ccccccttag gaggttgggc
3661 tttcatatca cctcagccaa ctgtggctct taatttattg
     cataatgata tccacatcag
3721 ccaactgtgg ctctttaatt tattgcataa tgatattcac
     atcccctcag ttgcagtgaa
3781 ttgtgagcaa aagatcttga aagcaaaaag cactaattag
     tttaaaatgt cacttttttg
3841 gtttttatta tacaaaaacc atgaagtact ttttttattt
     gctaaatcag attgttcctt
3901 tttagtgact catgtttatg aagagagttg agtttaacaa
     tcctagcttt taaaagaaac
3961 tatttaatgt aaaatattct acatgtcatt cagatattat
     gtatatcttc tagcctttat
4021 tctgtacttt taatgtacat atttctgtct tgcgtgattt
     gtatatttca ctggtttaaa
4081 aaacaaacat cgaaaggctt attccaaatg gaag
(SEQ ID NO:231)
1    magsamsskf flvalaiffs faqvvieans wwslgmnnpv
     qmsevyiiga qplcsqlagl
61   sqgqkldchl yqdhmqyige gaktgikecq yqfrhrrwnc
     stvdntsvfg rvmqigsret
121  aftyavsaag vvnamsracr egelstcgcs raarpkdlpr
     dwlwggcgdn idygyrfake
181  fvdarereri hakgsyesar ilmnlhnnea grrtvynlad
     vackchgvsg scslktcwlq
241  ladfrkvgda lkekydsaaa mrlnsrgklv qvnsrfnspt
     tqdlvyidps pdycvrnest
301  gslgtqgrlc nktsegmdgc elmccgrgyd qfktvqterc
     hckfhwccyv kckkcteivd
361  qfvck

Putative function

Wnt oncogene

Example 22 (Category 3)

Line ID—392

Phenotype—Lethal phase larval stage 3-pharate adult, small brain and optic lobes, high mitotic index, rod-like overcondensed chromosomes, fewer ana- and telophases, overcondensed chromosomes in ana- and telophase

Annotated Drosophila genome genomic segment containing P element insertion site (and map position)—AE003495 (12D)

P element insertion site—35,688

Annotated Drosophila genome Complete Genome candidate

CG12482—novel protein

(SEQ ID NO:232)
ATGGGTTGCACCTGCTGTGACAATAAACCCAAGCCGGAGACCATTGAGAT
ATATTCGGTGAAAATCCGTGAGAATGGTACATACAAGTTGATCAAGATGC
AATTGGCGGATATTTGGAGTCACGGATGGGAGCTGCGTATCAATAACTTT
GCCGACAAGGAAAAGGTGCCGCACAACGAGAAGGATATTCGCAATCAGGT
GTCGGTGGCGCGCAAAGCCAAACAGAGTCTGTGGAACAATAATAAGCATT
TTGTGTACTGGTGCCGCTACGGAAGTCGTCAGCAGGATCTGCGAAAGCGA
CAGGTAACGACGAGTGCCAATCACGTGCTGCTGCACCTGATCAATTGA
(SEQ ID NO:233)
MGCTCCDNKPKPETIEIYSVKIRENGTYKLIKMQLADIWSHGWELRINNF
ADKEKVPFINEKDIRNQVSVARKAKQSLWNNNKHFVYWCRYGSRQQDLRK
RQVTTSANHVLLHLIN

Human homologue of Complete Genome candidate

none

Putative function

unknown

Example 23 (Category 3)

Line ID—37

Phenotype—Lethal phase larval stage 3. Small brain, few cells in mitosis, badly defined chromosomes form a broad bend, weak chromosome condensation, abnormal anaphases with broken chromosomes

Annotated Drosophila genome genomic segment containing P element insertion site (and map position)—AE003418 (1C1-2)

P element insertion site—105,970

Annotated Drosophila genome Complete Genome candidate

CG16983—skpA, SCF ubiquitin ligase subunit (3 splice variants)

(SEQ ID NO:234)
CCATTTGAAAGTATCGGTGTAATTTGTTTTCAGAGAAATTAATTTCCGTT
TACTGTGCAATTCGGTGTGAAAGTGTTCAGATTTATCAATGCGTATTCTG
CTTTCGACTTCGCCACCAATCTGTGCTGCAAGTTACCATTACCAGGTCCA
CCTGGTTCCCGCCAGTTTTCTTTCATTGTGGCTAGTTGTTGTTCGTGCCT
TCGATAAAGACGTTTAGAGGTGTTTTTAGAGTTTCGCCATCTGGTCACTA
TAGCCGTTTCGTTTTTTACATGCCCAGCATCAAGTTGCAATCTTCGGATG
AGGAGATCTTTGACACGGATATCCAGATCGCCAAGTGCTCCGGCACTATC
AAGACCATGCTGGAGGACTGCGGCATGGAGGACGATGAGAATGCCATTGT
GCCGTTGCCCAATGTGAATTCGACGATTCTTCGCAAGGTGCTTACCTGGG
CTCACTACCACAAGGACGACCCCCAGCCAACGGAGGATGATGAGAGCAAG
GAGAAGCGCACAGACGACATTATCTCATGGGATGCAGATTTCCTAAAAGT
CGACCAGGGCACACTGTTTGAGCTGATATTGGCAGCGAACTATCTGGACA
TTAAGGGCCTTCTGGAGCTCACCTGCAAGACTGTTGCAAACATGATTAAG
GGAAAGACTCCCGAGGAAATACGCAAGACCTTCAACATTAAGAAGGACTT
TTCGCCCGCCGAGGAGGAGCAGGTGCGCAAGGAGAACGAGTGGTGCGAGG
AGAAGTAAAGCGCGGCATTTCGCGGGACCAACATTAAGTTGAAACAGCTA
GGGGATTCGGGAACGAATTGGATTTGCAGCATTGCAACTTTACTTAGTTG
CTACTTTCATTTACATTTTTTTTTATTTTTAACCCCAGCAGAGACTCGAT
TTAAATTGTGTATAAATGATCTGTTGCTGATTTGATTCGCGGGGTTCATT
TTTTGTCGTAAATATATCTCATATACATACATATGCGAGATTGTAACACT
CTCTTTAACCTATTGGAGTAACACTTGATTTCACTTTAATAAATATAACT
ACCCAACAC
(SEQ ID NO:235)
MPSIKLQSSDEEIFDTDIQIAKCSGTIKTMLEDCGMEDDENAIVPLPNVN
STILRKVLTWAHYHKDDPQPTEDDESKEKRTDDIISWDADFLKVDQGTLF
ELILAANYLDIKGLLELTCKTVANMIKGKTPEEIRKTFNIKKDFSPAEEE
QVRKENEWCEEK
(SEQ ID NO:236)
TTTCGCCATCTGGTCACTATAGCCGTTTCGTTTTTTACGTGAGTATTGTG
AATTTGGTGTGTTGATTTATATCTCAGTTGGAGCCTGCGTGGAAATAGTG
TCAGTACGTTTAAAGGCATCATCGTAAGGAAAGCCCAAAATGCCCAGCAT
CAAGTTGCAATCTTCGGATGAGGAGATCTTTGACACGGATATCCAGATCG
CCAAGTGCTCCGGCACTATCAAGACCATGCTGGAGGACTGCGGCATGGAG
GACGATGAGAATGCCATTGTGCCGTTGCCCAATGTGAATTCGACGATTCT
TCGCAAGGTGCTTACCTGGGCTCACTACCACAAGGACGACCCCCAGCCAA
CGGAGGATGATGAGAGCAAGGAGAAGCGCACAGACGACATTATCTCATGG
GATGCAGATTTCCTAAAAGTCGACCAGGGCACACTGTTTGAGCTGATATT
GGCAGCGAACTATCTGGACATTAAGGGCCTTCTGGAGCTCACCTGCAAGA
CTGTTGCAAACATGATTAAGGGAAAGACTCCCGAGGAAATACGCAAGACC
TTCAACATTAAGAAGGACTTTTCGCCCGCCGAGGAGGAGCAGGTGCGCAA
GGAGAACGAGTGGTGCGAGGAGAAGTAAAGCGCGGCATTTCGCGGGACCA
ACATTAAGTTGAAACAGCTAGGGGATTCGGGAACGAATTGGATTTGCAGC
ATTGCAACTTTACTTAGTTGCTACTTTCATTTACATTTTTTTTTATTTTT
AACCCCAGCAGAGACTCGATTTAAATTGTGTATAAATGATCTGTTGCTGA
TTTGATTCGCGGGGTTCATTTTTTGTCGTAAATATATCTCATATACATAC
ATATGCGAGATTGTAACACTCTCTTTAACCTATTGGAGTAACACTTGATT
TCACTTTAATAAATATAACTACCCAACAC
(SEQ ID NO:237)
MPSIKLQSSDEEIFDTDIQIAKCSGTIKTMLEDCGMEDDENAIVPLPNVN
STILRKVLTWAHYHKDDPQPTEDDESKEKRTDDIISWDADFLKVDQGTLF
ELILAANYLDIKGLLELTCKTVANMIKGKTPEEIRKTFNIKKDFSPAEEE
QVRKENEWCEEK
(SEQ ID NO:238)
AAACATCGAAAGTGCACAATCGTTTGTTATCTTTGTACGAAAACAACGGT
GATTTCCACACAGGCATAACCTGCAAGAGAAAGCCCAAAATGCCCAGCAT
CAAGTTGCAATCTTCGGATGAGGAGATCTTTGACACGGATATCCAGATCG
CCAAGTGCTCCGGCACTATCAAGACCATGCTGGAGGACTGCGGCATGGAG
GACGATGAGAATGCCATTGTGCCGTTGCCCAATGTGAATTCGACGATTCT
TCGCAAGGTGCTTACCTGGGCTCACTACCACAAGGACGACCCCCAGCCAA
CGGAGGATGATGAGAGCAAGGAGAAGCGCACAGACGACATTATCTCATGG
GATGCAGATTTCCTAAAAGTCGACCAGGGCACACTGTTTGAGCTGATATT
GGCAGCGAACTATCTGGACATTAAGGGCCTTCTGGAGCTCACCTGCAAGA
CTGTTGCAAACATGATTAAGGGAAAGACTCCCGAGGAAATACGCAAGACC
TTCAACATTAAGAAGGACTTTTCGCCCGCCGAGGAGGAGCAGGTGCGCAA
GGAGAACGAGTGGTGCGAGGAGAAGTAAAGCGCGGCATTTCGCGGGACCA
ACATTAAGTTGAAACAGCTAGGGGATTCGGGAACGAATTGGATTTGCAGC
ATTGCAACTTTACTTAGTTGCTACTTTCATTTACATTTTTTTTTATTTTT
AACCCCAGCAGAGACTCGATTTAAATTGTGTATAAATGATCTGTTGCTGA
TTTGATTCGCGGGGTTCATTTTTTGTCGTAAATATATCTCATATACATAC
ATATGCGAGATTGTAACACTCTCTTTAACCTATTGGAGTAACACTTGATT
TCACTTTAATAAATATAACTACCCAACAC
(SEQ ID NO:239)
MPSIKLQSSDEEIFDTDIQIAKCSGTIKTMLEDCGMEDDENAIVPLPNVN
STILRKVLTWAHYHKDDPQPTEDDESKEKRTDDIISWDADFLKVDQGTLF
ELILAANYLDIKGLLELTCKTVANMIKGKTPEEIRKTFNIKKDFSPAEEE
QVRKENEWCEEK

Human homologue of Complete Genome candidate

XP_—054159—hypothetical protein

(SEQ ID NO:240)
1   gcctcccagc tctcgtcagc ctcctgctgg ccatctcctt aacaccaaac actatgcctt
61  caattcagtt gcagagtttt gatggagaga tatttgcagt tgatgtggaa attgccaaac
121 aatctgtgac tatcaagacc acgttggaag atttgggaat ggatgatgaa ggagatgacc
181 cagttcctct accaaatgtg aatgcagcag tattaaaaaa ggtcattcag tggtgcaccc
241 accacaagga tgaccctcct ccccctgaag atgatgagaa caaagaaaag caaacagacg
301 atatccctgt ttgggaccaa gaattcctga aagttgctca aggaacactt tttgaactca
361 ttcgggctgc aaactactta gacatcaaag gtttgcttga tgttacatgc aagactgttg
421 ccaatatgat caaggggaaa actcctgagg agattcgcaa gacattcaat atcaaaaatg
481 actttactga agaggaggaa gcccaggtac gcaaagagaa ccagtggtgt gaagagaagt
541 gaaatgttgt gcctgacact gtaacactgt aaggat
(SEQ ID NO:241)
1   mpsiqlqsfd geifavdvei akqsvtiktt ledlgmddeg ddpvplpnvn aavlkkviqw
61  cthhkddppp peddenkekq tddipvwdqe flkvaqgtlf eliraanyld ikglldvtck
121 tvanmikgkt peeirktfni kndfteeeea qvrkenqwce ek

Putative function

Cell cycle protein, ubiquitin ligase

Example 24 (Category 3)

Line ID—186

Phenotype—Lethal phase larval stage 3. Small brain, high mitotic index, rod-like overcondensed chromosomes, fewer ana- and telophases.

Annotated Drosophila genome genomic segment containing P element insertion site (and map position)—AE003494 (12C6-7)

P element insertion site—123,540

Annotated Drosophila genome Complete Genome candidate

CG18319—bendless ubiquitin conjugating enzyme

(SEQ ID NO:242)
TTAGTCACAGCAACGCACACACACACTACCAAACGGCTACATTTTTTTTC
GAGTGTGTTCGACATTCATAATTTTTGTGGTGGAGCTGCCTGCAAAATCG
AATTTTATCAGTTTGCCAACGAAGTTATCGGCCATAACTGCAAATAAAGT
TCAGCAATAACTTGGCGCTGTTACGATCTCAACGAGAAGGTCCAGACTCA
ACCCGCGTTTCCAGTTCACCGCGTAAAAGGAACCAGCTAAACGATGTCCA
GCCTGCCACGTCGCATCATCAAGGAGACTCAACGTTTGATGCAGGAGCCA
GTGCCTGGGATCAATGCCATTCCCGATGAGAACAATGCCCGTTACTTCCA
TGTGATCGTGACCGGACCGAACGATTCGCCCTTCGAGGGCGGCGTGTTCA
AGCTGGAGCTGTTCCTACCGGAGGACTATCCAATGTCAGCGCCCAAAGTG
CGCTTCATCACGAAGATCTACCATCCGAACATCGATCGTTTGGGCCGCAT
TTGCCTCGACGTGCTGAAGGACAAGTGGAGTCCAGCCCTGCAGATCCGGA
CCATATTGCTATCCATTCAGGCACTGCTCAGTGCACCCAATCCCGACGAT
CCGCTGGCCAACGATGTGGCTGAGTTGTGGAAGGTCAACGAGGCGGAGGC
CATTCGCAATGCCCGCGAGTGGACCCAGAAATATGCCGTCGAAGACTGAA
CGCCCGAGGTCAGGAGGAAAGTCAGAAAGCGGATCCGTCAGTTGTATCGG
CGTTTTTCCAGAAAGTGGGTGCGTGACATGAACGGGCGGGTGGGTAAATT
GAATACTTTAAAAGCAACCAGAAAAACCTAAAACATACGAAAGAAAACAT
AAAATAAGAAAAAAGTAAGGAAGCAAACATAAAAAAAAACGATTTAAGAA
CACATTTTTTTTTCGAACCTTCTGGGGCGGGATATACATATAAAATATTA
ATATATATATTTTTTTCAACCAATCGATCGGGGCGATCGGCGAAATGGAG
GAGAGATAGCGAAAGCATTCTTTATGTAAGACGTATACATGTATCCGAAA
CAAACTAAAAACGAAAAAAAAAAAAAAAAAAAAAAACAGTAATTGGTTTT
AGTCGTTTCTATTGATTTGTTCGAGGGTTCTGGTGTCTATATACATATAG
CCGTATATAATTCTATGTGTAACTGAAATAACCAACCCATAACCATTAAC
ACATGTAGCATCAGATATGATAAATCAATTGGAAAGGCAAACAAGAAGGG
ATTTTGATTTCCTTTAACTCGTCATTTGAAAACTCGGCTTAAATGTCAAT
TCAAAATAGAGAATTTTGATTGTATCATTTTCAGTGTTTCAGAAAATTTA
AGATGTGATCGTCCAACTTGTAGACTTTACTTTTCTTAACTAAGAGTTCA
CCATTTCGATTGATACTTGAGCTTTGCCTGGGTTGTGTCAGAGTCCCTTT
GATAAACGATAAATAGTTTTTACTCGAAAACAATTTTTTTTAACCAAACA
ATGAAGCCTTTAAGCTATTAGTAATTTTTGAAAAAAAAAAAAAATAAAAA
TATATATATAAAAAATATACAAAAATATGATACATGATCAAAATACAATG
AATGCATACACTATATATTTATACAAAAAAAATACAAAAAGAAAAACAAA
AGTAGTGGCTTGATTGCGTGAAAATTTCAAGTGCAGTTCTCAACAAAAAT
TGTGTACAGTAATTAAATGTTTGTCACCGAAATCACTAAAGGATAATCCA
AAAAACAATAGCAACCGAAAAGCAACCATAAATCAAAGAGTAAGCGAAAA
TAAAAATTCAGTTTTCTTTAATTTTAATTAATTTTTTTCTAAGAAAAATA
AATAAAAACGAAAAATTCAAAT
(SEQ ID NO:243)
MSSLPRRIIKETQRLMQEPVPGINAIPDENNARYFHVIVTGPNDSPFEGG
VFKLELFLPEDYPMSAPKVRFITKIYHPNIDRLGRICLDVLKDKWSPALQ
IRTILLSIQALLSAPNPDDPLANDVAELWKVNEAEAIRNAREWTQKYAVE
D

Human homologue of Complete Genome candidate

BAA11675—ubiquitin-conjugating enzyme E2 UbcH-ben

(SEQ ID NO:244)
1    actcgtgcgt gaggcgagag gagccggaga cgagaccaga ggccgaactc gggttctgac
61   aagatggccg ggctgccccg caggatcatc aaggaaaccc agcgtttgct ggcagaacca
121  gttcctggca tcaaagccga accagatgag agcaacgccc gttattttca tgtggtcatt
181  gctggccctc aggattcccc ctttgaggga gggactttta aacttgaact attccttcca
241  gaagaatacc caatggcagc ccctaaagta cgtttcatga ccaaaattta tcatcctaat
301  gtagacaagt tgggaagaat atgtttagat attttgaaag ataagtggtc cccagcactg
361  cagatccgca cagttctgct atcgatccag gccttgttaa gtgctcccaa tccagatgat
421  ccattagcaa atgatgtagc ggagcagtgg aagaccaacg aagcccaagc catagaaaca
481  gctagagcat ggactaggct atatgccatg aataatattt aaattgatac gatcatcaag
541  tgtgcatcac ttctcctgtt ctgccaagac ttcctcctct ttgtttgcat ttaatggaca
601  cagtcttaga aacattacag aataaaaaag cccagacatc ttcagtcctt tggtgattaa
661  atgcacatta gcaaatctat gtcttgtcct gattcactgt cataaagcat gagcagaggc
721  tagaagtatc atctggattg ttgtgaaacg tttaaaagca gtggcccctc cctgctttta
781  ttcatttccc ccatcctggt ttaagtataa agcactgtga atgaaggtag ttgtcaggtt
841  agctgcaggg gtgtgggtgt ttttatttta ttttatttta ttttattttt gaggggggag
901  gtagtttaat tttatgggct cctttccccc ttttttggtg atctaattgc attggttaaa
961  agcagctaac caggtcttta gaatatgctc tagccaagtc taactttatt tagacgctgt
1021 agatggacaa gcttgattgt tggaaccaaa atgggaacat taaacaaaca tcacagccct
1081 cactaataac attgctgtca agtgtagatt ccccccttca aaaaaagctt gtgaccattt
1141 tgtatggctt gtctggaaac ttctgtaaat cttatgtttt agtaaaatat tttttgttat
1201 tct
(SEQ ID NO:245)
1    maglprriik etqrllaepv pgikaepdes naryfhvvia gpqdspfegg tfklelflpe
61   eypmaapkvr fmtkiyhpnv dklgricldi lkdkwspalq irtvllsiqa llsapnpddp
121  landvaeqwk tneaqaieta rawtrlyamn ni

Putative function

Ubiquitin conjugating enzyme

Example 25 (Category 3)

Line ID—301

Phenotype—semilethal male and female, Low mitotic index, badly defined chromosomes, weak/uneven staining, fewer ana- and telophases

Annotated Drosophila genome genomic segment containing P element insertion site (and map position)—AE003422 (2B7-10)

P element insertion site—96,307

Annotated Drosophila genome Complete Genome candidate

CG 14813—deltaCOP, component of cotamer involved in retrograde (golgi to ER) transport

(SEQ ID NO:246)
TCGCAGAACCGAACACGTCAGCTACGGGGATTGATTGTTAAACAACGTTT
CTATCGCCCCGCAAATCCGATCCGTAGCAGCAGTCCATCCTGCGCCGTCC
GCATCCGATCCGCGAAGTATTTTCCAGGGCAAAAACGTCAAACGCAGCAG
CAAAATGGTATTAATTGCTGCGGCTGTCTGCACGAAGAATGGCAAAGTGA
TTCTGTCACGTCAGTTCGTCGAGATGACGAAGGCACGCATCGAGGGACTG
CTGGCTGCCTTTCCCAAGCTGATGACTGCTGGCAAGCAGCACACTTACGT
GGAGACGGACTCCGTGCGCTACGTCTACCAGCCGATGGAGAAACTATATA
TGCTGCTCATCACCACTAAGGCCAGCAACATTCTGGAGGATCTGGAGACC
CTGCGCCTCTTCTCGAAAGTGATTCCCGAGTACAGCCACTCGCTCGACGA
GAAGGAGATTGTGGAGAATGCCTTCAATCTGATCTTCGCATTTGACGAGA
TCGTGGCACTCGGCTACAGGGAGAGCGTCAACTTGGCCCAGATCAAGACC
TTCGTGGAGATGGACTCACATGAGGAGAAGGTCTACCAGGCAGTGCGTCA
GACGCAGGAGCGTGATGCGCGCCAGAAGATGCGCGAGAAGGCCAAGGAAC
TGCAGCGGCAGCGCATGGAGGCCAGCAAACGGGGTGGTCCCTCCCTGGGT
GGCATTGGCAGCCGCAGCGGCGGCTTTAGCGCCGACGGAATTGGCAGTAG
CGGCGTGAGCAGCAGTTCCGGTGCCTCCAGCGCCAACACCGGCATCACCT
CCATCGATGTGGACACCAAATCCAAGGCGGCTGCCAGTAAACCAGCTTCC
CGCAATGCCCTCAAGCTAGGTGGCAAGTCCAAGGACGTCGATAGTTTCGT
GGATCAGCTGAAGAACGAGGGCGAGAAGATTGCCAATCTGGCACCGGCGG
CGCCCGCTGGAGGTTCCAGTGCTGCAGCTAGCGCCAGTGCAGCGGCCAAG
GCAGCTATCGCGTCGGACATTCACAAAGAGAGCGTACATCTGAAGATTGA
GGACAAGCTAGTAGTGCGTCTGGGACGCGATGGTGGCGTGCAGCAGTTCG
AGAACTCGGGCCTCCTGACGTTGCGCATTACGGACGAGGCCTACGGACGC
ATTTTGCTGAAGCTGTCTCCCAACCACACACAGGGCCTGCAGTTGCAGAC
CCACCCCAACGTGGACAAGGAGCTGTTCAAGTCGCGCACTACCATCGGAC
TAAAGAACTTGGGCAAGCCGTTTCCCCTTAACACCGATGTGGGTGTGCTC
AAGTGGCGCTTCGTCTCGCAGGACGAGTCGGCAGTCCCGCTGACCATTAA
CTGCTGGCCATCGGATAATGGAGAGGGTGGATGCGATGTTAACATTGAGT
ATGAACTGGAGGCGCAGCAGCTAGAGCTGCAGGACGTGGCCATTGTCATT
CCCTTGCCAATGAATGTGCAGCCTTCGGTGGCGGAGTACGACGGCACCTA
CAACTACGATTCACGCAAGCATGTGCTCCAGTGGCACATTCCAATAATCG
ATGCCGCCAACAAGTCCGGTTCTATGGAGTTCAGCTGCAGTGCCTCCATT
CCCGGTGACTTCTTCCCCTTGCAGGTGTCCTTCGTCTCGAAAACGCCGTA
TGCGGGCGTCGTGGCCCAGGATGTGGTGCAGGTGGACAGCGAGGCGGCGG
TCAAGTATTCAAGCGAGTCCATTCTGTTCGTGGAAAAGTACGAGATCGTG
TAGGCCGCGCCGCTGGCCACGCCCACCTAAGTAGTACATAAATATACATA
ATTTCCCGGGGTCATCCGATGCGATGCAATTAATTCAACTGCTGCAGCAT
GTTGAGAATTATTTTTCCATGTGCGAACTTTACATATTTATGGCGCAGAC
AGCTTCTCAGAGCGAGTAATTGATTCC
(SEQ ID NO:247)
MVLIAAAVCTKNGKVILSRQFVEMTKARIEGLLAAFPKLMTAGKQHTYVE
TDSVRYVYQPMEKLYMLLITTKASNILEDLETLRLFSKVIPEYSHSLDEK
EIVENAFNLIFAFDEIVALGYRESVNLAQIKTFVEMDSHEEKVYQAVRQT
QERDARQKMREKAKELQRQRMEASKRGGPSLGGIGSRSGGFSADGIGSSG
VSSSSGASSANTGITSIDVDTKSKAAASKPASRNALKLGGKSKDVDSFVD
QLKNEGEKIANLAPAAPAGGSSAAASASAAAKAAIASDIHKESVHLKIED
KLVVRLGRDGGVQQFENSGLLTLRITDEAYGRILLKLSPNHTQGLQLQTH
PNVDKELFKSRTTTGLRNLGRPFPLNTDVGVLKWRFVSQDESAVPLTINC
WPSDNGEGGCDVNIEYELEAQQLELQDVAIVIPLPMNVQPSVAEYDGTYN
YDSRKHVLQWHIPIIDAANKSGSMEFSCSASIPGDFFPLQVSFVSKTPYA
GVVAQDVVQVDSEAAVKYSSESILFVEKYEIV

Human homologue of Complete Genome candidate

CAA57071—archain, possible role in vesicle structure or trafficking

(SEQ ID NO:248)
1    cgggcggttc ctgtcaaggg ggcagcaggt ccagagctgc tggtgctccc gttccccaga
61   ccctacccct atccccagtg gagccggagt gcggcgcgcc ccaccaccgc cctcaccatg
121  gtgctgttgg cagcagcggt ctgcacaaaa gcaggaaagg ctattgtttc tcgacagttt
181  gtggaaatga cccgaactcg gattgagggc ttattagcag cttttccaaa gctcatgaac
241  actggaaaac aacatacgtt tgttgaaaca gagagtgtaa gatatgtcta ccagcctatg
301  gagaaactgt atatggtact gatcactacc aaaaacagca acattttaga agatttggag
361  accctaaggc tcttctcaag agtgatccct gaatattgcc gagccttaga agagaatgaa
421  atatctgagc actgttttga tttgattttt gcttttgatg aaattgtcgc actgggatac
481  cgggagaatg ttaacttggc acagatcaga accttcacag aaatggattc tcatgaggag
541  aaggtgttca gagccgtcag agagactcaa gaacgtgaag ctaaggctga gatgcgtcgt
601  aaagcaaagg aattacaaca ggcccgaaga gatgcagaga gacagggcaa aaaagcacca
661  ggatttggcg gatttggcag ctctgcagta tctggaggca gcacagctgc catgatcaca
721  gagaccatca ttgaaactga taaaccaaaa gtggcacctg caccagccag gccttcaggc
781  cccagcaagg ctttaaaact tggagccaaa ggaaaggaag tagataactt tgtggacaaa
841  ttaaaatctg aaggtgaaac catcatgtcc tctagtatgg gcaagcgtac ttctgaagca
901  accaaaatgc atgctccacc cattaatatg gaaagtgtac atatgaagat tgaagaaaag
961  ataacattaa cctgtggacg agacggagga ttacagaata tggagttgca tggcatgatc
1021 atgcttagga tctcagatga caagtatggc cgaattcgtc ttcatgtgga aaatgaagat
1081 aagaaagggg tgcagctaca gacccatcca aatgtggata aaaaactttt cactgcagag
1141 tctctaattg gcctgaagaa tccagagaag tcatttccag tcaacagtga cgtaggggtg
1201 ctaaagtgga gactacaaac cacagaggaa tcttttattc cactgacaat taattgctgg
1261 ccctcggaga gtggaaatgg ctgtgatgtc aacatagaat atgagctaca agaagataat
1321 ttagaactga atgatgtggt tatcaccatc ccactcccgt ctggtgtcgg cgcgcctgtt
1381 atcggtgaga tcgatgggga gtatcgacat gacagtcgac gaaataccct ggagtggtgc
1441 ctgcctgtga ttgatgccaa aaataagagt ggcagcctgg agtttagcat tgctgggcag
1501 cccaatgact tcttccctgt tcaagtttcc tttgtctcca agaaaaatta ctgtaacata
1561 caggttacca aagtgaccca ggtagatgga aacagccccg tcaggttttc cacagagacc
1621 actttcctag tggataagta tgaaatcctg taataccaag aagagggagc tgaaaaggaa
1681 aattttcaga ttaataaaga agacgccaat gatggctgaa gagtttttcc cagatttaca
1741 agccactgga gacccctttt ttctgataca atgcacgatt ctctgcgcgc aaggaccctc
1801 gactcacccc catgtttcag tgtcacagag acattctttg ataaggaaat ggcacaaaca
1861 taaagggaaa ggctgctaat tttctttggc agattgtatt ggccagcagg aaagcaagct
1921 ctccagagaa tgcccccagt taaatacctc ctctaccttt acctaagttg ctcctttatt
1981 tttattttat aataataa
(SEQ ID NO:249)
1    mvllaaavct kagkaivsrq fvemtrtrie gllaafpklm ntgkqhtfve tesvryvyqp
61   meklymvlit tknsniledl etlrlfsrvi peycraleen eisehcfdli fafdeivalg
121  yrenvnlaqi rtftemdshe ekvfravret qereakaemr rkakelqqar rdaerqgkka
181  pgfggfgssa vsggstaami tetiietdkp kvapaparps gpskalklga kgkevdnfvd
241  klksegetim sssmgkrtse atkmhappin mesvhmkiee kitltcgrdg glqnmelhgm
301  imlrisddky grirlivene dkkgvqlqth pnvdkklfta esliglknpe ksfpvnsdvg
361  vlkwrlqtte esfipitinc wpsesgngcd vnieyelqed nlelndvvit iplpsgvgap
421  vigeidgeyr hdsrrntlew clpvidaknk sgslefsiag qpndffpvqv sfvskknycn
481  iqvtkvtqvd gnspvrfste ttflvdkyei l

Putative function

Role in vesicle trafficking

Example 26 (Category 3)

Line ID—148

Phenotype—Lethal phase pupal to pharate adult. Lagging chromosomes and bridges in ana- and telophase

Annotated Drosophila genome genomic segment containing P element insertion site (and map position)—AE003438 (6B-C)

P element insertion site—116,914

Annotated Drosophila genome Complete Genome candidate

CG8655—cdc7 kinase

(SEQ ID NO:250)
ATGCGTTATGACGCCTCCGCCGCTTTCGTGATGCCCTTCATGGCACATGA
CCGATTCCAGGACTTTTACACGCGCATGGATGTGCCCGAGATCCGGCAGT
ATATGCGCAATCTCCTGGTGGCACTGCGTCATGTCCACAAGTTCGATGTC
ATCCATCGCGACGTGAAGCCGAGCAACTTTCTCTACAATCGACGTCGGCG
AGAGTTTCTCCTCGTCGATTTCGGTCTGGCCCAGCATGTGAATCCTCCGG
CTGCGCGATCTTCCGGAAGTGCCGCCGCCATCGCCGCAGCCAACAACAAA
AACAACAACAATAATAACAATAATAATAGCAAACGGCCACGAGAGCGCGA
ATCAAAGGGGGATGTGCAGCAAATTGCGCTGGATGCTGGTTTGGGTGGAG
CAGTGAAGCGTATGCGTTTGCACGAGGAGTCCAACAAGATGCCCCTGAAA
CCGGTCAACGATATTGCGCCAAGCGATGCGCCGGAGCAGTCAGTAGATGG
GTCCAATCACGTCCAGCCACAGCTAGTGCAGCAAGAGCAGCAACAACTGC
AGCCGCAACAGCAGCAGCAACAACAGCAGCAGCAACAACAGTCGCAACAG
CAGCAGCAGCCGCAGCAGCAGTCGCAACAGCAGCACCCACAACGACAGCC
ACAACTGGCGCAGATGGATCAAACAGCATCGACGCCATCTGGCAGCAAGT
ACAATACGAATCGAAATGTCTCGGCAGCAGCGGCTAATAATGCCAAGTGC
GTTTGCTTTGCAAATCCCTCAGTTTGCCTCAACTGTCTGATGAAGAAGGA
GGTGCACGCCTCCAGGGCAGGAACACCTGGCTATCGGCCGCCCGAGGTTC
TGCTCAAGTACCCAGATCAGACCACTGCCGTGGACGTTTGGGCGGCGGGT
GTGATATTCCTTTCGATCATGTCAACGGTGTATCCGTTTTTCAAAGCGCC
CAACGATTTTATCGCGCTGGCCGAGATTGTAACAATATTTGGAGATCAGG
CGATACGGAAGACGGCCTTGGCTCTCGACCGTATGATCACCCTGAGCCAG
AGGTCCAGGCCACTGAATCTGCGAAAGTTGTGCCTGCGCTTTCGCTATCG
TTCCGTTTTTAGTGATGCCAAGCTCCTCAAGAGCTACGAATCTGTGGACG
GAAGCTGCGAAGTGTGCCGGAATTGTGATCAATACTTCTTCAACTGCCTA
TGCGAGGATAGCGATTACTTGACAGAGCCACTGGACGCATACGAATGTTT
TCCACCCAGCGCCTATGACCTACTGGATCGCCTGCTCGAGATTAATCCCC
ATAAACGAATTACCGCCGAAGAGGCACTAAAGCATCCATTCTTTACGGCC
GCCGAGGAGGCCGAGCAGACGGAGCAGGATCAGTTGGCCAATGGAACGCC
GCGCAAGATGCGTCGACAAAGATATCAAAGTCACAGAACGGTGGCCGCCT
CACAGGAGCAGGTCAAGCAGCAGGTTGCCCTTGATCTGCAGCAAGCGGCC
ATTAACAAGCTGTGA
(SEQ ID NO:251)
MRYDASAAFVMPFMAHDRFQDFYTRMDVPEIRQYMRNLLVALRHVHKFDV
IHRDVKPSNFLYNRRRREFLLVDFGLAQHVNPPAARSSGSAAAIAAANNK
NNNNNNNNNSKRPRERESKGDVQQIALDAGLGGAVKRMRLHEESNKMPLK
PVNDIAPSDAPEQSVDGSNHVQPQLVQQEQQQLQPQQQQQQQQQQQQSQQ
QQQPQQQSQQQHPQRQPQLAQMDQTASTPSGSKYNTNRNVSAAAANNAKC
VCFANPSVCLNCLMKKEVHASRAGTPGYRPPEVLLKYPDQTTAVDVWAAG
VIFLSIMSTVYPFFKAPNDFIALAEIVTIFGDQAIRKTALALDRMITLSQ
RSRPLNLRKLCLRFRYRSVFSDAKLLKSYESVDGSCEVCRNCDQYFFNCL
CEDSDYLTEPLDAYECFPPSAYDLLDRLLEINPHKRITAEEALKHPFFTA
AEEAEQTEQDQLANGTPRKMRRQRYQSHRTVAASQEQVKQQVALDLQQAA
INKL

Human homologue of Complete Genome candidate

AAB97512—HsCdc7

(SEQ ID NO:252)
1    atggaggcgt ctttggggat tcagatggat gagccaatgg ctttttctcc ccagcgtgac
61   cggtttcagg ctgaaggctc tttaaaaaaa aacgagcaga attttaaact tgcaggtgtt
121  aaaaaagata ttgagaagct ttatgaagct gtaccacagc ttagtaatgt gtttaagatt
181  gaggacaaaa ttggagaagg cactttcagc tctgtttatt tggccacagc acagttacaa
241  gtaggacctg aagagaaaat tgctgtaaaa cacttgattc caacaagtca tcctataaga
301  attgcagctg aacttcagtg cctaacagtg gctggggggc aagataatgt catgggagtt
361  aaatactgct ttaggaagaa tgatcatgta gttattgcta tgccatatct ggagcatgag
421  tcgtttttgg acattctgaa ttctctttcc tttcaagaag tacgggaata tatgcttaat
481  ctgttcaaag ctttgaaacg cattcatcag tttggtattg ttcaccgtga tgttaagccc
541  agcaattttt tatataatag gcgcctgaaa aagtatgcct tggtagactt tggtttggcc
601  caaggaaccc atgatacgaa aatagagctt cttaaatttg tccagtctga agctcagcag
661  gaaaggtgtt cacaaaacaa atcccacata atcacaggaa acaagattcc actgagtggc
721  ccagtaccta aggagctgga tcagcagtcc accacaaaag cttctgttaa aagaccctac
781  acaaatgcac aaattcagat taaacaagga aaagacggaa aggagggatc tgtaggcctt
841  tctgtccagc gctctgtttt tggagaaaga aatttcaata tacacagctc catttcacat
901  gagagccctg cagtgaaact catgaagcag tcaaagactg tggatgtact gtctagaaag
961  ttagcaacaa aaaagaaggc tatttctacg aaagttatga atagtgctgt gatgaggaaa
1021 actgccagtt cttgcccagc tagcctgacc tgtgactgct atgcaacaga taaagtttgt
1081 agtatttgcc tttcaaggcg tcagcaggtt gcccctaggg caggtacacc aggattcaga
1141 gcaccagagg tcttgacaaa gtgccccaat caaactacag caattgacat gtggtctgca
1201 ggtgtcatat ttctttcttt gcttagtgga cgatatccat tttataaagc aagtgatgat
1261 ttaactgctt tggcccaaat tatgacaatt aggggatcca gagaaactat ccaagctgct
1321 aaaacttttg ggaaatcaat attatgtagc aaagaagttc cagcacaaga cttgagaaaa
1381 ctctgtgaga gactcagggg tatggattct agcactccca agttaacaag tgatatacag
1441 gggcatgctt ctcatcaacc agctatttca gagaagactg accataaagc ttcttgcctc
1501 gttcaaacac ctccaggaca atactcaggg aattcattta aaaaggggga tagtaatagc
1561 tgtgagcatt gttttgatga gtataatacc aatttagaag gctggaatga ggtacctgat
1621 gaagcttatg acctgcttga taaacttcta gatctaaatc cagcttcaag aataacagca
1681 gaagaagctt tgttgcatcc attttttaaa gatatgagct tgtga
(SEQ ID NO:253)
1    measlgiqmd epmafspqrd rfqaegslkk neqnfklagv kkdieklyea vpqlsnvfki
61   edkigegtfs svylataqlq vgpeekiavk hliptshpir iaaelqcltv aggqdnvmgv
121  kycfrkndhv viampylehe sfldilnsls fqevreymln lfkalkrihq fgivhrdvkp
181  snflynrrlk kyalvdfgla qgthdtkiel lkfvqseaqq ercsqnkshi itgnkiplsg
241  pvpkeldqqs ttkasvkrpy tnaqiqikqg kdgkegsvgl svqrsvfger nfnihssish
301  espavklmkq sktvdvlsrk latkkkaist kvmnsavmrk tasscpaslt cdcyatdkvc
361  siclsrrqqv apragtpgfr apevltkcpn qttaidmwsa gviflsllsg rypfykasdd
421  ltalaqimti rgsretiqaa ktfgksilcs kevpaqdlrk lcerlrgmds stpkltsdiq
481  ghashcpais ektdhkascl vqtppgqysg nsfkkgdsns cehcfdeynt nlegwnevpd
541  eaydlldkll dlnpasrita eeallhpffk dmsl

Putative function

Protein kinase which regulates the G1/S phase transition and/or DNA replication in mammalian cells.

Example 27 (Category 3)

Line ID—335

Phenotype—Lethal phase, pupal. Uneven chromosome condensation, lagging chromosomes in anaphase

Annotated Drosophila genome genomic segment containing P element insertion site (and map position)—AE003424 (3B1-2)

P element insertion site—286,560

Annotated Drosophila genome Complete Genome candidate

CG2621—shaggy, protein serine/threonine kinase

(SEQ ID NO:254)
ATGTTTACCTTCTACACCAATATAAATAATACACTGATCAACAACAACAA
TTTTAATAATAATACTAGTAACAGTAATAATAATAATAACAACGTTATAA
GCCAGCCGATTAAAATACCGCTAACCGAGCGCTTCTCATCGCAAACATCG
ACGGGCTCGGCGGATAGCGGTGTAATTGTTTCCAGTGCATCGCAGCAGCA
ACTGCAGTTGCCACCACCACGCAGTAGCAGTGGATCGCTGAGTCTGCCAC
AAGCGCCACCTGGCGGCAAGTGGCGGCAGAAGCAGCAGCGCCAACAGTTG
CTGCTCAGCCAGGACAGCGGCATCGAAAATGGTGTCACCACTCGTCCATC
GAAAGCCAAGGACAACCAGGGTGCGGGAAAAGCCAGTCACAATGCCACAA
GCTCGAAGGAGAGCGGCGCGCAGTCGAACAGCAGCAGCGAGAGCCTGGGC
AGCAATTGCTCCGAGGCCCAGGAGCAGCAGAGAGTAAGAGCCTCCTCCGC
TCTGGAGCTCAGCAGCGTGGACACTCCCGTGATCGTCGGCGGTGTGGTCA
GTGGAGGCAACAGCATCTTGCGCAGCCGCATTAAGTACAAGAGTACGAAC
AGCACCGGAACCCAGGGATTCGATGTGGAGGATCGCATCGATGAGGTGGA
TATCTGTGATGATGATGATGTCGACTGCGATGATCGCGGATCGGAGATCG
AGGAGGAGGAGGAGGACCAAACCGAACAAGAGGAGGAGGTCGATGAGGTG
GATGCCAAGCCGAAGAACCGACTTTTGCCACCGGATCAGGCGGAACTCAC
AGTGGCGGCGGCCATGGCACGTCGACGCGATGCCAAGAGCCTGGCCACCG
ACGGTCACATATATTTCCCACTGCTCAAGATCAGCGAGGATCCGCACATT
GATTCGAAGCTGATCAATCGCAAGGATGGCCTCCAGGACACCATGTATTA
TTTGGACGAATTCGGCAGTCCAAAGTTGCGAGAGAAGTTCGCCCGCAAGC
AGAAGCAGCTGCTCGCCAAGCAGCAGAAGCAGTTGATGAAACGTGAAAGG
AGGAGCGAGGAGCAGCGCAAGAAGCGAAACACCACCGTGGCATCCAACTT
GGCGGCCAGCGGAGCGGTGGTGGACGACACCAAAGATGATTACAAACAAC
AACCACACTGTGATACTAGCTCTAGGAGCAAAAATAACTCGGTACCCAAT
CCACCCAGCAGCCATCTCCATCAGAACCACAATCATCTCGTTGTGGATGT
GCAAGAGGATGTGGATGATGTGAATGTGGTTGCCACCAGCGACGTGGACA
GTGGTGTCGTCAAGATGCGCCGCCATAGCCACGATAACCACTACGACCGA
ATTCCCCGGAGCAATGCTGCCACCATTACCACCCGCCCTCAAATCGACCA
ACAGTCGTCGCACCACCAGAACACCGAGGATGTGGAGCAAGGAGCTGAGC
CCCAAATCGATGGCGAAGCGGATCTGGATGCGGATGCGGATGCGGACAGC
GATGGGAGTGGCGAGAACGTTTAAGACTGCCAAATGGCCAGAACACAGTC
CTGCAAAAACCAAACAGGTCGCGATGGTTCTAAAATCACAACAGTTGTTG
CAACACCCGGCCAAGGCACCGATCGCGTACAAGAGGTCTCCTATACAGAC
ACAAAGGTCATCGGCAATGGCAGCTTCGGCGTCGTGTTCCAGGCAAAGCT
CTGCGATACCGGCGAACTGGTGGCAATCAAAAAAGTTTTACAAGACAGAC
GATTTAAGAATCGCGAATTGCAAATAATGCGCAAATTGGAGCATTGTAAT
ATTGTGAAGCTTTTGTACTTTTTCTATTCGAGTGGTGAAAAGCGTGATGA
AGTATTTTTGAATTTAGTCCTCGAATATATACCAGAAACCGTATACAAAG
TGGCTCGCCAATATGCCAAAACCAAGCAAACGATACCAATCAACTTTATT
CGGCTCTACATGTATCAACTGTTCAGAAGTTTGGCCTACATCCACTCGCT
GGGCATTTGCCATCGTGATATCAAGCCGCAGAATCTTCTGCTCGATCCGG
AGACGGCTGTGCTGAAGCTCTGTGACTTTGGCAGCGCCAAACAGCTGCTG
CACGGCGAGCCGAATGTATCGTATATCTGCTCCCGGTATTACCGCGCCCC
CGAGCTCATCTTTGGCGCCATCAATTATACAACAAAGATCGATGTCTGGA
GTGCCGGTTGCGTTTTGGCCGAACTGCTGCTGGGCCAGCCCATCTTCCCT
GGCGATTCCGGTGTGGATCAGCTCGTCGAGGTCATCAAGGTCCTGGGCAC
ACCGACAAGAGAACAGATACGCGAAATGAATCCAAACTACACGGAATTCA
AGTTCCCTCAGATTAAGAGTCATCCATGGCAGAAAGTTTTCCGTATACGC
ACTCCTACAGAAGCTATCAACTTGGTGTCCCTGCTGCTCGAGTATACGCC
CAGTGCCAGGATCACACCGCTCAAGGCCTGCGCACATCCGTTCTTCGATG
AGCTACGCATGGAGGGTAATCACACCTTGCCCAACGGTCGCGATATGCCG
CCGCTGTTCAACTTCACAGAGCATGAGCTCTCAATACAGCCCAGCCTAGT
GCCGCAGTTGTTGCCCAAGCATCTGCAGAACGCATCCGGACCTGGCGGCA
ATCGACCCTCGGCCGGCGGAGCAGCCTCCATTGCGGCCAGCGGCTCCACC
AGCGTCTCGTCAACGGGCAGTGGTGCCTCGGTGGAAGGATCCGCCCAGCC
ACAGTCGCAGGGTACAGCAGCAGCTGCGGGATCCGGATCGGGCGGAGCAA
CAGCAGGAACCGGCGGAGCGAGTGCCGGTGGACCCGGATCTGGTAACAAC
AGTAGCAGCGGCGGAGCATCGGGAGCGCCGTCCGCTGTGGCTGCCGGAGG
AGCCAATGCCGCCGTCGCTGGCGGTGCTGGTGGTGGTGGCGGAGCCGGTG
CGGCGACCGCAGCTGCAACAGCAACTGGCGCTATAGGCGCGACTAATGCC
GGCGGCGCCAATGTAACAGATTCATAGGGGAAATAGTAACATACATACAC
ACACTAAATATATATCCAAGCATATATATATAGTAATCATTATATATAAC
ACCTACACCCACAACAACAACAACAGCAATTATATATAATAACCATAAAC
AAGAATGGAGAAAGCCAATCCAGCAATCACAGCAAACTATATACACAACA
ACAACAATTAAATTAATTAATGCAATTGATGAAAGAACAGCAGCAGCAGC
AGCAGCAGCAGCAGCAGCAGCATCAACCGCAATTTCAAAAGAACTCTAGA
AACAGCAAAGGCATAAAATATAACAAAAGAAATATTTTACTTAGGTAAAA
CATTAAATTTATTTTAAATCTAAAATAAACTAATAAGCATTAAATAATAC
ATGATAATGGTAAATAAACACACAATAATTATAATAGTAGAGCGAGCGCT
GATCGATTGTCATTTTATTGCTGCCGC
(SEQ ID NO:255)
MFTFYTNINNTLINNNNNNNNTSNSNNNNNNVISQPIKIPLTERFSSQTS
TGSADSGVIVSSASQQQLQLPPPRSSSGSLSLPQAPPGGKWRQKQQRQQL
LLSQDSGIENGVTTRPSKAKDNQGAGKASHNATSSKESGAQSNSSSESLG
SNCSEAQEQQRVRASSALELSSVDTPVIVGGVVSGGNSILRSRIKYKSTN
STGTQGFDVEDRIDEVDICDDDDVDCDDRGSEIEEEEEDQTEQEEEVDEV
DAKPKNRLLPPDQAELTVAAAMARRRDAKSLATDGHIYFPLLKISEDPHI
DSKLINRKDGLQDTMYYLDEFGSPKLREKFARKQKQLLAKQQKQLMKRER
RSEEQRKKRNTTVASNLAASGAVVDDTKDDYKQQPHCDTSSRSKNNSVPN
PPSSHLHQNHNHLVVDVQEDVDDVNVVATSDVDSGVVKMRRHSHDNHYDR
IPRSNAATITTRPQIDQQSSHHQNTEDVEQGAEPQIDGEADLDADADADS
DGSGENVKTAKLARTQSCKNQTGRDGSKITTVVATPGQGTDRVQEVSYTD
TKVIGNGSFGVVFQAKLCDTGELVAIKKVLQDRRFKNRELQIMRKLEHCN
IVKLLYFFYSSGEKRDEVFLNLVLEYIPETVYKVARQYAKTKQTIPINFI
RLYMYQLFRSLAYIHSLGICHRDIKPQNLLLDPETAVLKLCDFGSAKQLL
HGEPNVSYICSRYYRAPELIFGAINYTTKIDVWSAGCVLAELLLGQPIFP
GDSGVDQLVEVIKVLGTPTREQIREMNPNYTEFKFPQIKSHPWQKVFRIR
TPTEAINLVSLLLEYTPSARITPLKACAHPFFDELRMEGNHTLPNGRDMP
PLFNFTEHELSIQPSLVPQLLPKHLQNASGPGGNRPSAGGAASLAASGST
SVSSTGSGASVEGSAQPQSQGTAAAAGSGSGGATAGTGGASAGGPGSGNN
SSSGGASGAPSAVAAGGANAAVAGGAGGGGGAGAATAAATATGAIGATNA
GGANVTDS

Human homologue of Complete Genome candidate

NP_—002084—glycogen synthase kinase 3 beta

(SEQ ID NO:256)
1    ggagaaggaa ggaaaaggtg attcgcgaag agagtgatca tgtcagggcg gcccagaacc
61   acctcctttg cggagagctg caagccggtg cagcagcctt cagcttttgg cagcatgaaa
121  gttagcagag acaaggacgg cagcaaggtg acaacagtgg tggcaactcc tgggcagggt
181  ccagacaggc cacaagaagt cagctataca gacactaaag tgattggaaa tggatcattt
241  ggtgtggtat atcaagccaa actttgtgat tcaggagaac tggtcgccat caagaaagta
301  ttgcaggaca agagatttaa gaatcgagag ctccagatca tgagaaagct agatcactgt
361  aacatagtcc gattgcgtta tttcttctac tccagtggtg agaagaaaga tgaggtctat
421  cttaatctgg tgctggacta tgttccggaa acagtataca gagttgccag acactatagt
481  cgagccaaac agacgctccc tgtgatttat gtcaagttgt atatgtatca gctgttccga
541  agtttagcct atatccattc ctttggaatc tgccatcggg atattaaacc gcagaacctc
601  ttgttggatc ctgatactgc tgtattaaaa ctctgtgact ttggaagtgc aaagcagctg
661  gtccgaggag aacccaatgt ttcgtatatc tgttctcggt actatagggc accagagttg
721  atctttggag ccactgatta tacctctagt atagatgtat ggtctgctgg ctgtgtgttg
781  gctgagctgt tactaggaca accaatattt ccaggggata gtggtgtgga tcagttggta
841  gaaataatca aggtcctggg aactccaaca agggagcaaa tcagagaaat gaacccaaac
901  tacacagaat ttaaattccc tcaaattaag gcacatcctt ggactaaggt cttccgaccc
961  cgaactccac cggaggcaat tgcactgtgt agccgtctgc tggagtatac accaactgcc
1021 cgactaacac cactggaagc ttgtgcacat tcattttttg atgaattacg ggacccaaat
1081 gtcaaacatc caaatgggcg agacacacct gcactcttca acttcaccac tcaagaactg
1141 tcaagtaatc cacctctggc taccatcctt attcctcctc atgctcggat tcaagcagct
1201 gcttcaaccc ccacaaatgc cacagcagcg tcagatgcta atactggaga ccgtggacag
1261 accaataatg ctgcttctgc atcagcttcc aactccacct gaacagtccc gacgagccag
1321 ctgcacagga aaaaccacca gttacttgag tgtcactcag caacactggt cacgtttgga
1381 aagaatatt
(SEQ ID NO:257)
1    msgrprttsf aesckpvqqp safgsmkvsr dkdgskvttv vatpgqgpdr pqevsytdtk
61   vigngsfgvv yqaklcdsge lvaikkvlqd krfknrelqi mrkldhcniv rlryffyssg
121  ekkdevylnl vldyvpetvy rvarhysrak qtlpviyvkl ymyqlfrsla yihsfgichr
181  dikpqnllld pdtavlklcd fgsakqlvrg epnvsyicsr yyrapelifg atdytssidv
241  wsagcvlael llgqpifpgd sgvdqlveii kvlgtptreq iremnpnyte fkfpqikahp
301  wtkvfrprtp peaialcsrl leytptarlt pleacahsff delrdpnvkh pngrdtpalf
361  nfttqelssn pplatilipp hariqaaast ptnataasda ntgdrgqtnn aasasasnst
421

Putative function

Serine/threonine kinase involved in winglwess signaling pathway

Example 28 (Category 3)

Dlg1 (CG1725) as a candidate gene is detected in a screen of a P-element insertion library covering the X chromosome of Drosophila melanogaster (Peter et al. 2001) as mutant phenotype in fly line 342 , as described above.

Mitotic defects are observed in brain squashes: high mitotic index, overcondensed chromosomes, lagging chromosomes and a high proportion of anaphases and telophases compared to normal brains.

Rescue and sequencing of genomic DNA flanking the P-element insertion site indicates that the P-element is inserted into the 5′ region of gene Dlg1 (CG1725).

Line ID—342

Phenotype—Lethal phase pupal. Higher mitotic index, colchicine-like overcondensed chromosomes, many ana- and telophases, lagging chromosomes

Annotated Drosophila genome genomic segment containing P element insertion site (and map position)—AE003486 (10B8-10)

P element insertion site—1128 and 3755

Annotated Drosophila genome Complete Genome candidate

CG1725—dlg, membrane-associated guanylate kinase homologs, role in cell junctions and proliferation (version 1)

(SEQ ID NO:258)
CACAAACAACACGCTCGTGCGTGCGATTTAAATATATAGATGTTTCAAAA
GTCAACCTCTCTGTTCGCAATTGTGTGCATTTTCGTTTGTCTAGTGCAAA
AAGTTGGATAATCACAGGCGGCAAATAAAATAGTAACGAATCGAGTTCAA
GAAGAAGAAGAAGAGAAGAGGAAGCAGAGGCAGCAGCGCCGGCATTTGTC
CGTGTGTTGTTGTTGTTGTTTGTGCGCGGCTGTAACTTTAACCCTCGAAC
GCCATAAGATTAAAAAACCAAGTATAACAATAAGTTATAAAATCAATTAA
ACAAAAGCCGCTGCGATATGACAACGAGGAAAAAGAAGCGCGACGGCGGC
GGCAGCGGCGGCGGATTCATCAAGAAAGTTTCGTCACTCTTCAATCTGGA
TTCGGTGAATGGCGATGATAGCTGGTTATACGAGGACATTCAGCTGGAGC
GCGGCAACTCCGGATTGGGCTTTTCCATTGCCGGCGGTACGGATAATCCG
CACATCGGCACCGACACCTCCATCTACATCACCAAGCTCATTTCCGGTGG
AGCAGCTGCCGCCGATGGACGTCTGAGCATCAACGATATCATCGTATCGG
TGAACGATGTGTCCGTGGTGGATGTGCCACATGCCTCCGCCGTGGATGCC
CTCAAGAAGGCGGGCAATGTTGTTAAGCTGCATGTGAAGCGAAAACGTGG
AACGGCCACCACCCCGGCAGCGGGATCGGCGGCAGGAGATGCTCGGGATA
GTGCGGCCAGCGGACCGAAGGTCATCGAAATCGATCTGGTCAAGGGCGGC
AAGGGACTGGGCTTCTCAATTGCCGGCGGCATTGGCAACCAGCACATCCC
CGGCGACAATGGCATCTATGTGACCAAGTTGATGGACGGCGGAGCAGCGC
AGGTGGACGGACGTCTCTCCATCGGAGATAAGCTGATTGCAGTGCGCACC
AACGGGAGCGAGAAGAACCTGGAGAACGTAACGCACGAACTGGCGGTGGC
CACGTTGAAATCGATCACCGACAAGGTGACGCTGATCAATGGAAAGACAC
AGCATCTGACCACCAGTGCGTCCGGCGGCGGAGGAGGAGGCCTTTCATCC
GGACAACAATTGTCGCAGTCCCAATCGCAGTTGGCCACCAGCCAGAGCCA
AAGTCAGGTGCATCAGCAGCAGCATGCGACGCCGATGGTCAATTCGCAGT
CGACAGGTGCGCTAAATAGTATGGGACAGACGGTTGTCGATTCACCATCA
ATACCACAAGCAGCCGCAGCAGTAGCAGCAGCAGCAAATGCATCTGCATC
TGCATCAGTCATTGCAAGCAACAACACAATCAGCAACACCACAGTCACCA
CAGTCACGGCCACGGCCACAGCCAGCAACAGTAGCAGCAAGTTGCCGCCG
TCGCTTGGCGCTAACAGCAGCATTAGCATTAGCAATAGCAATAGCAATAG
CTTCAGCTTTAATATCAACAACATTAATAGCATCAACAACAACAACAGTA
GCAGCAGCAGCACGACGGCAACTGTTGCAGCAGCAACACCAACAGCAGCA
TCAGCAGCAGCAGCAGCAGCATCATCTCCACCCGCCAACTCCTTCTATAA
CAATGCTTCCATGCCCGCCCTGCCTGTCGAATCCAATCAAACAAACAACC
GATCCCAATCACCCCAGCCGCGCCAGCCCGGGTCGCGATACGCCTCTACA
AATGTCCTAGCCGCCGTTCCACCAGGAACTCCACGCGCTGTCAGCACCGA
GGATATAACCAGAGAACCGCGCACCATCACCATCCAGAAGGGACCGCAGG
GCCTGGGCTTCAATATCGTTGGCGGCGAGGATGGCCAGGGTATCTATGTG
TCCTTCATCCTGGCCGGCGGCCCAGCGGATCTCGGGTCGGAGTTGAAGCG
TGGCGACCAGCTGCTCAGCGTGAACAATGTCAATCTCACGCACGCCACCC
ACGAAGAGGCAGCCCAGGCGCTCAAGACTTCTGGCGGTGTGGTGACCCTG
TTGGCGCAGTACCGCCCAGAGGAGTACAATCGCTTCGAGGCACGCATTCA
AGAGTTGAAACAACAGGCTGCCCTCGGTGCCGGCGGATCGGGAACGCTGC
TGCGCACCACGCAAAAGCGATCGCTGTATGTGCGCGCCCTGTTTGACTAC
GATCCGAATCGGGATGATGGATTGCCCTCGCGAGGATTGCCCTTTAAGCA
CGGCGATATCCTGCACGTGACCAATGCCTCCGACGATGAATGGTGGCAGG
CACGACGAGTTCTCGGCGACAACGAGGACGAGCAAATCGGTATTGTACCA
TCGAAAAGGCGTTGGGAGCGCAAAATGCGAGCTAGGGACCGCAGCGTTAA
GTTCCAGGGACATGCGGCAGCTAATAATAATCTGGATAAGCAATCGACAT
TGGATCGAAAGAAAAAGAATTTCACATTCTCGCGCAAATTTCCGTTTATG
AAGAGTCGCGATGAGAAGAATGAAGATGGCAGCGACCAAGAGCCCAATGG
AGTTGTGAGCAGCACCAGCGAGATTGACATCAATAATGTCAACAACAACC
AGTCAAATGAACCGCAACCTTCCGAGGAGAACGTGTTGTCCTACGAGGCC
GTACAGCGTTTGTCCATCAACTACACGCGCCCGGTGATTATTCTGGGACC
CCTGAAGGATCGCATCAACGATGACCTTATATCAGAGTATCCCGACAAGT
TCGGCTCTTGTGTGCCACACACCACCCGACCCAAGCGAGAGTACGAGGTG
GATGGTAGGGACTACCACTTTGTATCCTCTCGCGAGCAAATGGAACGGGA
TATTCAGAATCATCTGTTCATCGAGGCGGGACAGTATAACGACAATCTGT
ACGGCACATCGGTGGCCAGCGTGCGCGAAGTGGCCGAGAAGGGTAAACAC
TGCATCCTGGACGTGTCCGGGAACGCCATCAAGCGACTCCAAGTTGCCCA
GCTGTATCCCGTCGCCGTGTTCATCAAGCCCAAGTCGGTGGATTCAGTGA
TGGAAATGAATCGTCGCATGACGGAGGAGCAGGCCAAGAAGACTTACGAG
CGGGCGATTAAAATGGAGCAAGAATTCGGCGAATACTTTACGGGCGTTGT
CCAAGGCGATACCATCGAGGAGATTTACAGCAAAGTGAAATCGATGATTT
GGTCCCAGTCGGGACCAACCATTTGGGTACCTTCCAAGGAATCTCTATGA
CCAACAGCCACCACAACTTGGACACTGCCGCCTCGAGTTCGATGTCGACC
AGTCTCGAGAACAACAATAGGAGCAACAGCAGCAGCAACAAATCAGCAGC
CGCAGCAGAAGACGCCGCACTGATGATGCATCACAGTAACAACAGATACT
TTTACTTCTACTTCAACAACAAGAACAACAACAACAACAGCAACCACAGC
AGCAGCCACAGCGACAACAACAAAAACAACAACACTGACAACGACAGGAA
ACGG
(SEQ ID NO:259)
MTTRKKKRDGGGSGGGFIKKVSSLFNLDSVNGDDSWLYEDIQLERGNSG
LGFSIAGGTDNPHIGTDTSIYITKLISGGAAAADGRLSINDIIVSVNDVS
VVDVPHASAVDALKKAGNVVKLHVKRKRGTATTPAAGSAAGDARDSAASG
PKVIEIDLVKGGKGLGFSIAGGIGNQHIPGDNGIYVTKLTDGGRAQVDGR
LSIGDKLIAVRTNGSEKNLENVTHELAVATLKSITDKVTLIIGKTQHLTT
SASGGGGGGLSSGQQLSQSQSQLATSQSQSQVHQQQHATPMVNSQSTGAL
NSMGQTVVDSPSIPQAAAAVAAAANASASASVIASNNTISNTTVTTVTAT
ATASNDSSKLPPSLGANSSISISNSNSNSNSNNINNINSINNNNSSSSST
TATVAAATPTAASAAAAAASSPPANSFYNNASMPALPVESNQTNNRSQSP
QPRQPGSRYASTNVLAAVPPGTPRAVSTEDITREPRTITIQKGPQGLGFN
IVGGEDGQGIYVSFILAGGPADLGSELKRGDQLLSVNNVNLTHATHEEAA
QALKTSGGVVTLLAQYRPEEYNRFEARIQELKQQAALGAGGSGTLLRTTQ
KRSLYVRALFDYDPNRDDGLPSRGLPFKHGDILHVTNASDDEWWQARRVL
GDNEDEQIGIVPSKRRWERKMRARDRSVKFQGHAAANNNLDKQSTLDRKK
KNFTFSRKFPFMKSRDEKNEDGSDQEPNGVVSSTSEIDINNVNNNQSNEP
QPSEENVLSYEAVQRLSINYTRPVIILGPLKDRINDDLISEYPDKFGSCV
PHTTRPKREYEVDGRDYHFVSSREQMERDIQNHLFIEAGQYNDNLYGTSV
ASVREVAEKGKHCILDVSGNAIKRLQVAQLYPVAVFIKPKSVDSVMEMNR
RMTEEQAKKTYERAIKMEQEFGEYFTGVVQGDTTEEIYSKVKSMIWSQSG
PTTWVPSKESL

CG1725—dlg, membrane-associated guanylate kinase homologs, role in cell junctions and proliferation, genbank accession number M73529 (version 2)

(SEQ ID NO:260)
1    cccccccccc cccagttggg tgtgttgttt tcgtcgcgtt cggttgctcg ctttattttt
61   ttgtttgttt attttgtttt gtgcaatgga aatgtgaaca caaatgtttc aaaagtcaac
121  ctctctgttc gcaattgtgt gcattttcgt ttgtctagtg caaaaagttg gataacacag
181  gcggcaaata aaatagtaac gaatcgagtt caagaagaag aagaagagaa gaggaagcag
241  aggcagcagc gccggcattt gtccgtgtgt tgttgttgtt gtttgtgcgc ggctgtaact
301  ttaaccctcg aacgccataa gattaaaaaa ccaactataa caataagtta taaaatcaat
361  taaacaaaag ccgctgcgat atgacaacga ggaaaaagaa gcgcgacggc ggcggcagcg
421  gcggcggatt catcaagaaa gtttcgtcac tcttcaatct ggattcggtg aatggcgatg
481  atagctggtt atacgaggac attcagctgg agcgcggcaa ctccggattg ggcttttcca
541  ttgccggcgg tacggataat ccgcacatcg gcaccgacac ctccatctac atcaccaagc
601  tcatttccgg tggagcagct gccgccgatg gacgtctgag catcaacgat atcatcgtat
661  cggtgaacga tgtgtccgtg gtggatgtgc cacatgcctc cgccgtggat gccctcaaga
721  aggcgggcaa tgttgttaag ctgcatgtga agcgaaaacg tggaacggcc accaccccgg
781  cagcgggatc ggcggcagga gatgctcggg atagtgcggc cagcggaccg aaggtcatcg
841  aaatcgatct ggtcaagggc ggcaagggac tgggcttctc aattgccggc ggcattggca
901  accagcacat ccccggcgac aatggcatct atgtgaccaa gttgacggac ggcggacgag
961  cgcaggtgga cggacgtctc tccatcggag ataagctgat tgcagtgcgc accaacggga
1021 gcgagaagaa cctggagaac gtaacgcacg aactggcggt ggccacgttg aaatcgatca
1081 ccgacaaggt gacgctgatc attggaaaga cacagcatct gaccaccagt gcgtccggcg
1141 gcggaggagg aggcctttca tccggacaac aattgtcgca gtcccaatcg cagttggcca
1201 ccagccagag ccaaagtcag gtgcatcagc agcagcatgc gacgccgatg gtcaattcgc
1261 agtcgacagg tgcgctaaat agtatgggac agacggttgt cgattcacca tcaataccac
1321 aagcagccgc agcagtagca gcagcagcaa atgcatctgc atctgcatca gtcattgcaa
1381 gcaacaacac aatcagcaac accacagtca ccacagtcac ggccacggcc acagccagca
1441 acgatagcag caagttgccg ccgtcgcttg gcgctaacag cagcattagc attagcaata
1501 gcaatagcaa tagcaacagc aataatatca acaacattaa tagcatcaac aacaacaaca
1561 gtagcagcag cagcacgacg gcaactgttg cagcagcaac accaacagca gcatcagcag
1621 cagcagcagc agcatcatct ccacccgcca actccttcta taacaatgct tccatgcccg
1681 ccctgcctgt cgaatccaat caaacaaaca accgatccca atcaccccag ccgcgccagc
1741 ccgggtcgcg atacgcctct acaaatgtcc tagccgccgt tccaccagga actccacgcg
1801 ctgtcagcac cgaggatata accagagaac cacgcaccat caccatccag aagggaccgc
1861 agggcctggg cttcaatatc gttggcggcg aggatggcca gggtatctat gtgtccttca
1921 tcctggccgg cggcccagcg gatctcgggt cggagttgaa gcgtggcgac cagctgctca
1981 gcgtgaacaa tgtcaatctc acgcacgcca cccacgaaga ggcagcccag gcgctcaaga
2041 cttctggcgg tgtggtgacc ctgttggcgc agtaccgccc agaggagtac aatcgcttcg
2101 aggcacgcat tcaagagttg aaacaacagg ctgccctcgg tgccggcgga tcgggaacgc
2161 tgctgcgcac cacgcaaaag cgatcgctgt atgtgcgcgc cctgtttgac tacgatccga
2221 atcgggatga tggattgccc tcgcgaggat tgccctttaa gcacggcgat atcctgcacg
2281 tgaccaatgc ctccgacgat gaatggtggc aggcacgacg agttctcggc gacaacgagg
2341 acgagcaaat cggtattgta ccatcgaaaa ggcgttggga gcgcaaaatg cgagctaggg
2401 accgcagcgt taagttccag ggacatgcgg cagctaataa taatctggat aagcaatcga
2461 cattggatcg aaagaaaaag aatttcacat tctcgcgcaa atttccgttt atgaagagtc
2521 gcgatgagaa gaatgaagat ggcagcgacc aagagcccaa tggagttgtg agcagcacca
2581 gcgagattga catcaataat gtcaacaaca accagtcaaa tgaaccgcaa ccttccgagg
2641 agaacgtgtt gtcctacgag gccgtacagc gtttgtccat caactacacg cgcccggtga
2701 ttattctggg acccctgaag gatcgcatca acgatgacct tatatcagag tatcccgaca
2761 agttcggctc ctgtgtgcca cacaccaccc gacccaagcg agagtacgag gtggatggta
2821 gggactacca ctttgtatcc tctcgcgagc aaatggaacg ggatattcag aatcatctgt
2881 tcatcgaggc gggacagtat aacgacaatc tgtacggcac atcggtggcc agcgtgcgcg
2941 aagtggccga gaagggtaaa cactgcatcc tggacgtgtc cgggaacgcc atcaagcgac
3001 tccaagttgc ccagctgtat cccgtcgccg tgttcatcaa gcccaagtcg gtggattcag
3061 tgatggaaat gaatcgtcgc atgacggagg agcaggccaa gaagacttac gagcgggcga
3121 ttaaaatgga gcaagaattc ggcgaatact ttacgggcgt tgtccagggc gataccatcg
3181 aggagatcta cagcaaagtg aaatcgatga tttggtccca gtcgggacca accatttggg
3241 taccttccaa ggaatctcta tga
(SEQ ID NO:261)
MTTRKKKRDGGGSGGGFIKKVSSLFNLDSVNGDDSWLYEDIQLE
RGNSGLGFSIAGGTDNPHIGTDTSIYITKLISGGAAAADGRLSINDIIVSVNDVSVVD
VPHASAVDALKKAGNVVKLHVKRKRGTATTPAAGSAAGDARDSAASGPKVIEIDLVKG
GKGLGFSIAGGIGNQHIPGDNGIYVTKLTDGGRAQVDGRLSIGDKLIAVRTNGSEKNL
ENVTHELAVATLKSITDKVTLIIGKTQHLTTSASGGGGGGLSSGQQLSQSQSQLATSQ
SQSQVHQQQHATPMVNSQSTGALNSMGQTVVDSPSIPQAAAAVAAAANASASASVIAS
NNTISNTTVTTVTATATASNDSSKLPPSLGANSSISISNSNSNSNSNNINNINSINNN
NSSSSSTTATVAAATPTAASAAAAAASSPPANSFYNNASMPALPVESNQTNNRSQSPQ
PRQPGSRYASTNVLAAVPPGTPRAVSTEDITREPRTITIQKGPQGLGFNIVGGEDGQG
IYVSFILAGGPADLGSELKRGDQLLSVNNVNLTHATHEEAAQALKTSGGVVTLLAQYR
PEEYNRFEARIQELKQQAALGAGGSGTLLRTTQKRSLYVRALFDYDPNRDDGLPSRGL
PFKHGDILHVTNASDDEWWQARRVLGDNEDEQIGIVPSKRRWERKMRARDRSVKFQGH
AAANNNLDKQSTLDRKKKNFTFSRKFPFMKSRDEKNEDGSDQEPNGVVSSTSEIDINN
VNNNQSNEPQPSEENVLSYEAVQRLSINYTRPVIILGPLKDRINDDLISEYPDKFGSC
VPHTTRPKREYEVDGRDYHFVSSREQMERDIQNHLFIEAGQYNDNLYGTSVASVREVA
EKGKHCILDVSGNAIKRLQVAQLYPVAVFIKPKSVDSVMEMNRRMTEEQAKKTYERAI
KMEQEFGEYFTGVVQGDTIEEIYSKVKSMIWSQSGPTIWVPSKESL

Human homologue of Complete Genome candidate

XP_—012060—discs, large (Drosophila) homolog 2, channel-associated protein of synapses-110′ (version 1)

(SEQ ID NO:262)
1    gggaattctg gcctgggatt cagtattgct ggggggacag ataatcccca cattggagat
61   gaccctggca tatttattac gaagattata ccaggaggtg ctgcagcaga ggatggcaga
121  ctcagggtca atgattgtat cttgcgggtg aatgaggttg atgtgtcaga ggtttcccac
181  agtaaagcgg tggaagccct gaaggaagca gggtctatcg ttcggctgta tgtgcgtaga
241  agacgaccta ttttggagac cgttgtggaa atcaaactgt tcaaaggccc taaaggttta
301  ggcttcagta ttgcaggagg tgtggggaac caacacattc ctggagacaa cagcatttat
361  gtaactaaaa ttatagatgg aggagctgca caaaaagatg gaaggttgca agtaggagat
421  agactactaa tggtaaacaa ctacagttta gaagaagtaa cacacgaaga ggcagtagca
481  atattaaaga acacatcaga ggtagtttat ttaaaagttg gcaaacccac taccatttat
541  atgactgatc cttatggtcc acctgatatt actcactctt attctccacc aatggaaaac
601  catctactct ctggcaacaa tggcacttta gaatataaaa cctccctgcc acccatctct
661  ccaggaaggt actcaccaat tccaaagcac atgcttgttg acgacgacta caccaggcct
721  ccggaacctg tttacagcac tgtgaacaaa ctatgtgata agcctgcttc tcccaggcac
781  tattcccctg ttgagtgtga caaaagcttc ctcctctcag ctccctattc ccactaccac
841  ctaggcctgc tacctgactc tgagatgacc agtcattccc aacatagcac cgcaactcgt
901  cagccttcaa tgactctcca acgggccgtc tccctggaag gagagcctcg caaggtagtc
961  ctgcacaaag gctccactgg cctgggcttc aacattgtcg gtggggaaga tggagaaggt
1021 atttttgtgt ccttcattct ggctggtgga ccagcagacc taagtgggga gctccagaga
1081 ggagaccaga tcctatcggt gaatggcatt gacctccgtg gtgcatccca cgagcaggca
1141 gctgctgcac taaagggggc tggacagaca gtgacgatta tagcacaata tcaacctgaa
1201 gattacgctc gatttgaggc caaaatccat gacctacgag agcagatgat gaaccacagc
1261 atgagctccg ggtccggatc cctgcgaacc aatcagaaac gctccctcta cgtcagagcc
1321 atgttcgact acgacaagag caaggacagt gggctgccaa gtcaaggact tagttttaaa
1381 tatggagata ttctccacgt tatcaatgcc tctgatgatg agtggtggca agccaggaga
1441 gtcatgctgg agggagacag tgaggagatg ggggtcatcc ccagcaaaag gagggtggaa
1501 agaaaggaac gtgcccgatt gaagacagtg aagtttaatg ccaaacctgg agtgattgat
1561 tcgaaagggt cattcaatga caagcgtaaa aagagcttca tcttttcacg aaaattccca
1621 ttctacaaga acaaggagca gagtgagcag gaaaccagtg atcctgaacg tggacaagaa
1681 gacctcattc tttcctatga gcctgttaca aggcaggaaa taaactacac ccggccggtg
1741 attatcctgg ggcccatgaa ggatcggatc aatgacgact tgatatctga attccctgat
1801 aaatttggct cctgtgtgcc tcatactacg aggccaaagc gagactacga ggtggatggc
1861 agagactatc actttgtcat ttccagagaa caaatggaga aagatatcca agagcacaag
1921 tttatagaag ccggccagta caatgacaat ttatatggaa ccagtgtgca gtctgtgaga
1981 tttgtagcag aaagaggcaa acactgtata cttgatgtat caggaaatgc tatcaagcgg
2041 ttacaagttg cccagctcta tcccattgcc atcttcataa aacccaggtc tctggaacct
2101 cttatggaga tgaataagcg tctaacagag gaacaagcca agaaaaccta tgatcgagca
2161 attaagctag aacaagaatt tggagaatat tttacagcta ttgtccaagg agatacttta
2221 gaagatatat ataaccaatg caagcttgtt attgaagagc aatctgggcc tttcatctgg
2281 attccctcaa aggaaaagtt ataaattagc tactgcgcct ctgacaacga cagaagagca
2341 tttagaagaa caaaatatat ataacatact acttggaggc ttttatgttt ttgttgcatt
2401 tatgtttttg cagtcaatgt gaattcttac gaatgtacaa cacaaactgt atgaagccat
2461 gaaggaaaca gaggggccaa agggtg
(SEQ ID NO:263)
1    mvnnysleev theeavailk ntsevvylkv gkpttiymtd pygppdiths ysppmenhll
61   sgnngtleyk tslppispgr yspipkhmlv dddytrppep vystvnklcd kpasprhysp
121  vecdksflls apyshyhlgl lpdsemtshs qhstatrqps mtlqravsle geprkvvlhk
181  gstglgfniv ggedgegifv sfilaggpad lsgelqrgdq ilsvngidlr gasheqaaaa
241  lkgagqtvti iaqyqpedya rfeakihdlr eqmmnhsmss gsgslrtnqk rslyvramfd
301  ydkskdsglp sqglsfkygd ilhvinasdd ewwqarrvml egdseemgvi pskrrverke
361  rarlktvkfn akpgvidskg sfndkrkksf ifsrkfpfyk nkeqseqets dpergqedli
421  lsyepvtrqe inytrpviil gpmkdrindd lisefpdkfg scvphttrpk rdyevdgrdy
481  hfvisreqme kdiqehkfie agqyndnlyg tsvqsvrfva ergkhcildv sgnaikrlqv
541  aqlypiaifi kprsleplme mnkrlteeqa kktydraikl eqefgeyfta ivqgdtledi
601  ynqcklviee qsgpfiwips kekl

DLG2: discs, large homolog 2, chapsyn-110 channel-associated protein of synapses-110′ genbank accession number U32376 (version 2)

(SEQ ID NO:264)
1    aaaagcaact gaggtcttaa ctttcagacg ctgaattctc atctaattga aattactggg
61   cataatgcta tatatagcca atgaagagat tttgagctct cactcagtgc cttcaagaca
121  tgtcgttttg tagtcagaga aaacagagat caatgcattt tcaaactgac agagggaacg
181  gatgctcttt agtagcacat gcccaggatc gtgtgtgtgg ggcttgcgct gtgctgagaa
241  gctgaatacc ggtccatatg ctccttattt actgcaatgt tctttgcatg ttactgtgca
301  ctccggacta acgtgaagaa gtatcgatat caagatgagg acgctccaca tgatcattcc
361  ttacctcgac taacccacga agtaagaggc ccagaactcg tgcatgtatc agaaaagaac
421  ctctctcaaa tagaaaatgt ccatggatat gtcctgcagt ctcatatttc tcctctgaag
481  gccagtcctg ctcctataat tgtcaacaca gatactttgg acacaattcc ttatgtcaat
541  gggacagaaa ttgaatatga atttgaagaa attacactgg agagggggaa ttctggcctg
601  ggattcagta ttgctggggg gacagataat ccccacattg gagatgaccc tggcatattt
661  attacgaaga ttataccagg aggtgctgca gcagaggatg gcagactcag ggtcaatgat
721  tgtatcttgc gggtgaatga ggttgatgtg tcagaggttt cccacagtaa agcggtggaa
781  gccctgaagg aagcagggtc tatcgctcgg ctgtatgtgc gtagaagacg acctattttg
841  gagaccgttg tggaaatcaa actgttcaaa ggccctaaag gtttaggctt cagtattgca
901  ggaggtgtgg ggaaccaaca cattcctgga gacaacagca tttatgtaac taaaattata
961  gatggaggag ctgcacaaaa agatggaagg ttgcaagtag gagatagact actaatggta
1021 aacaactaca gtttagaaga agtaacacac gaagaggcag tagcaatatt aaagaacaca
1081 tcagaggtag tttatttaaa agttggcaac cccactacca tttatatgac tgatccttat
1141 ggtccacctg atattactca ctcttattct ccaccaatgg aaaaccatct actctctggc
1201 aacaatggca ctttagaata taaaacctcc ctgccaccca tctctccagg gaggtactca
1261 ccaattccaa agcacatgct tgttgacgac gactacacca ggcctccgga acctgtttac
1321 agcactgtga acaaactatg tgataagcct gcttctccca ggcactattc ccctgttgag
1381 tgtgacaaaa gcttcctcct ctcagctccc tattcccact accacctagg cctgctacct
1441 gactctgaga tgaccagtca ttcccaacat agcaccgcaa ctcgtcagcc ttcaatgact
1501 ctccaacggg ccgtctccct ggaaggagag cctcgcaagg tagtcctgca caaaggctcc
1561 actggcctgg gcttcaacat tgtcggtggg gaagatggag aaggtatttt tgtgtccttc
1621 attctggctg gtggaccagc agacctaagt ggggagctcc agagaggaga ccagatccta
1681 tcggtgaatg gcattgacct ccgtggtgca tcccacgagc aggcagctgc tgcactaaag
1741 ggggctggac agacagtgac gattatagca caatatcaac ctgaagatta cgctcgattt
1801 gaggccaaaa tccatgacct acgagagcag atgatgaacc acagcatgag ctccgggtcc
1861 ggatccctgc gaaccaatca gaaacgctcc ctctacgtca gagccatgtt cgactacgac
1921 aagagcaagg acagtgggct gccaagtcaa ggacttagtt ttaaatatgg agatattctc
1981 cacgttatca atgcctctga tgatgagtgg tggcaagcca ggagagtcat gctggaggga
2041 gacagtgagg agatgggggt catccccagc aaaaggaggg tggaaagaaa ggaacgtgcc
2101 cgattgaaga cagtgaagtt taatgccaaa cctggagtga ttgattcgaa agggtcattc
2161 aatgacaagc gtaaaaagag cttcatcttt tcacgaaaat tcccattcta caagaacaag
2221 gagcagagtg agcaggaaac cagtgatcct gaacgtggac aagaagacct cattctttcc
2281 tatgagcctg ttacaaggca ggaaataaac tacacccggc cggtgattat cctggggccc
2341 atgaaggatc ggatcaatga cgacttgata tctgaattcc ctgataaatt tggctcctgt
2401 gtgcctcata ctacgaggcc aaagcgagac tacgaggtgg atggcagaga ctatcacttt
2461 gtcatttcca gagaacaaat ggagaaagat atccaagagc acaagtttat agaagccggc
2521 cagtacaatg acaatttata tggaaccagt gtgcagtctg tgagatttgt agcagaaaga
2581 ggcaaacact gtatacttga tgtatcagga aatgctatca agcggttaca agttgcccag
2641 ctctatccca ttgccatctt cataaaaccc aggtctctgg aatctcttat ggagatgaat
2701 aagcgtctaa cagaggaaca agccaagaaa acctatgatc gagcaattaa gctagaacaa
2761 gaatttggag aatattttac agctattgtc caaggagata ctttagaaga tatatataac
2821 caatgcaagc ttgttattga agagcaatct gggcctttca tctggattcc ctcaaaggaa
2881 aagttataaa ttagctactg cgcctctgac aacgacagaa gagcatttag aagaacaaaa
2941 tatatataac atactacttg gaggctttta tgtttttgtt gcatttatgt ttttgcagtc
3001 aatgtgaatt cttacgaatg tacaacacaa actgtatgaa gccatgaagg aaacagaggg
3061 gccaaagggt g
(SEQ ID NO:265)
FFACYCALRTNVKKYRYQDEDAPHDHSLPRLTHEVRGPELVHV
EKNLSQIENVHGYVLQSHISPLKASPAPIIVNTDTLDTIPYVNGTEIEYEFEEITLE
GNSGLGFSIAGGTDNPHIGDDPGIFITKIIPGGAAAEDGRLRVNDCILRVNEVDVSE
SHSKAVEALKEAGSIARLYVRRRRPILETVVEIKLFKGPKGLGFSIAGGVGNQHIPG
NSIYVTKIIDGGAAQKDGRLQVGDRLLMVNNYSLEEVTHEEAVAILKNTSEVVYLKV
NPTTIYMTDPYGPPDITHSYSPPMENHLLSGNNGTLEYKTSLPPISPGRYSPIPKHM
VDDDYTRPPEPVYSTVNKLCDKPASPRHYSPVECDKSFLLSAPYSHYHLGLLPDSEM
SHSQHSTATRQPSMTLQRAVSLEGEPRKVVLHKGSTGLGFNIVGGEDGEGIFVSFIL
GGPADLSGELQRGDQILSVNGIDLRGASHEQAAAALKGAGQTVTIIAQYQPEDYARF
AKIHDLREQMMNHSMSSGSGSLRTNQKRSLYVRAMFDYDKSKDSGLPSQGLSFKYGD
LHVINASDDEWWQARRVMLEGDSEEMGVIPSKRRVERKERARLKTVKFNAKPGVIDS
GSFNDKRKKSFIFSRKFPFYKNKEQSEQETSDPERGQEDLILSYEPVTRQEINYTRP
IILGPMKDRINDDLISEFPDKFGSCVPHTTRPKRDYEVDGRDYHFVISREQMEKDIQ
HKFIEAGQYNDNLYGTSVQSVRFVAERGKHCILDVSGNAIKRLQVAQLYPIAIFIKP
SLESLMEMNKRLTEEQAKKTYDRAIKLEQEFGEYFTAIVQGDTLEDIYNQCKLVIEE
SGPFIWIPSKEKL

DLG1: discs, large (Drosophila) homolog 1, genbank accession number U13896

(SEQ ID NO:266)
1    gttggaaacg gcactgctga gtgaggttga ggggtgtctc ggtatgtgcg ccttggatct
61   ggtgtaggcg aggtcacgcc tctcttcaga cagcccgagc cttcccggcc tggcgcgttt
121  agttcggaac tgcgggacgc cggtgggcta gggcaaggtg tgtgccctct tcctgattct
181  ggagaaaaat gccggtccgg aagcaagata cccagagagc attgcacctt ttggaggaat
241  atcgttcaaa actaagccaa actgaagaca gacagctcag aagttccata gaacgggtta
301  ttaacatatt tcagagcaac ctctttcagg ctttaataga tattcaagaa ttttatgaag
361  tgaccttact ggataatcca aaatgtatag atcgttcaaa gccgtctgaa ccaattcaac
421  ctgtgaatac ttgggagatt tccagccttc caagctctac tgtgacttca gagacactgc
481  caagcagcct tagccctagt gtagagaaat acaggtatca ggatqaagat acacctcctc
541  aagagcatat ttccccacaa atcacaaatg aagtgatagg tccagaattg gttcatgtct
601  cagagaagaa cttatcagag attgagaatg tccatggatt tgtttctcat tctcatattt
661  caccaataaa gccaacagaa gctgttcttc cctctcctcc cactgtccct gtgatccctg
721  tcctgccagt ccctgctgag aatactgtca tcctacccac cataccacag gcaaatcctc
781  ccccagtact ggtcaacaca gatagcttgg aaacaccaac ttacgttaat ggcacagatg
841  cagattatga atatgaagaa atcacacttg aaaggggaaa ttcagggctt ggtttcagca
901  ttgcaggagg tacggacaac ccacacattg gagatgactc aagtattttc attaccaaaa
961  ttatcacagg gggagcagcc gcccaagatg gaagattgcg ggtcaatgac tgtatattac
1021 aagtaaatga agtagatgtt cgtgatgtaa cacatagcaa agcagttgaa gcgttgaaag
1081 aagcagggtc tattgtacgc ttgtatgtaa aaagaaggaa accagtgtca gaaaaaataa
1141 tggaaataaa gctcattaaa ggtcctaaag gtcttgggtt tagcattgct ggaggtgttg
1201 gaaatcagca tattcctggg gataatagca tctatgtaac caaaataatt gaaggaggtg
1261 cagcacataa ggatggcaaa cttcagattg gagataaact tttagcagtg aataacgtat
1321 gtttagaaga agttactcat gaagaagcag taactgcctt aaagaacaca tctgattttg
1381 tttatttgaa agtggcaaaa cccacaagta tgtatatgaa tgatggctat gcaccacctg
1441 atatcaccaa ctcttcttct cagcctgttg ataaccatgt tagcccatct tccttcttgg
1501 gccagacacc agcatctcca gccagatact ccccagtttc taaagcagta cttggagatg
1561 atgaaattac aagggaacct agaaaagttg ttcttcatcg tggctcaacg ggccttggtt
1621 tcaacattgt aggaggagaa gatggagaag gaatatttat ttcctttatc ttagccggag
1681 gacctgctga tctaagtgga gagctcagaa aaggagatcg tattatatcg gtaaacagtg
1741 ttgacctcag agctgctagt catgagcagg cagcagctgc attgaaaaat gctggccagg
1801 ctgtcacaat tgttgcacaa tatcgacctg aagaatacag tcgttttgaa gctaaaatac
1861 atgatttacg ggagcagatg atgaatagta gtattagttc agggtcaggt tctcttcgaa
1921 ctagccagaa gcgatccctc tatgtcagag ccctttttga ttatgacaag actaaagaca
1981 gtgggcttcc cagtcaggga ctgaacttca aatttggaga tatcctccat gttattaatg
2041 cttctgatga tgaatggtgg caagccaggc aggttacacc agatggtgag agcgatgagg
2101 tcggagtgat tcccagtaaa cgcagagttg agaagaaaga acgagcccga ttaaaaacag
2161 tgaaattcaa ttctaaaacg agagataaag ggcagtcatt caatgacaag cgtaaaaaga
2221 acctcttttc ccgaaaattc cccttctaca agaacaagga ccagagtgag caggaaacaa
2281 gtgatgctga ccagcatgta acttctaatg ccagcgatag tgaaagtagt taccgtggtc
2341 aagaagaata cgtcttatct tatgaaccag tgaatcaaca agaagttaat tatactcgac
2401 cagtgatcat attgggacct atgaaagaca ggataaatga tgacttgatc tcagaatttc
2461 ctgacaaatt tggatcctgt gttcctcata caactagacc aaaacgagat tatgaggtag
2521 atggaagaga ttatcatttt gtgacttcaa gagagcagat ggaaaaagat atccaggaac
2581 ataaattcat tgaagctggc cagtataaca atcatctata tggaacaagt gttcagtctg
2641 tacgagaagt agcaggaaag ggcaaacact gtatccttga tgtgtctgga aatgccataa
2701 agagattaca gattgcacag ctttacccta tctccatttt tattaaaccc aaatccatgg
2761 aaaatatcat ggaaatgaat aagcgtctaa cagaagaaca agccagaaaa acatttgaga
2821 gagccatgaa actggaacag gagtttactg aacatttcac agctattgta cagggggata
2881 cgctggaaga catttacaac caagtgaaac agatcataga agaacaatct ggttcttaca
2941 tctgggttcc ggcaaaagaa aagctatgaa aactcatgtt tctctgtttc tcttttccac
3001 aattccattt tctttggcat ctctttgccc tttcctctgg aaaaaa
(SEQ ID NO:267)
MPVRKQDTQRALHLLEEYRSKLSQTEDRQLRSSIERVINIFQSN
LFQALIDIQEFYEVTLLDNPKCIDRSKPSEPIQPVNTWEISSLPSSTVTSETLPSSLS
PSVEKYRYQDEDTPPQEHISPQITNEVIGPELVHVSEKNLSEIENVHGFVSHSHISPI
KPTEAVLPSPPTVPVIPVLPVPAENTVILPTIPQANPPPVLVNTDSLETPTYVNGTDA
DYEYEEITLERGNSGLGFSIAGGTDNPHIGDDSSIFITKIITGGAAAQDGRLRVNDCI
LQVNEVDVRDVTHSKAVEALKEAGSIVRLYVKRRKPVSEKIMEIKLIKGPKGLGFSIA
GGVGNQHIPGDNSIYVTKIIEGGAAHKDGKLQIGDKLLAVNNVCLEEVTHEEAVTALK
NTSDFVYLKVAKPTSMYMNDGYAPPDITNSSSQPVDNHVSPSSFLGQTPASPARYSPV
SKAVLGDDEITREPRKVVLHRGSTGLGFNIVGGEDGEGIFISFILAGGPADLSGELRK
GDRIISVNSVDLRAASHEQAAAALKNAGQAVTIVAQYRPEEYSRFEAKIHDLREQMMN
SSISSGSGSLRTSQKRSLYVRALFDYDKTKDSGLPSQGLNFKFGDILHVINASDDEWW
QARQVTPDGESDEVGVIPSKRRVEKKERARLKTVKFNSKTRDKGQSFNDKRKKNLFSR
KFPFYKNKDQSEQETSDADQHVTSNASDSESSYRGQEEYVLSYEPVNQQEVNYTRPVI
ILGPMKDRINDDLISEFPDKFGSCVPHTTRPKRDYEVDGRDYHFVTSREQMEKDIQEH
KFIEAGQYNNHLYGTSVQSVREVAGKGKHCILDVSGNAIKRLQIAQLYPISIFIKPKS
MENIMEMNKRLTEEQARKTFERAMKLEQEFTEHFTAIVQGDTLEDIYNQVKQIIEEQS
GSYIWVPAKEKL

Putative function

Component of cell junctions, possible role in proliferation

Example 28B

Validation of GENE Function by RNA Interference (RNAi) Knockdown in Drosophila Cultured Cells

To confirm the mitotic role of the target protein, knockdown of GENE expression is performed in cultured Drosophila Dmel-2 cells using a double stranded RNA (dsRNA) from within the Dlg1 (CG1725) gene corresponding to the following sequence:

(SEQ ID NO:268)
GGAGGCCTTTCATCCGGACAACAATTGTCGCAGTCCCAATCGCAGTTGGC
CACCAGCCAGAGCCAAAGTCAGGTGCATCAGCAGCAGCATGCGACGCCGA
TGGTCAATTCGCAGTCGACAGGTGCGCTAAATAGTATGGGACAGACGGTT
GTCGATTCACCATCAATACCACAAGCAGCCGCAGCAGTAGCAGCAGCAGC
AAATGCATCTGCATCTGCATCAGTCATTGCAAGCAACAACACAATCAGCA
ACACCACAGTCACCACAGTCACGGCCACGGCCACAGCCAGCAACAGTAGC
AGCAAGTTGCCGCCGTCGCTTGGCGCTAACAGCAGCATTAGCATTAGCAA
TAGCAATAGCAATAGCAACAGCAATAATATCAACAACATTAATAGCATCA
ACAACAACAACAGTAGCAGCAGCAGCACGACGGCAACTGTTGCAGCAGCA
ACACCAACAGCAGCATCAGCAGCAGCAGCAGCAGCATCATCTCCACCCGC
CAACTCCTTCTATAA

dsRNA is prepared by annealing complimentary RNAs made by in vitro transcription from a PCR fragment created with the following PCR primers:

(SEQ ID NO:269)
TAATACGACTCACTATAGGGAGAGGAGGCCTTTCATCCGGACAACAAT
(SEQ ID NO:270)
TAATACGACTCACTATAGGGAGATTATAGAAGGAGTTGGCGGGTGGAG

Cells are transfected with double stranded RNA in the presence of ‘Transfast’ transfection reagent. A control transfection of a non-endogenous RNA corresponding to RFP (red fluorescent protein) is carried out in parallel.

Analysis of Dlg1 Knockdown by RNAi in D-Mel2 Cells by Cellomics Mitotic Index Assay

For the transfection, 1 μg dsRNA is added to a well of a 96-well Packard viewplate and 35 μl of logarithmically growing DMel-2 cells diluted to 2.3×10⁵ cells/ml in fresh Drosophila-SFM/glutamine/Pen-Strep are added. Cells are incubated with the dsRNA (60 nM) in a humid chamber at 28° C. for 1 hr before addition of 100 μl Drosophila-SFM/glutamine/Pen-Strep. Cells are incubated at 28° C. for 72 hours before analysis. For the assay, cells were fixed and stained using the Cellomics Mitotic Index HitKit following manufacturers instructions. The mitotic index of cells in each well was determined using the ArrayScan HCS System, running the Application protocol Mike_—250502_Polgen_MitoticIndex_—10×_p2.0 with the 10× objective and the DualBGlp filter set. This automated screening system detects the levels of a specific antigen (phosphorylated histone H3) which is only detectable during mitosis while the chromosomes are condensed.

Results for Dlg1 (CG1725) are shown in FIG. 5. A reproducible and significant reduction in mitotic index is observed in this assay indicating a reduction in the number of cells entering mitosis after RNAi

Analysis of Dlg1 Knockdown by RNAi in D-Mel2 Cells by Microscopy

For transfection 9 μl of Transfast reagent (Promega) is added to 3 μg gene specific dsRNA in 500 μl Drosophila Schneiders medium (no additives) and incubated at room temperature for 15 min. For control wells an equivalent amount of RFP dsRNA is used. This mix is added to a well of a 6-well tissue culture plate containing a glass coverslip and 500 μl of a Dmel-2 cells at 1×10⁶ cells/ml in shneiders medium. After a 1 hour incubation at 28° C., 2 mls Schneiders medium+10% FCS and pen/strep solution is added and cells are incubated at 28° C. for 48 hours. Cells on the coverslip are fixed in formaldehyde and stained with antibodies which detect α-tubulin and γ-tubulin (centrosomes), and are co-stained with DAPI to detect DNA.

Although no pronounced increase in the frequency of chromosomal defects (see Table 3 below) was observed upon RNAi, there was a small increase (30% compared to 10% in control cells) of spindle defects, of which the majority (>90%) had multiple centrosomes (more than 2).

TABLE 3
Mitotic defects observed in Dmel-2 cells
after siRNA with Dlg1 (CGI725)
	Number	Number of	% of chromosomal
	cells with	cells with	defects (no
	chromosomal	normal	defects/total
dsRNA	defects	mitosis	cells in mitosis)
No RNA	135	314	39.47
RFP	137	309	40.29
CG1725	152	169	47.35

Example 28B

Human Dlg1 and Dlg2 are Human Homologues of Drosophila Dlg1

BLASTP with Drosophila Dlg1 reveals 59% (306/517) sequence identity with regions of the human discs, large (Drosophila) homolog 1 (GENBANK ACCESSION U13896), and 60% (318/524) sequence identity with regions of human discs, large (Drosophila) homolog 2 (GENBANK ACCESSION U32376) that human Dlg1 and Dlg2 are is a homologues of Drosophila Dlg1. The BLASTP results are shown in FIG. 6. FIG. 7 shows a Clustal W alignment of Drosophila Dlg1 and the five human Dlg homologues that are currently detailed in the NCBI database. Considering the homology between the human Dlg proteins, it is probable that some or all of them are functionally similar to Drosophila Dlg1.

The nucleotide sequence of the human Dlg1 and human Dlg2 genes and their deduced amino acid sequences are shown in example 28 above.

Example 28C

Validation of the Mitotic Role of the Human Homologue by siRNA Knockdown of GENE Expression in Human Cultured Cells

Generation of siRNA human Dlg1 and Dlg2 Knockdowns

Knockdown of human Dlg1 and Dlg2 gene expression is achieved by siRNA (short interfering RNA, Elbashir et al, Nature 2001 May 24; 411(6836):494-8). We used synthetic double stranded RNAs corresponding to two different regions of each of the human Dlg1 and Dlg2 mRNAs. Synthetic siRNAs are obtained from Dharmacon Inc (our supplier). The siRNA sequences are:

COD1652	dlg2-1	AACAUUGUCGGUGGGGA	Corresponds to
		AGAU	nucleotides
		(SEQ ID NO:271)	1576-1596 in human
			Dlg-2 (see example
			28 above)
COD1653	dlg2-2	AAAACCCAGGUCUCUGG	Corresponds to
		AACC	nucleotides
		(SEQ ID NO:272)	2664-2684 in human
			Dlg-2 (see example
			28 above)
COD1654	dlg1-1	AAAGGGGAAAUUCAGGG	Corresponds to
		CUUG	nucleotides
		(SEQ ID NO:273)	871-891 in human
			Dlg-1 (see example
			28 above)
COD1655	dlg1-2	AAGUAGCAGGAAAGGGC	Corresponds to
		AAAC	nucleotides
		(SEQ ID NO:274)	2647-2667 in human
			Dlg-1 (see example
			28 above)

Analysis of siRNA Hu Dlg1 and Dlg2 Knockdowns in U2OS Cells by Flow Cytometry Analysis

Cells are seeded in 6-well tissue culture dishes at 1×10⁵ cells/well in 2 ml Dulbecco's Modified Eagle's Medium (DMEM) (Sigma)+10% Foetal Bovine Serum (FBS) (Perbio), and incubated overnight (37° C./5% CO₂).

For each well, 12 μl of 20 μM siRNA duplex (Dharmacon, Inc) (in RNAse-free H₂O) is mixed with 200 μl of Optimem (Invitrogen). In a separate tube 8 μl of oligofectamine reagent (Invitrogen) was mixed with 52 μl of Optimem, and incubated at room temperature for 7-10 mins. The oligofectamine/Optimem mix is then added dropwise to the siRNA/Optimem mix, and this is then mixed gently, before being incubated for 15-20 mins at room temperature. During this incubation the cells are washed once with DMEM (with no FBS or antibiotics added). 600 μl of DMEM (no FBS or antibiotics) is then added to each well.

Following the 15-20 min incubation, 128 μl of Optimem is added to the siRNA/oligofectamine/optimem mix, and this was added to the cells (in 600 μl DMEM). The transfection mix is added at the edge of each well to assist dilution before contact is made with the cells. Cells are then incubated with the transfection mix for 4 h (37° C./5% CO₂). Subsequently 1 ml DMEM+20% FBS is added to each well. Cells are then incubated at 37° C./5% CO₂ for 72 h. Cells are harvested by trypsinisation, washed in PBS, fixed in ice-cold 70% EtOH and stained with propidium iodide before Facs analysis.

siRNA Hu Dlg1 and Dlg2 knockdowns are conducted in U2OS. As shown in FIG. 8 major changes in the distribution of cells between cell cycle compartments (G1, S, G2/M) are seen with Dlg1 siRNA COD1564 and Dlg2 siRNA COD1562. In both cases an accumulation of cells with a 2N DNA content, indicated as the G2/M compartment of the cell cycle, is observed with a concomitant reduction in the 1N DNA content G1 compartment population. This indicates that a proportion of cells may unable to exit mitosis and renter G1 and so may be unable to complete cytokinesis, or have entered the next cycle as polyploid cells.

Subsequent microscopic analysis is performed in order to phenotype the Hu Dlg1 and Dlg2 siRNA induced defect and check for the presence of large multinucleate cells which may, due to their size and ploidy, be excluded from the FACS analysis.

Analysis of Hu Dlg1 and Dlg2 siRNA Knockdowns in U2OS Cells by Microscopy

The transfection method for samples for microscopy is identical to that for Facs except that cells are plated in wells containing a sterile glass coverslip. Cells are incubated with siRNA for 48 hours before formaldehyde fixation and co-staining with Dapi to reveal DNA (blue) and antibodies to reveal microtubules (red) and centrosomes (green). Antibodies used are: rat anti-alpha tubulin (YL12) (supplier Serotec) with secondary antibody goat anti-rat IgG-TRITC (supplier Jackson Immunoresearch) and mouse anti-gamma-tubulin (GTU88) with secondary antibody Alexagreen488-goat anti-mouseIgG (supplier Sigma).

Phenotype analysis by microscopy is conducted on U2OS cells. Results from duplicate experiments in U2OS cells are shown in FIGS. 9 and 10, and Table 4 below. Generally after siRNA more of the cells in mitosis seem to be in the early stages, prometaphase rather than the later stages (metaphase, anaphase telophase) a high frequency of cells have multiple centrosomes as is also observed in RNAi with Dmel-2 cell siRNA (see above). In addition transfected cells appear to be unable to successfully carry out cytokinesis which may account for the increase in polyploid cells.

TABLE 4
Brief description of significant cell division
defects after Dlg1 and 2 siRNA in U2OS cells.
Gene/siRNA	Dlg1/COD1564	Dlg2/COD1562
Cell Type	U2OS	U2OS
Polyploidy	Increased (4.8/field	Increased (4.8/field
	compared to 1.6/field in	compared to 1.6/field in
	nuntreated)	nuntreated)
Mitotic	Increased (23%	Increased (36% compared
Defects	compared to 13% in	to 13% in untreated)
	untreated)
Main knockout	Increased number of	Increased number of
phenotype	multi -centrosomal cells	multi -centrosomal cells
	(7.3% compared to 2.6%	(6.6% compared to 2.6%)
	in untreated)	in untreated)
	Cytokinesis defects (10%	Cytokinesis defects (23%
	compared to 0% in	compared to 0% in
	untreated)	untreated)
	Large increase in	Large increase in
	apoptotic cells	apoptotic cells
Additional	Increase in ratio of	Increase in ratio of
observations	prophase to	prophase to prometaphase
	prometaphase (61%	(72% compared to 43%
	compared to 43% in	in untreated cells)
	untreated cells)	Decrease in ratio of
	Decrease in ratio of	metaphase (6% compared
	metaphase (5% compared	to 22% in untreated cells)
	to 22% in untreated cells)	Decrease in ratio of
		anaphase and telophase
		(19% compared to 27%
		in untreated cells)

The above results confirm that Dlg1 and Dlg2 are involved in cell cycle progression, in particular, in achieving successful cell separation during cytokinesis. The mutiplication of centrosomes in many cells after Dlg 1 or 2 RNAi may reflect failure to undergo cytokinesis so that cells prematurely enter the next cycle, or may indicate that the centrosome duplication cycle is overriding normal cell cycle checkpoints. Accordingly, modulators of Dlg1 and Dlg2 activity (as identified by the assays described above) may be used to treat any proliferative disease.

Example 28D

Expression of Recombinant Hu Dlg Protein in Insect Cells

A cDNA encoding the Human Dlg1 or Dlg2 coding region derived by RT-PCR is inserted into the baculovirus expression vector pFastbacHTc (Life Technologies). A baculovirus stock is generated and western blot of subsequent infections of Sf9 insect cells demonstrates expression of N-terminal 6-His tagged proteins of approximately 100 kD (Dlg1 ) and 97 kD (Dlg2). The recombinant protein is purified by Ni-NTA resin affinity chromatography.

Similarly 6-His tagged Dlg proteins are expressed in bacteria by inserting cDNAs into bacterial expression plamids pDest17 or pET series. Protein expression in cultures of host E. coli cells transformed with recombinant plasmid is induced by addition of inducer chemical IPTG. The recombinant protein is purified by Ni-NTA resin affinity chromatography

Example 28E

Assay for Modulators of Dlg Activity

Dlgs are Membrane-associated guanylate kinase (MAGUK) homologues and contain several protein-protein interaction domains including PDZ domains, SH3 domains and a C-terminal guanylate kinase homology region that does not possess guanylate kinase activities but may act as a protein-protein interaction domain. Several proteins are known to bind huDlg1 including the adenomatous polposis coli (APC) tumour suppressor protein, the human papillomavirus E6 transforming protein, transforming adenovirus E4 protein, and the PDZ-binding kinase PBK (Gaudet et al 2000). An assay for modulators of Dlg activity would consist of an ELISA type assay where full length Dlg protein, or individual PDZ domains of Dlg protein expressed in bacteria or insect cells (as described above) are bound to a solid support, and interaction with the PDZ binding proteins described above could be measured by antibody detection of, or radioactive labelling of the PDZ binding proteins.

Example 29 (Category 3)

Line ID—419

Phenotype—Lethal phase, prepupal-pupal. High mitotic index, colchicines-like chromosome condensation, metaphase arrest

Annotated Drosophila genome genomic segment containing P element insertion site (and map position)—AE003450 (9C)

P element insertion site—292,726

Annotated Drosophila genome Complete Genome candidate

CG12638—sprint, ras associated protein

(SEQ ID NO:275)
ATGTTTGCCATATCATTGCAGCTGCTCAGCTCGCTGGCCAGCGATTTGGA
CATAATGCTAAACGATCTTCGATCGGCGCCGAGTCATGCTGCAACAGCAA
CAGCAACAGCAACAACAACGGCAACAGTTGCAACTGCAACCGCAACAACA
ACGGCCAACCGGCAGCAGCAACATCATAATCACCATAATCAGCAGCAAAT
GCAATCAAGGCAATTGCATGCACATCATTGGCAGAGCATTAACAACAATA
AGAATAACAACATTAGTAACAAAAACAACAACAACAACAACAATAATAAC
AATAACATTAATAACAATAATAATAATAATAATCATTCGGCACACCCACC
TTGCCTGATCGATATTAAGCTGAAGTCAAGCCGATCGGCAGCAACAAAAA
TAACCCATACAACAACCGCCAATCAGCTGCAGCAACAACAACGCCGCCGT
GTGGCACCCAAGCCACTGCCACGCCCACCGCGACGTACCCGCCCAACGGG
ACAAAAGGAGGTGGGGCCGTCTGAAGAGGATGGGGACACGGATGCCAGTG
ACCTGGCCAATATGACATCACCGCTGAGCGCCAGTGCAGCGGCCACTCGA
ATCAACGGCCTCTCGCCGGAAGTGAAGAAAGTCCAGCGGTTGCCACTGTG
GAATGCGCGAAACGGAAACGGAAGTACCACCACCCACTGTCACCCAACCG
GCGTCTCTGTGCAACGCCGTCTGCCCATCCAAAGTCATCAGCAGCGAATT
CTAAACCAACGATTTCATCACCAGCGAATGCATCATGGGTAA
(SEQ ID NO:276)
MFAISLQLLSSLASDLDIMLNDLRSAPSHAATATATATTTATVATATATT
TANRQQQHHNHHNQQQMQSRQLHAHHWQSINNKNNNISNKNNNNNNNNN
NNINNNNNNNNHSAHPPCLIDIKLKSSRSAATKITHTTTANQLQQQQRRR
VAPKPLPRPPRRTRPTGQKEVGPSEEDGDTDASDLANMTSPLSASAAATR
INGLSPEVKKVQRLPLWNARNGNGSTTTHCHPTGVSVQRRLPIQSHQQRI
LNQRFHHQRMHHG

Human homologue of Complete Genome candidate

B38637—Ras inhibitor (clone JC265)—human (fragment)

(SEQ ID NO:277)
1    ggccggcagc ggctgagcga catgagcatt tctacttcct cctccgactc gctggagttc
61   gaccggagca tgcctctgtt tggctacgag gcggacacca acagcagcct ggaggactac
121  gagggggaaa gtgaccaaga gaccatggcg ccccccatca agtccaaaaa gaaaaggagc
181  agctccttcg tgctgcccaa gctcgtcaag tcccagctgc agaaggtgag cggggtgttc
241  agctccttca tgaccccgga gaagcggatg gtccgcagga tcgccgagct ttcccgggac
301  aaatgcacct acttcgggtg cttagtgcag gactacgtga gcttcctgca ggagaacaag
361  gagtgccacg tgtccagcac cgacatgctg cagaccatcc ggcagttcat gacccaggtc
421  aagaactatt tgtctcagag ctcggagctg gaccccccca tcgagtcgct gatccctgaa
481  gaccaaatag atgtggtgct ggaaaaagcc atgcacaagt gcatcttgaa gcccctcaag
541  gggcacgtgg aggccatgct gaaggacttt cacatggccg atggctcatg gaagcaactc
601  aaggagaacc tgcagcttgt gcggcagagg aatccgcagg agctgggggt cttcgccccg
661  acccctgatt ttgtggatgt ggagaaaatc aaagtcaagt tcatgaccat gcagaagatg
721  tattcgccgg aaaagaaggt catgctgctg ctgcgggtct gcaagctcat ttacacggtc
781  atggagaaca actcagggag gatgtatggc gctgatgact tcttgccagt cctgacctat
841  gtcatagccc agtgtgacat gcttgaattg gacactgaaa tcgagtacat gatggagctc
901  ctagacccat cgctgttaca tggagaagga ggctattact tgacaagcgc atatggagca
961  ctttctctga taaagaattt ccaagaagaa caagcagcgc gactgctcag ctcagaaacc
1021 agagacaccc tgaggcagtg gcacaaacgg agaaccacca accggaccat cccctctgtg
1081 gacgacttcc agaattacct ccgagttgca tttcaggagg tcaacagtgg ttgcacagga
1141 aagaccctcc ttgtgagacc ttacatcacc actgaggatg tgtgtcagat ctgcgctgag
1201 aagttcaagg tgggggaccc tgaggagtac agcctctttc tcttcgttga cgagacatgg
1261 cagcagctgg cagaggacac ttaccctcaa aaaatcaagg cggagctgca cagccgacca
1321 cagccccaca tcttccactt tgtctacaaa cgcatcaaga acgatcctta tggcatcatt
1381 ttccagaacg gggaagaaga cctcaccacc tcctagaaga caggcgggac ttcccagtgg
1441 tgcatccaaa ggggagctgg aagccttgcc ttcccgcttc tacatgcttg agcttgaaaa
1501 gcagtcacct cctcggggac ccctcagtgt agtgactaag ccatccacag gccaactcgg
1561 ccaagggcaa ctttagccac gcaaggtagc tgaggtttgt gaaacagtag gattctcttt
1621 tggcaatgga gaattgcatc tgatggttca agtgtcctga gattgtttgc tacctacccc
1681 cagtcaggtt ctaggttggc ttacaggtat gtatatgtgc agaagaaaca cttaagatac
1741 aagttctttt gaattcaaca gcagatgctt gcgatgcagt gcgtcaggtg attctcactc
1801 ctgtggatgg cttcatccct g
(SEQ ID NO:278)
1    grqrlsdmsi stsssdslef drsmplfgye adtnssledy egesdqetma ppikskkkrs
61   ssfvlpklvk sqlqkvsgvf ssfmtpekrm vrriaelsrd kctyfgclvq dyvsflqenk
121  echvsstdml qtirqfmtqv knylsqssel dppieslipe dqidvvleka mhkcilkplk
181  ghveamlkdf hmadgswkql kenlqlvrqr npqelgvfap tpdfvdveki kvkfmtmqkm
241  yspekkvmll lrvckliytv mennsgrmyg addflpvlty viaqcdmlel dteieymmel
301  ldpsllhgeg gyyltsayga lsliknfqee qaarllsset rdtlrqwhkr rttnrtipsv
361  ddfqnylrva fqevnsgctg ktllvrpyit tedvcqicae kfkvgdpeey slflfvdetw
421  qqlaedtypq kikaelhsrp qphifhfvyk rikndpygii fqngeedltt s

Putative function

Ras associated effector protein

REFERENCES

Altschul, S. F. and Lipman, D. J. (1990) Protein database searches for multiple alignments. Proc. Natl. Acad. Sci. USA 87: 5509-5513

Burge, C. and Karlin, S. (1997) Prediction of complete gene structures in human genomic DNA. J. Mol. Biol. 268, 78-94.

Deak, P., Omar, M. M., Saunders, R. D. C., Pal, M., Komonyi, O., Szidonya, J., Maroy, P., Zhang, Y., Ashburner, M., Benos, P., Savakis, C., Siden-Kiamos, I., Louis, C., Bolshakov, V. N., Kafatos, F. C., Madueno, E., Modolell, J., Glover, D. M. (1997) Correlating physical and cytogenetic maps in chromosomal region 86E-87F of Drosophila melanogaster. Genetics 147:1697-1722.

Gaudet S, Branton D and Lue R A (2000) Characterisation of PDZ-binding kinase, a mitotic kinase PNAS 97, 5167-5172

Jowett, T. (1986) Preparation of nucleic acids. In “Drosophila: A Practical Approach.” Ed Roberts, D. B. IRL Press Oxford.

Lefevre, G. (1976) A photographic representation and interpretation of the polytene chromosomes of Drosophila melanogaster salivary glands. In: The Genetics and Biology of Drosophila, Eds Ashburner, M. and Novitski, E. Academic Press.

Pirrotta, V. (1986) Cloning Drosophila genes. In: In “Drosophila: A Practical Approach.” Ed Roberts, D. B. IRL Press Oxford.

Saunders, R. D. C., Glover, D. M., Ashburner, M., Siden-Kiamos, I., Louis, C., Monastirioti, M., Savakis, C., Kafatos, F. C. (1989) PCR amplification of DNA microdissected from a single polytene chromosome band: a comparison with conventional microcloning. Nucleic Acids Res. 17:9027-9037

Takada T, Matozaki T, Takeda H, Fukunaga K, Noguchi T, Fujioka Y, Okazaki I, Tsuda M, Yamao T, Ochi F, Kasuga M. (1998) Roles of the complex formation of SHPS-1 with SHP-2 in insulin-stimulated mitogen-activated protein kinase activation. J Biol Chem 1998 Apr. 10; 273(15):9234-42

Torok, T., Tick, G., Alvarado, M., Kiss, I. (1993) P-lacW insertional mutagenesis on the second chromosome of Drosophila melanogaster: isolation of lethals with different overgrowth phenotypes. Genetics 135(1):71-80

Each of the applications and patents mentioned in this document, and each document cited or referenced in each of the above applications and patents, including during the prosecution of each of the applications and patents (“application cited documents”) and any manufacturer's instructions or catalogues for any products cited or mentioned in each of the applications and patents and in any of the application cited documents, are hereby incorporated herein by reference. Furthermore, all documents cited in this text, and all documents cited or referenced in documents cited in this text, and any manufacturer's instructions or catalogues for any products cited or mentioned in this text, are hereby incorporated herein by reference.

Various modifications and variations of the described methods and system of the invention will be apparent to those skilled in the art without departing from the scope and spirit of the invention. Although the invention has been described in connection with specific preferred embodiments, it should be understood that the invention as claimed should not be unduly limited to such specific embodiments. Indeed, various modifications of the described modes for carrying out the invention which are obvious to those skilled in molecular biology or related fields are intended to be within the scope of the claims.

Claims

1. Use of a polynucleotide as set out in Table 5, or a polypeptide encoded by the polypeptide, in a method of prevention, treatment or diagnosis of a disease in an individual.

2. A use as claimed in claim 1, in which the polynucleotide comprises a human polypeptide as set out in column 3 of Table 5.

3. A use as claimed in claim 1 or 2, in which the polynucleotide or polypeptide is used to identify a substance capable of binding to the polypeptide, which method comprises incubating the polypeptide with a candidate substance under suitable conditions and determining whether the substance binds to the polypeptide.

4. A use as claimed in claim 1, 2 or 3, in which the polynucleotide or polypeptide is used to identify a substance capable of modulating the function of the polypeptide, the method comprising the steps of: incubating the polypeptide with a candidate substance and determining whether activity of the polypeptide is thereby modulated.

5. A use as claimed in any preceding claim, in which the polynucleotide or polypeptide is administered to an individual in need of such treatment.

6. A use as claimed in any preceding claim, in which the substance identified by the method is administered to an individual in need of such treatment.

7. A use as claimed in claim 1 or 2 in a method of diagnosis, in which the presence or absence of a polynucleotide is detected in a biological sample in a method comprising: (a) bringing the biological sample containing nucleic acid such as DNA or RNA into contact with a probe comprising a fragment of at least 15 nucleotides of the polynucleotide as set out in Table 5 under hybridising conditions; and (b) detecting any duplex formed between the probe and nucleic acid in the sample.

8. A use as claimed in claim 1 or 2 in a method of diagnosis, in which the presence or absence of a polypeptide is detected in a biological sample in a method comprising: (a) providing an antibody capable of binding to the polypeptide; (b) incubating a biological sample with said antibody under conditions which allow for the formation of an antibody-antigen complex; and (c) determining whether antibody-antigen complex comprising said antibody is formed.

9. A use as claimed in any preceding claim, in which the disease comprises a proliferative disease such as cancer.

10. A method of modulating, preferably down-regulating, the expression of a polynucleotide as set out in Table 5 in a cell, the method comprising introducing a double stranded RNA (dsRNA) corresponding to the polynucleotide, or an antisense RNA corresponding to the polynucleotide, or a fragment thereof, into the cell.

11. A polynucleotide selected from: (a) polynucleotides comprising any one of the nucleotide sequences set out in Example 19, preferably Shp2 polynucleotide, or the complement thereof; (b) polynucleotides comprising a nucleotide sequence capable of hybridising to the nucleotide sequences set out in Example 19, preferably Shp2 polynucleotide, or a fragment thereof; (c) polynucleotides comprising a nucleotide sequence capable of hybridising to the complement of the nucleotide sequences set out in Example 19, preferably Shp2 polynucleotide, or a fragment thereof; (d) polynucleotides comprising a polynucleotide sequence which is degenerate as a result of the genetic code to the polynucleotides defined in (a), (b) or (c).

12. A polynucleotide selected from: (a) polynucleotides comprising any one of the nucleotide sequences set out in Example 28, preferably Dlg1 or Dlg2 polynucleotide, or the complement thereof; (b) polynucleotides comprising a nucleotide sequence capable of hybridising to the nucleotide sequences set out in Example 28, preferably Dlg1 or Dlg2 polynucleotide, or a fragment thereof; (c) polynucleotides comprising a nucleotide sequence capable of hybridising to the complement of the nucleotide sequences set out in Example 28, preferably Dlg1 or Dlg2 polynucleotide, or a fragment thereof; (d) polynucleotides comprising a polynucleotide sequence which is degenerate as a result of the genetic code to the polynucleotides defined in (a), (b) or (c).

13. A polynucleotide selected from: (a) polynucleotides comprising any one of the nucleotide sequences set out in Table 5 or the complement thereof; (b) polynucleotides comprising a nucleotide sequence capable of hybridising to the nucleotide sequences set out in Table 5, or a fragment thereof; (c) polynucleotides comprising a nucleotide sequence capable of hybridising to the complement of the nucleotide sequences set out in Table 5, or a fragment thereof; (d) polynucleotides comprising a polynucleotide sequence which is degenerate as a result of the genetic code to the polynucleotides defined in (a), (b) or (c).

14. A polynucleotide selected from: (a) polynucleotides comprising any one of the nucleotide sequences set out in Examples 1 to 18, 20 to 27 and 29 or the complement thereof; (b) polynucleotides comprising a nucleotide sequence capable of hybridising to the nucleotide sequences set out in Examples 1 to 18, 20 to 27 and 29, or a fragment thereof; (c) polynucleotides comprising a nucleotide sequence capable of hybridising to the complement of the nucleotide sequences set out in Examples 1 to 18, 20 to 27 and 29, or a fragment thereof; (d) polynucleotides comprising a polynucleotide sequence which is degenerate as a result of the genetic code to the polynucleotides defined in (a), (b) or (c).

15. A polynucleotide selected from: (a) polynucleotides comprising any one of the nucleotide sequences set out in Examples 1, 2, 2A, 2B and 2C or the complement thereof; (b) polynucleotides comprising a nucleotide sequence capable of hybridising to the nucleotide sequences set out in Examples 1, 2, 2A, 2B and 2C, or a fragment thereof; (c) polynucleotides comprising a nucleotide sequence capable of hybridising to the complement of the nucleotide sequences set out in Examples 1, 2, 2A, 2B and 2C, or a fragment thereof; (d) polynucleotides comprising a polynucleotide sequence which is degenerate as a result of the genetic code to the polynucleotides defined in (a), (b) or (c).

16. A polynucleotide selected from: (a) polynucleotides comprising any one of the nucleotide sequences set out in Examples 3 to 9 and 9A or the complement thereof; (b) polynucleotides comprising a nucleotide sequence capable of hybridising to the nucleotide sequences set out in Examples 3 to 9 and 9A, or a fragment thereof; (c) polynucleotides comprising a nucleotide sequence capable of hybridising to the complement of the nucleotide sequences set out in Examples 3 to 9 and 9A, or a fragment thereof; (d) polynucleotides comprising a polynucleotide sequence which is degenerate as a result of the genetic code to the polynucleotides defined in (a), (b) or (c).

17. A polynucleotide selected from: (a) polynucleotides comprising any one of the nucleotide sequences set out in Examples 10 to 29 or the complement thereof; (b) polynucleotides comprising a nucleotide sequence capable of hybridising to the nucleotide sequences set out in Examples 10 to 29, or a fragment thereof; (c) polynucleotides comprising a nucleotide sequence capable of hybridising to the complement of the nucleotide sequences set out in Examples 10 to 29, or a fragment thereof; (d) polynucleotides comprising a polynucleotide sequence which is degenerate as a result of the genetic code to the polynucleotides defined in (a), (b) or (c).

18. A polynucleotide probe which comprises a fragment of at least 15 nucleotides of a polynucleotide according to any of claims 11 to 16.

19. A polypeptide which comprises any one of the amino acid sequences set out in any of the following: (a) Example 19, preferably Shp2 polypeptide; (b) Example 28, preferably Dlg1 or Dlg2 polypeptide; (c) Table 5; (d) Examples 1 to 18, 20 to 27 and 29; (e) Examples 1 to 2, 2A, 2B and 2C; (f) Examples 3 to 9 and 9A; (g) Examples 10 to 29; or a homologue, variant, derivative or fragment thereof.

20. A polynucleotide encoding a polypeptide according to claim 19.

21. A vector comprising a polynucleotide according to any of claims 11 to 18 and 20.

22. An expression vector comprising a polynucleotide according to any of claims 11 to 19 and 20 operably linked to a regulatory sequence capable of directing expression of said polynucleotide in a host cell.

23. An antibody capable of binding a polypeptide according to claim 19.

24. A method for detecting the presence or absence of a polynucleotide according to any of claims 11 to 18 and 20 in a biological sample which comprises: (a) bringing the biological sample containing DNA or RNA into contact with a probe according to claim 18 under hybridising conditions; and (b) detecting any duplex formed between the probe and nucleic acid in the sample.

25. A method for detecting a polypeptide according to claim 19 present in a biological sample which comprises: (a) providing an antibody according to claim 23;(b) incubating a biological sample with said antibody under conditions which allow for the formation of an antibody-antigen complex; and (c) determining whether antibody-antigen complex comprising said antibody is formed.

26. A polynucleotide according to according to any of claims 11 to 18 and 20 for use in therapy.

27. A polypeptide according to claim 19 for use in therapy.

28. An antibody according to claim 23 for use in therapy.

29. A method of treating a tumour or a patient suffering from a proliferative disease comprising administering to a patient in need of treatment an effective amount of a polynucleotide according to any of claims 11 to 18 and 20.

30. A method of treating a tumour or a patient suffering from a proliferative disease, comprising administering to a patient in need of treatment an effective amount of a polypeptide according to claim 17.

31. A method of treating a tumour or a patient suffering from a proliferative disease, comprising administering to a patient in need of treatment an effective amount of an antibody according to claim 23 to a patient.

32. Use of a polypeptide according to claim 19 in a method of identifying a substance capable of affecting the function of the corresponding gene.

33. Use of a polypeptide according to claim 19 in an assay for identifying a substance capable of inhibiting the cell division cycle.

34. Use as claimed in claim 33, in which the substance is capable of inhibiting mitosis and/or meiosis.

35. A method for identifying a substance capable of binding to a polypeptide according to claim 19, which method comprises incubating the polypeptide with a candidate substance under suitable conditions and determining whether the substance binds to the polypeptide.

36. A method for identifying a substance capable of modulating the function of a polypeptide according to claim 19 or a polypeptide encoded by a polynucleotide according to any of claims 11 to 18 and 20, the method comprising the steps of: incubating the polypeptide with a candidate substance and determining whether activity of the polypeptide is thereby modulated.

37. A substance identified by a method or assay according to any of claims 32 to 36.

38. Use of an antibody according to claim 23 or a substance according to claim 36 in a method of inhibiting the function of a polypeptide.

39. Use of an antibody according to claim 23 or a substance according to claim 37 in a method of regulating a cell division cycle function.

40. A method of identifying a human nucleic acid sequence, by: (a) selecting a Drosophila polypeptide identified in any of Examples 11 to 39; (b) identifying a corresponding human polypeptide; (c) identifying a nucleic acid encoding the polypeptide of (b).

41. A method according to claim 40, in which a human homologue of the Drosophila sequence, or a human sequence similar to the Drosophila sequence, is identified in step (b).

42. A method according to claim 40 or 41, in which the human polypeptide has at least one of the biological activities, preferably substantially all the biological activities of the Drosophila polypeptide.

43. A human polypeptide identified by a method according to claim 40, 41 or 42.